



HOW DELAYED SBIR/STTR REAUTHORIZATION THREATENS AMERICA'S MOST INNOVATIVE SMALL BUSINESS

Stories from small businesses across the United States devastated by the
lapse in SBIR/STTR Reauthorization

January 2026



Executive Summary

Established by Congress in 1982, the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are among the federal government's most effective investments in US innovation. These programs enable small businesses to convert early-stage research into mission-critical, commercially viable technologies—delivering exceptional returns for taxpayers.

Through FY2025, SBIR/STTR has invested approximately **\$4.0 billion** each year through **11 federal agencies**, resulting in **4,000–5,000 awards** that fuel innovation among the nation's most promising small businesses. An analysis of Phase II awards granted by the Department of War show a return on investment (ROI) of roughly **\$22 in total economic output for every federal dollar invested**. Similarly, a National Cancer Institute study found that approximately \$787 million in Phase II awards generated roughly **\$91 billion in economic impact**, created tens of thousands of jobs, and supported the commercialization of critical healthcare technologies.

Urgent Call to Action

Since SBIR/STTR was left to expire on September 30, 2025, the lapse in authorization is already harming small businesses, disrupting federal R&D pipelines, and delaying technologies critical to economic competitiveness, public health, and national security. **More than 1,000 CEOs and Innovation Leaders from every state** have co-signed a letter urging Congress to immediately reauthorize SBIR/STTR.

The case studies that follow provide concrete, real-world examples of these impacts. They highlight small businesses and innovation leaders across the country working in priority areas of public health, defense, and national security. The message from these businesses is clear: **urgent reauthorization of SBIR/STTR is necessary to prevent further damage, protect taxpayer ROI, and ensure the United States remains a global leader in innovation.**

Eva Garland, Ph.D.
CEO, Eva Garland Consulting

Liz Powell, ESQ., MPH
Founder & President, G2G Consulting

Jake Reder, Ph.D.
Cofounder & CEO, Celdara Medical
Director of New Ventures, Geisel School of Medicine at Dartmouth
Principal Investigator, DRIVEN Accelerator Hub

Contact:
Eva Garland Consulting, LLC
4242 Six Forks Rd
Raleigh, NC 27609
outreach@evagarland.com

Table of Contents

<i>Alabama</i>	1
Arie Nakhmani, Ph.D., <i>Birmingham, AL</i>	2
CerFlux, <i>Birmingham, AL</i>	2
Forsee, LLC, <i>Prattville, AL</i>	3
InhiProt, LLC, <i>Auburn, AL</i>	3
Quadrus Corporation, <i>Huntsville, AL</i>	4
Saeed Latif, Ph.D., <i>Mobile, AL</i>	4
<i>Alaska</i>	5
Bialume Technologies, <i>Juneau, AK</i>	5
GRAYSTAR Pacific, Inc., <i>Anchorage, AK</i>	6
PKS Consulting, <i>Anchorage, AK</i>	6
<i>Arizona</i>	7
BMSEED LLC, <i>Tempe, AZ</i>	8
Bettina Cuneo, MD, <i>Tucson, AZ</i>	9
Cristy Salanga, <i>Flagstaff, AZ</i>	9
Gila Diagnostics Inc., <i>Phoenix, AZ</i>	9
Gravitrex Inc, <i>Phoenix, AZ</i>	10
Julie Ledford, Ph.D., <i>Tucson, AZ</i>	10
Kris Vijay, MD, <i>Phoenix, AZ</i>	10
LeanRAQA, <i>Oro Valley, AZ</i>	11
Michael Shafer, <i>Flagstaff, AZ</i>	11
NeuTherapeutics, <i>Tucson, AZ</i>	12
ReviR Therapeutics, <i>Oro Valley, AZ</i>	12
UGenome AI, <i>Phoenix, AZ</i>	12
Wiley Larson, <i>Phoenix, AZ</i>	13
Woman Centered, <i>Scottsdale, AZ</i>	13
<i>Arkansas</i>	14
NuShores Biosciences, <i>Jonesboro, AR</i>	14
<i>California</i>	15
3D BioAnalytiX, <i>San Diego, CA</i>	23

3Fates-Xray, Inc., Sunnyvale, CA	23
Activ Sitting, Inc., Los Angeles, CA	24
Advanced Dermatology Care, Los Angeles, CA	24
Anixa Biosciences, San Carlos, CA	24
Arinna, Inc., South San Francisco, CA	25
Arroyo Sleep Research, Pasadena, CA	25
BioSuperior Technology, Menlo Park, CA	25
BlueBird Ventures, Palo Alto, CA	26
CatenaBio, Berkeley, CA	26
Ceiba Bio, San Diego, CA	27
CF Bioworks, Fremont, CA	27
Chascii Inc., Pasadena, CA	28
Circumvent Pharmaceuticals, San Francisco, CA	28
Danny Wang, Ph.D., Los Angeles, CA	28
dfusion Inc, Scotts Valley, CA	29
DIMERx, Mill Valley, CA	29
Doug Kollmyer, Riverside, CA	30
EndoCyclic Therapeutics, Los Angeles, CA	30
Enspectra Health, Mountain View, CA	30
Equilibrium, Inc, La Jolla, CA	31
Evolve Genomix, Pleasanton, CA	31
Ex-Amplify Therapeutics, San Diego, CA	32
Fauna Bio, Emeryville, CA	32
FloraPulse Co., Davis, CA	32
Fogarty Innovation, Mountain View, CA	33
Foreground Capital, San Francisco, CA	33
Forta Bio, San Francisco, CA	33
Fossil Energy Research Corp., Laguna Hills, CA	34
General Nanotherapeutics LLC, Santa Monica, CA	34
Genexgen Inc., Los Altos, CA	34
Health Tequity LLC, Berkeley, CA	35
HEPT Lab, Inc., Pasadena, CA	35
HHITT, Inc., San Francisco, CA	35
icosiMED, Berkeley, CA	36

Indrio Technologies Inc, <i>Riverside, CA</i>	36
InHomePharmacy LLC, <i>Newbury Park, CA</i>	36
iNFixion Bioscience, Inc., <i>San Diego, CA</i>	37
Integrated Medical Sensors Inc., <i>Irvine, CA</i>	37
Interacta Bio, <i>San Diego, CA</i>	38
Intelligent Fiber Optic Systems Corporation, <i>Fremont, CA</i>	38
Intellisense Systems, Inc., <i>Torrance, CA</i>	38
Intrinsic Powers, Inc., <i>Santa Rosa, CA</i>	39
Invasive Species Corporation, <i>Davis, CA</i>	39
iSono Health Inc., <i>San Francisco, CA</i>	39
Janus Pharmaceutical Consulting LLC, <i>Sunnyvale, CA</i>	40
JB HealthTech, Inc., <i>Rancho Santa Margarita, CA</i>	41
Judith Campbell, Ph.D., <i>Pasadena, CA</i>	41
Karamedica, Inc., <i>San Diego, CA</i>	42
Malcova, Inc., <i>Berkeley, CA</i>	42
Mark Therapeutics, Inc., <i>Los Angeles, CA</i>	43
MAX BioPharma Inc., <i>Los Angeles, CA</i>	43
Million Marker, <i>Berkeley, CA</i>	44
Mittal Consulting, <i>Irvine, CA</i>	44
MobLab, <i>Pasadena, CA</i>	45
Molhill Inc., <i>San Leandro, CA</i>	45
MPM Advisors, <i>Hillsborough, CA</i>	46
Muse Engine, <i>Santa Cruz, CA</i>	46
Nahlia Inc, <i>Los Altos, CA</i>	47
NANOS, Inc., <i>Loma Linda, CA</i>	47
Neuronics Medical, <i>Los Angeles, CA</i>	48
Nigel Calcutt, <i>La Jolla, CA</i>	48
Novoron Bioscience, <i>San Diego, CA</i>	49
Nura Health, <i>Los Angeles, CA</i>	49
Onyx Spectrum Technology, Inc., <i>Lompoc, CA</i>	50
Opal AI Inc., <i>Los Angeles, CA</i>	50
Oro Therapeutics, <i>Sausalito, CA</i>	51
Pacific Optica, <i>Santa Barbara, CA</i>	51
Powell Development Group, Inc., <i>Torrance, CA</i>	52

Pyra Bio, Inc., San Rafael, CA	52
Pyrois Nanotechnology, Inc., Scotts Valley, CA	52
Quantum Applied Science & Research, Inc., San Diego, CA	53
RadiaBeam Technologies LLC, Los Angeles, CA	53
Rebecca Chinn, La Jolla, CA	54
Ribo-Therapeutics LLC, San Diego, CA	54
Rio Pharmaceuticals, San Francisco, CA	54
Rowland Robert Reeves, Sacramento, CA	55
Richard Schneeberger, San Diego, CA	55
Samay, Inc., Mountain View, CA	55
Scaling Care, San Francisco, CA	56
SixPoint Materials, Inc., Buellton, CA	56
Skylar Consulting, Pasadena, CA	57
SonALAsense, Inc., San Carlos, CA	57
Spectral Labs Incorporated, San Diego, CA	58
Spectral Therapeutics, San Diego, CA	58
Stellar Engiine, Los Altos, CA	58
SunnyBay Biotech Inc., Fremont, CA	59
Symmetry Wood, Los Angeles, CA	59
The Provenance Chain Network, Vista, CA	60
Transition Biomining, San Francisco, CA	60
Vala Sciences, Inc., San Diego, CA	60
Verpond, Inc., Carlsbad, CA	61
WUI-Go!, San Rafael, CA	61
XCellAssay, Inc, San Francisco, CA	62
Colorado	63
Anchor Point Clinical Consulting, Durango, CO	64
C Tivy Consulting & Cervu Health, Denver, CO	64
Clinic Chat, LLC, Denver, CO	65
KMLabs, Boulder, CO	65
LumenAstra, Inc. P, and Board Member, Boulder, CO	66
Lumos Imaging, Denver, CO	66
Pat Nicholson, Fort Collins, CO	67
PharmaJet, Inc., Golden, CO	67

Prohibix, Boulder, CO	67
TissueForm, Inc., Boulder, CO	68
Connecticut	69
Biopeptides Corp, Ridgefield, CT	70
Joseph Michael Vinetz, New Haven, CT	70
LifePharms, LLC, New London, CT	71
Luna Bioscience, Westport, CT	71
RevMedica, Middletown CT	72
Virtus Therapeutics, Groton, CT	72
Yukov Scientific, Orange, CT	73
Delaware	74
SAS Nanotechnologies Inc., Newark, DE	74
District of Columbia	75
Atlantic Fish Co., Washington, DC	75
Hoffmann & Baron LLP, Washington, DC	76
Florida	77
AllerGene AI Therapeutics, Miami, FL	78
Amarastesia, Ltd., West Palm Beach, FL	79
AnekaBio LLC, Gainesville, FL	79
BC Engineered Products, Brooksville, FL	80
Blue Physics LLC, Lutz, FL	80
Convergent Engineering, Inc., Gainesville, FL	80
iScreen 2 Prevent LLC, Pembroke Pines, FL	81
Live Advantage Bait LLC., Fort Pierce, FL	81
ObjectiveEd, Inc., Wellington, FL	82
Otolith Labs, Gainesville, FL	82
Quantum Nanostim LLC, Palm Harbor, FL	83
ReNeuroGen LLC, North Fort Myers, FL	83
Skyliners Global, Inc., Ft. Myers, FL	84
SynMatter Co., Orlando, FL	84
WaveArray Antifouling Systems, LLC, Naples, FL	85
Georgia	86
Armor Medical, Inc., Atlanta, GA	87
CogBias AI, Atlanta, GA	88

InfraredRx, Inc., Athens, GA	88
Kinemo, Inc., Atlanta, GA	89
MapHabit, Inc., Atlanta, GA	89
Mimir Security, Inc., Warner Robins, GA	90
Moonlight Therapeutics, Inc., Marietta, GA	90
Radyus Research, Atlanta, GA	91
SocialRx Inc., Atlanta, GA	91
Valor.VC, Atlanta, GA	92
Hawaii	93
Laura Young, Kailua Kona, HI	93
Namaka Algae, Inc., Kamuela, HI	94
Portal Diabetes, Inc., Kihei, HI	94
Idaho	95
Pentamer Biologics, Boise, ID	95
Illinois	96
Cathleen Dohrn, Ph.D., Libertyville, IL	97
Chicago Biomedical Consortium, Chicago, IL	98
Clarix Imaging Corporation, Chicago, IL	98
CU Aerospace, Chicago, IL	98
Flavin Ventures, LLC, Darien, IL	99
Illinois Science & Technology Coalition, Chicago, IL	99
IROX, Evanston, IL	99
Phase3D, Chicago, IL	100
SimBioSys, Inc., Chicago, IL	100
Indiana	101
Amplified Sciences, Inc., West Lafayette, IN	102
Cascade Metrix, Inc., West Lafayette, IN	102
DMAG USA, Evansville, IN	103
Glassboard Product Development, Indianapolis, IN	103
GRAVICOM, LLC, Evansville, IN	103
PrimSphera, South Bend, IN	104
Scioto Biosciences, Indianapolis, IN	104
Tessellated Inc., South Bend, IN	105
Iowa	106

PathoVacs, Inc., Ames, IA	106
Syndicate of Sound and Synapse, Council Bluffs, IA	107
Kansas	108
GO Topeka/Link Innovation Labs, Topeka, KS	108
Oak Therapeutics, Inc., Lawrence, KS	109
Kentucky	110
Bioptics Technology, LLC, Lexington, KY	111
dSenz, Inc., Louisville, KY	111
Kentucky Science and Engineering Foundation, Lexington, KY	111
LaGrange Scientific, LLC, LaGrange, KY	112
Lepidext, Inc., Lexington, KY	112
LifeSciKY, Covington, KY	113
UK Innovate - University of Kentucky, Lexington, KY	113
XLerateHealth, Louisville, KY	114
Louisiana	115
AL-POWER, Baton Rouge, LA	116
Konstantin G. Kousoulas, Baton Rouge, LA	116
Oleolive Inc., Shreveport, LA	116
SimplyBreathe Inc, New Orleans, LA	117
Maine	118
Compotech, Inc., Brewer, ME	118
Maryland	119
Advanced In Vitro, LLC, Frederick, MD	122
Art Pharmacy, Baltimore, MD	123
AstraZeneca, Bethesda, MD	123
AusculTech Dx, Silver Spring, MD	123
BioFactura Inc., Frederick, MD	124
CarrTech Corp., Frederick, MD	124
CFrame, Inc., Frederick, MD	125
Composites Automation LLC, Arnold, MD	125
CraniUS, Baltimore, MD	125
Euclid Techlabs LLC, Beltsville, MD	126
Evergreen Strategic Consulting, Catonsville, MD	126
Evimero, LLC, Hagerstown, MD	127

Fetal Therapy Technologies, Baltimore, MD	127
Fzata, Inc., Halethorpe, MD	128
IECBio LLC, Poolesville, MD	128
Irazu Oncology, Baltimore, MD	128
Just Strive, Germantown, MD	129
Key Courier LLC, Frederick, MD	129
LEI Sales, LLC, Greenbelt, MD	130
Lumo Imaging LLC, Rockville, MD	130
Medical Decision Logic, Inc., Baltimore, MD	130
Mesa Science Associates Inc., Frederick, MD	131
MelaTech, Baltimore, MD	131
Nanocrine, Inc., Frederick, MD	131
New Integration Photonics, Chevy Chase, MD	132
OncoVanta Therapeutics, Inc. Hagerstown, MD	132
PediaMetrix, Rockville, MD	133
Relative Dynamics, Inc., Laurel, MD	133
Rise Therapeutics LLC, Rockville, MD	134
Society of Physician Entrepreneurs, Potomac, MD	135
TelohealthDx LLC, Clarksburg, MD	135
Tiami Networks, Inc., Hanover, MD	136
TTi Health Research & Economics, Westminster, MD	136
Veralox Therapeutics, Inc., Frederick, MD	137
WB Engineers + Consultants, Frederick, MD	137
Massachusetts	138
1910, Boston, MA	141
Absco Therapeutics, Inc., Boston, MA	142
American Veritas Engineering LLC., Leverett, MA	142
Bodkin Design & Engineering, LLC, Newton, MA	143
Boston Immune Technology & Therapeutics, Cambridge, MA	143
Busek Co. Inc., Natick, MA	143
Corcoran Engineering, Inc., Waltham, MA	144
Crimson Biopharm Inc., Brookline, MA	144
E&M BioLab, Cambridge, MA	145
Extend Biosciences Inc., Newton, MA	145

General Biologics, Inc., Boston, MA	146
General Biophysics, Framingham, MA	146
GlycoSeal Med, Newburyport, MA	147
Guardion, Inc., Reading, MA	147
Hopeful Aging, Woburn, MA	147
ImmunoChem Therapeutics, LLC, Newton, MA	148
Kephera Diagnostics, LLC, Framingham, MA	148
Lumia Health, Inc., Boston, MA	149
M. Elizabeth Fini, Boston, MA	149
Mark Grinstaff, Boston, MA	150
Matrisome Bio, Cambridge, MA	150
Microbiotix, Inc., Worcester, MA	150
Mirtech, Inc., Brockton, MA	151
NeuroFieldz Inc, Newton, MA	151
Physical Sciences Inc., Andover, MA	152
Polymerix Technologies LLC, Allston, MA	152
Procure Bio, Boston, MA	153
ReGENE LLC, Belchertown, MA	153
Skeletalis, Boston, MA	153
Sky Park Labs LLC, Concord, MA	154
Soterya Inc., Boston, MA	154
Spheric Bio, Chelsea, MA	155
SynsoryBio, Boston, MA	155
USMAT, Inc., Natick, MA	155
Yankee Environmental Systems, Inc., Turners Falls, MA	156
ZEeST Bio, Watertown, MA	157
Zola Therapeutics, Needham, MA	157
Michigan	158
Akna Health, Inc., Grand Rapids, MI	159
Alchemie Solutions, Inc., Bloomfield Hills, MI	159
Backyard Brains, Ann Arbor, MI	160
GeneToBe, Ann Arbor, MI	160
GreenMark Biomedical, Inc., Ann Arbor, MI	161
Iaso Therapeutics, Inc., East Lansing, MI	162

Kenneth Mitton, Ph.D., <i>Sterling Heights, MI</i>	162
Wanqing Liu, <i>Novi, MI</i>	163
Minnesota	164
Agnitron Technology, Inc., <i>Chanhassen, MN</i>	165
Aplos Medical, <i>Eden Prairie, MN</i>	165
Catalytic Advisors LLC, <i>Minneapolis, MN</i>	166
Innovative Surface Technologies, Inc., <i>St. Paul, MN</i>	166
m.zoro Consulting, <i>Minneapolis, MN</i>	167
Momease Solutions, <i>Plymouth, MN</i>	167
PhysiAroma, LLC, <i>Minneapolis, MN</i>	168
Sierra Medical, LLC, <i>Minneapolis, MN</i>	168
Weathervane Labs, LLC, <i>Minneapolis, MN</i>	169
Mississippi	170
Missouri	171
Antiger Therapeutics Inc., <i>St. Louis, MO</i>	171
CapyBio Inc., <i>St. Louis, MO</i>	172
dfusion Inc., <i>Kansas City, MO</i>	172
ThermAvant Technologies, <i>Columbia, MO</i>	172
Montana	173
Bird Dog Innovation Strategies, <i>Anaconda, MT</i>	174
MagDrive Technologies, Inc., <i>Bozeman, MT</i>	174
Montana Molecular, <i>Bozeman, MT</i>	175
Opio Connect, Inc., <i>Kalispell, MT</i>	175
Salient Technologies Inc., <i>Bozeman, MT</i>	176
Sunburst Sensors, <i>Missoula, MT</i>	176
Nebraska	177
Nevada	178
Heligenics, <i>Las Vegas, NV</i>	178
Lucidify, <i>Zephyr Cove, NV</i>	179
UME Health LLC, <i>Henderson, NV</i>	179
PATH2Caregiving, <i>Reno, NV</i>	180
New Hampshire	181
Celdara Medical, <i>Hanover, NH</i>	181
Kim Rosenfield, JD, <i>Hanover, NH</i>	182

Simbex LLC, Lebanon, NH	182
New Jersey	183
Energy Research Company (ERCo), Plainfield, NJ	184
High Throughput Biology, Inc., Summit, NJ	185
KivviMed Inc., Glen Ridge, NJ	185
Linnaeus Therapeutics, Haddonfield, NJ	185
Murck-Neuroscience LLC, Westfield, NJ	186
PartyGem AI, Union City, NJ	186
Structured Materials Industries, Inc., Piscataway, NJ	186
Versi Consulting, LLC, Gladstone, NJ	187
ZSX Medical, LLC, Moorestown, NJ	187
New Mexico	188
NeuroGeneces, Inc., Santa Fe, NM	188
New York	189
Abraham Stroock, Ph.D., Ithaca, NY	192
Annovis Bio, New York, NY	192
Blue Skye Development, Inc., Penfield, NY	193
Charmtech Labs, LLC, Buffalo, NY	193
Clarkson University, Potsdam, NY	193
CMTx Biotech, Inc., Stony Brook, NY	194
Envisagenics, Inc., New York, NY	194
FABimation, Inc, Mount Sinai, NY	194
Feinstein Institutes Hofstra Medical School, Manhasset, NY	195
Hair Life Regeneration, Copiague, NY	195
Healthy Directions Inc., New York, NY	195
Hudson Valley Healing Arts Center, Staatsburg, NY	196
MDDx, Inc., Tarrytown, NY	196
MicroEra Power, Inc., Rochester, NY	196
Milkshaker, Inc., New York, NY	197
OKO Labs, Rhinebeck, NY	197
Oligomerix, Inc., Bronx, NY	198
Omnitek Partners, LLC, Ronkonkoma, NY	198
Pathway to Cures, New York, NY	199
PelvicSense, Inc., Sag Harbor, NY	199

Pospea, LLC, Pittsford, NY	200
Raadysan Biotech, Inc., Fishkill, NY	200
Rashi.ai, Woodmere, NY	201
Telephus Biomedical, LLC, Rochester, NY	201
University of Rochester, Rochester, NY	201
Upsilon Health, Women's Health Access Matters (WHAM), New York, NY	202
Ventureneer, New York, NY	202
VoiceLove, Inc., Scarsdale, NY	203
North Carolina	204
3F, LLC, Hickory, NC	209
410 Medical, Inc., Durham, NC	210
Acclivity Technologies, Inc., Rougemont, NC	210
Aegis Power Systems, Murphy, NC	210
AxNano, Durham, NC	211
Barbara Vilen, Ph.D., Chapel Hill, NC	211
Bear Fiber, Inc., Morganton, NC	212
BioBridges, Morrisville, NC	212
BioSensys, Inc., Raleigh, NC	212
BioTechnology Transfer, Raleigh, NC	213
Cerulean Scientific Inc, Durham, NC	213
Chipmunk Enterprises, Efland, NC	213
Collaborations Pharmaceuticals, Inc., Raleigh, NC	214
CytxOrtho, Durham, NC	214
Deep Creek Pharma, Winston-Salem, NC	215
Delgen Biosciences, Chapel Hill, NC	215
Dignify Therapeutics, Durham, NC	216
DNALI Data Technologies, Inc, Cary, NC	216
East America Science, Inc., Durham, NC	217
Epicypher, Durham, NC	217
ForagR Medicines, Durham, NC	218
H3Pelvic Therapy Systems, Lewisville, NC	218
Hutchison PLLC, Raleigh, NC	219
Impulse Wellness, Raleigh, NC	219
INHEALTH USA, Inc., Elizabeth City, NC	220

Innovation Therapies PLLC, Fayetteville, NC	220
Innovative Viral Solutions, Inc., Leland, NC	220
Intelli-Products Inc., Asheville, NC	221
iOrganBio, Chapel Hill, NC	221
Jason Doherty, Durham, NC	222
MEMWKS, Raleigh, NC	222
Mireya McKee, Ph.D., Raleigh, NC	222
mithrilAI Corp, Raleigh, NC	223
MSI Software Solutions and iMass Innovations, Raleigh, NC	223
Mucommune, LLC, Durham, NC	224
MyoMech, Inc., Raleigh, NC	224
NabGen, Inc., Durham, NC	225
NC SBTDC, Raleigh, NC	225
NOBiotics, Raleigh, NC	226
Olfax Medical, Asheville, NC	226
OpenAgBio LLC, Cary, NC	227
PATH2Caregiving, Chapel Hill, NC	227
Perfusio Corp., Greenville, NC	227
Piximune, Inc., Durham, NC	228
PolyPV LLC, Cary, NC	228
Practical Scientific Solutions, Inc., Fuquay Varina, NC	229
PRSONAS Software, Inc., Raleigh, NC	229
Qi LLC, Raleigh, NC	230
Quanticision Diagnostics Inc., Chapel Hill, NC	230
Ramona Optics, Durham, NC	231
RFPi, Inc., Raleigh, NC	231
Scyntek, Inc., Morrisville, NC	232
Silent Crown, Wendell, NC	232
SimplusDx, Durham, NC	233
Spinrance, LLC, Chapel Hill, NC	233
Teen Health Research, Raleigh, NC	234
Timothy N. Martin, Raleigh, NC	234
Trig, LLC, Chapel Hill, NC	235
Verenovo Energy, North Wilkesboro, NC	235

ViaVerus LLC, Mebane, NC	236
Vindhya Data Science Inc., Morrisville, NC	236
Vitality Robotics, Inc., Cary, NC	236
XSONX, LLC, Charlotte, NC	237
North Dakota	238
Microbeam Technologies Inc., Grand Forks, ND	238
Ohio	239
ArthroNovus, Inc., Cleveland, OH	240
AOHBIO Corporation, Dayton, OH	240
CollaMedix Inc., Cleveland, OH	241
Innovision, Dayton, OH	241
Renalis Health, Cleveland, OH	241
Silk Technologies, Ltd., Lewis Center, OH	242
Spectral Energies, LLC, Dayton, OH	242
TritonX, Cleveland, OH	243
Oklahoma	244
Monte Caldera Technologies, Inc., Tulsa, OK	244
Velogenix, Inc., Tulsa, OK	244
Oregon	245
FaceView Mask, LLC, Medford, OR	245
Intellectual Assets, Inc., Portland, OR	246
InVivo Biosystems, Inc., Eugene, OR	246
KeyBiome, Inc., Eugene, OR	247
LATERAL.Systems, Lake Oswego, OR	247
Loza & Loza, LLP, Beaverton, OR	248
Madorra, Portland, OR	248
Narnar, LLC, Lake Oswego, OR	249
Saravir Biopharma, Portland, OR	249
Pennsylvania	250
Behaivor LLC, Pittsburgh, PA	254
Ben Franklin Technology Partners, Philadelphia, PA	254
Bruce Freeman, Ph.D., Pittsburgh, PA	254
Captis Diagnostics, Pittsburgh, PA	255
Carola Neumann, MD, Pittsburgh, PA	255

Eamon Gallagher, <i>Havertown, PA</i>	256
Energy Driven Technologies, LLC, <i>Stage College, PA</i>	256
Epivario, Inc., <i>Philadelphia, PA</i>	257
Feta Med, Inc., <i>Philadelphia, PA</i>	257
Gavin Schmidt, MBA, <i>Pittsburgh, PA</i>	257
Glya Health, <i>Malvern, PA</i>	258
Guilding Technologies Corp., <i>Philadelphia, PA</i>	258
iotaMotion, <i>Pittsburgh, PA</i>	259
Johnson & Johnson, <i>Prospect Park, PA</i>	259
Media and Process Technology, Inc., <i>Pittsburgh, PA</i>	260
Melanie Simko, M.S., <i>Pittsburgh, PA</i>	260
Merlin Biotech, Inc., <i>Doylestown, PA</i>	260
Mynari Biomedical, LLC, <i>Horsham, PA</i>	261
OsciFlex LLC, <i>Philadelphia, PA</i>	261
Patrick J. Cahill, <i>Merion Station, PA</i>	261
Paul Petrovich, <i>Pittsburgh, PA</i>	262
Pennsylvania Biotechnology Center, <i>Doylestown, PA</i>	262
Pennsylvania's Innovation Partnership (IPart), <i>Harrisburg, PA</i>	262
Philadelphia Department of Commerce, <i>Philadelphia, PA</i>	263
Polygon Health Analytics LLC, <i>Philadelphia, PA</i>	263
Pulkit Grover, Ph.D., <i>Pittsburgh, PA</i>	264
Quantitative Imaging Systems (Qi), <i>Pittsburgh, PA</i>	264
Recupero Robotics LLC, <i>Philadelphia, PA</i>	264
RedShift Energy, Inc., <i>Warminster, PA</i>	265
Robert Ricciardi, Ph.D., <i>Philadelphia, PA</i>	265
RTM Vital Signs, LLC, <i>Philadelphia, PA</i>	266
Ship of Theseus, LLC, <i>Eagleville, PA</i>	267
Serentrix, <i>Exton, PA</i>	267
Spinrance, LLC, <i>Philadelphia, PA</i>	267
Starship Health Technologies, <i>Fort Washington, PA</i>	268
Takashi Koxai, <i>Pittsburgh, PA</i>	268
Trevarx Biomedical, Inc., <i>Philadelphia, PA</i>	269
Valisci Inc., <i>Coatesville, PA</i>	269
Vasowatch Inc., <i>Philadelphia, PA</i>	269

<i>X-Biomedical Inc., Clifton Heights, PA</i>	270
<i>Puerto Rico</i>	271
<i>Marcos Lopez, Ph.D., Humacao, PR</i>	271
<i>Rhode Island</i>	272
<i>Xmark Labs, LLC, Barrington, RI</i>	272
<i>South Carolina</i>	273
<i>EMF Disturbance Monitors, Inc., Fripp Island, SC</i>	273
<i>FibroTherapeutics, Inc., Charleston, SC</i>	274
<i>Leukogene Therapeutics, Inc., Charleston, SC</i>	274
<i>Palmetto Innovative Education LLC, Mount Pleasant, SC</i>	275
<i>Somatoceutics LLC, Mount Pleasant, SC</i>	275
<i>Zylo Therapeutics, Greenville, SC</i>	276
<i>South Dakota</i>	277
<i>Houdek, Brookings, SD</i>	277
<i>Tennessee</i>	278
<i>EnvisBio, Memphis, TN</i>	279
<i>HeroWear, LLC, Nashville, TN</i>	279
<i>Orion Therapeutics, Inc., Knoxville, TN</i>	280
<i>Safire, Knoxville, TN</i>	280
<i>Verora Solutions, Kingsport, TN</i>	280
<i>Whisper Aero, Crossville, TN</i>	281
<i>Texas</i>	282
<i>7 Hills Pharma, Houston, TX</i>	284
<i>Affirmed Pharma, LLC, Conroe, TX</i>	285
<i>Analytical Scientific Products LLC, Dallas, TX</i>	286
<i>Asylia Therapeutics, Houston, TX</i>	286
<i>Base Pair Biotechnologies, Pearland, TX</i>	287
<i>Big Lake Midstream Industries LLC, Big Lake, TX</i>	287
<i>Chrysalis BioTherapeutics, Inc., Galveston, TX</i>	288
<i>Corallis Consulting, Houston, TX</i>	288
<i>Elemental Advanced Materials Inc., Houston, TX</i>	289
<i>EMPIRI, Inc., Houston, TX</i>	289
<i>Field Data Services, Austin, TX</i>	289
<i>Freyya, Inc., San Antonio, TX</i>	290

Gap Analytics LLC, <i>San Antonio, TX</i>	290
Greenfire Bio, <i>Round Rock, TX</i>	291
Houston Angel Network, <i>Houston, TX</i>	291
Incuentro LLC, <i>Houston, TX</i>	292
Koda Health, <i>Houston, TX</i>	292
Koo & Associates International, Inc., <i>Austin, TX</i>	293
Lucidify, <i>Frisco, TX</i>	293
NovoThelium, LLC, <i>San Antonio, TX</i>	294
Polykala Technologies LLC, <i>San Antonio, TX</i>	294
The Provenance Chain Network, <i>Dallas, TX</i>	294
Remunity Therapeutics, Inc., <i>Houston, TX</i>	295
Ridgeline Therapeutics, <i>Houston, TX</i>	295
Sanarentero LLC, <i>Pearland, TX</i>	296
Seth J. Schwartz, Ph.D., <i>Austin, TX</i>	296
SmartBreast Corporation, <i>Tyler, TX</i>	296
SygnaMap, <i>San Antonio, TX</i>	297
Texas High Energy Materials LLC, <i>Austin, TX</i>	297
Utah	298
Coreform Inc., <i>Orem, UT</i>	299
Diagnostic Ventures, <i>Saratoga Springs, UT</i>	299
Epitel, <i>Salt Lake City, UT</i>	300
Eyescreen, <i>Salt Lake City, UT</i>	300
Freyya Inc, <i>Salt Lake City, UT</i>	300
Glafabra Therapeutics, <i>Park City, UT</i>	301
iHub Utah, <i>Provo, UT</i>	301
Imessa Research Inc., <i>Salt Lake City, UT</i>	301
Inherent Biosciences, <i>Salt Lake City, UT</i>	302
nCAP Medical Inc, <i>Heber City, UT</i>	302
Path Fertility, <i>Salt Lake City, UT</i>	303
Peel Therapeutics, <i>Salt Lake City, UT</i>	303
SINTX Technologies, <i>Salt Lake City, UT</i>	303
Storagenergy Technologies, Inc., <i>Salt Lake City, UT</i>	304
SymbioCellTech, <i>Salt Lake City, UT</i>	304
Vira Regen Inc., <i>Salt Lake City, UT</i>	305

<i>Vermont</i>	306
QUEL Imaging, <i>White River Junction, VT</i>	307
SpikeSense LLC, <i>South Duxbury, VT</i>	307
Tina Thornton, Ph.D., <i>Burlington, VT</i>	308
<i>Virginia</i>	309
Avant Genomics, <i>Charlottesville, VA</i>	310
Barron Associates, <i>Charlottesville, VA</i>	311
Colvin Run Networks, Inc., <i>Tysons, VA</i>	311
Finnegan LLP, <i>Reston, VA</i>	312
GATACA, LLC, <i>Newport, VA</i>	312
JivaJet Inc, <i>McLean, VA</i>	313
Liquet Medical Inc, <i>Glen Allen, VA</i>	313
Mayfair Group LLC d/b/a esumry, <i>Norfolk, VA</i>	314
Medical Predictive Science Corporation, <i>Charlottesville, VA</i>	314
Morphix Technologies, Inc, <i>Virginia Beach, VA</i>	315
NanoSonic Inc, <i>Pembroke, VA</i>	315
SonoFx, <i>Charlottesville, VA</i>	316
Synap Biotech Inc., <i>Norfolk, VA</i>	316
The Tiny Cargo Company, <i>Roanoke, VA</i>	317
Tralyte Health, Inc., <i>Richmond, VA</i>	317
WynnVision LLC, <i>Richmond, VA</i>	318
<i>Washington</i>	319
Anavatos Bio, Inc., <i>Seattle, WA</i>	320
EARLY MARKERS (Bsolutions, Inc.), <i>Seattle, WA</i>	320
HaRT3S, <i>Spokane, WA</i>	321
HypnoScientific, <i>Kirkland, WA</i>	322
Lila Biologics, Inc., <i>Seattle, WA</i>	322
Patchclamp Medtech, Inc., <i>Seattle, WA</i>	323
Posture Wings, <i>Everett, WA</i>	324
<i>West Virginia</i>	325
ExesaLibero, <i>Morgantown, WV</i>	325
Parthian Battery Solutions, <i>Morgantown, WV</i>	326
Universal Schedule and Booking (USB), <i>Harpers Ferry, WV</i>	327
<i>Wisconsin</i>	328

Function Therapeutics, Milwaukee, WI	329
Intrinsic Powers Inc., Madison, WI	329
KODA Ideaworks, Inc, Waunakee, WI	329
Maxwave, LLC, Madison, WI	330
Proteovista, LLC, Madison, WI	330
Scott Reeder, MD, Ph.D., Madison, WI	331
Stem Pharm, Fitchburg, WI	331
SynXT Therapeutics Inc, Milwaukee, WI	331
Terra Bioforge, Madison, WI	332
Wisconsin Center for Technology Commercialization (CTC), Madison, WI	332
<i>Wyoming</i>	333
Nutriwyd, LLC, Laramie, WY	333

State-by-State Impact

Alabama

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,392,322,635**
Small Business SBIR/STTR Awards: **3,949**

Letter to Congress Co-signers

Dr. Karim I. Budhwani	CEO	CerFlux
Stephen A. Giles, Ph.D.	Senior Engineer	CFD Research
Joseph N. Garner, Ph.D.	CEO	Endomimetics, Inc.
Paul Cox	CEO	Evimero, LLC
Chera Howard	CEO	Forsee, LLC
Ricardo Azziz, MD, MPH, MBA	Executive Director	Foundation for Research and Education Excellence
Alexei Kisselev, Ph.D.	Founder and CSO	InhiProt, LLC
Sheron Ganatra	President and CEO	PCS Chazaq, LLC
Joe Sims, Ph.D.	Director of Advanced Manufacturing	Quadrus Corporation
Anthony Brayer, Ph.D.	CEO and CTO	TruSpin Nanomaterial Innovation
Arie Nakhmani, Ph.D.	Associate Professor of Electrical and Computer Engineering	University of Alabama at Birmingham
Saeed I. Latif	Associate Professor	University of South Alabama
Barbara S. Schuler, MPH	CEO and Founder	VAX 2 STOP CANCER

Selected Case Studies from Impacted Companies:

Arie Nakhmani, Ph.D., Birmingham, AL

Arie Nakhmani, Ph.D.

Associate Professor of Electrical and Computer Engineering
University of Alabama at Birmingham



Our NIH STTR Phase I was funded last September. **We still didn't get any money and invested our personal resources to cover project costs.**

CerFlux, Birmingham, AL

Karim Budhwani, Ph.D.

CEO
CerFlux



The lapse in SBIR/STTR reauthorization has created **uncertainty for life-saving biomedical innovations** and their associated economic impact. **These programs serve as a critical bridge between early scientific discovery and private-sector investment**, particularly in high-risk, high-reward fields where patient lives are at stake. Delays disrupt research timelines, slow workforce growth, and weaken the innovation pipeline that underpins U.S. competitiveness. Just as importantly, this uncertainty reverberates across investors, partners, and regional economies that rely on predictable federal support to translate breakthrough science into therapies for patients and jobs that remain in America.

National Science Foundation and National Institutes of Health SBIR/STTR portfolio company.

Forsee, LLC, *Prattville, AL*

Chera Howard

CEO

Forsee, LLC



Forsee, LLC relies on SBIR/STTR funding to advance early-stage R&D, validate prototypes, and retain specialized technical talent. The lapse in reauthorization has created significant financial uncertainty, delaying planned experiments, pausing collaborations with university and laboratory partners, and forcing us to defer hiring critical personnel. Operational timelines have been disrupted, increasing costs and slowing our ability to translate innovative, high-impact technologies toward commercialization. **Continued delays risk the loss of momentum, partnerships, and the competitive advantage that federal innovation programs are designed to support.**

National Science Foundation SBIR/STTR portfolio company.

InhiProt, LLC, *Auburn, AL*

Alexei Kisseelev, Ph.D.

Founder and Chief Scientific Officer

InhiProt, LLC



I have a revised phase I STTR grant, which got a score of 36 on the first submission waiting for review.

National Institutes of Health SBIR/STTR portfolio company.

Quadrus Corporation, *Huntsville, AL*

Joseph Sims, Ph.D.

Director of Advanced Manufacturing
Quadrus Corporation



I have a small team of a dozen engineers and scientists. **I stand to lose half of them in February if the SBIR program is not reauthorized.** I have \$4M in new awards awaiting reauthorization and funding.

Department of War and National Aeronautics and Space Administration SBIR/STTR portfolio company.

Saeed Latif, Ph.D., *Mobile, AL*

Saeed Latif, Ph.D.

Associate Professor
University of South Alabama



We have several SBIR proposals pending. **The funding will boost the economy here in the Gulf Coast region.**

Alaska

Economic Impact of Program:

SBIR/STTR Funds Received: **\$21,979,533**

Small Business SBIR/STTR Awards: **102**

Letter to Congress Co-signers

Keith Cox, Ph.D.	CEO	Bialume Technologies
Joseph Thomas, MS	Environmental Protection Specialist	Booz Allen Hamilton
Stephen Grabacki, FP-C	President	GRAYSTAR Pacific, Inc.
Patrick Simpson	President	PKS Consulting, Inc.
Ronni Wilcock, Ph.D.	Scientist	Two Bears Environmental Consulting, LLC

Selected Case Studies from Impacted Companies:

Bialume Technologies, Juneau, AK

Keith Cox, Ph.D.
CEO
Bialume Technologies




Our company has been consistently impressed by the federal government's ability to anticipate critical technology gaps and strategically deploy SBIR/STTR funding to enable small businesses to address those needs. At Bialume, we have made deliberate efforts to align our mission, research direction, and commercialization strategy with priorities identified by U.S. government agencies. The SBIR/STTR framework establishes a disciplined pathway that emphasizes sound science, technical validation, and responsible commercialization. **Unlike traditional venture capital models, which often compress or bypass rigorous research and development, SBIR/STTR programs promote due diligence and technical credibility. The absence of such rigor has historically led to high-profile failures, underscoring the continued importance of these programs.**

GRAYSTAR Pacific, Inc., Anchorage, AK

Stephen Grabacki, FP-C

President

GRAYSTAR Pacific, Inc.



We are waiting for a Phase 2 award decision from USDA, and a response to a Project Pitch from NSF. **We have paused all internal innovation projects until SBIR funding restarts.**

United States Department of Agriculture SBIR/STTR portfolio company.

PKS Consulting, Anchorage, AK

Patrick Simpson

President

PKS Consulting



Our Phase II funding was held up for 3 months during the Government Shutdown. **We had to lay off most of our staff as a result.** Now we need to rebuild our staff, which is expensive and takes valuable time away from achieving optimal success on our project.

United States Department of Agriculture and Environmental Protection Agency SBIR/STTR portfolio company.

Arizona

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,292,415,264.49**

Small Business SBIR/STTR Awards: **3,760**

Letter to Congress Co-signers

Wiley Larsen	Director of SBIR/STTR Support and University Partnerships	Arizona Commerce Authority
Laimonas Kelbauskas	Founder and CEO	Biomorph Technologies
Oliver Graudejus, Ph.D.	Founder and CEO	BMSEED, LLC
Jim Hauert	CEO	Gila Diagnostics, Inc.
Kira Burns	CEO	Gravitrex
Richard S. Burns, MD	Scientific Director	
Travis Dunckley	Co-Founder	Illuminos Therapeutics
Keith Stoneback	Managing Director	Lanesborough, LLC
Michelle Lott, RAC	Principal and Founder	leanRAQA
Kaitlyn Fitzgerald	CEO	Majic Branding and UltraAdapt
Cynthia Grabowski	Founder	Mind Grove
Michel Birnbaum	CEO	Mindsigns Health, Inc.
Roberta Diaz Brinton, Ph.D.	Founder and President	NeuTherapeutics
Charles Chadwell, Ph.D., PE	Dean of Engineering	Northern Arizona University
Andrew Koppisch, Ph.D	Associate Vice President for Research	Northern Arizona University
Cristy Salanga, MBA, MS, MLS	Patent Manager	Northern Arizona University
Sonia Vohnout	President and CEO	OppsSpot, LLC
Paul R. August, Ph.D.	CSO	ReviR Therapeutics
Zachary Holman, Ph.D.	CTO	Swift Coat

Kenneth D. Noonan, Ph.D.	Managing Director	T/K Associates
Michael W. Shafer, Ph.D.	Associate Dean for Research	The Steve Sanghi College of Engineering, Northern Arizona University
Zachary S. Brooks, Ph.D.	Founder and CEO	UGenome AI
Kris Vijay, MD	President, Innovative Cardiometabolic Center and Clinical Professor	University of Arizona
Julie Ledford, Ph.D.	Professor	University of Arizona
Bettina Cuneo, MD	Clinical Scholar and Professor of Surgery and Pediatrics	University of Arizona College of Medicine
Jay Roberts, MBA	Partner	Ventac Partners
Mitzi Krockover, MD	Founder and CEO	Woman Centered

Selected Case Studies from Impacted Companies:

BMSEED LLC, Tempe, AZ

Oliver Graudejus, Ph.D.

CEO, Founder
BMSEED LLC



The SBIR funding was critical for the transition from university research to commercial use. **Without this funding, BMSEED's core technology would have remained unused commercially.**

National Institutes of Health SBIR/STTR portfolio company.

Bettina Cuneo, MD, *Tucson, AZ*

Bettina Cuneo, MD

Clinical Scholar and Professor of Surgery and Pediatrics
University of Arizona College of Medicine

We will be unable to move forward with our clinical decision-making tool to identify the baby at risk for stillbirth.



Cristy Salanga, *Flagstaff, AZ*

Cristy Salanga, MBA, MS, MLS

Patent Manager
Northern Arizona University

As part of the NAU Technology Transfer Office, we look to the SBIR/STTR program to help our academic startups commercialize research and development at the university to make an impact in society. **Please reauthorize this program!!**



Gila Diagnostics Inc., *Phoenix, AZ*

Jim Hauert

CEO
Gila Diagnostics Inc.

The funds are **desperately needed** to support the life science and bioscience communities for the advancement of human and animal health, creation of jobs, and continued research and development efforts.



Gravitrex Inc, *Phoenix, AZ*

Richard Burns, MD

Scientific Director

Gravitrex Inc.




We are a startup company in the rehab tech field. **The absence of SBIR grant funding has put projects on stroke and cerebral palsy on hold.** The shift in investments to AI has made the continuation of the SBIR grant program even more critical to starting new businesses in Arizona.

Julie Ledford, Ph.D., *Tucson, AZ*

Julie Ledford, Ph.D.

Professor

University of Arizona



I am a University Professor that has spun out 2 small businesses focused on development of new drugs for asthma and COPD. **These grants are critical to move our companies forward towards better drugs for patients.**

Kris Vijay, MD, *Phoenix, AZ*

Kris Vijay, MD

President, Innovative Cardiometabolic Center

Clinical Professor, University of Arizona



We are fundraising for a novel innovative AI/ML based platform utilizing complex biomarkers in Cardiovascular Kidney Metabolic space (CKM) at POC level with blood, urine and handheld devices to bring up an output that will be accurate and time efficient for HCPs. We are getting stymied in this process due to lack of funds. This Project will improve outcomes and save lives, and **we are getting a short end of it with no available funding.**

LeanRAQA, Oro Valley, AZ

Michelle Lott, RAC
Principal and Founder
LeanRAQA



I serve as a consultant to FDA regulated medical device companies. Prior to the cut to grant funding, my clients were primarily startups with innovative technology needing regulatory strategy and submission support to bring new products to market. Many of them relied heavily on grant funding to get through early stages of product development. **Since the cut to grant funding, these important new medical device companies don't have the resources they need to get off the ground.** Patients are missing out on important, life-saving, and life-improving medical devices.

Michael Shafer, Flagstaff, AZ

Michael W. Shafer, Ph.D.
Associate Dean for Research
The Steve Sanghi College of Engineering, Northern Arizona University



As we look to expand our capacity for translating research into economic development through entrepreneurship, university researchers rely heavily on US SBIR/STTR programs. There have been a number of successful SBIR programs at my institution that have helped to push research toward the public good. Among others, these include research in cardiovascular medical devices and orthopedic exoskeleton systems to restore and improve mobility to those with disabilities.

NeuTherapeutics, Tucson, AZ

Roberta Diaz Brinton, Ph.D.

Founder and President
NeuTherapeutics



SBIR funding has been critical for developing NeuTherapeutics, LLC pipeline of therapeutics to prevent and cure Alzheimer's and Parkinson's disease. SBIR support will enable bringing our therapeutics to market while also advancing our therapeutic development for ALS.

National Institutes of Health SBIR/STTR portfolio company.

ReviR Therapeutics, Oro Valley, AZ

Paul R. August, Ph.D.

Chief Scientific Officer
ReviR Therapeutics



I've started a couple companies in the past that have grown from early innovation grant. At the moment, I'm hesitant to start anything new given the absence of clear funding opportunities.

UGenome AI, Phoenix, AZ

Zachary Brooks, Ph.D.

CEO, Founder
UGenome AI



SBIR/STTR funding is fundamental to the United States' competitiveness in the world. Do you want to be competitive and lead or do you want to take a step back?

Wiley Larson, *Phoenix, AZ*

Wiley Larson

Director of SBIR/STTR Support and University Partnerships
Arizona Commerce Authority



The gap between research and a scalable technology product is gigantic. **This is the “D” in R&D: Taking an idea created in a lab by Ph.D.-level engineers on million-dollar pieces of equipment, and transforming that into a product that a normal person can afford to buy and use in a regular environment.** It requires significant funding and a unique skillset. It's the SBIR/STTR program that funds the “D” and its startup founders that bring the skillset. It bridges this gap between “R” and “scale” and it's the only thing that does. **And it's working.** The U.S. Small Business Administration (SBA) recently reported that the SBIR/STTR program has an 8.5X return in private investment, and 2.2X in government contracts. I urge you and your colleagues to reauthorize the SBIR and STTR program for an additional five (5) years.

Woman Centered, *Scottsdale, AZ*

Mitzi Krockover, MD

Founder and CEO
Woman Centered



As an investor, I mentor founders and invest in healthcare companies. **These founders rely on SBIR and STTR grants to provide non-dilutive funding that advance their companies through clinical trials and the regulatory process and connect them to other important resources.**

Investors see these grants as **indications of the validation of the potential impact** of these companies and a vehicle that de-risks their investment, encouraging more funding from angel and VC funding. SBIR funding has enabled companies that provide quantitative information on hemorrhage during bleeding, a breakthrough device for treatment of osteopenia, and new ways of teaching surgery to trainees, identification of viable embryos for IVF transfer via AI, and many, many more novel solutions that might never have seen the light of day, if not for these grants.

Arkansas

Economic Impact of Program:

SBIR/STTR Funds Received: **\$202,999,241.27**

Small Business SBIR/STTR Awards: **572**

Letter to Congress Co-signers

Bryan Barnhouse	President and CEO	Arkansas Research Alliance
Malathi Srivatsan, Ph.D.	Senior Biomedical Research Consultant	NuShores Biosciences
Sarah Berg, MD, FACOG, MSCP	Founder	Selfority
Toby Teeter	Executive Director of the U. of A. Collaborative	University of Arkansas
Yong Zhu, Ph.D.	Professor	University of Arkansas for Medical Sciences

Selected Case Studies from Impacted Companies:

NuShores Biosciences, Jonesboro, AR

Malathi Srivatsan, Ph.D.

Senior Biomedical Research Consultant

NuShores Biosciences



I was a PI on SBIR Fast Track and also on a SBIR commercialization readiness grant. I had witnessed how this funding **helped a small biomedical devices company innovate**, reach its potential to provide an optimal solution for regeneration. Lack or delay of this SBIR funding, which is non-dilutive, **will push small companies to shut down**, hamper research and innovation to try out new ideas and eventually will interfere with health care options for patients. **More importantly it will push US back from being a global leader.**

National Institutes of Health and Department of War SBIR/STTR portfolio company.

California

Economic Impact of Program:

SBIR/STTR Funds Received: **\$15,902,575,170.53**

Small Business SBIR/STTR Awards: **43,771**

Letter to Congress Co-signers

Sandra Pankow	CEO	3D BioAnalytiX
Yao-Te Cheng	CTO and Co-Founder	3Fates-Xray, Inc.
Julie E. Fouquet, Ph.D.	CEO	3newable, LLC
Roger Leib	CEO	Activ Sitting, Inc.
Doug Foster, MBA	Partner	ADS
Michael Tabibian	Director	Advanced Dermatology Care
Sandra Manosalvas-Kjono, Ph.D.	COO	Aeromutable Corporation
Hassan Alam	CEO	AI Asset
Amir Emadi	CEO	Airwai, Inc.
Jennifer Neff, Ph.D.	CEO	Allvivo Vascular, Inc.
Lisa Thee	CEO	AMP Solutions, LLC
Pamela D. Garzone, Ph.D.	Pharmaceutical Executive	Anixa BioSciences
Xiaowu Liang, Ph.D.	President and CEO	Antigen Discovery, Inc.
Maxwell Goodman	President	Applied Physics Systems
Koosha Nassiri Nazif	CEO	Arinna, Inc.
Alex Shearer, Ph.D.	CTO	
Edward Perkins	CTO	
Marie Csete, MD, Ph.D.	Director of Research	Arroyo Sleep Research
David Craford	CEO	BacStitch DNA
Ming Zhao	Founder and CEO	Bacura Therapeutics
Jacob Painter	Scientist	Bausch+Lomb
Katarina Klett, Ph.D.	Innovation Discovery Program Manager	Berkeley
Marco Biamonte, Ph.D.	CEO	Big Eye Diagnostics

S. Russ Lehrman, Ph.D.	CEO	BioSuperior Technology, Inc.
Sheryl Flynn, PT, Ph.D.	Co-Founder and CEO	Blue Marble Health
Jeffrey Bird, MD, Ph.D.	Managing Director	Bluebird Ventures
Robert Fremeau	Founder and CEO	Brainstorm Therapeutics
Judith Campbell, Ph.D.	Professor of Biology and Chemistry	California Institute of Technology
Odilo Mueller	Co-Founder and CEO	Callisto BioMed
Babak Hassibi	Mose and Lilian Bohn Professor of Electrical Engineering and Computing and Mathematical Sciences	Caltech
Bethany Young Holt, Ph.D., MPH	Founder and Executive Director	CAMI Health
Mark A. Bernard, Ph.D.	CEO and President	Capienda Biotech
Marco Lobba, Ph.D.	CEO	CatenaBio
Zhaoqing Ding, MS, Ph.D.	CEO and Co-Founder	Ceiba Bio
Adam Markaryan, Ph.D.	Chief Research Officer	Celllectgen, Inc.
Jeremy Acosta	Laboratory Technician	CellVi Bioscience
Jon Kuchenreuther, Ph.D.	CEO	CF Bioworks
Dr. Jose Velazco	CEO	Chascii, Inc.
Christina Saylor	Senior Consultant	Chris Saylor Consulting
Daniel Chelsky	CSO	Circumvent Pharmaceuticals
Raja Ghanem	Principal Consultant and Owner	Cognesium Biomed, LLC
Sarah Lindley	CEO	Coreless Technologies, Inc.
Calvin Lin, Ph.D.	Co-Founder	Cosine Corp.
Susan Prohaska, Ph.D.	Biotech Founder and Consultant	Creekside Biotech Consulting, BioSuperior Technology
HyunDae Cho	CEO	CrossLife Technologies, Inc.
Josh Gregorio	Founder and CEO	Dauntless Biotherapeutics

Carey Chern, JD	President and CBO	DeepSeq.AI, Inc.
Katherine Steinberg, MPP, MBA	President and Co-Founder	Determined Health
Tamara Kuhn	CEO	dfusion, Inc.
Nikhilesh Singh	CEO	DIMERx
Robert B. Bilhorn, Ph.D.	President and CEO	Direct Electron, LP
Tobias Funk, Ph.D.	Founder	Dose Insight
Laura Lynn Gonzalez	CEO	Dynamoid, Inc.
Nina Warner, Ph.D.	CEO	Edulis Labs
Arnaud Delorme	Principal	EEGWave
Reen Wu	President	EffectoBio
Joseph Knight, Ph.D., MBA	CEO	Elumn8 Medical
Tanya Petrossian, Ph.D.	CEO	EndoCyclic Therapeutics
Bill Beasley	President and COO	Enspectra Health, Fogarty Innovation
Fabio Tucci, Ph.D.	COO	Epigen Biosciences, Inc.
Christine Zedelmayer	Chief Operating Officer	Equillium, Inc.
Tyler Radka	Inventor	Ergonomics
Elizabeth Gress, MPA	Head of Clinical Research	Esperto Medical
Jenna Eissmann, MS	CEO	Everest Medical Solutions, Inc.
Prasanna Thwar	CEO	Evolve Genomix
Surya Shrivastava, Ph.D	Co-Founder and CEO	Ex-Amplify Therapeutics
Isolde Callihan	Scientist	ExoPolymer
Ashley Zehnder, DVM, Ph.D.	CEO	Fauna Bio
Michael Santiago, Ph.D.	CEO	FloraPulse
Andrew Broderick	Director of Research	Focus Academy
Marga Ortigas-Wedekind	Chief Commercial Strategy Officer	Fogarty Innovation
Allie Gregorian	Chief Alliance Officer	Fogarty Innovation
Stasia Obremskey	Managing Partner	Foreground Capital
Juliana Di Simone	CEO	Forela Health
Dr. Zoya Gluzman-Poltorak	CEO and Co-Founder	Forsta Bio

Lawrence J. Muzio	Vice President	Fossil Energy Research Corp.
Harry Garland, Ph.D.	Chairman	Garland Actuarial, LLC
Chuhua Zhong	President and CEO	Gencyte Therapeutics, Inc.
David A Horwitz, MD	CEO	General Nanotherapeutics, LLC
Amir Kiani	CEO	Genexgen, Inc.
Amy Boggs	Owner	Grantsport
Daniel Tusé, Ph.D.	CEO	GROW Biomedicine, LLC
Katherine Kim, Ph.D., MPH, MBA	Founder and CEO	Health Tequity, LLC
Lauren Orlick HeartSnug	Co-Founder	HeartSnug
Aroutin Khachaturian, Ph.D.	CEO	HEPT Lab, Inc.
Mike Piha	CEO	HHITT, Inc.
Uppili Sridhar	CRO	Himet Materials, LLC
Paul Reginato, Ph.D.	Executive Director	Homeworld Collective
Sobha Pisharody, Ph.D.	CEO	icosiMED
Sargis Babakhanian	Controller	IFOS
Lidio Meireles, Ph.D.	CEO	Immunomatics, Inc.
Ritobrata Sur	CEO	Indrio Technologies, Inc.
Greg Hayward	CEO	InHomePharmacy, LLC
Herb Sarnoff, MBA	CEO	Inifxon Bioscience
Muhammad Mujeeb-U-Rahman, Ph.D.	CEO	Integrated Medical Sensors, Inc.
Behzad Moslehi, Ph.D.	CEO and CTO	Intelligent Fiber Optic Systems Corporation
Shilpa Pradhan	Vice President Emerging Technologies	Intellisense Systems, Inc.
Ravi Ramenani	CEO	Interaca Bio
Anna Chukaeva	CEO	Intercellular
Alexander Koch, MBA	CFO	Intrinsic Powers, Inc.
Pam Marrone	Executive Chair and Co-Founder	Invasive Species Corporation
Shadi Saberi Neda Razavi, MBA	Founder and CTO CEO and Chairwoman	iSono Health
Matthew Guggemos, M.S. CCC-SLP/CSU	Principal Investigator and University Lecturer	iTherapy, LLC
Joseph Hansen	Co-Founder and Advisor	Jaan Biotherapeutics, Inc.

Jan Scicinski, Ph.D., FRSC, CChem	CEO	Janus Pharmaceutical Consulting, LLC
Gary Chen Sharon Wang, Ph.D.	CEO President and Founder	JB HealthTech, Inc.
Jennifer Marples	Founder and Owner	Jennifer Marples, LLC
Tammy Schwalb, BS, EM	Owner	JIT Labs
Bryan Cheezem	Founder and CEO	Just Get Wet, LLC
Jonathan Romanowsky	Principal	Kadima Spark
Lindsay Wray, Ph.D.	CEO	Kapha Bio
Eric Gosink, Ph.D.	Senior Vice President – Corporate Strategy	Karamedica, Inc.
Elena Brin, Ph.D.	CEO and Co- Founder	Keystone Therapeutics
James J. Huang, Ph.D.	Co-Founder and CSO	King Stem Cell
Arjun Tambe	CEO	Kipo AI
Alexander Bykanov, Ph.D.	Principal Scientist	KLA Corporation
Emma Skoog, Ph.D.	CSO	Krokos Bio
Tanmay Aggarwal	Founder and CEO	Lambda Function, Inc.
Tomas Babak	CSO	Leapfrog Bio
Arthur L. Palisoc, Ph.D.	CTO Emeritus	L'Garde, Inc.
Divya Chander, MD, Ph.D.	CEO and Founder	Lucidify
Zack Spica	CEO	Lumetec, Inc.
Maureen Lamb	CFO	Mabere, LLC
Yemi Onakunle	CEO	Mabswitch, Inc.
Joseph Kao	CEO	Magnefy
Mika Eddy	CEO	Malama Health
Peymon Ghazi, Ph.D.	CEO	Malcova, Inc.
Tara Ghazi, Ph.D.	Co-Founder	
Victoria Bolotina, Ph.D.	President and CSO	Mark Therapeutics, Inc.
Farhad Parhami, Ph.D., MBA	Founder, President, and CEO	MAX BioPharma, Inc.
Jenna Hua	CEO	Million Marker

Anya Bekhtel, BS, RAPS RCC-MDR	Regulatory Affairs Specialist	Mittal Consulting
Walter Yuan, Ph.D.	CEO and Founder	MobLab
Brian Mendoza, Ph.D.	CEO	Molhill, Inc.
Peggy McLaughlin	Principal	MPM Advisors
Mike Gardner, MD	CEO	MyBackHub
Maribel Yazdanifar	Scientific Project Manager	MyOme, Inc.
Jayant Menon, MD, MEng	CEO	Nahlia, Inc.
Arlin Blood	Co-Founder and Associate Professor	NANOS, Inc. and Loma Linda University
Ana Moreno	CEO	Navega Therapeutics
Caryn Bradley, Ph.D.	CEO	NeoCare Innovations, Inc.
Michel Baudry	CSO	NeurAegis, Inc.
Radoslav Raychev, MD	CEO	Neuronics Medical
Michael Shaw	Engineer	Northrop Grumman
Shawn Gahr	COO and Co- Founder	Novoron Bioscience
Varun Kapoor, MD	Founder and CEO	Nura Health
Mythili Subharam	Founder and CEO	OmicXHealth
Stephen Scopatz, MSEng	CTO and Principle Engineer	Onyx Spectrum Technology, Inc.
Ryan Alimo	CEO	Opal AI, Inc.
Mehrdad Moslehi	President and CEO	Opterro, Inc.
Matt Smith, MBA	CEO and Co- Founder	Oro Therapeutics
Spencer LaVere Smith, Ph.D. Ryan McGreal	CEO COO	Pacific Optica
Sophia Yen, MD, MPH	CEO and Co- Founder	Pandia Health
Shital Tripathi, Ph.D.	CEO	Pari Biosciences
Judy Villacorte	Office Manager	Pasadena Bio Collaborative, Incubator
Joshua Enriquez, JD	Treasurer	Pegasus MedTech Group, Inc.
Bruno Kajiyama	CEO	Photozig, Inc.
Renee Ryan	Founder and CEO	PlnPrint, Inc.
Raju Chiluvuri	CEO	Pioneer-soft, Inc.
Charles Powell	Founder and CEO	Powell Development Group, Inc.
Aadeel Akhtar, Ph.D.	CEO and Founder	PSYONIC

Lital Gilad	CEO and Founder	Purpose Bio, Inc.
Gouri Yogalingam, Ph.D.	CEO and Founder	Pyra Bio, Inc.
Cara Beasley	CEO	Pyrois Nanotechnology, Inc.
Lise Barbe	Grants Coordinator	QB3 UC Berkeley
Gayle Guy	Proposal Manager	Quantum Applied Science and Research, Inc.
Sanghee Yoo, Ph.D.	Head of Biology	Qureator, Inc.
Djian S	Operating Partner	R3 Experiential
Alex Murokh, Ph.D.	CEO	RadiaBeam Technologies, LLC
Arzu Sandikci, Ph.D.	CEO	Rhea's Factory
Prashant Khade,	President	Ribo-Therapeutics, LLC
John Forsayeth, Ph. D.	Executive Chair	Rio Pharmaceuticals
Charles Garvin	CEO	Riptide Bioscience, Inc.
Rowland Reeves	CEO	ROWLAND ROBERT REEVES
Mark van Zee, Ph.D.	CEO	Saku Biosciences, Inc.
Richard Schneeberger	Director Innovation Partnerships	Salk Institute for Biological Studies
Maria Artunduaga, MD, MPH, MTM	CEO	Samay
Evan Y. Snyder, MD, Ph.D., FAAP, FCNS	Professor	Sanford Burnham Prebys Medical Discovery Institute and UCSD
Lauren Taylor	General Partner	Scaling Care
Sanjay V. Patel, Ph.D.	CTO	Seacoast Science, Inc.
Shahab Asgharzadeh	Professor of Pediatrics	Simurx, Inc.
Nikole Kimes, Ph.D.	CEO	Siolta Therapeutics
Dr. Tadao Hashimoto	CEO	SixPoint Materials, Inc.
Evan Tsang	Managing Partner	Skylar Consulting
David Harrison	COO	Skywalk, Inc.
Mark de Souza, Ph.D.	President and CEO	SonALAsense, Inc.
Andy McGibbon	Operating Advisor	Sonder Capital
Don Parker, MBA, MBT	President	SonoFusion MD, Inc.
Eric Ackermann	CEO	Spectral Labs, Inc.
Alexander Price, Ph.D.	CTO	Spectral Therapeutics
Babak Adibi, Ph.D.	President	Stellar Engine
James Page, MS, ME	VP SW	Stratasys
Feng Wang, MD	CEO and Founder	SunnyBay Biotech, Inc.

Viktor Chekh, Ph.D.	Senior Computer Vision Engineer	Supernal, LLC
Tim Keating	Co-Founder and Chief Sustainability Officer	Symmetry Wood
Nafiseh Moghimi	Lead Scientist	Technobiom
Ryan Williams	CEO	The Blockchain Academy
Charlie McGillis	VP, Public Sector	The Provenance Chain Network
Kristin Gentry	Founder and CEO	Tovocor, Inc.
Aleksandr Milshteyn, Ph.D.	CEO	Transition Biomining
Shiva Bhowmik, Ph.D.	President and CSO	TRIO Pharmaceuticals, Inc.
Mark Mascal, Ph.D.	Professor	University of California Davis
Doug Kollmyer	Entrepreneur in Residence	University of California Riverside
Karen Christman, Ph.D.	Professor	University of California San Diego
Nigel Calcutt, Ph.D.	Professor	University of California San Diego
Benjamin Legum	Director	University of California Santa Cruz
Paul Orlando	Incubator Director	University of Southern California
Danny Wang	Professor	University of Southern California
Mylene Yao, MD	CEO	Univfy, Inc.
Kara L. Gordon, Ph.D.	Director of Neurobiology	Vala Sciences, Inc.
Valerie Toler	Associate Director, Pharmacovigilance Operations	VDT Pharmacovigilance Consultants
Stuart Bussell, Ph.D.	President	Verpond, Inc.
Alicia Scheffer-Wong	Senior Director, External Partnerships	Visby Medical
Melissa Kotterman, Ph.D.	CEO	Vivere Oncotherapies, Inc.
Dr. Sarah Lindbergh	CEO	WUI-Go!
Fred Schaufele, Ph.D.	CEO	XCellAssay, Inc.
Fran Wang	CEO	Yona Care
Nadja Mannowetz	CSO	YourChoice Therapeutics
Dr. Gilbert H. Hong	CEO	Zepto Biotech Laboratories

Selected Case Studies from Impacted Companies:

3D BioAnalytiX, San Diego, CA

Sandra Pankow, Ph.D.

CEO

3D BioAnalytiX



We currently have an STTR pending with a letter of intent to award that was supposed to start in December. We counted on this to advance a diagnostic blood test that could prevent heart failure in millions of patients towards commercialization after a successful clinical trial. **Businesses need certainty and need to be able to plan to be successful and the uncertainty of reauthorization is creating real dilemmas.**

Now, we completely have to overthrow our business plans and won't know if our company will survive past April even with stretching resources to the max. Then this test would never see the light of day and patients would continue to needlessly suffer and waste resources with getting false or no diagnosis at all. Even the delay is causing a lot of stress - laboratory lease, employees, accounting services and a myriad of other services big and small all can't just be canceled at a whim, this takes months to do and has devastating effects on the entire economy including the companies providing said services. Many of us have stopped buying services, advancing therapies and diagnostics and are just in survival mode- benefiting no one.

National Institutes of Health SBIR/STTR portfolio company.

3Fates-Xray, Inc., Sunnyvale, CA

Yao-Te Cheng

Co-Founder, CTO

3Fates-Xray, Inc.

3Fates-Xray, Inc.

Our company is developing next-generation X-ray imaging technology to help TSA more accurately detect threats and assist CBP in intercepting narcotics in inbound mail. **This innovation enhances national security while potentially saving the government billions** by reducing the need for expanded TSA screening infrastructure and lowering medical and enforcement costs related to drug use. **The 2023 NSF SBIR Phase I award was pivotal in advancing our AI-driven imaging platform, and continued SBIR support is vital to bring these benefits to reality.**

National Science Foundation SBIR/STTR portfolio company.

Activ Sitting, Inc., Los Angeles, CA

Roger Leib, FAIA, ACHA

CEO

Activ Sitting, Inc.



We are developing a solution of global significance to combat sedentariness and get people moving again at work, at leisure, and even in transit—without disrupting their daily activities. We expect to impact explosive rates of cardiometabolic chronic disease and obesity. **After teaming up with both a world-class hospital and a world-class university, this interruption effectively halts our development. PLEASE RESTART IT!**

National Institutes of Health SBIR/STTR portfolio company.

Advanced Dermatology Care, Los Angeles, CA

Michael Tabibian

Director

Advanced Dermatology Care



Just applied to an SBIR program but was immediately turned down.

Anixa Biosciences, San Carlos, CA

Pamela Garzone, Ph.D.

Chief Development Officer

Anixa Biosciences



My company, in collaboration with the esteemed Cleveland Clinic Taussig Cancer Center, submitted a grant in 2025. We were encouraged by the Program Director to resubmit our application once we addressed the weaknesses. We were to re-submit the application but due to the expiration of the funding for the specific section, we have not been able to re-submit the application. The proposal, an evaluation of a vaccine for HR+ and TNBC breast cancer in the neoadjuvant setting in mouse models, **could potentially impact the outcome and quality of life of many women diagnosed with breast cancer.**

Arinna, Inc., South San Francisco, CA

Alex Shearer, Ph.D.

CTO

Arinna, Inc.



We are a pre-seed/seed energy infrastructure start up with very limited financial and physical resources. **We rely on SBIR/STTR funding to operate and support our soon to be 8 employees and our goal of improving American energy independence and resilience.**

National Science Foundation SBIR/STTR portfolio company.

Arroyo Sleep Research, Pasadena, CA

Marie Csete MD, Ph.D.

Director of Research

Arroyo Sleep Research



SBIRs are ESSENTIAL for driving innovative business in the U.S. With a relatively small investment, an SBIR grant can move a great new idea from theory toward practical science that leads to commercialization. A business-oriented administration should have SBIR funding on the top of its to-do list.

BioSuperior Technology, Menlo Park, CA

Susan Prohaska, Ph.D.

Biotech Founder, BioSuperior Technology

Consultant, Creekside Biotech Consulting



We submitted an SBIR in September to advance a lung-targeted therapeutic to treat acute respiratory distress syndrome (ARDS) and other severe lung conditions with high unmet medical need. The scheduled review was delayed due to the shutdown and even if we receive a favorable review, the funds have not been authorized so no funding could be received. I have written several SBIRs in the past for startups, that were funded by NIH and led to significant results. Without these funds we cannot hire professionals and contract with the US based companies that will help us advance the development of this therapeutic to the benefit of upwards of 200,000 to 400,000 patients annually in ICUs in the US. NSF

previously funded this program with a Phase I SBIR, and we are looking to build on that investment and success. **These and all programs from NIH and NSF are engines of science and technology advancement respected and emulated around the world. They are one of America's treasures and hallmark of our scientific and entrepreneurial leadership and should be restored as soon as possible!**

National Science Foundation SBIR/STTR portfolio company.

BlueBird Ventures, Palo Alto, CA

Jeffrey Bird, MD, Ph.D.
Managing Director
BlueBird Ventures

The earliest stage of Biotech companies are often **dependent on SBIRs for completing their groundbreaking work!**



CatenaBio, Berkeley, CA

Marco Lobba, Ph.D.
CEO
CatenaBio

We have \$4M in grant applications stalled after the lapse in SBIR funding. **These funds would be transformative in advancing lifesaving cancer therapeutics.**



Ceiba Bio, San Diego, CA

Zhaoqing Ding, MS, Ph.D.

CEO, Co-Founder

Ceiba Bio

We're a university spin out that is developing novel groundbreaking therapeutic strategies for Alzheimer's disease that is just too early for institutional funding. **Without a future STTR grant, all the last 15+ years of academic research will never be translated to patients.**



National Institutes of Health SBIR/STTR portfolio company.

CF Bioworks, Fremont, CA

Jon Kuchenreuther, Ph.D.

CEO

CF Bioworks

In my previous role and capacity as the co-founder & CSO of ZymoChem, I firmly attest to how critical the SBIR/STTR program and its funding were to catalyzing my prior biotech company. The first funding ZymoChem received was from two SBIR Phase I awards; 10 years since, ZymoChem has raised >\$50 MM in total funding and is still going strong!



Chascii Inc., Pasadena, CA

Jose Velazco, Ph.D.

CEO

Chascii Inc.



We are developing advanced space technologies based on lasers, with much of this work enabled by SBIR funding. The SBIR program has been fundamental to the successful development of our cutting-edge capabilities and remains critical as we transition these technologies to the commercial market. **Companies like ours—pushing the envelope on game-changing innovations that strengthen U.S. technological leadership and competitiveness—depend on the continued support of the SBIR/STTR programs.**

National Science Foundation and National Aeronautics and Space Administration SBIR/STTR portfolio company.

Circumvent Pharmaceuticals, San Francisco, CA

Daniel Chelsky, Ph.D.

CSO

Circumvent Pharmaceuticals



We need to resubmit two SBIR Phase I applications to fund our research in Alzheimer's disease treatment but are currently blocked from applying for this support.

National Institutes of Health SBIR/STTR portfolio company.

Danny Wang, Ph.D., Los Angeles, CA

Danny Wang, Ph.D.

Professor

University of Southern California



We have a spinoff startup from USC and applied for SBIR in 2025 with a promising score but need resubmission. **The SBIR program is critical for our startup which hires 5 US citizens.**

dfusion Inc, Scotts Valley, CA

Tamara Kuhn, MA

CEO

dfusion Inc



The reauthorization of SBIRs has been something we could always count on. It, rightfully, **had bipartisan support because our legislators knew how important small businesses are to their communities and how important innovation is in improving lives and livelihoods.** For the first time, we are at a precipice. If this stalling on reauthorization continues we will not get continuation funds. The work we have done around health literacy in children will immediately stop. We will be forced to cut our workforce to nearly zero. These are hardworking Americans who work in public health fields to make a difference in people's daily lives. Because we are remote this continued stall impacts employees from the west coast to the east coast, including the Midwest and southeast. These are people that will be unemployed due to a lack of action on a well-respected bipartisan program. Please help our small business and our research survive these times.

National Institutes of Health, Institute of Education Sciences, Administration for Community Living, Centers for Disease Control and Prevention, and National Science Foundation SBIR/STTR portfolio company.

DIMERx, Mill Valley, CA

Nikhilesh Singh, Ph.D.

CEO

DIMERx



SBIRs are bulwark of biotech innovation in the US. Without the SBIR support, **bio discoveries would become extinct and we would lose to other countries.**

Doug Kollmyer, *Riverside, CA*

Doug Kollmyer

Entrepreneur in Residence

Currently working on SBIR/STTR's for high power lasers, GPS denied navigation, and rare earth recovery projects critical for national security. Require follow through funding.



EndoCyclic Therapeutics, *Los Angeles, CA*

Tanya Petrossian, Ph.D.

CEO

EndoCyclic Therapeutics



The lapse in SBIR reauthorization is directly delaying critical clinical trial readiness for ENDO-205, our endometriosis peptide therapeutic program. Endometriosis is a major US health issue: a chronic, painful disease and the leading cause of infertility, affecting approximately 10% of women, including adolescents, and costing the US economy at least \$100B annually due to surgery, lost productivity, and long-term disability. There are no curative treatments. **Our SBIR-supported program received a perfect 10 grant score to build the infrastructure required to initiate clinical trials and commercialize our groundbreaking peptide therapeutic, ENDO-205**, designed to cure the disease once and for all, stop suffering, and prevent infertility. With uninterrupted funding, we can reach market within 3–4 years.

Enspectra Health, *Mountain View, CA*

Bill Beasley

President and COO

Enspectra Health



I have worked for two startup medical technology companies whose early survival and success depended on SBIR and other federal funding programs. **For early-stage med tech companies, this capital is not supplemental—it is foundational.** The costs of clinical data collection, regulatory compliance, and patient safety requirements create barriers that private capital alone is often unwilling to bear. SBIR funding enables innovation to progress responsibly from

concept to commercialization, supporting small businesses, high-skilled jobs, and life-saving technologies. **Reinstating the SBIR program promptly is essential to maintaining U.S. leadership in medical innovation and ensuring patients ultimately benefit from these advances.**

National Institutes of Health SBIR/STTR portfolio company.

Equillium, Inc, La Jolla, CA

Christine Zedelmayer, PMP

COO

Equillium, Inc



We filed for an STTR and received a score within the funding range in September. **While we were in discussions with the Program Officer, the STTR/SBIR funding closed for everyone. Unfortunately, we have not been able to fund our program in Alzheimer's Disease detection as a result and the program is stalled.** This has a direct negative impact on Alzheimer's patients, including pre-screening of patients for Alzheimer's. Pre-screening and early treatment can save the government millions of dollars.

Evolve Genomix, Pleasanton, CA

Prasanna Thwar, Ph.D.

CEO

Evolve Genomix



We are an early-stage, boot-strapped biotech company developing technologies for the Agriculture and Food industries, both of which are very critical for national food security but are historically less funded by VCs compared to other industries. We rely heavily on government funding like SBIR/STTR to establish feasibility and showcase commercial readiness, to support our ongoing research and to financially support our staff. The lapse in reauthorization has delayed our application for two grants that are ready to go and because of the funding shortage, we were forced to reduce the hours for a few of our employees, for whom our employment is their main source of sustenance. **We sincerely plead to the Congress to accelerate the reauthorization of funding for these vital, nation-building programs that have huge cascading benefits to the society.** Thank you!


National Science Foundation SBIR/STTR portfolio company.

Ex-Amplify Therapeutics, San Diego, CA

Surya Shrivastava, Ph.D.

CEO, Co-Founder

Ex-Amplify Therapeutics



I took a leap of faith and left my six-figure salary to start my own company in May 2025. Only SBIR can make it possible for us to turn clinical observations to therapeutic interventions for millions living with chronic migraine pain. **Not only is the delay of funds delaying scientific growth, it's decelerating the therapeutics development which in turn causes millions of dollars worth of losses due to patient's pain and presentism.**

Fauna Bio, Emeryville, CA

Ashley Zehnder, DVM, Ph.D.

CEO

Fauna Bio



We were supported by both SBIR and STTR mechanisms when we started our company 7 years ago and this early support was crucial for generating initial data and proof points to generate follow on investment from both investors and pharma!

National Institutes of Health SBIR/STTR portfolio company.

FloraPulse Co., Davis, CA

Michael Santiago, Ph.D.

CEO

FloraPulse Co.



Thanks to the SBIR program, we created FloraPulse, a business that now employs 6 people and makes \$1M annual revenues. We developed sensors that will help orchards and vineyards save up to 50% of water in California. Couldn't have done it without SBIR, as no investors would touch the business before the technology was proven.

National Science Foundation SBIR/STTR portfolio company.

Fogarty Innovation, *Mountain View, CA*

Marga Ortigas-Wedekind

Chief Commercial Strategy Officer
Fogarty Innovation



I work in a non-profit medical technology incubator geared at very young companies working to make a difference in life-saving medical technologies. Given the drought in equity funding for early-stage technologies, **SBIR and STTR grants are the lifeblood of these small, scrappy companies as they embark on their critical missions.** Innovation in medicine is key to reinforcing the US world-leading position in the field and the lack of funding will put us at a global disadvantage.

Foreground Capital, *San Francisco, CA*

Stasia Obremskey

Managing Partner
Foreground Capital



Our portfolio companies rely on this capital to further their product development and get them ready for additional risk capital.

Forta Bio, *San Francisco, CA*

Zoya Gluzman-Poltorak, Ph.D.

CEO and Co-Founder
Forta Bio



Forta Bio is a newly formed, founder-funded biotech, built on deep foundational research at City of Hope. We prepared and submitted an SBIR Concept Award application in October 2025, only to have that **opportunity cancelled due to the SBIR/STTR lapse.** We then invested significant time and resources to prepare a full SBIR submission for January 2026, which was also cancelled. These awards were critical to our survival during seed fundraising - non-dilutive funding would have sustained core R&D, enabled key preclinical milestones, and supported hiring. The lapse has forced us to slow execution and stretch limited runway. **We urgently need SBIR/STTR reopening to help startups like Forta bridge the “valley of death.”**

Fossil Energy Research Corp., Laguna Hills, CA

Lawrence J. Muzio, Ph.D.

Vice President

Fossil Energy Research Corp.



About 1-2 years ago the SBIR program funded by DOE allowed us to investigate a way to remove CO₂ from the atmosphere and in parallel produce a useful product for industry. **The SBIR/STTR program provides an easy way for a small company to perform research for new ideas.**

Department of Energy SBIR/STTR portfolio company.

General Nanotherapeutics LLC, Santa Monica, CA

David A. Horwitz, MD

CEO

General Nanotherapeutics LLC



Funding is vital to our Company Development.

National Institutes of Health SBIR/STTR portfolio company.

Genexgen Inc., Los Altos, CA

Amir Kiani, Ph.D.

CEO

Genexgen Inc.



We are developing drugs for a rare fatal pediatric disease and **SBIR could be the make or break point for us and thousands of American Children that are dealing with this horrible disease we are working on.**

National Science Foundation SBIR/STTR portfolio company.

Health Tequity LLC, Berkeley, CA

Katherine Kim, Ph.D., MPH, MBA
CEO, Founder
Health Tequity LLC


As startup digital health company, **we built our research and development strategy on the possibility of SBIR funding**. The delays and expiration of the program have seriously hindered our survival and competitiveness. **We had potential customers ready to be part of our research that were very disappointed at not being able to use our innovation.** Please reauthorize the program.



HEPT Lab, Inc., Pasadena, CA

Aroutin Khachaturian, Ph.D.
CEO
HEPT Lab, Inc.

SBIR funding will enable us to create new hardware and deliver our hardware proof of concept demo.



HHITT, Inc., San Francisco, CA

Mike Piha
CEO
HHITT, Inc.

We have two (2) SBIRs that were submitted in early August, 2025. Our innovation is moving forward and the DoD is missing out on important new innovations that will advance our country in a rapid pace. We also are seeking other funding opportunities as our development and R&D is continuing to advance. **The US is missing out on many leading edge opportunities to advance our counties technology and innovation!**



Department of War SBIR/STTR portfolio company.

icosiMED, Berkeley, CA

Sobha Pisharody, Ph.D.

CEO

icosiMED



The lapse in SBIR funding is **delaying a critical study on a drug to treat ovarian cancer.**

Indrio Technologies Inc, Riverside, CA

Ritobrata Sur

CEO

Indrio Technologies Inc



The delays in our SBIR has led us to lay off some research staff and also has severely delayed our commercialization of a new and exciting sensor because it was not de-risked yet.

National Science Foundation and Department of Energy SBIR/STTR portfolio company.

InHomePharmacy LLC, Newbury Park, CA

Greg Hayward

CEO, Founder

InHomePharmacy LLC



We were able to navigate the SBIR program with two phase I awards and a D2P2 that matured into a Phase III contract to deliver a platform that ingests data from wearable COTS devices that are SCIF approved. None of this would have been possible otherwise and one of the bases recently shared they know they **prevented a suicide due to the metrics we generate, so there is no more valuable indicator of ROI.**

Department of War SBIR/STTR portfolio company.

iNFixion Bioscience, Inc., San Diego, CA

Herb Sarnoff, MBA

CEO

iNFixion Bioscience, Inc.



iNFixion Bioscience received a great score on a recent SBIR grant application, but that grant is now on hold due to the lack of re-authorization. **Our company, including all previous SBIR investments, is now at risk of collapse due to the current situation.** We are just one of hundreds of entrepreneurial companies researching rare diseases.

Without this federal funding support, this research simply will not be done, and hope will disappear for many suffering with rare genetic disorders. Please reauthorize the SBIR quickly, before it's too late.

National Institutes of Health SBIR/STTR portfolio company.

Integrated Medical Sensors Inc., Irvine, CA

Muhammad Mujeeb-U-Rahman, Ph.D.

CEO

Integrated Medical Sensors Inc.



Integrated Medical Sensors (IMS) has experienced significant delays in multiple SBIR/STTR awards due to the lapse in program authorization. This uncertainty is creating immediate operational and financial strain: we need to sign a new lease to continue scaling our U.S.-based R&D, but we cannot responsibly commit without clarity on when delayed funds will be released. IMS has developed U.S.-engineered technology gaining traction with key U.S. market leaders, and we need timely SBIR/STTR support to meet partner timelines and maintain momentum. **The SBIR program has been instrumental to our progress, and delayed reauthorization risks slowing commercialization, hiring, and continued U.S. innovation just as demand is rising.**

National Institutes of Health SBIR/STTR portfolio company.

Interacta Bio, San Diego, CA

Ravi Ramenani

CEO

Interacta Bio



The SBIR lapse is freezing a core early-stage funding path for startups like Interacta. Since the authority expired October 1, 2025, agencies have paused new solicitations and awards, and NIH has said it cannot issue noncompeting continuation awards until reauthorization. NSF has also paused new SBIR/STTR project pitch submissions. **This creates sudden cash-flow gaps, forces hiring freezes or layoffs, and delays experiments that must run on biological timelines.** It also chills matching private capital because investors treat SBIR as hard validation. **Reauthorizing now restores predictable runway, keeps talent in the U.S., and speeds translation from lab to jobs and patients.**

Intelligent Fiber Optic Systems Corporation, Fremont, CA

Behzad Moslehi, Ph.D.

CEO/CTO

Intelligent Fiber Optic Systems Corporation



Created **financial hardships** in payroll, paying rent, utilities, vendors/suppliers.

Department of War, National Institute of Food and Agriculture, Department of Energy, National Air and Space Administration, and United States Department of Agriculture SBIR/STTR portfolio company.

Intellisense Systems, Inc., Torrance, CA

Shilpa Pradhan

Vice President Emerging Technologies

Intellisense Systems, Inc.



Our company is heavily involved in SBIR and without the reauthorization it's **impacting all of us financially** as now new contract has been started and we need to cut down on the resources.

Department of War SBIR/STTR portfolio company.

Intrinsic Powers, Inc., Santa Rosa, CA

Alexander Koch, MBA

CFO

Intrinsic Powers, Inc.



Without renewal of SBIR/STTR funding in 2026, we will be unable to expand much-needed headcount in this crucial year for our company (our consciousness-detection prototype is set to launch in June). Further, **lack of funds will severely limit our ability to run early-stage clinical studies, putting our company at a severe disadvantage on the regulatory and private capital fronts.**

Invasive Species Corporation, Davis, CA

Pamela Marrone, Ph.D.

Executive Chair, Co-Founder
Invasive Species Corporation



Several agbiotech startups I advise are using the SBIR money to get enough data to derisk to make the company fundable by VCs. **Without SBIR monies there will be job losses and company closures leading to lack of innovation in our field.**

iSono Health Inc., San Francisco, CA

Neda Razavi, MBA

CEO, Chairwoman
iSono Health Inc.



We are developing a low-cost robotic + AI breast imaging system designed to bring accurate cancer detection to clinics that lack specialty imaging staff—especially in rural and underserved areas. **The lapse in SBIR/STTR funding has directly delayed our clinical validation work**, forcing us to pause site readiness, reduce engineering and clinical support capacity, and postpone data collection needed to demonstrate real-world performance. Operationally, this slows timelines for deploying to additional care settings; financially, it stretches limited resources and increases uncertainty for partners and collaborators. Ultimately, **delayed reauthorization delays access for patients who would benefit most from earlier detection and fewer missed cancers.**

Shadi Saberi
Founder, CTO
iSono Health Inc.



We are a women-owned small business medical device company. Our R&D work has been funded by NSF SBIR which resulted in our FDA 510(k) clearance. Now we are working with NIH SBIR funding for our pivotal clinical study and commercialization. **SBIR funding and support has been instrumental for our success and reaching milestone.**

National Science Foundation and National Institutes of Health SBIR/STTR portfolio company.

Janus Pharmaceutical Consulting LLC, Sunnyvale, CA

Jan Scicinski, Ph.D., FRSC, CChem
CEO
Janus Pharmaceutical Consulting LLC



SBIR funding is key to the development of commercial ideas outside of academia for new therapeutics. An example is the development of Live Bacterial Products at Rise Therapeutics. **Without SBIR funding clinical proof of concept would not have been possible.**

JB HealthTech, Inc., Rancho Santa Margarita, CA

Sharon Wang, PharmD, MS

President

JB HealthTech, Inc.



Our company, JB Health, is developing a blood pressure monitoring system for critically ill infants. This work has been supported by the SBIR program through the National Institutes of Health. The technology is highly complex, and because neonates represent a very small market, large companies have been unwilling to invest in its development. As a result, it is deeply concerning that routine blood pressure measurement for the most vulnerable and precious patients remains inaccurate, impractical, or even potentially dangerous. **Without programs such as SBIR, innovations that address these critical unmet medical needs are unlikely to reach patients.**

National Institutes of Health SBIR/STTR portfolio company.

Judith Campbell, Ph.D., Pasadena, CA

Judith Campbell, Ph.D.

Professor of Biology and Chemistry

California Institute of Technology



We have discovered that the mitochondrial functions of the DNA2 helicase/nuclease that we discovered are inhibited by our DNA2 small molecule inhibitors and that these inhibitors completely inhibit CRC tumor growth with low or toxicity. We have therefore cured a form of human CRC. Examining large cohorts of mitochondrial defective CRC tumors available to our clinical collaborators, we show that DNA2 inhibitors stimulate the immune-checkpoint blockade making CRC tumors susceptible to ICI inhibitors for the first time. Importantly, microsatellite stable CRC (90%) become sensitive to ICI blockade. **Clinical collaborations promise an acceleration of commercialization of the DNA2 inhibitors but require immediate renewed funding for proof of principle experiments and IND approval.**

Karamedica, Inc., San Diego, CA

Eric Gosink, Ph.D.
Sr. VP, Corporate Strategy
Karamedica, Inc.

Our operational staff have been let go and management is unpaid.

National Institutes of Health portfolio company.



Malcova, Inc., Berkeley, CA

Peymon Ghazi, Ph.D.
CEO
Malcova, Inc.

The SBIR programs—the funding they provide and the credibility that comes with securing them—**have been essential to the research and development of our groundbreaking radiology technology.** Because of this program, we have been able to transition from R&D to the clinical phase of breast cancer imaging. This life-saving technology aims to address breast cancer detection in women with dense breast tissue, which is arguably the largest unsolved problem in radiology. We encourage Congress to continue appropriating funds for the SBIR programs so that we can continue on this path.



National Science Foundation and National Institutes of Health SBIR/STTR portfolio company.

Mark Therapeutics, Inc., Los Angeles, CA

Victoria Bolotina, Ph.D.

President and CSO

Mark Therapeutics, Inc.



The lapse in SBIR program is stalling preclinical studies/trials of the highly anticipated gene therapy for Parkinson's disease developed by Mark Therapeutics and supported by NINDS. This first-in-kind therapy can stop progression of devastating Parkinson's disease in millions of aging patients that currently have no cure or disease-modifying treatment. **Continuity in SBIR funding is vital for bringing advanced cure to Parkinson's patients!**

National Institutes of Health SBIR/STTR portfolio company.

MAX BioPharma Inc., Los Angeles, CA

Farhad Parhami, Ph.D., MBA

Founder, President, and CEO

MAX BioPharma Inc.



Because of support received from the NIH SBIR program, since becoming operational in 2014, we have been able to: 1) develop a new platform of novel therapeutic candidates (now more than 300) for various deadly and debilitating human diseases, 2) establish and support global academic collaborations to evaluate the therapeutic efficacy and safety of our compounds, 3) identify key therapeutic areas as first targets, 4) provide training opportunities for young scientists and entrepreneurs, and 5) create robust intellectual property. **The SBIR support has been critical and fundamental to our success, and its termination will translate into destruction of what we are best at in this country, i.e. innovation in life science and pharmaceutical industries.** Small companies like us provide what large pharma depends on, for the most part, to bring novel medicines to people worldwide. We hope that the program will be reinstated so that this immense edge that we have over all other countries can be preserved and continued. Thank you.

National Institutes of Health SBIR/STTR portfolio company.

Million Marker, Berkeley, CA

Jenna Hua, RD, MPH, Ph.D.

CEO

Million Marker



We are mainly funded by National Institute of Health to work on a product that focus on reducing the public's exposure to harmful environmental chemicals. These chemicals impact majority of chronic diseases, cancer, fertility and children's health. **The lapse in SBIR/STTR funding completely disrupted our progress in conducting crucial research and product development including collaborations with other known research organizations and public entities.** We also lost the opportunities to retain competent employees and hire others.

National Institutes of Health SBIR/STTR portfolio company.

Mittal Consulting, Irvine, CA

Anya Bekhtel, RAPS RCC-MDR

Regulatory Affairs Specialist

Mittal Consulting



I work in regulatory affairs consulting for medical device startups. Many of our clients or would be clients depend on SBIR funding to take their novel medical device to the stage where it can become a viable commercializable product. **Cuts to funding have created a massive bottleneck in this pathway to commercialization** that we will suffer the consequences of in the decades to come.

MobLab, Pasadena, CA

Walter Yuan, Ph.D.

CEO and Founder
MobLab



Although we have not secured SBIR/STTR funding to date, the program has been an **indispensable pillar of early-stage, no-strings-attached capital for lab-to-market innovation**. The current lapse is likely having a chilling effect on planning and execution across hundreds of teams, forcing delays in exploratory R&D and increasing reliance on private capital that often prioritizes near-term returns over foundational innovation. For science-driven companies, SBIR/STTR provides a critical bridge between research and commercialization—one that is difficult to replace and essential to maintaining U.S. leadership across emerging sectors.

Molhill Inc., San Leandro, CA

Brian Mendoza, Ph.D.

CEO
Molhill Inc.



At Molhill, we are developing critical enabling technology for critical mineral refining operations. Our technology boosts the competitiveness of US-based projects. The SBIR/STTR program not only functions as a key source of early funding for us to help mature this technology, but also acts as a market signal for us to secure funding from private investors. SBIR/STTR unequivocally accelerates our path to market, and **time is of the essence in the geopolitical battle for establishing critical mineral supply chains**.

MPM Advisors, Hillsborough, CA

Peggy McLaughlin

Principal

MPM Advisors



I work with very early-stage companies in the medtech space and the pause and uncertainty in grant funding has frozen forward progress for potentially lifesaving treatments and therapies. **This uncertainty affects not only our health but the economic environment of the healthtech community.** Let's be sensible and not whipsaw these hardworking scientists and entrepreneurs who are keep the United States at the forefront of medical innovation.

Muse Engine, Santa Cruz, CA

Benjamin Legum

Director, New Venture Development
University of California Santa Cruz



I am the CEO of Muse Engine, a US-based, early-stage, high-tech manufacturing company for domestic supply chain resiliency. We received a NASA SBIR Phase 1 in 2023 that helped translate our proof of concept to an early prototype.

Without the initial funds we would have never been able to develop this technology. Continued SBIR support would provide the gap funding we need to get a product on the market that would significantly increase US domestic manufacturing capabilities.

National Aeronautics and Space Administration SBIR/STTR portfolio company.

Nahlia Inc, Los Altos, CA

Jayant Menon, MD, MEng

CEO

Nahlia Inc



We have not received our remaining funding due to budget cuts and government layoffs. We are awaiting a decision on a NASA Phase II project with the work paused.

National Aeronautics and Space Administration SBIR/STTR portfolio company.

NANOS, Inc., Loma Linda, CA

Arlin Blood

Co-Founder and Associate Professor
NANOS, Inc.



My biotech startup company is trying to complete proof-of-concept studies for a novel pharmaceutical therapy for angina, diabetic foot ulcers, glaucoma, and congestive heart failure. We have one STTR already and would have submitted another one last week if the mechanism had been reauthorized.

Without the STTR mechanism we will be severely restricted by lack of funding.

National Institutes of Health SBIR/STTR portfolio company.

Neuronics Medical, Los Angeles, CA

Radoslav Raychev, MD, FAHA, FSVIN

CEO

Neuronics Medical



Our organization is a small, clinician-led medical technology startup developing AI-based tools to improve early stroke detection and triage. **The lapse in SBIR/STTR funding has had a significant operational impact, delaying critical R&D milestones, slowing hiring of engineering staff, and forcing us to defer planned clinical validation activities.** SBIR funding is not supplemental for companies like ours—it is foundational. Prolonged uncertainty disrupts innovation timelines, increases financial risk, and ultimately delays patient access to life-saving technologies. **Timely reauthorization is essential to sustain early-stage biomedical innovation.**

Nigel Calcutt, La Jolla, CA

Nigel Calcutt, Ph.D.

Professor

University of California San Diego



My laboratory uses the SBIR/STTR program to assist multiple early-stage biotechnology companies in developing new therapies for nerve damage and pain caused by diabetes, or as a side effect of chemotherapy. **The inability to receive, or indeed apply for, new SBIR/STTR funding means that I will have to lay off highly experienced technical staff by summer 2026.** Losing the unique skill sets of my staff will jeopardize the capacity for my laboratory to undertake such collaborations with small businesses in 2026 and beyond. **Loss of such expertise will impede the emergence of new treatments for common, yet currently untreatable, conditions that afflict millions of Americans daily and stifle the success of the currently dominant, but threatened, US biotechnology industry.**

Novoron Bioscience, San Diego, CA

Shawn Gahr, MIA

COO, Co-Founder

Novoron Bioscience



Without initial funding from the SBIR/STTR program to get our company off the ground at the discovery stage, we would not exist. This seed money allowed us to advance and de-risk our science to the point where we were attractive to invest in by the VC community.

National Institutes of Health SBIR/STTR portfolio company.

Nura Health, Los Angeles, CA

Varun Kapoor, MD

Founder & CEO

Nura Health



We have a pending SBIR grant paused in review due to the impact on the SBIR program. We are building innovations for endometriosis that are needed to be fast-tracked to market to accelerate solutions for 7 million American women today. Endometriosis is a debilitating disease that has received little historical funding and requires significant diagnostic and therapeutic transformation, which the SBIR program serves to propel through translational R&D. **The SBIR program is critical for companies, millions of patients, communities, clinicians, and health systems to receive the needed support for an unsolved high-prevalence disease that has historically lacked funding and research.**

Onyx Spectrum Technology, Inc., Lompoc, CA

Stephen Scopatz, MSEng

CTO, Principal Engineer

Onyx Spectrum Technology, Inc.



We are a small business that benefited from having research funds granted through the SBIR program. We provided a demonstration for counterfeit detection for US Customs. As a small but innovative group of engineers, we would like to have the opportunity to solve other problems that could lead to new products and solutions. **Without the SBIR program, technology advances are going to be coming more slowly or coming from other countries.** This is a relatively small investment to maintain the country's technological edge.

Department of Homeland Security SBIR/STTR portfolio company.

Opal AI Inc., Los Angeles, CA

Ryan Alimo, Ph.D.

CEO

Opal AI Inc.



We were selected for a USDOT SBIR Phase II award to advance our 'Complete Streets' innovation, but the funding lapse has been catastrophic. As a small business, we lack the reserves to survive indefinite delays. We have already been forced to lay off the specialized workforce we spent years assembling, and we are now on the brink of closing our doors entirely. **This delay is not just a pause; it is actively dismantling the very innovation capacity the government seeks to foster. We need immediate action to survive.**

National Science Foundation and National Aeronautics and Space Administration SBIR/STTR portfolio company.

Oro Therapeutics, Sausalito, CA

Matt Smith, MBA

CEO, Co-Founder
Oro Therapeutics



I am CEO and co-founder of a preclinical oncology biotech company focused on developing a treatment for retinoblastoma, a cancer that affects newborns. As part of my funding efforts I rely on the SBIR grants to fund my preclinical development activities. Please reinstate the program.

Pacific Optica, Santa Barbara, CA

Spencer LaVere Smith, Ph.D.

CEO
Pacific Optica



We're a new company. Set up in 2023, and in 2024 we had a highly successful Phase 1 grant-- nailed every milestone and went beyond. Now we have a reviewed Phase 2 grant application that is all set for funding and has been in limbo for months. It slows our hiring and innovation. We're trying to grow as quickly as possible, and the lapse in SBIR means that we cannot hire, grow, and innovate like we were doing in 2024 and early 2025. We did what we were supposed to do, and having the rug pulled like this is highly disruptive. Moreover, as a lifelong American taxpayer, I'm frustrated that so much potential is being wasted by this lapse. I understand that there is room for improving SBIR policy, but this lapse is massively destructive. **The policy concerns, at best, will never balance out the damage done by this lapse. It is irresponsible governance and legislation. Figure out a way forward without trashing the whole program, which everyone agrees is a massive engine for US innovation and economic growth. Let us get back to work driving US innovation through small business development.**

Ryan McGreal, MS

COO
Pacific Optica



Without additional support via STTR/SBIR grants, businesses here cannot out-innovate the world, like we have for decades.

National Institutes of Health SBIR/STTR portfolio company.


Powell Development Group, Inc., Torrence, CA

Charles Powell

Founder & CEO

Powell Development Group, Inc.

The recent shut down has delayed grant application review. This has pushed back timelines for potential start dates and the receipt of funds needed to complete important clinical research. **Early-stage funding for companies like ours is critical to de risking early-stage innovation and setting up a pathway to commercialization.**



Pyra Bio, Inc., San Rafael, CA

Gouri Yogalingam, Ph.D.

CEO, Founder

Pyra Bio, Inc.

I have no funding yet and was hoping to be awarded an SBIR to develop a drug for Alzheimer's disease in women.



Pyrois Nanotechnology, Inc., Scotts Valley, CA

Cara Beasley

CEO

Pyrois Nanotechnology, Inc.

I'm unable to hire anyone to help accelerate my technology until I can apply for an SBIR grant. I submitted a project pitch in early September 2025 and have not received feedback. Given the timelines it may be a year or more from planning on applying to getting funding, if my proposal is accepted. **This is devastating for early stage startups.**



Quantum Applied Science & Research, Inc., San Diego, CA

Gayle Guy

Proposal Manager

Quantum Applied Science & Research, Inc.



We have a Phase I Air Force proposal that's been selected for contract negotiation but hadn't been funded yet before lapse and one project that is between Phase I and Phase II with no way to submit the Phase II proposal. Our sister company has three Navy Phase II proposals submitted but not yet assessed. **Our businesses need the SBIR program to back to continue this research the government wanted done.**

Department of War, National Aeronautics and Space Administration, and National Institutes of Health SBIR/STTR portfolio company.

RadiaBeam Technologies LLC, Los Angeles, CA

Alex Murokh, Ph.D.

CEO

RadiaBeam Technologies LLC



RadiaBeam is a leading vertically integrated deep-tech US manufacturing business in the field of advanced accelerator technology and light sources. We are most grateful to the SBIR/STTR program, which support was instrumental to our success. **For us SBIR/STTR was a unique tool to organically align a product line roadmap to the real life needs of the broader scientific and industrial communities, and we are not aware of any other active programs to replace it.** Thus, it is most unfortunate that this program has lapsed, and we urge lawmakers to reauthorize it.

Rebecca Chinn, *La Jolla, CA*

Rebecca Chinn

NSF Graduate Research Fellow
University of California San Diego

The principal investigator that I worked under had plans to apply for an SBIR. He and the main researcher have a proposal to treat severe atopic dermatitis and need these funds to help translate their research into a clinical therapy.



Ribo-Therapeutics LLC, *San Diego, CA*

Prashant Khade, Ph.D.

President
Ribo-Therapeutics LLC

For over 40 years, the SBIR program—America's Seed Fund—has been the primary engine for high-risk, high-reward technological development. Today, that engine is stalled, and the consequences are severe: Losing the Global Tech Race, National Security Vulnerability, The Innovation Brain Drain etc.

Promising startups are being forced to lay off top scientists and ideas.



National Institutes of Health SBIR/STTR portfolio company.

Rio Pharmaceuticals, *San Francisco, CA*

John Forsayeth, Ph.D.

Executive Chair
Rio Pharmaceuticals

My company depends on access to federal funds. Keeping America innovation strong is essential to economic growth. **China is outstripping us because we are not defending the very source of technological strength: Our pre-eminent scientists.**



National Institutes of Health SBIR/STTR portfolio company.

Rowland Robert Reeves, Sacramento, CA

Rowland Reeves

Founder and CEO
US Space

Our New Advanced Rocket Engine would not have been built and tested without an NSF SBIR Phase I Grant. Such an invention is far too risky for regular investors.



National Science Foundation SBIR/STTR portfolio company.

Richard Schneeberger, San Diego, CA

Richard Schneeberger

Director, Innovation Partnerships
Salk Institute for Biological Studies




As a young entrepreneur I teamed up with a university professor to submit an NIH SBIR grant for detecting biological molecules involved in many aspects of human health and disease. We were fortunate to receive a direct to Phase II grant that enabled the company to complete proof of concept studies and build a vibrant biotechnology company that employs over 40 scientists and business people. **Without this funding the foundational university ideas and intellectual property licensed by the company would have died on the vine.** Please reauthorize this vital funding mechanism for US innovation!

Samay, Inc., Mountain View, CA

Maria Artunduaga, MD, MPH

CEO
Samay, Inc.



COPD kills one American every four minutes, affecting 16 million people and costing healthcare \$50 billion annually—projected to reach \$800 billion over 20 years. Sylvee detects COPD and catches exacerbations from home with high accuracy, giving patients lung visibility before crisis strikes. Early detection prevents hospitalizations and saves lives. NSF SBIR and NIH STTR grants funded our clinical validation and earned us the 2024 MedTech Innovator Global Prize. We're now waiting for Phase II funding to finalize the product and launch. **Private**

capital won't invest without commercial traction—a catch-22 that only government support can break. With COPD being one of America's most expensive and prevalent public health crises, government funding is imperative to bring this life-saving technology to market.

National Science Foundation and National Institutes of Health SBIR/STTR portfolio company.

Scaling Care, San Francisco, CA

Lauren Taylor
General Partner
Scaling Care



I am an investor in early stage health and bio. The companies we invest in rely on SBIR to complete clinical trials and pilots, generate data, and conduct the research that brings innovation to market, eventually saving lives. **We can't fund the sector without the government's support, and the United States needs this science to maintain our edge worldwide.** Thank you for your support!

SixPoint Materials, Inc., Buellton, CA

Tadao Hashimoto, Ph.D., MBA
CEO
SixPoint Materials, Inc.



SBIR/STTR program is the vital key mechanism for innovation and commercialization. SixPoint successfully developed one of our product through DOE SBIR Phase I, II, IIB, and IIC. **Without this program, my company has shut down and let the foreign counterpart to lead the technology.**

Department of Energy, Department of War, and National Science Foundation SBIR/STTR portfolio company.

Skylar Consulting, Pasadena, CA

Evan Tseng

Managing Partner
Skylar Consulting



I have watched space, biotech, energy, and military startups create jobs and new technology that helped the US maintain its lead in key technologies for the future. **This is key to competitiveness when corporations will not take the risks needed to bring risky new technologies to the market.**

SonALAsense, Inc., San Carlos, CA

Mark de Souza, Ph.D.

President and CEO
SonALAsense, Inc.



Our company used funds from 2 SBIR grants from NCI to demonstrate safety and efficacy of sonodynamic therapy (our noninvasive drug device combination) in two clinical trials of aggressive brain cancer tumors. There were no significant side effects. We applied for SBIR grants to expand our platform technology to bladder cancer and colorectal cancer but these are on hold. **Re-authorizing the SBIR program will bring a much needed noninvasive technology to cancer patients in need and continue to support our employees and consultants to innovate.**

National Institutes of Health SBIR/STTR portfolio company.

Spectral Labs Incorporated, San Diego, CA

Eric Ackermann

CEO

Spectral Labs Incorporated



SBIR dollars are a key source of funding for our R&D staff. Their work feeds our design engineering department which designs the products that we then manufacture for the Warfighter. **The diminished SBIR activity throughout 2025 and the current complete lapse in SBIR threatens the employment of R&D staff and the entire product development pipeline.**

Department of War SBIR/STTR portfolio company.

Spectral Therapeutics, San Diego, CA

Alexander Price, Ph.D.

CTO

Spectral Therapeutics



In a time when private venture funding into Biotech startups is scarce, the SBIR/STTR programs are crucial. We have a possible award that is being held up until reauthorization passes. With limited runway, **our company will close without those funds, and we will have to layoff all of our employees.** Furthermore, a very innovative idea that has the power to transform therapeutics will die on the vine. **Please keep America competitive in the sciences, otherwise we will continue to lose ground to the rest of the world.**

Stellar Engiine, Los Altos, CA

Babak Adibi, Ph.D.

President

Stellar Engiine



Stellar Engiine

Our initial SBIR has moved us to successful completion of C&F stage for remediation of semi equipment effluent. We have 3 months funding; our phase II applications is waiting that will commercialize our product within a year.

National Science Foundation SBIR/STTR portfolio company.

SunnyBay Biotech Inc., *Fremont, CA*

Feng Wang-Johanning, MD

CEO & Founder

SunnyBay Biotech Inc.



SunnyBay Biotech is focused on cancer research and developments of immunotherapies. One of our drugs is ready for first in human trials which costs more than 10 MM. It is very difficult to raise 10 MM directly. SBIR will be a good resource to help us to do some preclinical study before we are ready to do a Phase I clinical trial.

Symmetry Wood, *Los Angeles, CA*

Tim Keating

Co-Founder and Chief Sustainability Officer

Symmetry Wood



Symmetry Wood has taken the longer view for a startup company: our ideal is to be able to innovate in sustainable manufacturing within the U.S., without losing control of the company's mission. We've succeeded in an early SBIR Phase I award and have applied for a Phase II — for which we have a good chance of success — in order to further the innovation of our circular material, to create local jobs and outcompete imports. But the SBIR program suspension is leading the business further into debt, month by month. **We respectfully request that Congress reauthorize the SBIR/STTR program as soon as possible, so that U.S. companies can continue to innovate and compete, growing small businesses and jobs in the U.S.**

Environmental Protection Agency SBIR/STTR portfolio company.

The Provenance Chain Network, Vista, CA

Charlie McGillis

Vice President, Public Sector
The Provenance Chain Network




PCN is impacted by 2 opportunities (Navy and NIST). We are completing our Phase 1 with SSP and unless reauthorized will not have the opportunity for a Phase 2. Additionally, PCN was 1 of 17 small businesses awarded a NIST CHIPS SBIR Phase I & 2. None of the small businesses have been awarded a Phase 2 despite Phase II support to the leadership. Reauthorization delays halted funding, forcing IRAD sustainment and pushing delivery of this critical national security capability back 6–12 months.

National Institute of Standards and Technology and Department of War SBIR/STTR portfolio company.

Transition Biomining, San Francisco, CA

Aleksandr Milshteyn, Ph.D.

CEO
Transition Biomining



As a founder of an early stage startup working to sustainably unlock vast copper resources needed to drive the energy transition, I have been holding off on applying for SBIR/STTR funding because I cannot justify the time without the knowledge that the program is funded. This means additional financial risk and slower technology development timeline for my company.

Vala Sciences, Inc., San Diego, CA

Kara L Gordon, Ph.D.

Director of Neurobiology
Vala Sciences, Inc.



Our company has been receiving SBIR funding, with which we are building New Approach Methodologies (NAMs) for drug discovery, cardio and neuro safety, and efficacy. **With the lapse in SBIR funding, we are facing a financial shortfall in just a few months.** If we need to reduce our work

force, we would lay off key scientists developing these NAMs models that will allow pharma customers to reduce animal use in drug discovery and safety testing, halting our progress.

National Institutes of Health SBIR/STTR portfolio company.

Verpond, Inc., Carlsbad, CA

Stuart Bussell, Ph.D.

President

Verpond, Inc.



SBIR funding is an important component for Verpond's high risk/high reward project. **SBIR funds are the best way for our company to advance its high impact supplemental food, animal feeds, fertilizers, and fuels project that aims to improve supplies of critical raw materials for food producers like small farmers to make their operations more economical.** Disruptions to the program threaten the project's progress, and hence, the economic viability of the businesses we are working to help.

National Science Foundation SBIR/STTR portfolio company.

WUI-Go!, San Rafael, CA

Sarah Lindbergh, Ph.D.

CEO

WUI-Go!



WUI-Go! is an NSF SBIR-funded startup developing AI-driven digital twins to improve wildfire evacuation planning and real-time response—technology directly tied to preventing loss of life in high-risk U.S. communities. **The lapse in SBIR/STTR authorization has introduced serious uncertainty, forcing delays in hiring, slowing time-critical R&D, and putting skilled technical jobs at risk.** For small companies working at the frontier of public safety innovation, funding gaps don't just stall progress—they threaten America's leadership in life-saving technologies. At a time when wildfire risks are escalating nationwide, delayed reauthorization risks lost jobs, lost innovation, and ultimately, lost lives.

National Science Foundation SBIR/STTR portfolio company.

XCellAssay, Inc, San Francisco, CA

Fred Schaufele, Ph.D.

CEO

XCellAssay, Inc



XCellAssay has developed, with SBIR funding, novel methods of detecting exposures to health altering chemicals in you and your surroundings that are affordable to the average citizen.

SBIRs uniquely foster combining technical advances within the constraints of the marketplace to enable new products engineered for broad societal use.

National Institutes of Health SBIR/STTR portfolio company.

Colorado

Economic Impact of Program:

SBIR/STTR Funds Received: **\$3,475,281,599.71**

Small Business SBIR/STTR Awards: **9,921**

Letter to Congress Co-signers

Michael Duckwitz	CEO	Abrux
Floyd Taub, MD	CEO	aiGENE
Eric Distad	Founder and Lead Consultant	Anchor Point Clinical Consulting
Marjori Langhoff	Controller	Barn Owl Tech, Inc.
Caitlyn Tivy, PT, DPT	Consultant	C Tivy Consulting and Cervu Health
Adam Salyers	CEO	
Sheana Bull, Ph.D., MPH	President and Co-Founder	Clinic Chat
Kristen Morris, Ph.D.	Associate Professor	Colorado State University
Pat Nicholson	iCEO	CSU Strata Lab 2 Life
Mohammad Mahoor, Ph.D.	President and CEO	DreamFace Technologies, LLC
Robert Witkow	CEO	Emet Surgical, Inc.
Pieter de Waal	CMO	Insight Systems Security, Inc.
Brenda Armstrong	Founder and Advisor	ITEOM, LLC
Prof. Henry C. Kapteyn	CTO and Professor	KMLabs, Inc. and University of Colorado
Jim Pollock	CEO and Co-Founder	LumenAstra, Inc.
Fernando Gonzalez del Cueto, Ph.D.	CTO	Lumos Imaging
Ward Shalash, Ph.D.	Engineer	Mighty Oak Medical
Colin Bell	iCEO	Nitrocat Energies
Andrew Maertens, MD	CEO and Founder	OrthoBarrier Technologies
Heather Potters	Co-Founder, EVP, and Board Member	PharmaJet, Inc.
David Kitzenberg, MD, Ph.D.	Founder and CEO	Primer Pharmaceuticals Corp

Brendan Purcell	CEO and Founder	Prohibix
Andrew Hendrickson	CEO	Revalix Labs
Adrienne Delluva, Ph.D.	Senior Engineer	TDA Research, Inc.
Jeanne Barthold, Ph.D.	COO and Co-Founder	TissueForm, Inc.
Rex Martin, Ph.D.	Consultant	Warrior Resources, LLC
Anand Shukla	CEO	Witii Pharmaceuticals, Inc.

Selected Case Studies from Impacted Companies:

Anchor Point Clinical Consulting, Durango, CO

Eric Distad

Founder & Lead Consultant
Anchor Point Clinical Consulting



Due to confidentiality agreements, I am not able to name companies, but as a consultant to early-phase biotech companies, **I have seen firsthand the impact this has had on the development of novel therapies for complex CNS disorders.** The loss of this funding is risking further development of these therapies (3 companies that I work with) that aim to serve, in many cases, patients with little to no current therapeutic options.

C Tivy Consulting & Cervu Health, Denver, CO

Caitlyn Tivy, PT, DPT

Founder and President
C Tivy Consulting & Cervu Health



I have previously served as a principal investigator on an SBIR study that lead to validation of a novel tool for the management of chronic pelvic pain in female cancer survivors. Another SBIR study to which I'm contributing is on hold due to the **authorization lapse, impacting the development of life-changing care tools for those living with endometriosis.**

National Institutes of Health SBIR/STTR portfolio researcher.

Clinic Chat, LLC, Denver, CO

Adam Salyers

CEO

Clinic Chat, LLC



STTR has allowed us the necessary tools to develop real world use cases

for AI in promoting and increasing healthy behaviors for Americans, making them healthier for a far cheaper cost than other alternatives. We have now completed our product and are actively selling but with the STTR lapse, we may not be able to continue development. **This will affect five full time positions in Colorado, four in Texas, and will delay patient access to an important tool with high likelihood to efficiently impact the ongoing opioid crisis.** It will also reduce anticipated funding that small behavioral health organizations rely on to offer effective treatment for substance use disorders.

Sheana Bull, Ph.D., MPH

President, Co-Founder

Clinic Chat, LLC

The review of our September 5 submission for a Phase II STTR application was postponed two months because of the government shut down; **a further delay in reauthorization means even when funded, we cannot access funds.**

National Institutes of Health SBIR/STTR portfolio researcher.

KMLabs, Boulder, CO

Henry C. Kapteyn, Ph.D.

CTO

KMLabs

We are waiting to finalize an SBIR award on technologies critical for hypersonics R&D.



LumenAstra, Inc. P, and Board Member, *Boulder, CO*

Jim Pollock

CEO and Co-Founder
LumenAstra, Inc.



We are an early-stage spinout from Univ of Colorado with the first non-invasive sensor called of measuring brain temperature. This will save lives in cardiac surgery, ICU-trauma care and provide early warning of heat stroke for warfighters and firefighters. Our technology is challenging and too risky for venture funds. We have used SBIRs from the NSF and USARMY to derisk our technology. **We have been on hold with a follow-on NIH SBIR application that would carry us to commercialization. This is critical to reach the point where we can raise venture funds.**

National Science Foundation and Department of War SBIR/STTR portfolio researcher.

Lumos Imaging, Denver, CO

Fernando Gonzalez del Cueto, Ph.D.

CTO
Lumos Imaging



Thanks to NASA SBIR Phase I, we developed technology with vast applications across multiple industries—from aerospace to domestic manufacturing. **While our Phase I results were exceptional, the lapse in SBIR/STTR authority prevents us from securing follow-on funding to scale. This legislative delay effectively freezes the R&D cycle, preventing breakthrough innovations from reaching the market where they could drive economic growth. To maintain America's competitive edge in global tech, Congress must reauthorize these programs and provide the stability small businesses need to innovate.**

National Aeronautics and Space Administration SBIR/STTR portfolio company.

Pat Nicholson, *Fort Collins, CO*

Pat Nicholson
iCEO

The private sector will not provide sufficient funding for early stage research. The longer this lapse in funding continue, it has real impacts on the health and economic wellbeing of individuals and society more broadly.



PharmaJet, Inc., *Golden, CO*

Heather Potters
Co-Founder, EVP, and Board Member
PharmaJet, Inc.



We have relied on various grants over time to advance our technology. At an early stage, our SBIR support was essential, before any prospective outside investors would consider our technology to be viable. **This small program has a massive impact on innovation, and follow-on funding opportunities which both a company and investor can benefit from**, given the risk-mitigation facilitated by SBIR/STTR funding.

National Institutes of Health SBIR/STTR portfolio researcher.

Prohibix, *Boulder, CO*

Brendan Purcell
CEO/Founder
Prohibix



The SBIR programs are essential to translating new technologies to the marketplace and as such are a catalyst for our economy. **Reauthorizing is a no-brainer.**

National Institutes of Health SBIR/STTR portfolio company.

TissueForm, Inc., *Boulder, CO*

Jeanne Barthold, Ph.D.

COO and Founder

TissueForm, Inc.



We are stalled in moving forward as our NSF Phase I grant is complete and we are not able to apply for Phase II. Institutional Investors are excited about what we are doing but need our technology more derisked (further down the FDA pathway) before investing. The only dollars suited for this gap are SBIR dollars and therefore **without this program we are stuck, unable to grow or hire until it is reauthorized.**

National Science Foundation SBIR/STTR portfolio researcher.

Connecticut

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,064,850,625.06**

Small Business SBIR/STTR Awards: **3,382**

Letter to Congress Co-signers

William Korinek, Ph.D.	CEO	Astrocyte Pharmaceuticals
Raymond Dattwyler	President and CEO	Biopeptides, Corp.
Rebecca Turk MacLeod, Ph.D.	Director of Technology	CellsBin, Inc.
Emmanuel Eroume A. Egome, MD, Ph.D.	CEO	Centre D'Innovation Et De Commercialisation En Recherche Clinique Et Bio-Médicale Immânow'EL'/CIEL, Inc.
Max Xianyong Ma	Founder and CEO	EpigenoMax Therapeutics
Esteban Edward Mena	President	LiPharms, LLC
Carla Devillers, MBA	CEO	Luna Bioscience, Inc.
Xiuling Lu, Ph.D.	CSO	Nami Therapeutics
Tom Wenchell	CEO	RevMedica
Violet Aldaia	Founder and CEO	Sentai Health Solutions
Ludwig Lipp, Ph.D.	Vice President and Co-Founder	T2M Global
Jessica Regan, Ph.D.	Scientific Director	Virtus Therapeutics
Yulia Surovtseva, Ph.D.	Director	Yale Center for Molecular Discovery, Yale University School of Medicine
Joseph Michael Vinetz, MD	Professor of Medicine and Co- founder	Yale School of Medicine and Luna Bioscience
Igor Yukov, Ph.D.	President and Principal Investigator	Yukov Scientific, LLC

Selected Case Studies from Impacted Companies:

Biopeptides Corp, Ridgefield, CT

Raymond Dattwyler

President and CEO

Biopeptides Corp

Biopeptides Corp, in collaboration with UCLA, has developed highly innovative diagnostic technologies for the diagnosis of Lyme disease and other tick-borne infectious diseases with funding from the SBIR program. This technology was discussed in the recent NIH panel on Lyme disease. **The lapse in funding will have a significant impact on our ability to bring these advances to the public, as this effort is very dependent on SBIR funding.**



National Institutes of Health SBIR/STTR portfolio company.

Joseph Michael Vinetz, New Haven, CT

Joseph Michael Vinetz, MD, FACP, FIDSA, FASTMH

Professor of Medicine

Yale School of Medicine and Luna Bioscience

The STTR program is an essential way to apply fundamental discoveries to problems faced by American priorities, such as protecting the American war fighter, protecting our citizens from infectious diseases.



National Institutes of Health SBIR/STTR portfolio company.

LifePharms, LLC, New London, CT

Esteban Edward Mena

President

LifePharms, LLC



LifePharms is unable to pay its collaborators or our electric bill.

In addition, the project is seriously behind. Our project is to optimize an antifungal treatment that is also a treatment for the drug resistant pathogen *Candida auris* that has recently been identified in Connecticut.

National Institutes of Health SBIR/STTR portfolio company.

Luna Bioscience, Westport, CT

Carla Devillers, MBA

CEO

Luna Bioscience, Inc.



We are stopped in our tracks from carrying out experiments to be funded by STTR grants that are in the final steps of being authorized/funded. These grants are for the development of diagnostics and **vaccines that the DOW/DOD wants for infectious diseases near the top of the U.S. military's infectious diseases threats list** that can seriously affect the U.S. warfighter in tropical regions such as Central and South America.

National Science Foundation SBIR/STTR portfolio researcher.

RevMedica, Middletown CT

Tom Wenchell

CEO

Revmedica



We had a good score last year but the delay and budget cuts knocked us out of the pay scale. We've grown from 2 engineers to 13 and will hit the market this year. **NIH funding is critical for R&D growth.**

National Institutes of Health SBIR/STTR portfolio researcher.

Virtus Therapeutics, Groton, CT

Jessica Regan, Ph.D.

Scientific Director

Virtus Therapeutics Corporation



Due to the lapse in SBIR funding, our small startup company has to close its doors. Our company is developing a therapy for a rare pediatric neurodegenerative disease which has no treatment option. **Due to this lapse in funding, we do not have the chance to advance our program to provide children a therapeutic option to relieve symptoms, improve quality of life, and extend their lives well past adolescence.**

National Institutes of Health SBIR/STTR portfolio researcher.

Yukov Scientific, Orange, CT

Igor Yukov, Ph.D.

President & Principal investigator
Yukov Scientific, LLC.



YUKOV SCIENTIFIC

As founder of Yukov Scientific LLC, I am outraged by the recent SBIR/STTR grant cancellations. Our Yukov Method is a de novo ultrasound diagnostic that outperforms MRI and eliminates many invasive biopsies for breast cancer patients. **Despite successful clinical trials, these government cancellations have left my company practically non-functioning.** By stalling our review, the government is blocking a safer, lower-cost, life-saving technology. I urge Congress to provide immediate oversight and restore the review process for these vital innovations. Don't let American medical breakthroughs die in a bureaucratic vacuum.

National Institutes of Health SBIR/STTR portfolio researcher.

Delaware

Economic Impact of Program:

SBIR/STTR Funds Received: **\$352,096,462.90**

Small Business SBIR/STTR Awards: **1,070**

Letter to Congress Co-signers

John W. Gillespie, Jr.	Chief Technology Officer	Composites Automation, LLC
Roger Crane, Ph.D.	Senior Engineer	
Alex Wang	Head of Clinical Development	Einsenca, Inc.
Chris Hawn	President and Founder	Fidere Solutions
Sumedh Surwade, Ph.D.	Founder and CEO	SAS Nanotechnologies, Inc.

Selected Case Studies from Impacted Companies:

SAS Nanotechnologies Inc., Newark, DE

Sumedh Surwade, Ph.D.

Founder and CEO

SAS Nanotechnologies Inc.



The EPA and USDA SBIR funding cut has significantly impacted our research and product development. We are working on a breakthrough technology that will help US farmers produce crops more sustainably with high yield. **The funding cut has slowed down and decelerated our research and development.**

National Science Foundation SBIR/STTR portfolio researcher.

District of Columbia

Economic Impact of Program:

SBIR/STTR Funds Received: **\$218,759,341.07**

Small Business SBIR/STTR Awards: **616**

Letter to Congress Co-signers

Doug Grant	CEO	Atlantic Fish Co
Musa A. Aquil	President	Bedrock Energy Management, LLC
Kevin Cleary	Professor	Childrens National Hospital
Karen Mulhauser	Coordinator	Consulting Women
Liz Powell, ESQ., MPH	Founder and President	G2G Consulting
Joseph W. Ricigliano, JD, Ph.D.	Partner	Hoffmann and Baron, LLP
Nao Gamo, Ph.D.	Founder and CEO	NaoCorp, LLC
Angela B. Stepancic	CEO	Reproductive Village Cryobank
Matt Martensen	Director of Government Services	Two Five

Selected Case Studies from Impacted Companies:

Atlantic Fish Co., Washington, DC

Doug Grant
CEO
Atlantic Fish Co.



The SBIR program supports technical innovation and serves as the gap from idea to venture backed business. **We, and many other startups, would not exist without this program.** Startups should be an easy bipartisan win. Please reauthorize this program immediately.

National Science Foundation and United States Department of Agriculture SBIR/STTR portfolio researcher.

Hoffmann & Baron LLP, *Washington, DC*

Joseph W. Ricigliano J.D., Ph.D.

Partner

Hoffmann & Baron LLP

SBIRs represent a major source of new technology that drives the economy and innovation.



Florida

Economic Impact of Program:

SBIR/STTR Funds Received: **\$2,145,797,522.75**

Small Business SBIR/STTR Awards: **5,822**

Letter to Congress Co-signers

David Steinberg, PharmD, JD	CEO	Algia Pharma
Sidharth Kerkar, MD	Founder and CEO	AllerGene AI Therapeutics
Francisco Marchi, Ph.D.	CEO and Co-Founder	ALMA Genomics, Inc.
Dr. Roxana Belciu-Kerns	CEO	Amarastesia Ltd
Vijayendran Chandran, Ph.D.	Founder and Chief Scientist	AnekaBio, LLC
Renee JG Arnold, PharmD, RPh	President and CEO	Arnold Consultancy and Technology, LLC
Lucinda Camras, Ph.D.	Consultant	Balance Ophthalmics, LIQID Medical, and Neocis
Damon Johnston	President	BC Technical Center, LLC dba BC Engineered Products
Marcos Feijoo	CEO	Blue Physics, LLC
Carolyn Kreuzkamp, MBA	Federal Funding Strategist	C. Kreuz Consulting, LLC
Roland Silverio	Executive Development Advisor	Celdara Medical
Neil Euliano, Ph.D.	President	Convergent Engineering
Xiaohong Wei	CEO	Dioxide Materials, Inc.
Farukh Khambaty, Ph.D.	Consultant	F Khambaty, SP
David Jackson	Retired SBA Director	Fifth Third Bank
Anthony Amadio	Owner	First Dimension Software, LLC
Allan Amir Varshovi	Founder and CEO	GreenTechnologies, LLC
David Mills, Ph.D.	President	Interdisciplinary Consulting Corporation
Delia DeBuc	CEO	iScreen 2 Prevent, LLC
Nicole Kirchhoff, Ph.D.	CEO and Founder	Live Advantage Bait, LLC

Grace B. Arhancet, Ph.D.	President	NanoSUR, LLC
Marty Schultz	President and Co-Founder	ObjectiveEd, Inc.
Sam Owen	CEO	Otolith Labs
Thomas Reilly, MD	CEO	Quantum Nanostim, LLC
Eric Graban, MS	Founder and CEO	QuarryBio, LLC
Billy W. Day, Ph.D.	COO	ReNeuroGen
Dustin Hawley	Executive Director, Commerical	Simbec-Orion
Steven R. Lynch	Founder and CEO	Skyliners Global, Inc.
Benjamin Pearman, Ph.D.	CEO and Founder	SynMatter Co.
Richard Thompson	Consultant	Thompson International Consulting
David E. Martin, PharmD	President and CEO	TrippBio, Inc.
Elizabeth Franzmann, MD	Professor Department of Otolaryngology	University of Miami
W. David Freeman, MD	CEO	VM Robotics, LLC
James V. DiLorenzo	Founder and CEO	WaveArray Antifouling Systems, LLC
Jane Muir, RTTP	Executive Director	Women's Health Innovation Network (WHIN)

Selected Case Studies from Impacted Companies:

AllerGene AI Therapeutics, Miami, FL


Sidharth Kerkar, MD

Founder & CEO

AllerGene AI Therapeutics

Dear Congress,

I am a physician-scientist and trained at the NIH Clinical Center (2006-2015) with some of the world's most respected scientists and Nobel Laureates. I have always viewed the NIH as the Crown Jewel of the United States Government and one of the most prestigious scientific



organizations in the world. The U.S has always led the world in innovation and programs such as the SBIR/STTR are critical to nurturing early startup companies with ambitious goals. I recently founded AllerGene AI Therapeutics, a new cell and gene therapy company with the mission to cure all allergic diseases with a single treatment at the cost of a COVID vaccine. This is not the kind of business plan that is endearing to most large corporations or venture capital investors. We had planned to submit our SBIR grant to NIAID in January 2026. Without this support, our research will not be able to proceed unless our business plan is altered and our mission does not challenge the goals of maximizing profits.

Amarastesia, Ltd., West Palm Beach, FL

Roxana Belciu-Kerns

Founder and Advisor
Amarastesia, Ltd.




We are trying to advance minimally invasive, safe accessible to all women, devices for uterine access, to transform and democratize gynecology. The lack of funding has delayed our project for 3 years now, delaying preventable 50,000 deaths yearly and a total of 2B economic burden, yearly.

AnekaBio LLC, Gainesville, FL

Vijayendran Chandran, Ph.D.

Founder & Chief Scientist
AnekaBio LLC



AnekaBio is a pre-revenue University of Florida spin-out developing a novel therapy for Friedreich's Ataxia, a rare and fatal neurological disease. The SBIR/STTR programs are our primary mechanism to translate NIH-funded discoveries into regulated therapies. The lapse in SBIR/STTR reauthorization has created uncertainty in funding continuity, delayed planning for follow-on milestones, and constrained our ability to retain key personnel and engage CRO/CDMO partners. For rare-disease startups like ours, even short disruptions in SBIR/STTR funding significantly slow therapeutic development and delay potential treatments for patients with no effective options.

National Institutes of Health SBIR/STTR portfolio company.

BC Engineered Products, Brooksville, FL

Damon Johnston

President

BC Technical Center, LLC, dba BC Engineered Products



Over eight years, we've executed SBIR projects that saved the U.S. military \$100M+ in parts costs. SBIR helped grow us from a one-person shop to a 14,000-sq-ft BCEP facility with 20+ staff delivering rapid, in-house solutions. The current lapse in SBIR/STTR funding will directly reduce our ability to solve parts obsolescence and diminishing manufacturing sources and material shortages (DMSMS) quickly and affordably. **In one project, we achieved mission impaired capability awaiting parts (MICAP)-level parts supply in eight months—work a prime took 7+ years to complete—at one-tenth the cost. Delayed reauthorization harms military readiness.**

Department of War SBIR/STTR portfolio company.

Blue Physics LLC, Lutz, FL

Marcos Feijoo

Founder and CEO

Blue Physics LLC




Not able to develop programs to increase the quality of cancer treatments.

Convergent Engineering, Inc., Gainesville, FL

Neil Euliano, Ph.D.

President

Convergent Engineering, Inc.



The SBIR program has had a significant impact on the success of our company and the local community. We have commercialized 3 different SBIR funded projects, sold 2 companies to Philips Healthcare for \$50M+ and sold one to a company who has invested over \$20M into the company and community. I'm a regular

reviewer of SBIR projects and have been very disappointed in the lapse of the SBIR program.

National Science Foundation and National Institutes of Health SBIR/STTR portfolio company.

iScreen 2 Prevent LLC, Pembroke Pines, FL

Delia DeBuc
CEO and co-Founder
iScreen 2 Prevent LLC



Our company successfully completed a Phase I STTR award focused on developing a low-cost, AI-integrated retinal imaging device for early detection of neurodegenerative disease. However, **the lapse in SBIR/STTR reauthorization and resulting funding gap has significantly delayed our ability to apply for and receive Phase II support.** This disruption has affected us financially, stalled key R&D progress, and jeopardized timely commercialization of a solution urgently needed by patients. The gap not only risks losing momentum and team capacity, it threatens the translation of federally funded innovation into real-world clinical impact.

National Institutes of Health SBIR/STTR portfolio company

Live Advantage Bait LLC., Fort Pierce, FL

Nicole Kirchhoff, Ph.D.
CEO and Founder
Live Advantage Bait LLC



The lapse in SBIR authorization has immediately stalled my NOAA SBIR Phase II award, despite having been formally selected after years of peer-reviewed R&D. As a small farm and science-driven company in an FDA-regulated space, SBIR is the only viable pathway to complete required manufacturing scale-up, safety studies, and commercialization. To avoid losing years of progress, I have personally fronted costs to keep work moving, but that runway is now exhausted. This delay jeopardizes American manufacturing development, slows urgently needed aquaculture innovation, and risks pushing U.S. companies behind

foreign competitors—at a time when our industry is already constrained by imports and rising global competition.

Department of Commerce and United States Department of Agriculture SBIR/STTR portfolio company

ObjectiveEd, Inc., Wellington, FL

Marty Schultz

President & Co-Founder
ObjectiveEd, Inc.



We provide a **literacy improvement system that was created under NSF SBIR funding, and its already helped thousands of struggling readers, such as those with dyslexia or autism or ADHD.** We have several more innovations that can help even more students who are not reading at grade level, but the lapse in funding of SBIR has prevented these projects from moving forward. That's unfair to the children, their parents, and their teachers. The more children who get back on grade-level for reading, the more likely they will live productive lives, and become engaged citizens.

National Science Foundation SBIR/STTR portfolio company.

Otolith Labs, Gainesville, FL

Sam Owen

CEO
Otolith Labs



The SBIR program bridged us in our early technology development and without it we would not have been able to raise an additional \$20 million in private funding. We've now completed our FDA trials to become the first on-label therapy for vestibular migraines (which affects over 2% of the population). **None of this would have existed without the SBIR program helping in the early years.** It's critical this program continue to support US innovation.

Quantum Nanostim LLC, *Palm Harbor, FL*

Thomas Reilly, MD
CEO
Quantum Nanostim LLC


Quantum Nanostim LLC

Quantum Nanostim is a U.S.-based medical device startup developing next-generation neuromodulation technologies for chronic pain and neurologic disorders. **The lapse in SBIR/STTR funding has had a direct operational and financial impact on our organization. Delayed reauthorization has stalled critical R&D milestones, postponed preclinical validation studies, and disrupted planned collaborations with academic and clinical partners. These delays increase development risk, extend timelines, and limit our ability to retain specialized technical talent.** For early-stage innovators like Quantum Nanostim, predictable SBIR/STTR funding is essential to translate federally funded research into clinically meaningful, patient-ready solutions.

National Institutes of Health SBIR/STTR portfolio company.

ReNeuroGen LLC, *North Fort Myers, FL*

Billy W. Day, Ph.D.
COO
ReNeuroGen, LLC



Our company, which is developing treatments for rare blood diseases and babies of preterm birth, relies solely at present on SBIR funds. Without them, we will have to cease operations.

National Institutes of Health SBIR/STTR portfolio Company

Skyliners Global, Inc., Ft. Myers, FL

Steven R Lynch

CEO, Founder

Skyliners Global, Inc.



We worked on a new technology for over 4 years. The current climate for SBIR/STTR, plus the halting of DOD projects, has created a serious setback for us. We support the administration and hope they will be moving forward soon.

SynMatter Co., Orlando, FL

Benjamin Pearman, Ph.D.

CEO, Founder

SynMatter Co.



We are a small, woman-owned business is developing next-generation smart corrosion inhibiting materials. **The lapse SBIR/STTR funding is severely impacting our ability to further develop a technology that will protect and strengthen the US's crumbling infrastructure, move production of high-value chemicals to the US and save the defense, oil & gas, marine and chemical industries \$100s of millions in maintenance and replacement costs over the next 10 years.** Please reauthorize the program immediately and help us small businesses innovate and build.

National Science Foundation and National Aeronautics and Space Administration SBIR/STTR portfolio company.

WaveArray Antifouling Systems, LLC, Naples, FL

James V DiLorenzo

Founder & CEO

WaveArray Antifouling Systems, LLC



Without the SBIR program I would not have been able to develop the environmentally safe for the Seas Antifouling Products. It is a great program.

National Science Foundation SBIR/STTR portfolio company.

Georgia

Economic Impact of Program:

SBIR/STTR Funds Received: **\$930,964,231.88**

Small Business SBIR/STTR Awards: **2,261**

Letter to Congress Co-signers

Tyler Tatum	Program Manager	3PhaseSC
Kelsey Mayo, Ph.D.	CEO and Co-Founder	Armor Medical, Inc.
Pooja Tiwari, Ph.D.	CEO	ARNAV Biotech
Kristy Perez, Ph.D.	COO and VP of Clinical	CivaTech Oncology
Anatoly Shilman	CEO	Cogbias AI
Jesse Kallman	CEO	Danti
Andrew Sherrill, Ph.D.	Assistant Professor	Emory University
Brandon Beaty	Microbiologist	Fermworx, LLC
Joseph Patti, Ph.D.	President and CEO	FibroNox, Inc.
Kevin McCully, Ph.D.	President	Infraredrx, Inc.
Nordine Sebkhi, Ph.D.	Founder and CEO	Kinemo, Inc.
Andrea Braden, MD, IBCLC	CEO and Founder	Lybbie
Matt Golden	CEO	MapHabit, Inc.
Clinton Canal, Ph.D.	Associate Professor	Mercer University
Joshua Boutwell, MBA, MS	CEO	Mimir Security, Inc., Aquila Solutions, LLC, Delphinus Consulting, LLC
Charles Chase	VP Special Programs	Momentum Space
Samirkumar Patel, Ph.D.	CEO	Moonlight Therapeutics, Inc.
Nadja Zeltner, Ph.D.	Associate Professor	Neela Cell Therapeutics
Najam Azmat, MD	Owner and President	NJN Medical, LLC
L. Edward Cannon, Ph.D.	President and CEO	NovAb, Inc.

Ronald Shebuski, Ph.D.	President and CEO	Nytricx, Inc.
Jonathan Schwartz	CEO	OrthoPreserve
Ashley Cornelison	Executive Director	Portal Innovations
Marta New, Ph.D., MBA	CEO	Radyus Research
Josh Nickols, Ph.D., MBA	CEO	Sensa Neuroscience
Chris Appleton	CEO	SocialRx, Inc.
Richard T. Timmer, Ph.D.	Senior Patent Agent	Thomas Horstemeyer, LLP
Lisa Calhoun	Founder and Managing partner	Valor.VC
Eric Levitan	CEO	Vivo

Selected Case Studies from Impacted Companies:

Armor Medical, Inc., Atlanta, GA

Kelsey Mayo, Ph.D.

CEO and Co-Founder
Armor Medical, Inc.



Armor Medical Inc. is a women-led medical device startup developing a life-saving, non-invasive monitoring technology to detect postpartum hemorrhage—the leading cause of maternal death. **The lapse in SBIR/STTR funding has created meaningful uncertainty in our planning and operations, delaying key R&D milestones and forcing us to slow hiring and clinical preparation activities. For early-stage companies like ours, SBIR funding is not supplemental—it is foundational.** Delays disrupt carefully sequenced technical, regulatory, and clinical timelines, increasing risk and cost while slowing the delivery of urgently needed innovations to patients and providers.

National Institutes of Health SBIR/STTR portfolio company.

CogBias AI, Atlanta, GA

Anatoly Shilman

CEO

CogBias AI



The lapse in SBIR /STTR funding is creating an existential crisis for many projects and startups. What's more it's slowing innovation in our country and putting us more and more in danger of being overtaken by our adversaries.

This program is crucial to build the next great innovations and solutions. Our venture capital and other investor eco-system is not open enough to support bold innovative creations. This is where this SBIR /STTR come in.

We can't allow us to fall behind. China has announced massive new funds, yet here we are cutting and freeing for no obvious reason.

Let's let the innovators and researchers get back to work.

InfraredRx, Inc., Athens, GA

Kevin McCully, Ph.D.

President

InfraredRx, Inc.



Our company is transitioning from prior NIH support to investors. **The Phase IIB program, where there is matching funds, would help our company immensely.**

National Institutes of Health SBIR/STTR portfolio company.

Kinemo, Inc., Atlanta, GA

Nordine Sebksi, Ph.D.

Founder and CEO

Kinemo, Inc.



Kinemo is enabling veterans with disability to regain a better quality of life, especially for those with a high level of injury. SBIR is our main source of funding to build this technology since helping disabled Americans regain independence is not scalable enough for private investment. **Without SBIR funding, assistive technology for disabled Americans will remain an industry lacking innovation and underserving vulnerable Americans.**

Administration for Community Living SBIR/STTR portfolio company.

MapHabit, Inc., Atlanta, GA

Matt Golden

CEO

MapHabit, Inc.



MapHabit has been funded by the NIH-SBIR since 2019. **We have added 10 jobs in GA and improved the independence/quality of life of over 1,000 families.** Our SBIR project involves incorporating AI into our habit-building platform for people with cognitive support to stay in their homes longer and reduce the impact on our fractured healthcare system, potentially saving the government millions of dollars per year. **Our final year of funding is held up by the lack of action by Congress.** Please extend the SBIR program, which as a proven ROI, creates jobs and establishes the U.S. as the world's leader in innovation.

National Institutes of Health SBIR/STTR portfolio company.

Mimir Security, Inc., Warner Robins, GA

Joshua Boutwell, MBA, MS

CEO

Mimir Security, Inc.



Mimir is developing Database Encryption Technology that is highly sought after by the Air Force. Once developed and proven Mimir's technology will make it virtually impossible for a third party to hack DOW servers and access secure data while simultaneously reducing cloud costs. This technology is very high risk and as such is not suitable for private equity funding.

We received a Phase I STTR but have not yet secured a Phase II because the program has lapsed. **The lack of funding has severely restricted my ability to develop this technology and significantly slows this technology.**

United States Air Force SBIR/STTR portfolio company.

Moonlight Therapeutics, Inc., Marietta, GA

Samirkumar Patel, Ph.D.

CEO

Moonlight Therapeutics, Inc.



Delays in funding delay our clinical trial that will help bring new treatments to patients.

National Institutes of Health SBIR/STTR portfolio company.

Radyus Research, Atlanta, GA

Marta New, Ph.D., MBA

CEO

Radyus Research



Radyus Research supports U.S.-based early-stage biotech companies whose core R&D activities are funded through SBIR/STTR awards. During the recent lapse in reauthorization, multiple client programs experienced delayed payments and uncertainty around funding continuity. **As a result, critical preclinical studies, including IND-enabling toxicology and formulation work, were paused or slowed, creating schedule risk and increasing overall development costs. In some cases, small biotech teams were forced to defer CRO contracts and reallocate limited internal resources to bridge funding gaps.** These delays materially impacted program timelines and increased risk to otherwise promising therapeutic assets.

SocialRx Inc., Atlanta, GA

Chris Appleton

CEO

SocialRx, Inc.



We received a Fast Track award this fall and have completed our Phase I milestones ahead of schedule. **We were planning to start critical developmental and research work in early 2026 with the Phase II portion of this award, and now the future of this project is uncertain. We are building a companion application to our social prescription service that will help address loneliness and social isolation and mental health concerns among youth ages 15 to 18 by connecting them with community arts, culture, and nature based activities. Our NIH program officers cannot tell us when to expect funding or even if we will be able to continue this critical project.**

National Institutes of Health SBIR/STTR portfolio company.

Valor.VC, Atlanta, GA

Lisa Calhoun

Founder and Managing Partner
Valor.VC

SBIR is mission critical for US leadership in defense, health and science.



Hawaii

Economic Impact of Program:

SBIR/STTR Funds Received: **\$426,192,606.14**

Small Business SBIR/STTR Awards: **1,056**

Letter to Congress Co-signers

Dr. Arif Rahman	CEO	Hawaii Innovation, Inc.
Laura Young	Grants Administration Specialist	
Valerie Harmon, MA, OSUe	Founder and CEO	Namaka Algae, Inc.
Barry Jason Worchel, MD	CSO	NeuroGeneces
Peter Lord	Founder	Portal Diabetes, Peter Lord Consulting

Selected Case Studies from Impacted Companies:

Laura Young, Kailua Kona, HI

Laura Young

Grants Administration Specialist

A continued lapse in NIH SBIR funding will result in one of my companies having to lay off talented scientists and engineers who are working on our projects.



Namaka Algae, Inc., Kamuela, HI

Valerie Harmon

Founder and CEO

Namaka Algae, Inc.



The lapse has prevented us from applying for and receiving SBIR funding to accelerate our development of US manufacturing of aquaculture feed ingredients from microalgae for our fish feed manufacturers and farmers. This slows our progress toward setting up the facilities and providing the needed ingredients to our industry. American aquaculture can help to stabilize our countries food security, as part of our ability to supply quality, efficient and nutritious protein to our country. This is a priority we can all get behind regardless of our politics, we all have to eat, and we all want to eat well.

National Science Foundation SBIR/STTR portfolio company

Portal Diabetes, Inc., Kihei, HI

Peter Lord

Founder

Portal Diabetes, Inc.



The SBIR Program provided Seed Money for basic research to establish Portal Diabetes, Inc. **Now, with more than \$40M in follow on private investment, Portal Diabetes has created a fully implanted artificial pancreas which will be a functional cure for diabetes.** This will potentially eliminate the long-term consequences of diabetes, kidney disease and blindness. The impact on diabetes pain and suffering and the medical economics of diabetes will be huge. **The European Research Council is funding two major grants in this technology, and the EU will take the lead in commercialization if the US abandons this program.**

Idaho

Economic Impact of Program:

SBIR/STTR Funds Received: **\$144,798,659.82**

Small Business SBIR/STTR Awards: **350**

Letter to Congress Co-signers

Tyler Bland, Ph.D.	Founder	Panacea Interactive, LLC
Juliette Tinker, Ph.D.	CSO	Pentamer Biologics

Selected Case Studies from Impacted Companies:

Pentamer Biologics, Boise, ID

Juliette Tinker, Ph.D.

CSO

Pentamer Biologics



We were funded in 2023-24 with a USDA Phase I STTR. With these funds we were able to complete a small and promising bovine vaccine trial. We were unable to submit for the Phase II in the spring of 2025 due to government closures/delays, and **due to this we lost key members of our team**. However, we were able to submit for this grant in the fall of 2025. It is essential that this program be continued for us to continue to explore this promising vaccine to prevent bovine mastitis in dairy cows. This disease costs over an estimated \$1 billion/yr to the industry in the US.

United States Department of Agriculture SBIR/STTR portfolio company.

Illinois

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,438,867,490.75**

Small Business SBIR/STTR Awards: **3,938**

Letter to Congress Co-signers

Peter Farmakis	CEO	32 Biosciences
Dawn Matthews, MS, MBA	CEO	ADM Diagnostics, Inc.
Nick Sather, Ph.D.	CEO	Amphix Bio
Cory Guterman, MPH	CEO	Angiotensin Therapeutics
Jessica Irons, Ph.D.	Senior Associate Director of Innovation Programs and Operations	Chicago Biomedical Consortium
Kimberly Corn	Director of Finance and Operations	Chicago Biomedical Consortium
Xiao Han, Ph.D.	CEO	Clarix Imaging Corporation
Carol Barnett, MBA	Founder	Creek School, LLC
Julia Laystrom-Woodard	Director of Operations	CU Aerospace, LLC
Darren King	Laboratory Director	
William Q Sargent, Ph.D.	COO	Dolor Therapeutics, Inc.
Robert Georgantas, Ph.D.	CEO	eGlint Proteomics
Dana Sun, MBA	Partner	Equitage Ventures
Michael T. Flavin, Ph.D.	Managing Director	Flavin Ventures, LLC
Cathleen Dohrn, Ph.D.	VP Medical Strategy	
Helen Abad	Director of Strategic Partnerships	Illinois Science and Technology Coalition
John Misiaszek, Ph.D.	Entrepreneurial Postdoctoral Fellow	IROX
Fizan Abdullah, MD, Ph.D.	Professor of Surgery	Loyola University Chicago

Melissa Lederer	CXO	mHUB
Margaret Dunlap	Coach	MMD Coaching
Sameer Ansari	Professor	Northwestern University
Dr. Jan Wysocki	Research Associate Professor	Northwestern University
Ping Wang	Researcher	Northwestern University
Donald R. Cantrell, MD, Ph.D.	Neurointerventional Radiologist	Northwestern University
Richard Gershon	Doctor	Northwestern University
Niall O'Dowd, Ph.D.	Founder and CEO	Phase3D
Akul Goyal	Co-Founder	Provenance Security
Joseph R. Peterson, Ph.D.	CTO	SimBioSys, Inc.
Margaret Vorpahl	Membership Sales Director	The Illinois State Medical Society
Greg Smith, Ph.D.	President	Thyreos, Inc.
Eugene B. Chang	Professor	University of Chicago
Gene Robinson	Director Carl R. Woese Institute for Genomic Biology	University of Illinois Urbana-Champaign
Damien Despinoy	President and COO	Volexion
Chris Baek	Founder and CEO	Yubeck

Selected Case Studies from Impacted Companies:

Cathleen Dohrn, Ph.D., *Libertyville, IL*

Cathleen Dohrn, Ph.D.
VP Medical Strategy

As a Board member for a small start-up that lost SBIR/STTR funding this past year, I know well how this squelches good science.



Chicago Biomedical Consortium, *Chicago, IL*

Jessica Irons, Ph.D.

Senior Associate Director of Innovation Programs and Operations
Chicago Biomedical Consortium

We are trying to develop life saving therapeutics, devices, health tech, and diagnostics and this funding is a necessary part of this development.



Clarix Imaging Corporation, *Chicago, IL*

Xiao Han, Ph.D.

CEO and Co-Founder
Clarix Imaging Corporation

SBIR funding was instrumental for the company that I co-founded (Clarix Imaging) to get off the ground. Now with SBIR awards, we were able to develop commercial products that are clinical and used in many hospitals in the US. Our product improved breast cancer surgery outcome for tens of thousands of patients, and we are able to generate a multimillion dollar revenue and more than 20 full time jobs.



Department of Veterans Affairs SBIR/STTR portfolio company.

CU Aerospace, *Chicago, IL*

Darren King

Laboratory Director
CU Aerospace

We have worked on dozens of SBIR / STTR programs over the last ~27 years and **are now stalling R&D** to look for ways to sell our current tech while halting innovation.



Department of War and National Aeronautics and Space Administration SBIR/STTR portfolio company

Flavin Ventures, LLC, *Darien, IL*

Michael T. Flavin, Ph.D.

Managing Director

Flavin Ventures, LLC



I am assisting university company spinouts with the commercialization of some very exciting and impactful technologies. These early-stage companies are heavily reliant on the SBIR/STTR program for funding that allows them to take the initial step toward the market. **Without the SBIR/STTR program, many of these companies would not be started in the first place. Those that have been started are now basically on hold until the program is reauthorized** or alternative funding sources can be identified. These alternative sources are few and far between and take a considerable amount of time to engage, if at all. **I am very worried that many startup companies will fail without the SBIR/STTR program.**

Illinois Science & Technology Coalition, *Chicago, IL*

Helen Abad, MBA

Director of Strategic Partnerships

Illinois Science & Technology Coalition



The importance of SBIR/STTR funding enables early-stage founders with non-dilutive funding to continue their R&D towards commercialization. The Illinois Science & Technology Coalition provides Voucher Grants that is the first step towards SBIRs. **This is a vital lifeline for the technology and venture ecosystem.**

IROX, *Evanston, IL*

John Misiaszek, Ph.D.

Co-Founder

IROX



As a hardtech startup in the waste utilization sector, it is essential to derisk the IROX technology. This derisking is very difficult to do with private sector funding; the government's SBIR / STTR is playing an essential role in enabling hard tech to propel USA startups to commercialization.

Phase3D, Chicago, IL

Niall O'Dowd, Ph.D.

Founder, CEO
Phase3D



The SBIR and STTR program is single handedly responsible for the launch of Phase3D - our 2 SBIR Phase IIs have been used to develop technology in which we have commercialized in the market, selling over \$2M in product in 2025 alone. We rely on the SBIR program, especially TACFI/STRATFI as an integral part of our commercialization strategy.

United States Department of the Air Force SBIR/STTR portfolio company.

SimBioSys, Inc., Chicago, IL

Joseph R. Peterson, Ph.D.

Chief Technology Officer
SimBioSys, Inc.



SimBioSys' foundational cancer-fighting technology was developed with SBIR funds. SBIR funding provided critical validation and de-risked investment decisions for the first angel investors. SimBioSys' cancer-fighting technology is on the market, generating revenue and impacting breast cancer patients' lives. **Lapses in SBIR funding have required SimBioSys to pare back expansion of the technology beyond breast cancer, putting new life-saving technology at risk, and timelines at jeopardy.**

National Institutes of Health SBIR/STTR portfolio company.

Indiana

Economic Impact of Program:

SBIR/STTR Funds Received: **\$648,224,783.35**

Small Business SBIR/STTR Awards: **1,840**

Letter to Congress Co-signers

Rebecca Lyon, Ph.D.	Operations Manager	Amplified Sciences, Inc.
Kislaya Kunjan, Ph.D.	CEO	Cascade Metrix, Inc.
Dongwook Kim	CEO	DENCODA, LLC
Debbie Ann Maguire	President	DMAG USA
Hao Yu	President	EandE BioClub, LLC
Grant Chapman	CEO	Glassboard Product Development
Jamie Bass, CISSP-ISSEP	CEO	GRAVICOM, LLC
Kristin Jones	President and CEO	Indiana Life Sciences Association
Milton Aguirre, Ph.D.	Director of Healthcare StartUP	Livotion, LLC
Joe Trebley, Ph.D.	CEO	Monon Bioventures
Keira Sorrells	Executive Director	NICU Parent Network
Chris Rauh	CTO	PrimSphera
Jim Schulz	CFO	Scioto Biosciences
Larry C Blaszczak, Ph.D.	Co-Founder	Teichos Laboratories, LLC
Kevin Craig, EMBA	CEO	Tessellated, Inc.
Tengfei Luo	Professor	University of Notre Dame
Seunghyun Moon	Assistant Research Professor	University of Notre Dame
David Olawale, Ph.D.	CEO	Valgotech, LLC

Selected Case Studies from Impacted Companies:

Amplified Sciences, Inc., West Lafayette, IN

Rebecca Lyon, Ph.D.

Operations Manager
Amplified Sciences



Amplified Sciences is a start-up company that uses cutting-edge optical technology to develop diagnostic assays for devastating diseases. In a few months we are launching our first product for detection of pre-cancerous pancreatic lesions. This is a pivotal point for our company where we are turning from R&D to a commercial stage and we would not be here so quickly, or possibly at all, if it wasn't for funding that we received through the SBIR program. **Our company currently has a Phase II SBIR grant application submitted for a second diagnostic assay but it is on hold due to the SBIR program lapse.** Physicians we have interviewed say that this second assay will have an even more significant impact on patient healthcare than our current product. We exist to help patients and they are waiting for the life-changing technologies developed under the SBIR/STTR program.

National Science Foundation and National Institutes of Health SBIR/STTR portfolio company.

Cascade Metrix, Inc., West Lafayette, IN

Kislaya Kunjan, Ph.D.

CEO
Cascade Metrix, Inc.



Cascade Metrix is working on a paradigm-changing real-time sensing systems for critical care patients to support early diagnosis and ongoing therapeutic management. **Continued SBIR funding is essential to derisk the technology before private funding becomes a possibility to bring this clinically-proven need to acute care centers across the US and beyond.**

National Institutes of Health SBIR/STTR portfolio company.

DMAG USA, Evansville, IN

Debbie Ann Maguire

President
DMAG USA



Because of our SBIR grant through NSF, we were able to develop a coding that will be utilized by aerospace ammunition, and most importantly data centers to reduce energy costs and provide better cooling for the systems. Had we not received the grant this coding would not have been developed.

National Science Foundation SBIR/STTR portfolio company.

Glassboard Product Development, Indianapolis, IN

Grant Chapman

CEO
Glassboard Product Development



We've helped developed medical devices from SBIR grants that ended up changing the lives of the people in the clinical trials that received the innovative treatment.

GRAVICOM, LLC, Evansville, IN

Jamie Bass, CISSP-ISSEP

CEO
GRAVICOM, LLC



GRAVICOM LLC is a small and innovative company. We're developing high temperature coatings for hypersonics, and novel energy technologies. **We can't bring these to the world without the SBIR/STTR program funding and infrastructure. This is the #1 program to keep America innovating and first in the world.**

PrimSphera, South Bend, IN

Chris Rauh

Chief Technology Officer
PrimSphera

We have multiple SBIR/STTR (Air Force Open Topic & NIH) presently submitted that are presently stalled. The limbo state of these proposals is negatively impacting our ability to plan R&D funding as well as our ability to put together necessary financial plans required for our planned fund raising in 2026.



Department of War and National Institutes of Health SBIR/STTR portfolio company.

Scioto Biosciences, Indianapolis, IN

Jim Shulz

CFO, Scioto Biosciences
CFO, Monon Bioventures

Monon Bioventures depends on SBIR/STTR funding as a key source of non-dilutive capital to develop early-stage biotech innovations. These federal grants help them advance high-risk technologies from universities through preclinical stages without giving up equity. As biotech R&D is expensive and risky, SBIR/STTR funding bridges the gap between discovery and commercialization. **Without reauthorization in Washington, DC, Monon and similar companies could lose critical support, stalling innovation and economic growth. Reauthorization ensures continued access to vital funding that fuels biotech breakthroughs and keeps small U.S. firms competitive.**



National Institutes of Health SBIR/STTR portfolio company.

Tessellated Inc., *South Bend, IN*

Kevin Craig, EMBA

CEO

Tessellated Inc.



Tessellated Inc. has successfully solved multiple DoD challenges through the SBIR/STTR program, advancing a dual-use materials technology with applications across the Army, Air Force, NASA, DOE, and civilian markets. The lapse in SBIR/STTR reauthorization has had immediate and severe impacts on our operations, forcing layoffs of Indiana-based employees and delaying commercialization. Without bridge funding, even proven, high-impact technologies risk stalling before reaching the field. Continued delays jeopardize domestic innovation, workforce retention, and U.S. technological advantage over foreign adversaries.

Department of War and Department of Energy SBIR/STTR portfolio company.

Iowa

Economic Impact of Program:

SBIR/STTR Funds Received: **\$207,405,223.77**

Small Business SBIR/STTR Awards: **593**

Letter to Congress Co-signers

Natasha Gorski, MS, PMP	VP of Government Programs	Ibex Consulting
Manohar John	President and CSO	PathoVacs, Inc.
Michael Wheeldon, B.Sc.	Founder and Entrepreneur	Syndicate of Sound and Synapse

Selected Case Studies from Impacted Companies:

PathoVacs, Inc., Ames, IA

Manohar John, MD, Ph.D.

President and Chief Scientific Officer
PathoVacs, Inc.



We had to lay off highly trained personnel relevant to projects that were to be funded by SBIR Grants and Contracts that were to be awarded in mid to late 2025. We have also put all research projects impacting public health on hold.

Department of War SBIR/STTR portfolio company.

Syndicate of Sound and Synapse, *Council Bluffs, IA*

Michael Wheeldon

Founder/Entrepreneur

Syndicate of Sound & Synapse



I was absolutely ready to submit, I had contacts and reviewers helping me in the NIA. **Because of this, I am not able to submit to see if my valuable research can assist individuals suffering from Alzheimer's disease.** This isn't affecting just the recipients, but rather the individuals that scientists, researchers, and clinicians aim to serve. It does a huge disservice to these individuals.

Kansas

Economic Impact of Program:

SBIR/STTR Funds Received: **\$193,098,675.79**

Small Business SBIR/STTR Awards: **610**

Letter to Congress Co-signers

Ember Krech, Ph.D.	Lead Research and Development Engineer	Axioforce, Inc.
Stephanie Norwood, EDP	VP of Small Business and Entrepreneurship	GO Topeka Economic Partnership
Stephanie J. Moran	SVP of Innovation	GO Topeka/Link Innovation Labs
Edward Maliski, Ph.D.	CEO and CSO	
Sally Maliski, Ph.D., RN, FAAM	VP, Communications	Oak Therapeutics, Inc.
Lindsay Lebahn	Director	Plug and Play

Selected Case Studies from Impacted Companies:

GO Topeka/Link Innovation Labs, Topeka, KS

Stephanie J. Moran
SVP of Innovation
GO Topeka/Link Innovation Labs

SBIR/STTR funding is critical in supporting the startups who are working to advance technologies and products through Link Innovation Labs. These funds not only bring these important technologies closer to commercialization but also help create and support the environments like Link Innovation Labs where startups and resource partners can come together, connect, find mentorship or support partners who can advance these technologies much faster than startups working alone or independently to build these networks.



Oak Therapeutics, Inc., Lawrence, KS

Edward Malinski, Ph.D.

CEO and CSO

Oak Therapeutics, Inc.



Our work is focused on providing pediatric friendly medications. We are working on an oral dissolvable strip that is easy to administer. The approval was delayed for more than 6 months. 1,000 small children die each day from TB. That's the equivalent of 3 B-747's full of babies and toddlers crashing every day for 6 months.

Sally Maliski, Ph.D., RN, FAAM

VP, Communications

Oak Therapeutics, Inc.



Because of SBIR support, we have been able to develop an oral dissolvable strip for the treatment of pediatric latent and active TB. TB treatment is onerous, time-consuming, lengthy (4-6 weeks of daily medications), expensive (requiring direct observation by a health care provider), and traumatic for children, caregivers, and care providers. Non-adherence is high. By delivering rifapentine and INH on a dissolvable, taste-masked strip that sticks to the inside of the mouth, it is much less difficult for children, their parents, and care providers. **Defunding of the SBIR/STTR programs will eliminate breakthroughs like this that can save many healthcare dollars and more importantly decrease unnecessary illness and deaths.** TB is no longer a disease found only in under-resourced countries. It is rising rapidly in the United States.

National Institutes of Health SBIR/STTR portfolio company.

Kentucky

Economic Impact of Program:

SBIR/STTR Funds Received: **\$382,969,207.42**

Small Business SBIR/STTR Awards: **988**

Letter to Congress Co-signers

Jeffrey Petruska, Ph.D.	Co-Founder and CSO	dSenz, Inc.
Sundeep Dronawat, Ph.D.	CEO	Fetal Life
Tereza Paronyan	President	HeXalayer, LLC
Emilie Clemmens, Ph.D.	Associate Director of Innovation	Kentucky Science and Engineering Foundation
Stephen Carrithers, Ph.D.	President	LaGrange Scientific, LLC
Bruce Webb, Ph.D.	Founder	Lepidext, Inc.
Christin Godale, Ph.D.	Executive Director	LifeSciKY
Ginger Watkins	President	ORB Technologies, LLC
Angelika Fath-Goodin, Ph.D.	CEO	ParaTechs Corp.
Marc Stone	President	Stonebridge Hospitality
Guoqiang Yu, Ph.D.	Professor of Biomedical Engineering	University of Kentucky
Eric Hartman	Sr. Associate Director, UK Innovate	University of Kentucky
Dr. John Naber	Chair and Professor of Electrical and Computer Engineering	University of Louisville
Alli Truttmann	CEO and Founder	Wicked Sheets
Janelle Molloy, Ph.D.	CEO	Wild Dog Physics
Jackie Willmot	CEO and Co-Founder	XLerateHealth

Selected Case Studies from Impacted Companies:

Bioptics Technology, LLC, Lexington, KY

Guoqiang Yu, Ph.D.

Chief Engineer, Bioptics Technology, LLC
Professor of Biomedical Engineering, University of Kentucky



SBIR/STTR programs are critical to promote the translation and commercialization of novel biomedical devices to save lives.

National Institutes of Health SBIR/STTR portfolio company.

dSenz, Inc., Louisville, KY

Jeffrey Petruska, Ph.D.

Co-Founder and Chief Scientific Officer
dSenz, Inc.



dSenz is developing a novel non-opioid pain control drug for unmet needs outside of the "coastal" biotech and pharma environment. SBIR/STTR funding is vital. We have our first major private funding and a new development avenue pending a notice of award for an SBIR application. **We are losing prospective employees and investors to other opportunities.**

Kentucky Science and Engineering Foundation, Lexington, KY

Emilie Clemons, Ph.D.

Associate Director of Innovation
Kentucky Science and Engineering Foundation



We help small businesses in Kentucky apply for SBIR/STTR funding. Because of the lapse in authorization, several of our award winners have struggled to stay afloat, despite their successful grant applications. Many more are eager to apply for Phase I and Phase II grants but are unable to do so. These programs are so important to helping great ideas become solutions in our health, defense, energy, and agriculture sectors and more.

LaGrange Scientific, LLC, *LaGrange, KY*

Stephen Carrithers, Ph.D.

President

LaGrange Scientific, LLC



As President, CEO, and Principal Investigator of Kentucky-based biotech companies, I have experienced firsthand the damage caused by the lapse in SBIR/STTR reauthorization. NIH award delays have halted active therapeutic and diagnostic programs, frozen hiring, postponed payroll commitments, and stalled contracts with KY vendors and universities. **These are not abstract losses—they are paused jobs, deferred wages, and delayed life-saving innovations.** For small biotechnology companies in KY, SBIR/STTR is the bridge from discovery to commercialization. Without timely reauthorization, companies like mine are forced to idle innovation, weaken local economies, risk losing highly skilled scientific jobs from our state, and most likely dissolve.

National Institutes of Health SBIR/STTR portfolio company.

Lepidext, Inc., *Lexington, KY*

Bruce Webb, Ph.D.

Founder

Lepidext, Inc.



There are 4 full-time and 4 part-time jobs associated with the company. We will have first sales this year after a lengthy regulatory review. Failing to renew the SBIR program will impact our ability to develop this new biopesticide technology to broaden its impact and reduce dependence on chemicals and GMOs.

U.S. Department of Agriculture and National Science Foundation SBIR/STTR portfolio company.

LifeSciKY, Covington, KY

Christin Godale, Ph.D.

Executive Director
LifeSciKY



The lapse in funding created a real and immediate disruption for both LifeSciKY and the early-stage companies we support. Several of our clients were **unable to apply for critical SBIR/STTR funding during this period, delaying key milestones and directly impacting their ability to commit to relocating or expanding operations in Kentucky**. For startups operating on tight timelines and limited capital, even short funding gaps can stall momentum. Reliable, continuous access to federal innovation funding is essential for attracting, retaining, and growing high-quality life sciences companies in the Commonwealth.

UK Innovate - University of Kentucky, Lexington, KY

Eric Hartman, MS

Sr. Associate Director
University of Kentucky Innovate



As an emerging startup ecosystem, Kentucky is heavily reliant on the SBIR/STTR program to de-risk early-stage technology-based startups. At University of Kentucky (UK), I lead the team that supports new startup creation based on UK Research. The vast majority of our startups will rely on SBIR/STTR funding to begin the business and support early translational research efforts. **The lapse of the SBIR/STTR program has affected dozens of Kentucky startups and continued delay will have detrimental effects.**

XLerateHealth, Louisville, KY

Jackie Willmot, MBA

CEO and Co-Founder
XLerateHealth



XLerateHealth is a healthcare and biotechnology accelerator that supports early-stage companies reliant on SBIR/STTR funding to advance R&D and reach commercialization milestones. Since the lapse in SBIR/STTR authorization, multiple startups in our portfolio have delayed hiring, paused research activities, and postponed university collaborations due to funding uncertainty. Even short lapses in SBIR/STTR create outsized economic and operational harm for small businesses and the innovation ecosystems that support them.

Louisiana

Economic Impact of Program:

SBIR/STTR Funds Received: **\$207,230,725.27**

Small Business SBIR/STTR Awards: **568**

Letter to Congress Co-signers

Svetlana Oard, Ph.D.	Co-Founder and CEO	AL-POWER, Inc.
Arthur Landry	Owner	Clear Cut Solutions, LLC
Brianne Sullivan, Ph.D.	Associate Director, Business Development	Dianthus Therapeutics
Jordan Losavio, MS	CEO	Encore CO2
Molly Hegarty	Founder and CEO	Junum
Ethan Anderson, Ph.D.	Assistant Professor	Louisiana State University
Konstantin G. Kousoulas	Professor and Head	Louisiana State University
Fatima Rivas	Assistant Faculty	Louisiana State University
Kristopher Khalil	Executive Director	New Orleans BioInnovation Center
James Cardelli, Ph.D.	CTO	oleolive, Inc.
Cecil "Bo" Lewis, BSE, MS, MBA	President	SimplyBreathe, Inc.
Marilyn Sinkewicz, Ph.D., MSW	Research Investigator	University of Michigan
Gordon Morrison	CTO	VS Merlot, Inc.

Selected Case Studies from Impacted Companies:

AL-POWER, Baton Rouge, LA

Svetlana Oard, Ph.D.

Co-founder and CEO

AL-POWER, INC.



We have developed an effective preventive treatment for colorectal cancer which is on the rise in the U.S.A. and Europe. We are preparing to apply for NIH SBIR program, and this lapse may cause delays in reviewing and awarding SBIR grants. This funding is very critical to us, as we are a startup company in the early stage of development.

Konstantin G. Kousoulas, Baton Rouge, LA

Konstantin G. Kousoulas, Ph.D.

Professor and Head

Louisiana State University



The SBIR/STTR program allows for transfer of technology to start-up companies in Louisiana. These small companies can substantially enhance employment in Louisiana and contribute significantly to economic development for the state and the nation. It is highly important to continue and enhance this program.

Oleolive Inc., Shreveport, LA

James Cardelli, Ph.D.

Chief Technology Officer

Oleolive Inc.



Oleolive is a preclinical biotechnology company with multiple therapeutic assets under development and this lapse in SBIR programmatic funding is slowing down preclinical and IND enabling research to advance these therapeutics towards clinical trials to treat lung fibrosis, brain cancer, prostate cancer and MASH (metabolic dysfunction-associated steatohepatitis), to name a few.

Department of War and National Institutes of Health SBIR/STTR portfolio company.

SimplyBreathe Inc, New Orleans, LA

Cecil "Bo" Lewis, BSE, MS, MBA

President

SimplyBreathe Inc



Rhinitis affects 77 million Americans. Few patients and few Ear, Nose, and Throat doctors are happy with their options. At SimplyBreathe, we are developing a novel treatment for allergic and nonallergic rhinitis. Thanks to the help of the National Science Foundation through a STTR Phase 1 grant that finished in late 2024, we now have functional prototypes of this novel technology. With the help of another Phase 1 grant, we plan to prove out this novel technology in an animal model and move the company forward towards commercialization.

National Science Foundation SBIR/STTR portfolio company.

Maine

Economic Impact of Program:

SBIR/STTR Funds Received: **\$178,098,453.66**

Small Business SBIR/STTR Awards: **581**

Letter to Congress Co-signers

Paul Melrose	President	Compotech, Inc.
--------------	-----------	-----------------

Selected Case Studies from Impacted Companies:

Compotech, Inc., *Brewer, ME*

Paul Melrose

President

Compotech, Inc.



Compotech's DETECT-ML product is being delayed by the SBIR reauthorization delays. We strongly support the reauthorization of the SBIR program.

Department of War SBIR/STTR portfolio company.

Maryland

Economic Impact of Program:

SBIR/STTR Funds Received: **\$3,597,861,380.22**

Small Business SBIR/STTR Awards: **10,352**

Letter to Congress Co-signers

Prasad Konkalmatt, Ph.D.	Founder	AAVion, LLC
Holger Behrsing, Ph.D.	President and CEO	Advanced In Vitro, LLC
Jessica Bunin, MD	Co-Founder	All Levels Leadership
Luanne Houck	Director of Business Development	Allied Technologies and Consulting, LLC
Christopher Cooney, Ph.D.	CEO	Apogene, Inc.
Peter DiMilia, MPH	Research Manager	Art Pharmacy
Kenric Hoegler, Ph.D.	Associate Director	AstraZeneca and Princeton University
Raj Shekhar, Ph.D.	President and CEO	AusculTech Dx
Erin Evke Chapkin, Ph.D.	Founder and CEO	BioEvanescce, Inc.
Pam Bruce-Staskal, Ph.D.	Director, Analytical Development	BioFactura
Jonathan Nelson, Ph.D.	Director of Client Engagement	BioHealth Innovation
Mark Beliczky	President and CEO	CarrTech Corp.
Jacob Abuhamada	CEO	CFrame, Inc.
Kim Gonda, Ph.D.	CEO	CGT Consulting, LLC
Barbara Howard, MD	President	CHADIs, Inc.
Christopher M. Arunkumar	CEO	Cornerstone Accounting Services
Jill Pecon-Slattery, Ph.D.	CEO and Founder	Cornerstone Genomics Inc
Natalie Wisniewski, Ph.D.	CTO and CPO	CraniUS
Mason Scuderi	President	d'Vinci Interactive

Alexei Kanareykin	CEO and President	Euclid Techlabs, LLC
Carrie M Kuehn, MA, MPH, DLP, RAC-US	Principal Consultant and Founder	Evergreen Strategic Consulting
Julius Goepp, MD	CSO	Evimero, LLC
Mark Chen, Ph.D.	President	ExcelCoat Technologies, Inc.
Nicholas Pirolli, Ph.D.	Founder and CSO	Expora, Inc.
Selena Shirkin, BS, MSE	CEO	Fetal Therapy Technologies
Dawn Furman Gordon	CEO	Fingerboard Farm
Aisha Wood, MS, CCC-SLP	CEO	FlowaTree Craft
Kathie Callahan Brady	CEO	Frederick Innovative Technology Center, Inc.
Elizabeth Anne Smith, Ph.D., MBA	Chief Business Officer	Fzata, Inc.
Hafiz Ahmed, Ph.D.	President and CEO	GlycoMantra, Inc.
Mei Sun	CEO	Heyma Consulting
Amanda Haddaway	Managing Director	HR Answerbox
David M. Anderson, Ph.D.	Co-Founder	IECBio, LLC
John A. Bilello, Ph.D	President	Innovalyst ICAN, LLC
Jeff Strovel, Ph.D.	CEO	Irazu Oncology
Melissa Stundick, Ph.D.	Associate Director, Entrepreneurship	Johns Hopkins Tech Ventures
Raj Desai, MS, MBA	Founder	Just Strive
Fehmida Kapadia, Ph.D.	President	Kapamed Consulting
Bill Clem	President	Key Courier
Mohammad Amin Tadayon, Ph.D.	CEO and Founder	LEGIT (LensGuide Imaging Technology, Inc.)
Daniel Brower	CEO	LEI Sales, LLC
Davood Tashayyod	CEO	Lumo Imaging
Allen Tien, MD, MHS	President and CSO	Medical Decision Logic, Inc.
Radames J.B. Cordero	CEO	MelaTech, LLC
Nora Yang	CEO	Merlin Therapeutics, Inc.
Michael Mesa	President	Mesa Science Associates Inc

Patrick Calhoun, Ph.D.	President and CSO	Nanocrine, Inc.
Paul Aiyetan, MD, MS, Ph.D.	CEO and Director of Research, Development and Translation	NEOPATHOLOGY CORP.
Mario Dagenais	CEO	New Integration Photonics
Roman Owens, MSc	Founder and CEO	OncoVanta Therapeutics, Inc.
Brijen Joshi, MD	Founder	OnPoint Ventilation
Reza Seifabadi, Ph.D.	CEO	PediaMetrix
Jun Wang, Ph.D.	CEO	Phycin, Inc.
Anne Naclerio, MD, MPH	CMO	Polaris Genomics
Winnie Shi	Business Development and Coordinator	Quantum Startup Foundry
Michael Krainak Diane Ngo	CTO Opto-Mechanical Engineer	Relative Dynamics
Gary R. Fanger, Ph.D. Janet Stephens, Ph.D.	President and CEO Sr. Vice President, Operations	Rise Therapeutics, LLC
Cyrus Etemad-Moghadam	President and Founder	RPM Tech
Shannon Arnold	AI Research Engineer	SCA TECH III Partnership
Jeffrey N. Hausfeld, MD, MBA	Chairman of the Board	Society of Physician Entrepreneurs
Jeanne Marie O'Connell, MD	Co-Founder and Medical Director	Sylvana Medical and Aesthetic Center
R. Scott Russo	CEO and Founder	Synolus Medical, Inc.
Yun-Ling Zheng, Ph.D.	President	TelohealthDx, LLC
Sahee Abdelmomin	Senior Data Analyst	The State of Maryland
Leora Davalos	Founder and CEO	Thrive Digital Health
Tyrell Junius	Co-Founder	Tiami Networks, Inc.
Fernanda Nusbaum	Vice President of Client Relations	TTi Health Research and Economics

Laura Nnadi	Senior Research Project Coordinator	University of Maryland, Baltimore
Ravi Anchoori	CSO	UP THERAPEUTICS
Greg Merril	Managing Partner	Velocity Biofund
Michael Potter, Ph.D.	CEO	VeraChem, LLC
Matt Boxer	COO	Veralox Therapeutics, Inc.
Christopher Carmona	Business Development Manager	WB Engineers+Consultants
Thomas McCreery	Vice President and COO	Zeteo Tech, Inc.

Selected Case Studies from Impacted Companies:

Advanced In Vitro, LLC, *Frederick, MD*

Holger Behrsing, Ph.D.

President & CEO

Advanced In Vitro, LLC




The Small Business Innovative Research grant award system is critical for small businesses such as mine to take novel technology to the next level, but also for small businesses to survive. We have invented a novel CryoViable™ method by which we can process and freeze non-transplantable human donor tissue to serve as a model for research that reflects a diverse demographic background. **Help us expand this technology into other human tissues by reviving the SBIR/STTR program that gives us an opportunity to continue this work!**

Art Pharmacy, Baltimore, MD

Peter DiMilia, MPH
Research Manager
Art Pharmacy


We received a Fast Track award this fall and have completed our Phase I milestones ahead of schedule. We were planning to start critical developmental and research work in early 2026 with the Phase II portion of this award and now the future of this project is uncertain. We are building a companion application to our social prescription service that will help address loneliness and social isolation and mental health concerns among youth ages 15 to 18 by connecting them with community arts, culture, and nature-based activities. Our NIH program officers cannot tell us when to expect funding or even if we will be able to continue this critical project.



AstraZeneca, Bethesda, MD

Kenric Hoegler, Ph.D.
Associate Director
AstraZeneca, Princeton

I support a biotech startup creating innovations that help preserve life-changing medicines that could benefit millions every second we delay Science Funding; **the fate of those people hinges on us ending this nonsense.**



AusculTech Dx, Silver Spring, MD

Raj Shekhar, Ph.D.
President, CEO
AusculTech Dx

We have two pending proposals and two that we would have submitted on January 5th. **A lapse in the program is affecting our innovation and funding pipelines negatively.**



BioFactura Inc., Frederick, MD

Pam Bruce-Staskal, Ph.D.

Director, Analytical Development
BioFactura, Inc.



The unexpected and sudden **loss of government funding for mission-critical projects prevented our company from completing critical work**. Data wasn't summarized. Conclusions weren't determined. Critical findings were lost. **Over half our company was laid off and many are now on unemployment because there are so few open jobs**. These cuts were supposed to decrease waste, but all they did was increase waste and put more people in need of government assistance. Please reverse the cuts and focus on true waste and fraud.

Department of War SBIR/STTR portfolio company.

CarrTech Corp., Frederick, MD

Mark Beliczky

President and CEO
CarrTech Corp.



CarrTech Corp is a Maryland-based medical technology company commercializing the FDA-cleared FROG® device, designed to improve safety in the preparation of injectable medications. **The lapse in SBIR/STTR authorization has directly disrupted CarrTech's product development and clinical validation timeline. Planned non-dilutive funding was intended to support pilot manufacturing, hospital-based validation studies, and continued engineering optimization.** Without access to SBIR/STTR programs, CarrTech has been forced to redirect scarce operating capital, delay certain R&D activities, and slow hiring of critical technical resources. This uncertainty increases financial strain, extends time-to-market, and risks delaying innovations that directly improve clinician safety and patient care.

National Science Foundation SBIR/STTR portfolio company.

CFrame, Inc., Frederick, MD

Jacob Abuhamada

CEO

CFrame, Inc.



Our company is on the verge of taking off, transforming several industries through a significant conceptual innovation. We are also in great need of funding to do so. SBIR/STTR funding would allow us to grow rapidly, boosting the economy and helping tackle the growing mental health crisis. Without such funding available, it significantly slows our development.

Composites Automation LLC, Arnold, MD

Roger Crane, Ph.D.

Senior Engineer

Composites Automation LLC



Composites Automation has just completed a successful Phase I SBIR developing a repair process that PEO Ships thought could not be done. **Without the Phase II funding this technology cannot be transitioned to the fleet for in-service repair.** In addition, our company as well as the other small businesses that are participating will lose significant revenue.

Department of Energy, National Aeronautics and Space Administration, Department of War SBIR/STTR portfolio company.

CraniUS, Baltimore, MD

Natalie Wisniewski, Ph.D.

CTO/CPO

CraniUS



The lapse of SBIR/STTR funding has a significant impact on us as a small start-up. We are working on a much-needed glioblastoma treatment, and delays in funding slow down our research program and that means a slow down in getting new therapies to patients. **Specifically, we are on hold for funding of our device validation and verification program, and we are not able to advance to the next stage of clinical testing without that.**

Euclid Techlabs LLC, *Beltsville, MD*

Alexei Kanareykin
CEO, President
Euclid Techlabs LLC



Our company is conducting **critical SBIR-funded research for the DoD and DOE in normal-conducting and superconducting accelerator technologies**, as well as HPHT diamond technologies for quantum sensing (DoD) and radiation-hardened diamond transistors (NASA). The **ongoing delay in SBIR/STTR reauthorization has placed us in an extremely difficult financial position, directly affecting our employees and jeopardizing several DoD and DOE priority programs**. Past SBIR awards enabled successful commercialization, generating millions of dollars annually through sales to U.S. national laboratories. A notable example is the DOE-funded ultrafast pulser for transmission electron microscopy, now our primary product deployed across U.S. and international laboratories.

Department of War and Department of Energy SBIR/STTR portfolio company.

Evergreen Strategic Consulting, *Catonsville, MD*

Carrie Kuehn, MA, MPH, DLP, RAC-US
Principal Consultant, Founder
Evergreen Strategic Consulting



I am a medical device regulatory consultant with a client whose product could reach patients experiencing pulmonary embolism if they received an SBIR grant to conduct their clinical trial. **This product can save lives.** Please reauthorize these grants!

Evimero, LLC, Hagerstown, MD

Julius Goepp, MD
Chief Science Officer
Evimero, LLC



Using SBIR Phase I funding, Our company has developed a prevention medicine against norovirus, which is a growing threat, especially this year. We have demonstrated its effectiveness in the laboratory and have had productive conversations with FDA, and we have a feasible production schedule. **However, without our phase II SBIR program, our progress will slow. This affects our commercial development as a company, as an employer, and as an ultimate contributor to the federal tax base.**

National Institutes of Health SBIR/STTR portfolio company.

Fetal Therapy Technologies, Baltimore, MD

Selena Shirkin, BS, MSE
CEO
Fetal Therapy Technologies



SBIR funding would be the bridge for my company to continue operating full-time and helping create life-saving technologies. Fetal Therapy Technologies is a microsurgical device company developing tools to improve the safety of life-saving fetal surgery. **This field has no industry involvement right now, so the SBIR pathway is our best chance to secure funding and continue this work.**

Fzata, Inc., Halethorpe, MD

Elizabeth Anne Smith, Ph.D.

Chief Business Officer

Fzata, Inc.



Because of the delay in SBIR funding, **my job has been cut to 1/2 time and I have not been able to perform my typical job functions**, including raising dilutive capital for the company operations.

National Institutes of Health SBIR/STTR portfolio company.

IECBio LLC, Poolesville, MD

David M. Anderson, Ph.D.

Chief Executive Member

IECBio LLC



IECBio LLC collaborates with Potomac Affinity Proteins, which has a pending Phase 2 SBIR project. Obtaining this Grant to support the advancement and process development for some important innovative technology developed by Potomac Affinity would be very helpful to advance the commercialization. The commercialization of two useful examples of the application of Potomac Affinity's technology is the goal of IECBio LLC. We intend to apply the production to a worldwide market exceeding \$100 million.

Irazu Oncology, Baltimore, MD

Jeff Strovel, Ph.D.

CEO

Irazu Oncology



We are a per-series A biotech developing preclinical therapeutics for oncology. **Venture funding the last 2 years is non-existent for preclinical companies** forcing us to rely on the SBIR program to advance our innovative immunotherapies. Now that funding pathway has halted. We are struggling to stay afloat and our technology is outstanding. **We may have to work with China to advance the products.**

Just Strive, Germantown, MD

Raj Desai, MS, MBA

Founder

Just Strive



Dear Members of Congress, We urge Congress to renew the SBIR/STTR programs immediately. These initiatives are vital to America's innovation economy, enabling early-stage biotech, pharmaceutical, AI, and robotics companies to transform high-risk ideas into market-ready breakthroughs. At Just Strive Capital, we help innovators secure SBIR/STTR funding, which has accelerated R&D, attracted private investment, and created high-quality jobs. **Without these programs, many pioneering technologies would stall, undermining U.S. leadership in life sciences and advanced technologies.** Renewing SBIR/STTR is not just funding innovation; **it is securing America's future in health, security, and technology.** We ask for your leadership in acting now.

Respectfully,

Raj Desai, MS MBA

Founder Just Strive, Inc.

Key Courier LLC, Frederick, MD

Bill Clem

President

Key Courier LLC



I am a very small Courier business that relies on the medical, biotech, and research businesses to maintain my business. I work directly with medical billing, biotech firms, and hospitals. **Our area has seen a significant impact on the lack of funding and the trickle down to all the industries around here is being felt by everyone regardless of their politics.**

LEI Sales, LLC, *Greenbelt, MD*

Daniel Brower

CEO

LEI Sales, LLC

LEI Sales, LLC

The lapse in the authorization of the SBIR/STTR programs is taking a devastating toll on innovative small businesses and university research. **The lapse has directly impacted my business by reducing revenue by more than 20%.** Please reauthorize these programs and do your part to keep the USA in the forefront of technical innovation.

Lumo Imaging LLC, *Rockville, MD*

Davood Tashayyod

CEO

Lumo Imaging, LLC



With previous funding from the STTR, our company in collaboration with researchers from JHU has developed world's first dermoscopic resolution capable total body scanner. This is a world-beating technology that not only can improve the US's commercial position, but it also has the potential to save thousands of lives. **With the current state VC industry, companies like ours can only rely on SBIR/STTR programs to bring our prototypes to the market.**


National Science Foundation SBIR/STTR portfolio company.

Medical Decision Logic, Inc., *Baltimore, MD*

Allen Tien, MD, MHS

President, Chief Science Officer

Medical Decision Logic, Inc.



Our SBIR program is unique in the world, and is very important to our economy, prosperity, and security.


National Institutes of Health SBIR/STTR portfolio company.

Mesa Science Associates Inc., *Frederick, MD*

Michael Mesa

President

Mesa Science Associates Inc.



Meas Science Associates was awarded a 3-year SBIR contract to develop an antidote for cyanide poisoning found in smoke from structural fires. The tear was approved, but was delayed, leaving Mesa idle for months. **The first year was eventually awarded, leaving the next 2 years without funding. If the funding for the SBIR/STTR programs is not restored, it will have a detrimental impact on MSA and its employees.**


National Institutes of Health SBIR/STTR portfolio company.

MelaTech, *Baltimore, MD*

Radames J.B. Cordero

CEO

MelaTech



Our company develops radiation shielding technologies of critical importance for national security. **This lapse is affecting our operations in a critical way.** Please act now and restore the SBIR/STTR funding!

National Aeronautics and Space Administration and Department of War SBIR/STTR portfolio company.

Nanocrine, Inc., *Frederick, MD*

Patrick Calhoun, Ph.D.

President & CSO

Nanocrine, Inc.



The legislative actions being taken to defund science will result in a weaker, less competent, debilitated, and less technologically advanced country. These grants are instrumental in equipping startups with the capital requirements to bring high-tech IP into the marketplace.

Much of this IP would never make it to the marketplace, relying on large companies alone due to risk. These grants aren't only good for science. They are good for the economy, bolster our healthcare options, and safeguard our international interests.

-Signed, the rare Republican scientist and an enlisted Infantry Veteran of Iraq and Afghanistan.

National Science Foundation SBIR/STTR portfolio company.

New Integration Photonics, Chevy Chase, MD

Mario Dagenais
CEO
New Integration Photonics



Our Company depends heavily on the SBIR program for developing our products and bringing them to the market. We are working in the area of photonic integration and quantum computing.

National Aeronautics and Space Administration SBIR/STTR portfolio company.

OncoVanta Therapeutics, Inc. Hagerstown, MD

Roman Owens, MS
Founder & CEO
OncoVanta Therapeutics, Inc.



The current lapse in SBIR/STTR authority has already created significant uncertainty, delayed research timelines, and jeopardized ongoing collaborations with U.S. universities, federal laboratories, and clinical partners. For companies like OncoVanta, these delays do not simply affect balance sheets—they delay potential cures for patients who cannot afford to wait.

Cancer does not pause for legislative uncertainty.

Reauthorizing SBIR/STTR—whether through a clean extension or a long-term bipartisan solution—would immediately restore confidence, allow agencies to resume awards, and protect one of the most successful public-private innovation engines the United States has ever built. I respectfully ask you to support immediate reauthorization

of SBIR/STTR and advocate for a stable, long-term framework that ensures continuity for small, innovation-driven companies.

On behalf of our team, our academic collaborators, and—most importantly—the patients and families who are counting on American innovation, thank you for your leadership and service.

PediaMetrix, Rockville, MD

Reza Seifabadi, Ph.D.

CEO

PediaMetrix



PediaMetrix developed SoftSpot, the first and only FDA-cleared mobile app for infant head shape assessment, made possible through support from NSF and NIH SBIR funding.

Pediatric markets are often overlooked by private investors due to smaller perceived market size, making

SBIR support critical. SBIR funding enabled us to de-risk both the technology and regulatory pathway, allowing us to reach commercialization and attract private investment. SoftSpot has since supported thousands of parents and healthcare providers nationwide. PediaMetrix is now developing additional innovative pediatric products, such as EarSpot, has employed dozens of full-time and part-time U.S. contractors, and has contributed meaningfully to the U.S. economy.

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Relative Dynamics, Inc., Laurel, MD

Diane Ngo

Opto-Mechanical Engineer

Relative Dynamics, Inc.



Our R&D team has faced financial challenges due to the lapse in funding. We are heavily contracted with government agencies such as NASA, NOAA, NSA, and SDA. **As a result, half of the team has been laid off, making our continuing efforts challenging.**

National Aeronautics and Space Administration SBIR/STTR portfolio company.

Rise Therapeutics LLC, Rockville, MD

Gary Fanger, Ph.D.
President and CEO
Rise Therapeutics LLC



At Rise Therapeutics, the SBIR program has been instrumental in validating our new therapies for cancer, arthritis and inflammatory bowel disease. Patients are reporting disease improvements from our drugs, and we are on the cusp of a breakthrough in immunotherapy development. Since some of these clinical trials are funded by SBIR grants and the SBIR program was not reauthorized, we are beginning the process of letting doctors and patients know that our life saving medications will no longer be available and provided to help treat their disease because the federal government has cut off funding to support supply of their life-saving medication.

Janet Stephens, Ph.D.
Sr. Vice President, Operations
Rise Therapeutics LLC



I am writing to urge your immediate action to reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. As a senior executive at a U.S.-based biotechnology company developing innovative therapies for serious and life-threatening diseases, I see firsthand how SBIR funding bridges the gap between academic discovery and clinical development. These programs are not academic exercises — they are often the only viable source of non-dilutive capital for early-stage companies to advance promising science into regulated clinical trials. Without timely reauthorization, the interruption of SBIR/STTR funding will have immediate and severe consequences: Ongoing clinical programs may be delayed or terminated. Small businesses will be forced to lay off highly trained scientific and clinical personnel. U.S. leadership in biomedical innovation will erode, shifting talent and intellectual property overseas. For companies like ours, SBIR awards directly fund IND-enabling studies, manufacturing scale-up, regulatory interactions with the FDA, and first-in-human trials. These activities are capital-intensive, high-risk, and fundamental to bringing new treatments to patients who urgently need them. The uncertainty surrounding reauthorization is already having a chilling effect on planning and investment decisions across the biotech sector. Continued delays jeopardize not only individual companies, but the broader U.S. innovation ecosystem that has been carefully built over decades. I respectfully urge you to prioritize swift reauthorization of the SBIR and STTR programs and to advocate for their long-term stability. Doing so will protect American jobs, accelerate lifesaving medical breakthroughs, and ensure that the United States remains the global leader in biotechnology innovation. Thank you for your leadership and your service. I

would welcome the opportunity to discuss the impact of these programs in greater detail.

National Institutes of Health SBIR/STTR portfolio company.

Society of Physician Entrepreneurs, *Potomac, MD*

Jeffrey N. Hausfeld, MD

Co-Founder, Chairman of the Board
Society of Physician Entrepreneurs



The lack of funding from SBIR/STTR programs has stalled many of these programs early in their development stage. **This will cause significant delays, and in some cases abort, the availability of life-saving novel therapies to children and adults in need of care not presently available.** The lack of funding will also have significant implications in hiring young scientists who are just beginning their careers, altering the landscape of our scientific competitiveness on the global stage for decades to come. Please get these programs back up and functioning so the United States life science and healthcare startup engine can get back to business!

Thank you for your consideration and prompt action.

TelohealthDx LLC, *Clarksburg, MD*

Yun-Ling Zheng, Ph.D.

President
TelohealthDx LLC



Our company develops telomere signature tests to enhance the diagnosis and prognosis of pulmonary fibrosis, telomere biology disorders and for early detection of leukemia. These diseases affect millions of Americans. Our company is a startup company that depends on the SBIR and STTR funding for research and development. Currently, the R&D activities are on hold because of the lack of SBIR/STTR funding.

National Institutes of Health SBIR/STTR portfolio company.

Tiami Networks, Inc., Hanover, MD

Tyrell Junius

Co-Founder

Tiami Networks, Inc.



The lapse in SBIR/STTR funding has created material uncertainty for Tiami Networks, **directly impacting hiring decisions, project scheduling, and transition planning with government partners**. As a small business executing active and pending DoD-aligned R&D efforts, **delays in reauthorization disrupt cash flow, slow technical progress, and increase risk to retaining specialized engineering talent**.

National Science Foundation, Department of War, and United States Department of Agriculture SBIR/STTR portfolio company

TTi Health Research & Economics, Westminster, MD

Fernanda Nusbaum

Vice President of Client Relations
TTi Health Research & Economics



As a contract research organization (CRO) supporting early-stage innovators, we have seen firsthand how the lapse in SBIR/STTR funding has disrupted small businesses. Several clients were forced to pause or scale back critical clinical and health economics studies due to sudden funding uncertainty. These delays directly affect hiring, vendor commitments, and the generation of evidence needed to attract follow-on investment or payer support. For many startups, SBIR/STTR funding is not supplemental—it is foundational. **Interruptions jeopardize momentum, extend timelines, and threaten the viability of promising technologies intended to improve patient care.** Congress must act immediately!

Veralox Therapeutics, Inc., *Frederick, MD*

Matt Boxer

Co-Founde & COO

Veralox Therapeutics, Inc.



Our company was the recipient of one SBIR and one STTR grants, which were instrumental in us building the company to the point we were able to then raise venture capital for the development of a drug for a rare disease called heparin-induced thrombocytopenia.

National Institutes of Health SBIR/STTR portfolio company.

WB Engineers + Consultants, *Frederick, MD*

Christopher Carmona

Business Development Manager

WB Engineers + Consultants



At my previous company, we were developing a whole parasitic malaria vaccine. Funding for malaria was extremely difficult to impossible to secure through the private industry but the SBIR program provided millions of dollars for developing our vaccine. **These funds were used for R&D, clinical trial support, and commercialization readiness and were critical to the mission and sustaining the company.** These were competitive, peer-reviewed, merit-based grants that supported our company, our research partners, and those affected by malaria.

Massachusetts

Economic Impact of Program:

SBIR/STTR Funds Received: **\$9,510,284,290.61**

Small Business SBIR/STTR Awards: **26,649**

Letter to Congress Co-signers

Jen Asher, Ph.D.	Founder and CEO	1910
Paula Soteropoulos	Venture Partner	5AM Ventures
Stephen Linderman, MD, Ph.D.	CEO	Absco Therapeutics, Inc.
Dr. AnnMarie Hipsley	CEO	Ace Vision Group, Inc.
Nicole LeMaitre, CPA	Corporate Tax Manager	ADC CPA
Brice Lorho	Owner and CEO	Adjacent
Robert ietswaart, Ph.D.	CEO and Co-Founder	Aircyt, Inc.
Scott Cohen	CEO	Alpha Cure Therapeutics
Kristina Plogmeier	Senior Accounting Associate	Ambrosi Donahue Congdon & Co., P.C.
Lee Harrison, Ph.D.	CTO and Co-Founder	American Veritas Engineering, LLC
Michael LaFleur, Ph.D.	CEO	Arietis Corporation
Anna Jagielska	CEO	Artificial Axon Labs
Molly Magill, Ph.D.	Professor of Behavioral and Social Sciences	Behavior Change Hub, LLC
Andrew Bodkin Mark Villafuerte	Principal Senior Engineer	Bodkin Design and Engineering, LLC
Ken Olivier, Ph.D.	EVP	Boston Immune Technology and Therapeutics
Mark Grinstaff	Professor and Inventor	Boston University
Stephen D. Van Hooser, Ph.D.	Associate Professor and Owner	Brandeis University and Waltham Data Science, LLC
V. Hruby, Ph.D.	Founder	Busek Co., Inc.
Ed Jameson, CPA	Partner	Cherry Bekaert Advisory

Cherylene Plewa, Ph.D.	Biotechnology Consultant	Cherylene Plewa Consulting
Safia Rizvi, Ph.D., MBA	CEO and Founder	Cila Therapeutics
Daniel Goldman, Ph.D.	CSO	Constantiam Biosciences
Christopher J. Corcoran	President	Corcoran Engineering, Inc.
Nelson Monteiro	CEO	EandM BioLab
Michael Cardone, Ph.D.	CEO	Eutropic Pharmaceuticals
Laura Hales, Ph.D.	Founder	Extend Biosciences, Inc.
Michael Graffeo	CEO	FluidForm Bio
Marc Bucalo, CPA	President and CEO	g2 Consultant, Inc.
Robert R. Yocum, Ph.D.	CSO	General Biologics, Inc.
Ilya Ilyin, Ph.D., MBA	CEO	General Biophysics
Haiying Peng	President	Geode Therapeutics, Inc.
Kevin Skinner, VMD	CEO	GlycoSeal Med
Daniel Esposito	CEO	Guardion, Inc.
Daniel Cohen, Ph.D.	Chief Scientist	
Jean Zhao	Professor	Harvard Medical School and Dana-Farber Cancer Institute
Michael Skrajner, MA	Director of Research and Innovation	Hopeful Aging
Victor Shifrin, Ph.D.	CEO	ImmunoChem Therapeutics, LLC
Claire Barnes, Ph.D.	Director of Clinical Research	Intelon Optics
Andrew Levin, Ph.D.	CEO	Kephera Diagnostics, LLC
Jyotsna Mehta	CEO	Keva Health
Ratnam Srivastava, MS	Founder	LabOps
Yonatan Lipsitz, Ph.D.	CEO	Lilium Therapeutics, Inc.
Benjamin Freedman	President	Limax Biosciences, Inc.
Selina Zhu, Sc.D	Business Development Lead	Lumia Health, Inc.
Danny Concagh, M. Sc.	Vice President of Product and Process Development	Lyra Therapeutics

John Chen, MD, Ph.D.	Associate Professor	Massachusetts General Hospital
Monica Gostissa, Ph.D.	CSO	
Dennis Zimmermann, Ph.D.	Associate Director of Research	Matrisome Bio
Terry Bowlin, Ph.D.	CEO	
Michelle Butler, Ph.D.	Director of Pharmacology	Microbiotix, Inc.
Mirko Hrovat	Owner	Mirtech, Inc.
MJ Antonini, Ph.D.	CEO	NeuroBionics
Srinivas Sridhar	CEO	NeuroFieldz, Inc.
Michael Wootton	President and CEO	NF2 Therapeutics
Dr. Shahriar Khushrushahi	CEO	Notch, Inc.
Charles H. Rogers, Ph.D.	CEO	Opus KSD, Inc.
William Haskins	CEO	Owl Therapeutics
Minmin Yen, Ph.D.	CEO and Co-Founder	PhagePro
David B. Oakes, Ph.D.	Area Manager, Aerothermal Interactions	Physical Sciences, Inc.
Anuj Bellare, Ph.D.	President	Polymerix Technologies, LLC
Manijeh Goldberg, Ph.D., MBA, MS	CEO and Founder	Privo Technologies
Feyisayo Eweje, Ph.D.	Co-Founder and CEO	Procure Bio
Alexander Suvorov, Ph.D.	CEO	ReGENE, LLC
Col. (ret) Molly McGlaughlin	CEO	Revolution Biomanufacturing, Inc.
Pinar Gurel, Ph.D.	Director, Protein Engineering	Rhapsogen
W. Benton Swanson, DDS, Ph.D.	CEO	Skeletalis
Neal Checka	CEO	Sky Park Labs, LLC
Lina Williamson, DVM, Ph.D.	CEO	Soterya, Inc.
Dr. Robert Sundberg	President Emeritus	Spectral Sciences, Inc.
Connor Verheyen, Ph.D.	Co-Founder and CEO	Spheric Bio

Elliot Tague, Ph.D.	Founder	SynsoryBio
Alise S. Reicin	President and CEO	Tectonic Therapeutic
Vinod F. Patel, Ph.D.	President	TME Therapeutics
Nasser Rafire	CEO	Transmural Systems
Kimya Harris	CEO	TriCan Health
Arthur Gavron	VP of Advanced Materials	Triton Systems, Inc.
M. Elizabeth Fini, Ph.D.	Professor of Ophthalmology	Tufts University at Tufts Medical Center
Marta Garcia Montojo	Senior Director	Twilight Bioscience
Min Yun	Professor	University of Massachusetts
Demetrios Papageorgiou, Ph.D.	CEO	USMAT, Inc.
Emily Man, MS	CEO	Venova Technologies
Yuval Malinsky, MBA	CEO	Vigorous Mind, Inc.
Katie Kugler, Ph.D.	Head of Grants and Research Strategy	Vivid Bio
Gordon B. Hirschman	CEO	Vivonics, Inc.
Arash Aslani	VP	Vox Bio
Michael Dudley	CEO	Xelcis Bio, Inc..
Nicholas Bauer, Ph.D.	Principal Scientist	XGenomes Corp
Mark C. Beaubien	President	Yankee Environmental Systems, Inc.
Khashayar Vakili, MD	Founder and CEO	ZEeST Bio
Arthur M. Krieg, MD	CEO	Zola Therapeutics

Selected Case Studies from Impacted Companies:

1910, Boston, MA

Jen Asher, Ph.D.

Founder and CEO
1910

1910 Genetics received a Phase I STTR from the NIH's NINDS as part of the HEAL initiative in 2021. This funding was crucial to accelerating our drug discovery platform and pipeline of therapeutics. We kindly urge the government to reauthorize the SBIR and STTR programs.



National Institutes of Health SBIR/STTR portfolio company.

Absco Therapeutics, Inc., Boston, MA

Stephen Linderman, MD, Ph.D.
CEO
Absco Therapeutics, Inc.




Absco Therapeutics is a biotechnology company based on technology out of MIT, developing nonsurgical, locally injectable treatment opportunities for solid cancers starting with cervical pre-cancerous lesions. NIH and NSF SBIR support has been invaluable for our technology platform development, enabling new immunotherapies that will support commercial partnerships and clinical progress. The SBIR reauthorization is critical to enable continued development to treat cancer patients.

National Science Foundation SBIR/STTR portfolio company.

American Veritas Engineering LLC., Leverett, MA

Lee Harrison, Ph.D.
CTO/co-founder
American Veritas Engineering LLC, Leverett, MA



Our small team developed low-cost X-band phased array Doppler weather radars via a 2024 NOAA Phase I SBIR program. These novel weather radars capture important dangerous tornados and severe precipitation, effectively filling in the lower tropospheric gap between the 160 NOAA/FAA's WSR-88D NEXRAD radars. Phase II funding will build/test this technology proving compatibility with NEXRAD's processing.

Department of Commerce SBIR/STTR portfolio company.

Bodkin Design & Engineering, LLC, Newton, MA

Mark Villafuerte

Senior Engineer

Bodkin Design & Engineering, LLC



The SBIR/STTR lapse is slowing our R&D and making it harder to grow our team. Prompt reauthorization of the program would allow us to continue innovating and supporting the next generation of engineers.

Department of War and National Aeronautics and Space Administration SBIR/STTR portfolio company.

Boston Immune Technology & Therapeutics, Cambridge, MA

Ken Olivier, Ph.D.

Executive Vice President

Boston Immune Technologies and Therapeutics Inc.



We are awaiting key government shared funding to complete SBIR work that supports therapeutic development in oncology and immunology indications in American populations.

National Institutes of Health SBIR/STTR portfolio company.

Busek Co. Inc., Natick, MA

Vlad J. Hruby, Ph.D.

President

Busek Co. Inc.



Busek is now the major source of electric propulsion (EP) for satellites. We sell such EP devices worldwide. Busek is second in the world in the number of delivered electric propulsion devices. **All these products have started their development with SBIR funding.**


Department of War and National Aeronautics and Space Administration and National Science Foundation SBIR/STTR portfolio company.

Corcoran Engineering, Inc., Waltham, MA

Christopher J. Corcoran

President

Corcoran Engineering, Inc.



This lapse in SBIR funding has delayed the program I am performing for both DARPA and MDA. The DARPA program is to develop a high-power laser to enable a wireless power beam over large distances and the MDA program is to develop a high-power laser for National Defense. I had anticipated this funding in my yearly corporate budget and having this funding be eliminated has pushed my company near to being out of business.

Department of War SBIR/STTR portfolio company.

Crimson Biopharm Inc., Brookline, MA

Jean Zhao, Ph.D.

Professor

Harvard Medical School and Dana-Farber Cancer Institute



Our small biotech is developing a first-in-class, brain-targeted small-molecule therapy for CNS cancers with an exceptional safety profile. Support from an NIH Phase I STTR was critical in advancing this program from academic discovery to an active IND and first-in-human clinical trial in glioblastoma patients. Building on this momentum, we submitted a Phase II SBIR/STTR application in Fall 2025 to expand development into lung cancer with CNS metastases, an area of urgent unmet need. The current lapse in SBIR/STTR authorization has delayed funding decisions, disrupted clinical planning and hiring, and slowed patient access to promising new therapies.

National Institutes of Health SBIR/STTR portfolio company.

E&M BioLab, Cambridge, MA

Nelson Monteiro

CEO

E&M BioLab



E&M BioLab, a newly launched regenerative dental startup, depends on SBIR funding to advance its lead products, MCOLGEL and MCOLROOT, next-generation dental pulp capping and root canal biomaterial. **The lapse in SBIR/STTR funding has stalled critical R&D efforts, delayed hiring of key personnel, and jeopardized early-stage investor confidence.** Without funding, we risk losing momentum, partnerships, and the opportunity to deliver a transformative, U.S.-developed solution to patients. This uncertainty threatens our ability to grow and translate innovation into impact.

Extend Biosciences Inc., Newton, MA

Laura Hales, Ph.D.

Founder

Extend Biosciences Inc.



The SBIR program has been critical to the success of my company. We have received SBIR funding from NIH and FDA to support our therapy for a rare disease for the past 8 years. We are now in Phase 2 clinical trials and rely on continuing applications to the SBIR program for funding in order to finish our trial and get closer to FDA approval of this drug for patients who need it. We cannot simply stop the trial in the middle. Any further delay in reauthorization would require the ending of our trial. Massachusetts companies thrive on this funding. It has always been reauthorized until now, so please, come to a compromise and pass a bill. Thank you.

National Institutes of Health, National Science Foundation, and Department of War SBIR/STTR portfolio company.

General Biologics, Inc., Boston, MA

Robert R. Yocum, Ph.D.

CSO

General Biologics, Inc.



My company received a Phase I SBIR grant from the NIH. The actual funding was delayed by about 8 months due to RFK Jr's reckless screwing up of the entire NIH system. But more importantly, Phase I grants cannot fully support a project, much less a whole company, so we operate at a loss. The "real money" is in Phase II. We are depending on the SBIR being refunded so that we might get Phase II. The SBIR program should be funded "in perpetuity" so we don't ever face this disaster again.

Department of War SBIR/STTR portfolio company.

General Biophysics, Framingham, MA

Ilya Ilyin, Ph.D., MBA

CEO

General Biophysics



The consequential crisis is quietly unfolding. The SBIR/STTR programs remain unauthorized. This is not a technical delay. **It is a direct threat to the backbone of U.S. innovation.** Small businesses generate most net new jobs in the U.S. Scientific entrepreneurship is how discoveries become products, companies, and cures. And SBIR/STTR are the only federal programs designed specifically to fund applied research close to commercialization—the stage too risky for private capital but essential for society. These programs don't fund basic science. They fund solutions: medical therapies, advanced technologies, energy resilience, national security tools. The impact is measurable: over \$77B invested in ~33,000 U.S. small businesses, strong ROI for taxpayers, tens of thousands of high-skilled jobs created, and entire industries launched. Yet today, uncertainty is forcing startups to freeze hiring, cancel development programs, and burn through limited runway. Bankruptcies are coming. In my own company, we have ~3 months of runway left. **We relied on SBIR/STTR to develop lifesaving therapies for opioid addiction and Alzheimer's disease. Without reauthorization, that work stops—not slows, stops.** Meanwhile, China, Russia, and multiple Latin American countries are accelerating state support for strategic applied technologies. **The U.S. is standing still. This is not partisan. This is not ideological. This is about whether America still believes in turning science into real-world solutions.** Congress can fix this immediately. Reauthorizing SBIR/STTR would protect jobs, innovation, and U.S. leadership. **Silence has a cost:**

lost companies, lost cures, lost competitiveness. America cannot afford that.

National Institutes of Health SBIR/STTR portfolio company.

GlycoSeal Med, Newburyport, MA

Kevin Skinner, VMD
CEO
GlycoSeal Med

GlycoSeal Med

We were going to submit for a tissue adhesive to treat pulmonary air leaks following lung surgery in patients with lung cancer.

Guardion, Inc., Reading, MA

Daniel Cohen, Ph.D.
Chief Scientist
Guardion, Inc.



I am currently employed doing research on two SBIR Phase I awards through NASA, one as PI. Without the reauthorization of the program both of these projects will stall, even though our results are promising.

Department of War, National Science Foundation, and National Aeronautics and Space Administration SBIR/STTR portfolio company.

Hopeful Aging, Woburn, MA

Michael Skrajner, MA
Director of Research and Innovation
Hopeful Aging



Our company develops non-drug based interventions aimed at improving the quality of life of persons with dementia. We are a relatively new company that has several products in various levels of readiness for commercialization. We also have plans for future projects that would revolutionize the industry. However, the lapse in SBIR funding is placing our entire company of 5 employees at risk. Without additional grant funding, jobs would be in jeopardy and most importantly people with dementia will not be able to access the innovative interventions

that we have been planning to develop over the next few years.

National Institutes of Health SBIR/STTR portfolio company.

ImmunoChem Therapeutics, LLC, Newton, MA

Vicor Shifrin, Ph.D.

CEO

ImmunoChem Therapeutics, LLC



My small business ran a SBIR-supported Phase I clinical trial in patients with brain metastases. The lapse in SBIR funding prevents us from continuing into a Phase II trial.

National Institutes of Health SBIR/STTR portfolio company.

Kephera Diagnostics, LLC, Framingham, MA

Andrew Levin, Ph.D.

Chief Executive Officer

Kephera Diagnostics, LLC



As founder and CEO of Kephera Diagnostics, a small business that has been awarded a number of NIH SBIR grants that support the development of new diagnostic tests for emerging infectious diseases, I am writing to express my concern over the expiration of the SBIR program on Oct. 1, 2025. **SBIR funding has allowed us to develop new tests for Lyme disease, Chagas disease, and several other diseases that send people to the hospital but are difficult to diagnose. We need SBIR support to bring these tests to FDA approval and commercial launch, the key to becoming a revenue-generating company.**

National Institutes of Health and Centers of Disease Control SBIR/STTR portfolio company.

Lumia Health, Inc., Boston, MA

Selina Zhu, Sc.D

Business Development Lead
Lumia Health, Inc.



Lumia Health develops an advanced ear-worn wearable that provides continuous physiological monitoring for battlefield and civilian use, including blood pressure trends, sleep, and body temperature. **SBIR/STTR funding is foundational to our ability to conduct high-risk, early-stage research and to translate that research into next-generation wearable technology.** The lapse in SBIR/STTR funding has **directly disrupted our R&D timeline, delayed hardware and algorithm development, and created uncertainty in staffing and partner commitments.** These **delays slow innovation in mission-critical health monitoring and impede our ability to deliver capabilities urgently needed by warfighters and patients alike.**

Department of Defense and Department of Energy SBIR/STTR portfolio company.

M. Elizabeth Fini, Boston, MA

M. Elizabeth Fini, Ph.D.

Professor of Ophthalmology
Tufts University at Tufts Medical Center



Many academics collaborate with small businesses using Small Business Technology Transfer (STTR) grant mechanism. The main goal of the program is to stimulate technological innovation and commercialization by fostering formal cooperative research and development between U.S. small businesses and non-profit research institutions. This program is crucial for innovation.

Mark Grinstaff, *Boston, MA*

Mark Grinstaff

Professor and Inventor
Boston University




SBIR/STTR funding is critical to advancing new technology from the university to the market. It funds a critical time period in a company when investors, VC, etc. do not want to invest because the technology needs a little further development.

Matrisome Bio, *Cambridge, MA*

Dennis Zimmermann, Ph.D.

Associate Director of Research
Matrisome Bio



We were so fortunate in being awarded a Direct-to-Phase 2 SBIR through the NCI, a 2-year award, which is critical for our organization and mission to develop lifesaving, novel, minimally invasive and effective therapies to cancer patients. We are currently in year 1 of the funding period and given the current state of affairs cannot plan any studies in the upcoming year as we do not know whether we will even receive any subsequent Year 2 funding.

National Institutes of Health SBIR/STTR portfolio company.

Microbiotix, Inc., *Worcester, MA*

Michelle Butler, Ph.D.

Director of Pharmacology
Microbiotix, Inc.



Microbiotix is a small molecule anti-infectives company that develops antiviral, antibacterial and antifungal agents. We have been in business for 26 years and in the last few years, the ability to obtain small business grants has been drastically reduced.

The ongoing lapse in SBIR/STTR funding is preventing the company from advancing projects to the clinic, and subsequently depriving Americans and the global community from much needed anti-infective agents to counter the effects

of antimicrobial drug resistance.

National Institutes of Health SBIR/STTR portfolio company.

Mirtech, Inc., Brockton, MA

Mirko Hrovat

Owner

Mirtech, Inc.



Small businesses do not have the resources to fund projects temporarily for short periods of time. The SBIR/STTR program is crucial in funding small projects that might only be tackled by small businesses. **Delays and a reduction in funding are crucial in this regard. I've seen projects come to a halt not because they are not worthy but because funding has run out.** The realization of a project's potential can only be determined in many cases only after there has been some initial funding for development. Without it, these projects simply die on the vine. **Even the current delay has dramatically affected the company and the development of a medical device to improve MRI imaging of patients with ICDs.** At the least current development has halted. Please reconsider funding the SBIR/STTR program, which has been highly successful.

United States Department of Agriculture SBIR/STTR portfolio company.

NeuroFieldz Inc, Newton, MA

Srinivas Sridhar, Ph.D.

CEO

NeuroFieldz Inc



The reauthorization of the SBIR/STTR program is critical for NeuroFieldz Inc. as it serves as the company's primary lifeline for high-risk, high-reward research and development. To date, NeuroFieldz has secured over \$2.75 million in total funding from the NIH and NSF through these programs to advance its innovative NeuroVEP and Electric Field Encephalography (EFEG) technologies. With the program's authorization having lapsed on October 1, 2025, and federal agencies currently unable to issue new awards or solicitations, the company's ability to submit new grant applications for its Beta prototype design and essential validation testing is currently frozen. Timely reauthorization by early 2026 is vital to provide the non-dilutive capital needed to bridge

the "valley of death" as NeuroFieldz seeks to complete manufacturing and secure FDA 510(k) approval for its neuro-ophthalmic diagnostic devices.

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Physical Sciences Inc., Andover, MA

David B. Oakes, Ph.D.

Area Manager, Aerothermal Interactions
Physical Sciences Inc.



I am managing a Phase II SBIR program that will be delivering a critical piece of new test capability to the Navy later this year to support the development of new materials for hypersonic systems. The Navy would like to have us continue to advance the underlying technology through a follow-on 2nd Phase II SBIR, but this has been on hold for several months due to the lapse in the program. **The lapse in the SBIR program will delay the advancement of the technology and put us further behind our adversaries who are not stopping work on their technology development efforts.**

Defense Advanced Research Projects Agency, Department of Health Services, National Institutes of Health, National Aeronautics and Space Administration, Department of War, and Department of Energy SBIR/STTR portfolio company.

Polymerix Technologies LLC, Allston, MA

Anuj Bellare, Ph.D.

President
Polymerix Technologies LLC



At this early stage we have relied entirely on federal grant support, having been funded by NIH's NHLBI and NIAMS, as well as by the Department of Navy, all through the SBIR program. Without this program, our research comes to a halt, and we are forced to do some consulting work to make a steady income. **Reauthorization of SBIR will keep us on track to develop technologies for the Navy as well as lifesaving medical devices.**

National Institutes of Health SBIR/STTR portfolio company.

Procure Bio, *Boston, MA*

Feyisayo Eweje, Ph.D.

Co-founder, CEO

Procure Bio



STTR funding would be a critical piece of the financing we need to get our venture off the ground. Our timeline to move out of our academic origin and into a commercial setting where we can accelerate our medicines has been delayed because of this.

ReGENE LLC, *Belchertown, MA*

Alexander Suvorov, Ph.D.

CEO

ReGENE LLC



We are working on the development of an innovative Alzheimer's drug. Our research is frozen now because of SBIR funding interruption

National Institutes of Health SBIR/STTR portfolio company.

Skeletalis, *Boston, MA*

W Benton Swanson, DDS, Ph.D.

CEO

Skeletalis



The lapse in SBIR/STTR funding has had a direct and disruptive impact on our company. Delayed reauthorization has stalled planned research activities, forced us to slow hiring, and created uncertainty for academic and industry collaborators who depend on SBIR support to advance early-stage, high-risk biomedical innovation. **For small biotech companies like ours, SBIR/STTR funding is not supplemental—it is foundational.** Prolonged gaps threaten scientific momentum, increase financial risk, and undermine the public–private research pipeline Congress intended these programs to support.

Sky Park Labs LLC, Concord, MA

Neal Checka

CEO

Sky Park Labs LLC



We are unable to continue our groundbreaking work in munitions inspection as our Phase II is about to end. This program ensures safe munitions for our warfighters. The Army has shown interest in funding a follow-up sequential Phase II, but we cannot apply since there is no program.

Department of War and National Institutes of Health SBIR/STTR portfolio company.

Soterya Inc., Boston, MA

Lina Williamson, DVM, Ph.D.

CEO

Soterya Inc.



We operate under a Phase II SBIR. We had to slow down our market entry and are at risk of having to reduce our lab personnel- already stretched. Resolutions will give us a better runway to continue with operations

National Institutes of Health SBIR/STTR portfolio company.

Spheric Bio, Chelsea, MA

Connor Verheyen, Ph.D.

Co-Founder & CEO

Spheric Bio



As a very early-stage startup developing a life-saving cardiac device, the lapse in SBIR/STTR reauthorization has paralyzed our operations. At this stage of development, we rely on this non-dilutive funding to bridge the well-known 'valley of death' between research and patient care. The current uncertainty has forced us to freeze hiring and has made financial planning very difficult, directly delaying our ability to bring this technology to the patients who need it most.

National Institutes of Health SBIR/STTR portfolio company.

SynsoryBio, Boston, MA

Elliot Tague, Ph.D.

Founder

SynsoryBio



The SBIR program has made a transformative difference in the early days of SynsoryBio. SynsoryBio is creating a new way to "turn on" powerful medicines only at the site of disease. As a team of scientists-turned-founders, we used the SBIR Phase I program to take an idea to a validated proof-of-concept. We were planning on submitting our Phase II application in March of 2026, but the funds lapsed. The lapse of funds, even for 6 months, could be the difference of companies like ours surviving to commercialization.

National Science Foundation SBIR/STTR portfolio company.

USMAT, Inc., Natick, MA

Demetrios Papageorgiou, Ph.D.

CEO

USMAT, Inc.



The lapse in funding will shortly lead to furloughing of key employees whose experience and expertise developing strategic technologies is **critical to the success of our Navy programs**. We have been approached by many foreign (presumably including Chinese) venture funds willing to provide us with capital, and hope, like us, other

companies have/will elect to close than provide a method for our adversaries to acquire US technology.

Department of War and Department of Energy SBIR/STTR portfolio company.

Yankee Environmental Systems, Inc., Turners Falls, MA

Mark C Beaubien

President

Yankee Environmental Systems, Inc.



We have developed multiple new atmospheric weather environmental sensors that are now in routine use by various government monitoring programs, all enabled via SBIR funding. Examples include our Models UVB-1 and UVMFR-7 radiometers, now used by USDA's "UV-B Monitoring Program" and the TSI-660 used by Dept of Energy's "Atmospheric Radiation Monitoring Program" (arm.doe.gov).

Department of Commerce, National Aeronautics and Space Administration, Department of War, National Science Foundation, and Department of Energy SBIR/STTR portfolio company.

ZEeST Bio, Watertown, MA

Khashayar Vakili, MD

Founder & CEO

ZEeST Bio



Our small biomedical startup relies on NIH SBIR/STTR funding to advance early-stage technologies that focus on finding new therapies for liver cancer. **We received our first NCI/NIH STTR grant in September 2025. This prompted our Founder/CEO to leave his academic position to advance the technology towards the clinic. The lapse in SBIR/STTR reauthorization has forced us to delay planned research activities, postpone hiring of scientific staff, and defer engagements with U.S.-based CROs and manufacturers.** This uncertainty disrupts carefully planned development timelines and increases financial risk for small companies that lack alternative funding sources. Timely reauthorization is essential to maintain innovation momentum, retain high-skilled jobs, and ensure that federally funded research continues translating into patient-ready solutions.

National Institutes of Health SBIR/STTR portfolio company.

Zola Therapeutics, Needham, MA

Arthur M Krieg, MD

CEO

Zola Therapeutics



My company is developing a new approach to cancer immunotherapy building on several decades of work. The SBIR mechanism is the best option available for us to move this program forward, because investors have moved out of cancer immunotherapy and into other fields that are trendier, like obesity. The SBIR Direct-to-Phase II program plays a critical role in helping small biotech companies, like ours, get through the "valley of death" from early innovation into generating the clinical data that will attract further investment.

Michigan

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,594,544,567.41**

Small Business SBIR/STTR Awards: **4,363**

Letter to Congress Co-signers

D. Randall Armant, Ph.D.	Professor Emeritus, CSO	Akna Health, Inc.
Julia Winter	CEO	Alchemie Solutions, Inc.
Gregory J. Gage, Ph.D.	CEO	Backyard Brains
Curtis A. Bagne, Ph.D.	President	DataSpeaks
Hongqi Xin	CEO	Exoheal Biotech, Inc.
Eugene Chen Charles Bisgaier	Co-Founder CEO, Founder, and Board Chairman	GeneToBe
Steven Bloembergen, Ph.D.	Chairman and CEO	GreenMark Biomedical, Inc.
Nathan Jones, Ph.D.	VP of Technology	
Nate Abrams	CEO	
Robert Forgey, MS, MBA	President and CEO	Iaso Therapeutics, Inc.
Harrison Bartlett, Ph.D.	CTO	Little Room Innovations, LLC
Stephen LeBeau, Ph.D.	President	nanoMAG, LLC
Ming Han	President	Nusenics, LLC
Kenneth P. Mitton, Ph.D., FARVO	Associate Professor of Biomedical Sciences	Oakland University - Eye Research Institute
Christopher Sedlak	CEO and Lead Engineer	Orsted Biosciences Corp.
Dongshan Yang	Assistant Professor	University of Michigan
Jie Xu	Professor	University of Michigan
Scott Olson, MBA	Commercialization Director	Wayne State University

Jiemei Wang	Associate Professor	Wayne State University
Kezhong Zhang	Distinguished Professor	Wayne State University
Wanqing Liu	Professor	Wayne State University

Selected Case Studies from Impacted Companies:

Akna Health, Inc., Grand Rapids, MI

D. Randall Armant, Ph.D.

Chief Scientific Officer

Akna Health, Inc.



SBIR/STTR awards provide relatively brief periods of funding (1-2 years), boosting early start-up companies with a short runway. Recently funded companies, like Akna Health, generate great momentum from these awards, but will hit a wall before their innovations mature without the opportunity to apply for additional awards. **The huge infusion of US tax dollars made over the past two years may be wasted if those companies are allowed to flounder without continued opportunities through the SBIR/STTR programs.** Every tax dollar spent returns over \$25 to our economy when these companies remain on course, bringing innovative products into the marketplace.

National Institutes of Health SBIR/STTR portfolio company.

Alchemie Solutions, Inc., Bloomfield Hills, MI

Julia Winter

CEO

Alchemie Solutions, Inc.



As CEO of an SBIR-funded edtech company on a path to commercialization potentially serving millions of students, the reauthorization delay creates uncertainty during a critical compliance moment. **With the April 2026 ADA Title II deadline approaching, educational institutions need our directly accessible STEM tools, innovations developed through SBIR grants from four different agencies.** Yet our ability to scale and meet this demand is compromised by funding instability. **SBIR reauthorization isn't just about continuing grants, it's about ensuring students with disabilities have access to accessible learning**

materials when the law finally requires it. The delay directly impacts students who can't wait.

National Institutes of Health, National Science Foundation, and Department of Education SBIR/STTR portfolio company.

Backyard Brains, Ann Arbor, MI

Gregory J. Gage, Ph.D.

CEO

Backyard Brains



Backyard Brains relies on SBIR funding to sustain our core research and engineering team while we develop affordable neuroscience tools for education and research. We are currently awaiting an SBIR review from early 2025, and the ongoing delay has already had severe consequences. **We have been forced to let go of highly skilled, mission-critical staff because we can no longer afford salaries or healthcare.** This uncertainty disrupts product development, weakens institutional knowledge, and threatens the long-term viability of our work. **Delayed reauthorization directly translates into lost jobs and stalled innovation.**

National Institutes of Health SBIR/STTR portfolio company.

GeneToBe, Ann Arbor, MI

Eugene Chen, MD, Ph.D.

Co-Founder

GeneToBe



The lapse in SBIR/STTR reauthorization has forced our organization to delay hiring, pause key research activities, and slow technology development due to funding uncertainty. These interruptions disproportionately impact small, innovation-driven teams and weaken the path from research to commercialization.

Charles Bisgaier

CEO, Founder and Board Chairman
GeneToBe, LLC



GeneToBe is conducting State of the Art research to find treatments and cures for both rare and common Diseases. **The loss of funding through the SBIR has severely damaged our ongoing programs in Cystic Fibrosis, rare congenital eye diseases, as well as our program in common liver disease (MASH) that affects 30–40% of Americans.**

National Institutes of Health SBIR/STTR portfolio company.

GreenMark Biomedical, Inc., Ann Arbor, MI**Steven Bloembergen, Ph.D.**


Chairman, CEO
GreenMark Biomedical, Inc.



Dental caries (tooth decay) is the world's most prevalent chronic disease, affecting 96% of Americans. Current products contain minerals that are not bioavailable, and fluoride that merely seals early-stage caries lesions temporarily. Great on marketing, touting remineralization, but thin on science. GreenMark was founded in 2016 to develop a disruptive noninvasive technology platform based on corn, the largest US crop. Its mission is to revolutionize dental care by empowering 'No-Drill Dental Care in the Modern World' and to make painless, natural repair possible. Since 2018 GreenMark has been awarded \$4.0 million in NIH grants supporting development of its targeted starch nanotechnology for treatment that is better than fluoride and prevents cavities by filling early lesions noninvasively. The company received two Phase I SBIR's in 2025 and relies on Phase II SBIR funding in 2026 to finalize its products and cross the "Valley of Death" to global implementation.

Nathan Jones, Ph.D.

VP Technology
GreenMark Biomedical, Inc.



We are an early-stage company developing next generation dental treatment products that received 2 phase I SBIR grants (\$600k) in 2025. **Without additional Phase II funds, we will have to fire technical staff and may not survive, which would waste investor and grant funds received to date**

and lose a technology that could save billions in dental costs.


National Institutes of Health SBIR/STTR portfolio company.

Iaso Therapeutics, Inc., *East Lansing, MI*

Robert Forgey, MS, MBA

President, CEO

Iaso Therapeutics, Inc.



SBIR/STTR lapse made it necessary to find Bridge Financing from our current investors. **We were within days of closing the business.**

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Kenneth Mitton, Ph.D., *Sterling Heights, MI*

Kenneth Mitton, Ph.D., FARVO

Associate Professor of Biomedical Sciences

Oakland University, Eye Research Institute




I'm a vision scientist who discovered mechanisms forming rod-photoreceptors required for night vision, and mechanisms of inherited retinal dystrophies. I make targeted DNA-sequencing panels to diagnose rare pediatric retinal diseases. With the STTR/SBIR I invented a biotech production for Noregen, based on a growth factor that builds blood vessels in human retina. A US company, RetinNova*, is trying to get this to clinical trials to repair damaged retinal vasculatures, cause of most new blindness in US. (* I am not invested in the company, gave my IP rights for Zero \$.) **Bench to Bedside ideas will end without STTR/SBIR.**

Wanqing Liu, Novi, MI

Wanqing Liu, Ph.D.

Professor

Wayne State University



We have two new inventions in medical therapeutic field. The inventions have great potential leading to new therapies to treat chronic liver disease or kidney cancer. The recent development of our first invention has generated a lead drug showing highly promising effects on treating fatty liver disease for which currently only very limited therapy is available. The second invention has also led to a prototype therapy for renal cell carcinoma. If rapidly translating these inventions into clinical use, our new therapy will save many lives and significantly reduce medical cost for treating these patients. **The further development of these therapies relies on STTR/SBIR grants or otherwise we will not only lose the chance to save lives but also lose the competition with similar drug development pipelines in other countries, e.g. China.** We call to reauthorize the small business grant programs as soon as possible.

Minnesota

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,044,762,952.15**

Small Business SBIR/STTR Awards: **2,950**

Letter to Congress Co-signers

Nate Broscoff	Director of Finance	Agnitron Technology, Inc.
Claude Tihon, Ph.D.	CEO	Aplos Medical
Duza Baba, MHS/MA	Principal Innovation and Risk Advisory	Catalytic Advisors, LLC
Jim Stice	CEO	Cerovations
Stephen Otto, MBA	CFO	Champaign Imaging, LLC
Theresa Dahl	Chief Customer Officer	Delve Health
Courtney Hill, MD	Founder and CEO	Glimpse Diagnostics, Inc.
Ned Zimmerman-Bence, MEd	Co-Founder	GogyUp, Inc.
Yingling Fan, Ph.D.	Professor and Associate Dean for Faculty	Humphrey School of Public Affairs, University of Minnesota
Patrick Guire, Ph.D.	Founder and Chair	
Eric Guire, Ph.D.	Chief Innovation Officer and Principal	Innovative Surface Technologies, Inc.
Jeff Liter	CEO	Luminary Therapeutics, Inc.
Michele Zoromski, MBA	President and Life Science Commercialization Expert	m.zoro Consulting
Ashley Mooneyham, Ph.D.	Co-Founder and CEO	Momease Solutions
Scott Burwell, Ph.D.	President and CEO	Neurotype, Inc.
Mary Garry, Ph.D.	COO	NorthStar Genomics
Beth Groenke, DDS, MS	CEO	PhysiAroma, LLC
Gina Piazza Ward	Partner	Sierra Medical, LLC

Amogh Rajanna, Ph.D.	President	TFWireless, Inc.
Maurice Enriquez-Sarano, MD	Founder and CEO	ValThera, LLC
Brian Smoliak, Ph.D., CCM	President	Weathervane Labs, LLC

Selected Case Studies from Impacted Companies:

Agnitron Technology, Inc., Chanhassen, MN

Nate Broscoff
Director of Finance
Agnitron Technology, Inc.

We are awaiting an award for research to further develop a new material that will bring more power and energy to America's power grid.

Department of War, Department of Energy, National Science Foundation, and National Aeronautics and Space Administration SBIR/STTR portfolio company.



Aplos Medical, Eden Prairie, MN

Claude Tihon, Ph.D.
CEO
Aplos Medical

We developed a new treatment, Omega PF, for acid reflux that addressed fit failures of current treatments. It has been shown to be the **first treatment that is simple, effective and safe**, and could likely be the next standard of treatment. The NIH SBIR grants supported us from concept to the current human clinical validation. Without the SBIR program, this would not have been possible. **We are eagerly waiting for Congress to reauthorize SBIR to begin our final FDA trial so it can help millions of sufferers in the U.S. and globally.**



National Institutes of Health SBIR/STTR portfolio company.

Catalytic Advisors LLC, *Minneapolis, MN*

Duza Baba, MHS/MA

Principal, Innovation & Risk Advisory
Catalytic Advisors LLC

Catalytic Advisors LLC

Due to the delay in reauthorizing SBIR/STTR, a promising medical device startup I advise is exploring the possibility of raising foreign capital, which introduces potential risks around intellectual property control and the transfer of economic benefits to non-U.S. entities.

Innovative Surface Technologies, Inc., *St. Paul, MN*

Patrick Guire, Ph.D.

Founder, Chair
Innovative Surface Technologies, Inc.



The SBIR/STTR program has enabled the development of a profitable small business providing new coating technology for new and improved commercial medical devices and biosensor products. The recent failure to extend funding of this productive program has **prevented funding of approved grant projects for adding anti-infective properties to our implantable catheter and other medical device coating products.**

Eric Guire, Ph.D.

CINO, Principal
Innovative Surface Technologies, Inc.



Failure of Congress to reauthorize the SBIR program will prevent our organization from bringing new, promising life-saving medical technologies to the public, and may result in job loss for R&D staff.

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

m.zoro Consulting, Minneapolis, MN

Michele Zoromski, MBA

President and Life Science Commercialization Expert
m.zoro Consulting



The lack of SBIR reauthorization and funding is affecting the lives of the American people. From job stoppage, lost salaries, to slowing innovation, to honestly people suffering and dying due to lack of healthcare progress. Your job is to keep the government running. The SBIR program was established by Reagan and has existed for 40+ years with bipartisan support. Stop the stalling and reauthorize the SBIR in perpetuity or with a clean 1-year extension.

Momease Solutions, Plymouth, MN

Ashley Mooneyham, Ph.D.

Co-Founder and CEO
Momease Solutions



Momease Solutions received an NIH SBIR Phase I award to create the next generation of breast pump-enhancing technology to improve breastfeeding rates and maternal/infant health outcomes. After exceeding all Phase I milestones, we applied for Phase II and received a fundable score and priority funding designation. Despite this, our award was delayed with the federal shutdown and now lapse in SBIR reauthorization, **halting our momentum, weakening our position against overseas competitors, and ultimately risking our ability to support breastfeeding mothers and the infants who rely on them.** I urge reauthorization ASAP.

National Institutes of Health SBIR/STTR portfolio company.

PhysiAroma, LLC, Minneapolis, MN

Beth Groenke, DDS, MS
CEO
PhysiAroma, LLC



We submitted an SBIR application in September 2025 that has still not been reviewed. **We desperately need this funding to keep our company moving forward** as we develop a novel method to help teach people suffering from chronic pain how to better manage their pain via the use of machine learning algorithms and non-invasive neuromodulation. As of November 2025, we are unfunded for the first time since our initial funding tranche 3 years ago. **Not funding SBIR/STTR in general is creating a tough trickle-down effect in the whole segment that is hurting cutting-edge startups.**

Sierra Medical, LLC, Minneapolis, MN

Gina Piazza Ward
Partner
Sierra Medical, LLC



Healthcare innovation starts with grants to fuel their technology. **A lapse in funding will paralyze these companies, and it will severely impinge patient care.** Cutting or delaying these grants doesn't allow technologies to develop to the clinical stage and FDA approval. A case study would be HistoSonics. This breakthrough technology was funded by grants and is now impacting patient care and significantly improving quality of life.

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Weathervane Labs, LLC, Minneapolis, MN

Brian Smoliak, Ph.D., CCM

President

Weathervane Labs, LLC



The lapse in SBIR/STTR funding has caused my small business to slow the pace of development, not renew contracts with vendors, and reduce payroll. We had an FY25 NOAA SBIR Phase I proposal recommended for funding, but the award remains delayed indefinitely due to the lapse. This promising R&D on personalized weather intelligence may not advance toward practical applications for all Americans.

Department of Commerce SBIR/STTR portfolio company.

Mississippi

Economic Impact of Program:

SBIR/STTR Funds Received: **\$62,895,490.01**

Small Business SBIR/STTR Awards: **266**

Letter to Congress Co-signers

Max Wamsley	CEO and Founder	Clarus Labs
-------------	-----------------	-------------

Missouri

Economic Impact of Program:

SBIR/STTR Funds Received: **\$513,997,243.97**

Small Business SBIR/STTR Awards: **1,285**

Letter to Congress Co-signers

Hongjie Guo, Ph.D.	CEO	Antiger Therapeutics, Inc.
Alec Beeve, Ph.D.	Senior Associate	BioGenerator Ventures
Guillermo Rivera Gonzalez	CSO	CapyBio, Inc.
Elizabeth Schieber, Ph.D.	Research Associate	dfusion, Inc.
Elizabeth Schwartz, Ph.D.	COO	MathBRIX, LLC
Patrick Margavio	Director of Engineering	ThermAvant Technologies
Cuthbert Simpkins, MD	President and Chief Innovation Officer	Vivacelle Bio, Inc.
Che-Pei Kung	Staff Scientist	Washington University

Selected Case Studies from Impacted Companies:

Antiger Therapeutics Inc., St. Louis, MO

Hongjie Guo, Ph.D.
CEO
Antiger Therapeutics Inc.

Our company is developing therapeutic treatments for autoimmune diseases. We had SBIR Phase I grants before, which helped us develop the product and confirmed the efficiency in vitro. Now we are holding the project to further process for an IND-enabling study.



National Institutes of Health SBIR/STTR portfolio company.

CapyBio Inc., St. Louis, MO

Guillermo Rivera Gonzalez
CSO
CapyBio Inc

We had an SBIR application that had a good score but was not awarded due to the program lapsing in 2025. **This has impacted our ability to advance our internal development program and our hiring plans.**



dfusion Inc., Kansas City, MO

Elizabeth Schieber, Ph.D.
Research Associate
dfusion Inc.

We have two SBIR Phase II proposals with extremely encouraging Phase I results. We would love to see the completion of this work.



Department of Commerce, National Institutes of Health, and National Science Foundation SBIR/STTR portfolio company.

ThermAvant Technologies, Columbia, MO

Patrick Margavio
Director of Engineering
ThermAvant Technologies

The SBIR grants awarded to ThermAvant have returned on average 9x the investment over the course of the 3-5 years following the award in dollars to ThermAvant alone, not to mention enabling our customers' growth. The innovations enabled by those SBIR dollars have enabled ThermAvant to grow 5x in size in the last 5 years, with virtually all of ThermAvant's work for the aero defense industry focused on our national defense.



National Aeronautics and Space Administration, Department of War, and National Science Foundation SBIR/STTR portfolio company.

Montana

Economic Impact of Program:

SBIR/STTR Funds Received: **\$283,751,068.37**

Small Business SBIR/STTR Awards: **865**

Letter to Congress Co-signers

Jeff Carpenter, Ph.D.	Principal	Bird Dog Innovation Strategies
Stephen Sanford	COO and Co-Founder	MagDrive Technologies, Inc.
Christopher Johnson, Ph.D. Merrilee Anne Thomas, Ph.D.	Senior Director of Operations Scientist III	Montana Molecular
Amber Norbeck, PharmD	CEO	Opio Connect, Inc.
Pete Thomas	Designer	Pete Thomas Creative & Datmos
David Yakos	Co-Owner and Director of Creativity	Salient Technologies, Inc.
Reggie Spaulding, Ph.D. Brandon Wasser	Chemist Refurbishment Manager	Sunburst Sensors
Autumn Clowes, LCPC	Co-Founder and Therapist	Triple Tree Counseling
David Haworth, DVM, Ph.D.	Venture Partner	Vetted Capital

Selected Case Studies from Impacted Companies:

Bird Dog Innovation Strategies, Anaconda, MT

Jeff Carpenter, Ph.D., Certified Licensing Professional
Principal
Bird Dog Innovation Strategies



I work with multiple companies that are developing high-risk, high-reward technologies that need SBIR funding to bring the innovation to a point where they can raise money or find a commercialization partner. **If reauthorization doesn't happen soon, many will be forced to lay off technical experts who are the drivers of the innovations, and if that happens, the whole process will short circuit. In short, a delay of weeks in reauthorization could mean delays of months, or complete termination, of these potentially very high-reward research efforts.**

MagDrive Technologies, Inc., Bozeman, MT

Stephen Sanford
COO, Co-Founder
MagDrive Technologies, Inc.



This lapse in funding has delayed the development and testing of MagDrive's zero-emissions magnetic valve actuation technology, which is critical for space travel, nuclear energy, the oil & gas sector, among other things.

Reauthorization would keep development of important technologies like this, which set the US apart from—and give us a competitive edge on—other nations.

National Aeronautics and Space Administration SBIR/STTR portfolio company.

Montana Molecular, Bozeman, MT

Merrilee Anne Thomas, Ph.D.

Scientist III

Montana Molecular



Due to funding uncertainty, **we were unable to hire research and development personnel until our grant funds were secured. This delay caused a full year's setback in project progress.** Such uncertainty places small businesses like ours at a disadvantage compared to larger corporations with robust internal funding sources that can sustain continuous R&D.

Despite our size, we are driving meaningful progress in the field—developing innovative tools that lay the foundation for future pharmaceutical breakthroughs. With the support of the SBIR program, our work has advanced scientific understanding across multiple areas, including cancer and neurodegenerative disease research.

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Opio Connect, Inc., Kalispell, MT

Amber Norbeck, PharmD

CEO

Opio Connect, Inc.



SBIR/STTR reauthorization is critical to America's future. It protects the innovation pipeline that drives U.S. competitiveness and job growth. The lapse is already delaying R&D, freezing hiring, and stalling technologies ready for validation and deployment. When funding becomes unpredictable, private investment pulls back and momentum is lost. **Congress should reauthorize SBIR/STTR without delay to keep the U.S. leading in science, healthcare, and technology.**

National Institutes of Health SBIR/STTR portfolio company.

Salient Technologies Inc., Bozeman, MT

David Yakos

Co-Owner & Director of Creativity
Salient Technologies, Inc.



The lapse in funding due to the **slow funding reauthorization has caused Salient to pause on the development of several technologies, including important innovations that promise to advance the US military and space programs.** It is imperative for small businesses like ours that the government create a consistent position and follow through on its commitments so that planning, hiring, spending, and projects are predictable and secure.

Sunburst Sensors, Missoula, MT

Brandon Wasser

Refurbishment Manager
Sunburst Sensors



Sunburst Sensors builds autonomous sensors for detecting changes in water chemistry across the globe. Our business relies on SBIR grants to conduct research for further development of instruments for our customers around the world. Please support the SBIR program and allow us to continue world-class innovation in the future.

Department of Commerce SBIR/STTR portfolio company.

Nebraska

Economic Impact of Program:

SBIR/STTR Funds Received: **\$149,796,205.53**

Small Business SBIR/STTR Awards: **415**

Letter to Congress Co-signers

Dennis Hensen	Director, Biological Process Development Facility	University of Nebraska
---------------	---	------------------------

Nevada

Economic Impact of Program:

SBIR/STTR Funds Received: **\$244,856,217.84**

Small Business SBIR/STTR Awards: **738**

Letter to Congress Co-signers

Lorrel Brown Toft	CEO	cardiacSTAR
Chantal Kerssens, Ph.D.	Co-Founder and Health Research Lead	Friendi.fi Corporation
Martin Schiller, Ph.D.	CEO	Heligenics
Paddy Roberts	COO	Lucidify
Christy Pappas	Director of Operations	PATH2Caregiving
Cara O'Hare	VP of Operations	StartUpNV
Karina Bocker, MHA	Founder	UME Health, LLC
Lorrel Toft, MD	Professor of Medicine	University of Nevada Reno School of Medicine
Carol Johnson, BCPA	CEO	UterineKind
Nathan Lloyd, MD	CSO	VxMED, LLC

Selected Case Studies from Impacted Companies:

Heligenics, Las Vegas, NV

Martin Schiller, Ph.D.

Founder, CEO

Heligenics

This program is essential for the early phase of small business and well run.

National Institutes of Health SBIR/STTR portfolio company.



Lucidify, Zephyr Cove, NV

Paddy Roberts

COO

Lucidify



The lapse in SBIR/STTR funding has created a critical gap for Lucidify. As a neuroscience and medical-device startup, we rely on early-stage federal support to validate our science and run IRB-approved studies. **Without the chance of obtaining SBIR/STTR grants, we've had to delay key programs, slow hiring, and redirect scarce resources away from R&D.** This program is essential for companies like ours working to prove breakthrough technologies that private capital is often too risk-averse to fund at this stage

UME Health LLC, Henderson, NV

Karina Bocker, MHA

Founder

UME Health, LLC

UME Health LLC

UME Health is an early-stage digital health company developing an AI-powered care navigation companion designed to improve health literacy, follow-through, and equity for underserved, aging adults. **The lapse in SBIR/STTR reauthorization has delayed our ability to pursue Phase I research critical to validating usability and feasibility in disparity-affected populations. As a result, we have had to slow planned research activities, defer hiring and partnerships, and delay engagement with community sites prepared to participate in federally funded studies.** Timely reauthorizations is essential to ensure small businesses like ours can continue advancing evidence-based innovations that address health disparities and support public health priorities.

PATH2Caregiving, Reno, NV

Christy Pappas

Director of Operations
PATH2Caregiving



Prevents our healthcare app from full development and testing. Designed to address caregiver's physical and mental well-being when caring a discharged patient. Unique app that would assist, support & provide material to caregiver about themselves and for the patient. Greatly shortens response time, thereby anticipating fewer readmissions and recognized need for support of caregivers. **This money will allow us to move forward with insurance and IT maintenance fees.**

National Institutes of Health SBIR/STTR portfolio company.

New Hampshire

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,023,195,227.18**

Small Business SBIR/STTR Awards: **2,615**

Letter to Congress Co-signers

Jake Reder, Ph.D.	Co-Founder and CEO	Celdara Medical
Kim Rosenfield	Director, Technology Transfer	Dartmouth College
Laura Ray	Myron Tribus Professor of Engineering Innovation	Dartmouth College
Frederick S. Lauten, Ph.D.	Principal Scientist and Director	North Country Composites
Greg Lange Geoff Clark	CEO Senior Systems Engineer	Simbex LLC
John Stephens, MBA	Principal Architect	
Zhenglong Yuan, MD, MS	CEO	VIVCYTE, LLC

Selected Case Studies from Impacted Companies:


Celdara Medical, *Hanover, NH*

Jake Reder, Ph.D.

Co-Founder, CEO, Celdara Medical

Director of New Ventures, Geisel School of Medicine at Dartmouth

Principal Investigator, DRIVEN Accelerator Hub



The lapse in SBIR has left us with some very tough decisions, and some extremely **promising medical innovations about to die on the vine**. There is no reason for the lapse - congress can modify a program without letting it expire. With the geopolitical competition pushing the pedal down hard, this is not the time to run out of gas.

Kim Rosenfield, JD, Hanover, NH

Kim Rosenfield, JD
Director, Technology Transfer
Dartmouth College



SBIRs have been critical for the development of the very early-stage technologies that have come out of Dartmouth College, from guided imagery during **brain surgery**, to a protective mesh device for **women's health**, to **carbon capture**, technologies, and more.

Simbex LLC, Lebanon, NH

Greg Lange, MS
CEO
Simbex LLC



My company supports innovators in the medical device and consumer health space to develop new life-saving technologies. **Many of our clients have been negatively impacted** by the delays from NIH SBIR/STTR funding.

Geoff Clark
Senior Systems Engineer
Simbex LLC



Numerous projects have been delayed or stopped. This has impacted our ability to get new products to market and limited our ability to hire.

John Stephens, MBA
Principal Architect
Simbex LLC

Simbex has received SBIR and STTR to develop critical head impact sensing technology that is now providing safety information to most football organizations. It has also assisted SBIR/STTR funded organization in technical development and commercialization through our consulting teams.

National Institutes of Health, National Science Foundation, Department of War SBIR/STTR portfolio company.

New Jersey

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,725,474,866.94**

Small Business SBIR/STTR Awards: **5,198**

Letter to Congress Co-signers

Dinesh Kalaga, Ph.D.	CEO	Advanced Engineering Solutions, LLC
Roman Voronov	Founder and President	AltVIVO, Inc.
Derek Pendlebury, Ph.D.	Global VP Sales and Marketing	Belco Glass, Inc.
Erica McCarthy	President	Bloom Medical Simulation
Yuanyuan Jin	Co-Founder and CEO	Bound Therapeutics
Jodi Casabianca-Marshall	Founder and Chief Scientist	BroadMetrics
Glen Whitehouse	CEO	Continuum Dynamics, Inc.
Nicole Notar	Founder and Executive Director	Endo Excision for All
Robert De Saro	President	Energy Research Company
Melissa Wallace	CEO	Fierce Foundry
Zhong Li, Ph.D., MBA	President	High Throughput Biology, Inc.
Robert Harper	Founder and CEO	In Vitro Diagnostic Solutions
Maksim Mezhericher	Founder and CEO	Inaedis, Inc.
Thomas P. Richardson, Ph.D., MBA	President	Institute for Life Science Entrepreneurship
Nicholas Chiorazzi, MD	Professor	Institute of Molecular Medicine, Feinstein Institutes for Medical Research; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Kris Ramanathan	CFO	KivviMed Inc
Tina Garyantes	COO	Linnaeus Therapeutics
Harald Murck, MD, Ph.D.	Founder	Murck-Neuroscience, LLC
Naresh Chander, MD, FCCP	Doctor	N. Chander, MD, FCCP

Judith Sheft	Executive Director	NJ Commission on Science, Innovation and Technology
Syed Shah	CTO and Software Engineer	PartyGem AI
Cortney Cavanaugh, Ph.D.	New Ventures and Licensing Associate	Princeton University
Zhongren Zhou, MD, Ph.D.	Vice Chair of Department of Pathology and professor	Rutgers University
Colin Foster	Chairperson	Saatient Therapeutics, Inc.
Gary Tompa Dr. Kannan Vasudevan	President Scientist	Structured Materials Industries, Inc.
Ebrahim Versi, MD, Ph.D.	President	Versi Consulting, LLC
Dan Mazzucco, Ph.D.	President and CEO	ZSX Medical, LLC

Selected Case Studies from Impacted Companies:

Energy Research Company (ERCo), Plainfield, NJ

Robert De Saro
President
ERCo



The hold on restoring the SBIR/STTR programs has hurt my company's ability to hire and retain current employees. We have recently completed a Phase II STTR project to further develop our technology to measure biofuels and similar materials to optimize gasification processes producing synfuels. We are thus eligible, especially in light of our technical success, to apply for follow-on projects. These projects are critical to get our technology over the last hurdle and into the commercial marketplace. The longer reauthorization is delayed the worse off my company will be.

Department of Energy, Department of War, National Aeronautics and Space Administration, and National Institutes of Health SBIR/STTR portfolio company.

High Throughput Biology, Inc., *Summit, NJ*

Zhong Li, Ph.D., MBA

President

High Throughput Biology, Inc.



Our highly innovation R&D effort to validate and commercialize a patent-pending diagnostic technology that **may significantly reduce healthcare cost and improve patient outcomes** at the point of care is severely impacted negatively by the lapse in SBIR/STTR funding.

National Institutes of Health SBIR/STTR portfolio company.

KivviMed Inc., *Glen Ridge, NJ*

Kris Ramanathan

CFO

KivviMed Inc.



The lack of SBIR funding is significantly delaying our ability to bring our much-needed medical device/drug combo product - a nasal spray that can safely alleviate the excruciating pain of ear infections in tens of millions of US children and reduce the need for unnecessary use of antibiotics- to market. We were relying on this funding to help take our product through FDA Phase 1 and Phase 2 clinical trials.

Linnaeus Therapeutics, *Haddonfield, NJ*

Tina Garyantes

COO

Linnaeus Therapeutics



We are waiting on release of the second half of a grant that is funding a promising ongoing clinical trial. This hold up is **creating great uncertainty for patients and us.**

National Institutes of Health SBIR/STTR portfolio company.

Murck-Neuroscience LLC, *Westfield, NJ*

Harald Murck, MD, Ph.D.

Founder

Murck-Neuroscience LLC

We are prepared to submit an SBIR grant to develop a treatment for people at risk to be unresponsive to standard antidepressants. This is now on hold.



PartyGem AI, *Union City, NJ*

Syed Shah

CTO/Software Engineer

PartyGem AI

My small business, PartyGem AI, relies on SBIR/STTR funding to advance AI/ML research that powers our event management software. Without these grants, we cannot build or test AI-backed features that would improve KPIs and ROI for event organizers. The funding lapse has slowed research and delayed product milestones, limiting our ability to prove commercial viability and generate new revenue streams. Timely reauthorization is critical for small businesses like ours to turn research into deployable products that create real economic impact.



Structured Materials Industries, Inc., *Piscataway, NJ*

Gary Tompa, Ph.D.

President and CEO

Structured Materials Industries, Inc.

In my interactions with Scientists and Engineers from around the world they all remark how the SBIR/STTR program has become a model for their country to establish similar programs to **ignite advanced technology businesses and help their region - it works.** Lastly, holding up the SBIR/STTR program is a sure way to put 1000's of businesses out of business and their workers out of jobs.



National Institutes of Health, Department of War, Department of Energy, National Aeronautics and Space Administration, and National Science Foundation SBIR/STTR portfolio company.

Kannan Vasudevan, Ph.D.

Scientist

Structured Materials Industries, Inc.



Our small business largely depends on SBIR/STTR funding for running the company.

Versi Consulting, LLC, Gladstone, NJ

Ebrahim Versi, MD, Ph.D.

President

Versi Consulting, LLC



We started a new company with innovative patent coverage, but we need government funding to gather scientific data to raise capital for final development of a novel therapeutic for treatment of women's health conditions. This would be an **important new business that would provide employment for many professionals**. Without the SBIR/STTR programs, our efforts are stalled.

ZSX Medical, LLC, Moorestown, NJ

Dan Mazzucco, Ph.D.

President and CEO

ZSX Medical, LLC



We are finishing year 1 of the 3-year SBIR grant to perform a clinical study on an important surgical device. Without reauthorization, our clinical study will stop, and **this improvement in medical care will die on the vine**.

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

New Mexico

Economic Impact of Program:

SBIR/STTR Funds Received: **\$974,143,300.94**

Small Business SBIR/STTR Awards: **3,109**

Letter to Congress Co-signers

Tracy Kliphuis	CEO	EnviTrace
Denis Bragin, Ph.D.	Associate Professor	Lovelace Biomedical Research Institute
Karen Crow	CEO	NeuroGeneces
Dr. Dustin Offermann	Senior Scientist	Voss Scientific, LLC

Selected Case Studies from Impacted Companies:

NeuroGeneces, Inc., Santa Fe, NM

Karen Crow

CEO

NeuroGeneces, Inc.



Uncertainty in review timelines, award rates, or program continuity forces startups like ours to pause development, lay off talent, or abandon promising technologies. Unlike large firms, small businesses lack financial buffers, making SBIR/STTR instability a direct threat to sustained innovation and U.S. competitiveness.

National Science Foundation and National Institutes of Health SBIR/STTR portfolio company.

New York

Economic Impact of Program:

SBIR/STTR Funds Received: **\$3,446,527,333.50**

Small Business SBIR/STTR Awards: **9,393**

Letter to Congress Co-signers:

Alexander Morin	Director, Strategic Communications	Annovis Bio
Marc D. Hein, Ph.D.	CTO	AvantGuard, Inc.
Paul M. Arnaboldi, Ph.D.	Senior Research Scientist	Biopeptides, Corp.
Mark Ladenheim	CEO	Blue Skye Development, Inc.
Yevgen Borodin, Ph.D.	CEO	Charmtech Labs, LLC
Ajit Achuthan	Professor	Clarkson University
Joseph Scaduto, MS, MBA	Co-Founder and CEO	CMTx Biotech, Inc.
Zhou Yu	Associate Professor	Columbia University
Rochelle Mendonca, Ph.D., OTR/L	Assistant Professor	Columbia University
Phyllis Simon, OTD, OTR/L, FNAP	Assistant Professor, Academic Fieldwork Coordinator	Columbia University
Pat Precin	Associate Professor	Columbia University
Dawn M. Nilsen, EdD, OTR/L, FAOTA	Professor and Director, Programs in Occupational Therapy	Columbia University
Daniel Geller, EdD, MPH, OTR/L	Associate Professor	Columbia University
Michael J. Urban, MS, MBA, OTD, CEAS	Associate Professor	Columbia University
Will Heptig	Program Manager	Cornell University
Abraham Stroock	Professor	Cornell University
Kyle Parella, Ph.D.	CEO and Co-Founder	Cypris Therapeutics

Dayna Sessa	CEO	Datanomy
Shenglong Zhang	President	DirectSeq Biosciences, Inc.
Maria Luisa Pineda, Ph.D.	CEO	Envisagenics
James Murray, JD	Managing Partner	ExSight Ventures
Karlheinz Strobl	CEO	FABimation, Inc.
Bruce Volpe	Professor	Feinstein Institutes Hofstra Medical School Northwell Health
Hazel de Guzman, Ph.D.	CEO	Hair Life Regeneration
William Bayer, MD	CEO	HealthPozitive
BJ Carter	Director	Healthy Directions, Inc. dba Healthy Children Healthy Futures
Dr. Richard Horowitz	Medical Director	Hudson Valley Healing Arts Center
Kelsey Moody, Ph.D., MBA	CEO	Ichor Life Sciences, Inc.
Alexander Klose	CTO	In Vivo Analytics
Karen Wu, Ph.D.	President and Co-Founder	Lucerna, Inc.
Charles Kerr	President	Major Medical Devices, Inc.
John Martignetti, MD, Ph.D.	CEO and Co-Founder	MDDx, Inc.
Eleanor Rusling	CEO	MicroEra Power, Inc.
Valentina Marini Fichera	CEO	MilkShaker, Inc.
Alan Belicha, Ph.D.	CEO	Mitokrib, LLC
Jeiran Choupan, Ph.D.	CEO	Neuroscope, Inc.
Praveen Chander, MD	Professor	New York Medical College
Jin Montclare, Ph.D.	Professor	New York University
Matt Miller	CEO and Co-Founder	OKO Labs
James Moe, Ph.D., MBA	President, CEO, and Head of Discovery	Oligomerix, Inc.
Eliot Davidowitz, Ph.D.	CSO	
Jay Rastegar, Ph.D.	Managing Partner	Omnitek Partners, LLC
Suzanne Dance	CEO	Oradell Bio Corporation
Teri Willey, MBA	Managing Director	Pathway to Cures
Evelyn Hecht	Founder and CEO	PelvicSense, Inc.

Cetin Cetinkaya	CTO	Pharmacoustics Technologies, LLC
Andrew Eisenthal, MD, MSE	Co-Founder	Pneumonix Medical
Charles Silvestro	Founder and CEO	PNI Therapeutics
Betty Sun	CEO	Pospea, LLC
Noel Goddard, Ph.D.	CEO	Qunnect, Inc.
Rakhee Gupte, MS, Ph.D.	CEO and President	Raadysan Biotech, Inc.
Tommy Mehl	CEO	Rashi.ai
Katie Mueda	Nonprofit Relationships Manager	Rustic Roots
Kenny Burzynski	Co-Founder	segMedix, Co.
Ray Fujita	Co-Founder	segMedix, Co.
Andrea Ippolito, MS	CEO and Founder	SimpliFed
Klaus Mueller	Professor	Stony Brook University
Edward Schwarz, Ph.D.	CSO	Telephus Biomedical, LLC
John P. Vasilakos, Ph.D.	CEO	TLR Biosciences
Min Nie	CEO	Ultinat, Inc.
Jonathan Stone	Physician	University of Rochester
Ryan Molony, Ph.D.	Staff Scientist	University of Rochester
Antonella Sturniolo, MPH	Founder, CEO, and Director of Research	Upsilon Health, WHAM (Women's Health Access Matters)
Geri Stengel	President and CEO	Ventureneer
Gabriela Pelin, MALD, MBA	CEO	VoiceLove, Inc.

Selected Case Studies from Impacted Companies:

Abraham Stroock, Ph.D., Ithaca, NY

Abraham Stroock, Ph.D.

Professor

Cornell University




The SBIR program bridges the gap for truly new technologies that require maturation and derisking before commercialization or investment. Without it, we will produce only apps.

Annovis Bio, New York, NY

Alexander Morin, Ph.D.

Director, Strategic Communications
Annovis Bio



Annovis Bio develops therapies for patients with neurodegenerative diseases. The lapse in STTR funding has delayed our ability to apply for non-dilutive grants needed to advance early translational research and validate new approaches. Specifically, we planned to use the STTR program to advance our drug candidate for TBI treatment in clinical trials. This has forced us to postpone the studies and slow the progression of a promising program toward the clinic. For patients and families waiting for new treatment options, these delays matter. **Reauthorizing STTR would restore an essential pathway that helps small biotech companies turn scientific discoveries into real-world therapies.**

National Institutes of Health SBIR/STTR portfolio company.

Blue Skye Development, Inc., *Penfield, NY*

Mark Ladenheim, MBA

CEO

Blue Skye Development



Lack of funding is impacting our ability to help America commercialize domestic Rare Earth Element manufacturing. These elements are critical for **defense, high-tech, medical**, etc., and developing capability here strengthens the US security.

Charmtech Labs, LLC, *Buffalo, NY*

Yevgen Borodin

President and CEO

Charmtech Labs



NSF and IES SBIR funding have been instrumental for us to perform R&D and build an education technology product that has now **grown a multimillion-dollar business**.

National Institutes of Health, National Science Foundation, and Department of Education SBIR/STTR portfolio company.


Clarkson University, *Potsdam, NY*

Ajit Achuthan, M.S.

Professor

Mechanical and Aerospace Engineering

Clarkson University



Prior SBIR and STTR funding enabled my students and I to launch two startup companies and begin transitioning our technologies toward commercial products. Although we are still in the early stages of commercialization, my experience demonstrates that the SBIR/STTR program is critical to sustaining the nation's leadership in technological innovation.

CMTx Biotech, Inc., Stony Brook, NY

Joseph Scaduto, M.S., MBA

Co-Founder and CEO

CMTx Biotech



We are awaiting SBIR/STTR funding to advance and develop a novel, host-directed medical countermeasure against high priority biological threats to national defense and homeland security. **Without SBIR/STTR reauthorization, this project can't move forward.**

National Institutes of Health SBIR/STTR portfolio company.

Envisagenics, Inc., New York, NY

Maria Luisa Pineda, Ph.D.

CEO

Envisagenics



We have funded and commercialized our AI platform technology, SpliceCore, to develop therapeutics with SBIR grants and funding from investors like Bristol Myers Squib, Madrona Partners and ThirdKind Ventures. The lapse in SBIR is making a **huge impact in our ability to innovate and continue developing lifesaving drugs for patients and their families!**

National Institutes of Health SBIR/STTR portfolio company.

FABimation, Inc, Mount Sinai, NY

Karlheinz Strobl, Ph.D., MBA

CEO

FABimation



Our company is at a breakthrough stage in developing low-cost, ultra-sensitive biomarker detection for home and laboratory use—an approach that can replace expensive equipment and dramatically shorten diagnostic turnaround times. The lapse in SBIR/STTR funding has **disrupted progress at a critical inflection point**. We have been forced to delay validation studies, slow R&D, and defer essential hiring, **creating financial strain and**

jeopardizing key partnerships. These delays directly impact on our ability to advance accessible, high-performance diagnostic tools that address unmet public health needs.

Feinstein Institutes Hofstra Medical School, Manhasset, NY

Bruce Volpe, MD
Professor



I have had SBIR funding in the past, and I have a new approach to treat dystonia and Parkinson's disease-related cognitive impairment with focused electromagnetism, but I cannot apply for SBIR funding again until the reauthorization occurs.

Hair Life Regeneration, Copiague, NY

Hazel de Guzman, Ph.D.
CEO
Hair Life Regeneration



After years of research, we were finally planning on applying for SBIR/STTR funding to develop product prototypes for testing and further iteration. With the lapse in SBIR/STTR funding, product development is at a slower pace because we are struggling to find other funding sources. **Being a very small biotech startup, we heavily rely on federal/state non-dilutive funding to help us translate our research from bench to bedside.**

Healthy Directions Inc., New York, NY

BJ Carter
Director
Healthy Directions Inc.



I served as an SBIR reviewer and saw firsthand the quality of these applicants. I've consistently been impressed by the caliber of proposals—innovative, practical and creative, reflecting rigorous thinking and led by exemplary teams. SBIR/STTR funding is essential. **Without it, we risk losing breakthrough innovations and high impact solutions before they can be developed and commercialized, weakening U.S. competitiveness in emerging industries including health and security and allowing other countries to outpace us.**

Hudson Valley Healing Arts Center, Staatsburg, NY

Richard Horowitz, MD

Medical Director

Hudson Valley Healing Arts Center



I have an R34 NIH grant pending for the treatment of chronic Lyme and it has been held up in the middle of an epidemic. I would also like to eventually submit an SBIR for my novel and highly effective treatment.

MDDx, Inc., Tarrytown, NY

John Martignetti, MD, Ph.D.

Co-Founder and CEO

MDDx, Inc.



The lapse in SBIR/STTR reauthorization has had immediate consequences for MDDx, a U.S.-based women's health diagnostics company developing early detection tests for ovarian and endometrial cancers. Funding uncertainty has **delayed clinical validation, paused hiring of high-skilled scientific and regulatory staff, and slowed partnerships with U.S. academic medical centers**. SBIR is a critical bridge between federally funded discovery and private investment—particularly in women's health, where early-stage capital remains scarce. Interruptions weaken America's biomedical innovation pipeline, risk ceding leadership to better-capitalized international competitors, and delay delivery of life-saving diagnostics to patients who urgently need them.

National Institutes of Health SBIR/STTR portfolio company.

MicroEra Power, Inc., Rochester, NY

Elanor Rusling, M.S.

Founder and CEO

MicroEra Power, Inc.



MicroEra Power is a leading innovator in thermal energy storage - a critical technology for affordable energy, a resilient electric grid, and U.S. energy independence. **SBIR funding is catalytic capital for supporting development and early deployments of technologies** which support U.S. technology

global leadership and innovation. The current lapse in SBIR funding has precluded ongoing demonstration prospects much needed to derisk the technology for commercial readiness.

Department of Energy SBIR/STTR portfolio company.

Milkshaker, Inc., New York, NY

Valentina Marini Fichera, B.S.

Founder and CEO

Milkshaker



Early-stage hardware in health tech and fem-tech specifically are fueled primarily through federal grants. Without SBIR reauthorization, R&D and innovation in the U.S. is halted. My medical device company for breastfeeding women is delayed in R&D, waiting for federal responses and with limited opportunities for funding.

OKO Labs, Rhinebeck, NY

Matt Miller, M.S.

Co-Founder and CEO

OKO Labs



My company owes much of our success to the ED/IES SBIR Program. I am happy to help spread the word about the **positive impacts of the SBIR program in education.**

Department of Education SBIR/STTR portfolio company.

Oligomerix, Inc., Bronx, NY

James Moe, Ph.D., MBA

President and CEO

Oligomerix



Oligomerix is developing a small molecule drug that targets tau protein for neurodegenerative diseases for Alzheimer's and Progressive Supranuclear Palsy. It is in phase 1a clinical studies that finish in 2026. To date, it has a good safety profile, predictable exposure, and the efficacious dose level has been achieved. **It was discovered and developed with grant funding (R43/R44) from NIA/NIH.** This drug is highly differentiated from FDA approved therapeutics for Alzheimer's which are antibody based. The drug is oral, self-administered, stable and at a low cost. We are presently conducting safety studies that will enable long-term dosing in patients with SBIR funding.

Eliot Davidowitz, Ph.D.

CSO

Oligomerix



We have discovered an experimental drug for Alzheimer's Disease and rare tauopathies mostly through funding from SBIR grants and have a pending phase 2 award for the final chronic tox study required by FDA to enable clinical development in patients. Without timely SBIR funding this program and **our additional drug discovery and development work is in jeopardy** as our company may be forced to cease operations.

National Institutes of Health SBIR/STTR portfolio company.

Omnitek Partners, LLC, Ronkonkoma, NY

Jay Rastegar, Ph.D.

Managing Partner

Omnitek Partners



Omnitek is providing **critical design and prototyping work for the U.S. Navy** new munition and has designed and fabricated novel shock testing equipment and sensor for their fuzing systems. We are also in the middle of **two Phase II project for the U.S. Army**, that would provide a highly secure communication system and initiation devices for guided munitions. Using one of our previous SBIR projects, we developed a new highly safe and extremely reliable initiation device for gun-fired munitions, mortars, and

rockets that has significantly reduced duds. We are currently producing them for full range of guided munitions for prime contractors.

Department of War and National Aeronautics and Space Administration SBIR/STTR portfolio company.

Pathway to Cures, New York, NY

Teri Willey, MBA

Managing Director and Officer
Pathway to Cures



As an early-stage investor in life science, most of the companies in our portfolio and pipeline depend on SBIR funding to complement traditional investment. The review process for funding is an important step in validating the scientific and clinical approach to product development. During the ups and downs of the early-stage investment, SBIR funding provides value-creating non-dilutive resources which attract traditional investors and encourages their involvement. In my experience, the funding has been used to confirm proof of principle of therapeutic approaches, and in some cases, facilitate testing to confirm safety, efficacy or best manufacturing of the proposed therapy. Funding for these aspects is hard to come by, and these critical value inflection points are important to attracting smart money and **management necessary to bring new cures and therapies forward for the benefit of the public.**

PelvicSense, Inc., Sag Harbor, NY

Evelyn Hecht, P.T.

Founder and CEO
PelvicSense



While I have been able to bootstrap my company, many of my colleagues innovating in the medical and wellness fields rely heavily on funds from SBIR/STTR to prototype, beta test, research and launch their products and programs for the greater benefit of all Americans. Having these programs reauthorized **fuels the heartbeat of this great country: imagination and creativity.** Please don't let our American brilliant ideas languish on the conveyor belt to nowhere. Please reinstate the SBIR/STTR.

Pospea, LLC, *Pittsford, NY*

Betty Sun, Ph.D.

CEO

Pospea, LLC



The lapse in SBIR/STTR funding has stalled our early-stage R&D and created significant operational uncertainty. **We have paused key technical milestones, delayed contractor engagements, and postponed planned collaborations with university partners.** Without clarity on award timing, we cannot responsibly commit resources or maintain momentum on federally aligned innovation work. **The disruption has also strained cash flow, forcing us to defer equipment purchases and slow hiring.** This gap in funding jeopardizes progress on technologies that rely on SBIR/STTR precisely because private capital does not support this stage of development.

Department of War SBIR/STTR portfolio company.

Raadysan Biotech, Inc., *Fishkill, NY*

Rakhee Gupte, MS, Ph.D.

CEO, President

Raadysan Biotech, Inc.



We are developing potent first-in-class therapies for Triple Negative Breast Cancer (TNBC), which is very aggressive and has high occurrence and poor survival rates. Complex heterogeneity associated with its manifestation further complicates its treatment options. There are no effective targeted monotherapies currently available for its treatment, making it an unmet medical need.

Our SBIR grant proposing the development of innovative therapies for TNBC has received a fundable score, however, it will not be funded until Congress reauthorizes the SBIR/STTR program. We would appreciate Congress's help in preserving the future of medical innovations and therapies for the treatment of cancer patients.

Rashi.ai, Woodmere, NY

Tommy Mehl, M.B.A

Founder

Rashi.ai



We have a Phase I with the Department of War. It's been invaluable in enabling my "deep tech" incubation, as we otherwise wouldn't be ready for fundraising. **Without this SBIR, I'd be dead in the water.**

Department of War SBIR/STTR portfolio company.

Telephus Biomedical, LLC, Rochester, NY

Edward Schwarz, Ph.D.

CSO

Telephus Biomedical



SBIR/STTR funding is the only mechanism to provide proof-of-concept data for Biotech and Pharmaceutical companies to license patents from universities. **Without it there will be no new drug development.**

University of Rochester, Rochester, NY

Jonathan Stone, MD

Neurosurgeon

University of Rochester Medical Center



Small business formation is the cornerstone of United States Society and without this funding mechanism it is difficult to get a business off the ground in the biological space. **Please bring back the STTR/SBIR!**

Upsilon Health, Women's Health Access Matters (WHAM), New York, NY

Antonella Sturniolo, MPH

Founder, CEO, Director of Research
Upsilon Health, WHAM



Our organization applied for SBIR funding in 2025. We are a small medical device team focused on the health of women. Funding is already scarce for women's health and women founders, that we were advised by brilliant entrepreneurs and researchers who have worked with SBIR/STTR to look at government funding opportunities. We thought the government would be supportive of jumpstarting small business and economic opportunities for the country. It is disappointing to learn of the change. We could make such advancements in healthcare with non-dilutive funding opportunities.

Ventureneer, New York, NY

Geri Stengel

President and CEO
Ventureneer

I've written a number of times about the importance of SBIR funding for Forbes.



VoiceLove, Inc., Scarsdale, NY

Gabriela Pelin, MBA

CEO

VoiceLove

Our small U.S. health-technology company has received competitively awarded SBIR/STTR funding **that cannot be released due to the lapse**. As a result, we have delayed vendor payments, paused hiring, and slowed regulated product development tied to clinical milestones, including tools addressing high-prevalence mental health conditions and neurocognitive disorders, ultimately slowing the translation of taxpayer-funded research into patient-ready solutions.



National Institutes of Health SBIR/STTR portfolio company.

North Carolina

Economic Impact of Program:

SBIR/STTR Funds Received: **\$2,044,909,818.95**

Small Business SBIR/STTR Awards: **4,401**

Letter to Congress Co-signers

Larry Dickinson	President	3F, LLC
Kyle Chenet	CEO	
Luke Oltmans	VP of Quality and Regulatory	410 Medical
Kirk Pappan	CSO	Accivity Technologies, Inc.
Frank Fee	CFO	Ad Astra Diagnostics, Inc.
Guangyuan Cai	CEO	Adoratech, LLC
Arlissa Vaughn	CEO	Aegis Power Systems
Sharon Lee, MS	Director of Communication	AlphaMed
Joe Huber	CEO	AntiXero
Nicole Lindley	Senior Advisor	Armstrong McGuire
Ronald Berry, Jr.	CEO	Artificially Digital
Alexis Carpenter, Ph.D.	Chief Innovation Officer	AxNano
Rainer Ng, Ph.D.	Head of Technology Development	Baebies, Inc.
Christopher MacNevin, Ph.D.	Senior Staff Scientist, Chemistry	BD Biosciences
Guy Carpenter	President	Bear Fiber, Inc.
Anka Veleva, Ph.D.	CEO	Benanova, Inc.
Giles Shih, Ph.D.	Founder and Strategic Advisor	Big Ripple Innovations, LLC
Thomas Heck	SVP	BioBridges
Roger Nolan, Ph.D.	President	BioKier, Inc.
Lindsay La Fleur, Ph.D.	HOLDEN DELETE ME	BioSensys, Inc.
Joe Dahl, Ph.D.	Advanced R&D Manager	BioSkryb Genomics
Cynthia Pritchard, Ph.D.	CEO	BioTechnology Transfer
Michael Check, Ph.D.	CTO	Blue Ridge Semiconductor

Ellora McTaggart	Co-Founder and CEO	Carolina Instruments
Reid Barnett	Founder and CEO	Ceretune, LLC
Tess Cunningham	CAO	Cerulean Scientific, Inc.
Ingrid Harm-Ernandes, PT, WCS	Physical Therapist	Chipmunk Enterprises
Sean Ekins, Ph.D., DSc	CEO	Collaborations Pharmaceuticals, Inc.
Tony Voiers	COO	Continuity Biosciences
Angela Turner, MAg	Scientist/ Data Scientist/ Entrepreneur	Cosmic Eats
Bradley Estes, Ph.D.	President and CEO	CytexOrtho
Christine Estes	Director of Business and Finance	
Marc Haddle	CEO and Co-Founder	Datasolids
Yanchun Song	President and Co-Founder	Delgen Biosciences
Xinxia Peng	Founder	Depict Bio, LLC
Ed Burgard, Ph.D.	President	Dignify Therapeutics
Karl B. Thor, Ph.D.	CSO	
Ted Benson	COO	Diviner, Inc.
Kyle Tomek, Ph.D.	CEO	DNALI Data Technologies, Inc.
Jeff Welch	Director, New Ventures	Duke University
David Peterson	Principal	DWP Consulting Services, LLC
Joshua McMenemy	CTO	East America Science, Inc.
Roger Pechous, Ph.D.	Associate Professor	East Carolina University
Lee Lance	CEO	Ecobot
Jim Bone	President	Epicypher
Eva Garland, Ph.D.	CEO	Eva Garland Consulting
Andrea Epperly, Ph.D.	CEO	ForagR Medicines
Jordan Koehn, Ph.D.	Head of Platform and Chemical Genomics	
Nikolay Frick	CTO	Freescale, LLC
Breanna Ford, Ph.D.	Scientist	
Don Alexander	President	GeneCoda®

Jian Liu, Ph.D.	Founder	Glycan Therapeutics
Cesar Romero	Media & Events Sponsorships	GrepBeat
Zack Lyon	CEO and Founder	H3Pelvic Therapy Systems
Gwen Hodges	Partner	Hodges and Hergenrader, LLP
Fred Hutchison	Retired Founder	Hutchison PLLC
Leon DeJournett, MD	CEO	Ideal Medical Technologies
Jasper Mark	CEO	Impulse Wellness
John Whelan	CEO	Inhalon Biopharma, Inc.
Dr. Laverne Morrow Carter	President	INHEALTH USA, Inc.
Jiarui Li	CEO	Innatrix
Denise Dawson, Ph.D.	President and Owner	Innovation Therapies, PLLC
James Mark Hammer, DVM	President and Founder	Innovative Viral Solutions, Inc.
Stefan Roberts, Ph.D.	CEO	inSoma Bio
Rick Clemenzi, PE	Innovation Engineer	Intelli-Products, Inc.
Karol Jarzabek	COO	iOrganBio
Eric Bankaitis, Ph.D.	Principal Scientist and Funding Lead	
Amy young	CEO	Jigsawdio
John Ponton, Ph.D.	Founder and CEO	JP Drug Discovery
Molly Alesio, MMB	Strategic Account Manager	Kymanox
Karen LeVert	Managing Partner	LeVert Ventures
Yi Wang, Ph.D., MBA	CEO	Macaw Medical Technology
Joseph Lavoie, Ph.D.	Founder	MEMWKS
Sam Lai, Ph.D.	Founder and CEO	Mucommune, LLC
Karen Tsang	Founder and President	MyKare, Inc.
Nitin Sharma	Associate Professor	MyoMech, Inc.
Charles Askew, Ph.D.	President	NabGen, Inc.
Cheryl Wooten	Business Development Lead	Nicelle Technologies, Inc.
J. Bruce Pitner, Ph.D.	CSO	NIRvana Sciences
Jiten Pant	CEO	NOBiotics
Cassandra M Germain, Ph.D.	Associate Professor	North Carolina A&T State University

Megan Damico, Ph.D.	Associate Director, Focused Initiatives Team	North Carolina Biotechnology Center
Jason Doherty	Senior Director, Investments	North Carolina Biotechnology Center
Mary Hecht-Kissell, MBA	Vice President Corporate Communications	North Carolina Biotechnology Center
Ramya Vijapurapu	Technology Commercialization Counselor	North Carolina Small Business and Technology Development Center
Timothy N. Martin	Interim Assistant Vice Chancellor of New Ventures and Investments	North Carolina State University
Aydin Aysu, Ph.D.	Professor	North Carolina State University
David Muddiman, Ph.D.	Professor, CTO, and CSO	North Carolina State University, MSI Software Solutions, and iMass Innovations
Sunanda Dharmarajan	Venture Partner	Novellus Ventures
Jonathan Beckwith	CEO	Olfax Medical
William D. Reynolds, Jr.	Founder	Onda Vision Technologies
Kasi Azhakanandam, Ph.D.	CEO	OpenAgBio, LLC
Barbara Lutz, Ph.D., RN, CRRN, PHNA-BC	Founder	PATH2Caregiving
Elizabeth Clarke	Product Development Engineer	Perfusio Corp.
Michael Hannan	CEO	Piximune, Inc.
Michael Berger, Ph.D.	VP of Engineering	Plakous Therapeutics, Inc.
Harald Ade	CEO	PolyPV, LLC
Brandon Conover, Ph.D.	CEO	Practical Scientific Solutions, Inc.
Matthew Barnes	CEO and Principal Consultant	Praecur
Kevin Causey	CEO	Predictive, LLC
Kevin Gehsmann	CEO and Co-Founder	PROTECT3D
Charles Rinker	President and CEO	PRSONAS Software, Inc.

Raymond Lewis III, CPA	CFO	Qi, LLC
Jianbo Zhang	CEO	Quanticision Diagnostics, Inc.
Srisailas Muthialu, Ph.D.	Co-Founder and Vice President	R&S Chemicals, Inc.
Dr. Roarke Horstmeyer	Scientific Director	Ramona Optics
Jay Fisher, Ph.D.	CSO	Redbud Labs
Fioleda Kesseli, Ph.D.	CTO	Reselute
Thomas Bruce Ferguson, Jr., MD	CEO	RFPi, Inc.; PhysiolImage, Inc.
Karthik Ramakrishnan	Co-Founder and CTO	Scyntek, Inc.
Francene Chadwick	CEO	Serve
Ted Slusher	CEO	Silent Crown
Jacob Heggestad, Ph.D.	CEO	SimplusDx
Dr. Stephen Furst	CEO	Smart Material Solutions, LLC
Lucy Kosturko, Ph.D.	Co-Founder	Social Cascade
Daniel Estay, MBA	Founder and CEO	SonoVascular, Inc.
Lanea Foster	Executive Director	Southeast Community Resources
Shara Nejad, LEED AP, PEM	Director of Operations	Spinhance, LLC
Stephen Kadlecik, Ph.D.	Research Director	
Subba R. Katamreddy, Ph.D.	Founder and CEO	SPV THERAPEUTICS, Inc.
Laura Widman, Ph.D.	CEO and Founder	Teen Health Research
Shadia Oshodi	Founder and CEO	Texture Tech
Hafeez Dhalla, Ph.D.	CEO	Theia Imaging
Thomas K. Laundon	Managing Member	TopKan Associates
Ty Hagler, MBA	Principal	Trig, LLC
Ken Purchase, Ph.D.	COO	Trio Labs
Xiaomei Li	CEO	Tripill Biotechnology, Corp.
John Jans	Innovator	TriPoint Innovations, Inc.
Amy Josefsberg	Professor, Physics and Astronomy	University of North Carolina at Chapel Hill
Jason Franz, Ph.D.	Professor of Biomedical Engineering	University of North Carolina at Chapel Hill

Barbara Vilen, Ph.D.	Professor of Microbiology & Immunology	University of North Carolina at Chapel Hill
Mireya McKee, Ph.D.	Director, New Ventures and Partnerships	University of North Carolina at Chapel Hill
Michael Marshall, JD, Ph.D.	Director, Innovate UNCG	University of North Carolina Greensboro
Zach Hetzler	Co-Founder and CEO	Verdia Diagnostics
Brewer Logan	CEO	Verenovo Energy
Steven Noyce	CEO	Versametrics
Chris Morrison	Owner	ViaVerus, LLC
Anupama Reddy, Ph.D.	COO	Vindhya Data Science, Inc.
Joe Webb, Ph.D.	CEO	Vitality Robotics, Inc.
William Gmeiner, Ph.D., MBA	President	Wake Forest University School of Medicine, Deep Creek Pharma
Wade Farrow, MD, CWSP	CEO	XSONX, LLC

Selected Case Studies from Impacted Companies:

3F, LLC, Hickory, NC

Larry Dickinson, Ph.D.

President
3F, LLC

Delayed reauthorization of the SBIR/STTR program has directly resulted in the **delay and potential permanent loss of 2-3 new jobs** that were scheduled to start in 2026.


National Science Foundation, US Department of Agriculture, and Department of War SBIR/STTR portfolio company.



410 Medical, Inc., Durham, NC

Luke Oltmans

VP of Quality & Regulatory
410 Medical, Inc.



Our company develops innovative, life-saving medical devices that are making a difference in hospitals and EMS agencies across the country. The **SBIR/STTR funding sustains and creates new opportunities for our products to save lives while creating job opportunities in Durham, NC.**

Department of War SBIR/STTR portfolio company.

Acclivity Technologies, Inc., Rougemont, NC

Kirk Pappan

Co-Founder and CSO
Acclivity Technologies, Inc.




We're building evidence for a new first-in-class therapeutic that will prevent chronic diseases. **The lapse in SBIR/STTR funding is blocking our ability to test these drugs.**

Aegis Power Systems, Murphy, NC

Arlissa Vaughn

CEO
Aegis Power Systems



The US Army has identified a critical need regarding recharging batteries in contested locations. Our company has a useful new technology that would enable stealthy, stable, and simple charging for such environments. However, without this funding, we can only progress this effort at a slow pace between other paid jobs. **Since the SBIR program is halted, we cannot finish this development in a timely manner, and likewise, the Army cannot obtain a superior solution.**

Department of War SBIR/STTR portfolio company.

AxNano, Durham, NC

Alexis Carpenter, Ph.D.

Chief Innovation Officer
AxNano



SBIR/STTR Funding has helped propel our company into job creation (10 high-paying, high-technology jobs in NC) and commercializing technologies out of universities (return on investment from R&D funding), solving real-world problems (water), and raising private venture funding (\$3.3M).

National Science Foundation, Department of War, Department of Commerce, National Institutes of Health, National Aeronautics and Space Administration, and Environmental Protection Agency SBIR/STTR portfolio company.

Barbara Vilen, Ph.D., Chapel Hill, NC

Barbara Vilen, Ph.D.

Professor of Microbiology & Immunology
University of North Carolina at Chapel Hill



The University of North Carolina at Chapel Hill has a large ongoing research effort. The goal of academic research is 1.) discovery and 2.) application to human disease. The SBIR/STTR program fills an important niche in #2, application to human disease. Once research is no longer discoverable, researchers enter 'the valley of death' where NIH R01 funding is not appropriate, and venture capital and pharma are too risk-averse to fund. The NIH SBIR/STTR program fills this niche, allowing researchers to 'de-risk' their discoveries. Logically, more money should be dedicated to SBIR/STTR as applicants to this program have discovered something that has potential for treatment or to advance human health. Despite this, the budget for the SBIR/STTR program is disproportionately small compared to the discovery budget.

National Institutes of Health portfolio researcher.

Bear Fiber, Inc., *Morganton, NC*

Guy Carpenter, MBA

President
Bear Fiber, Inc.

Halted R&D

United States Department of Agriculture SBIR/STTR portfolio company. Department of Defense SBIR/STTR portfolio company.



BioBridges, *Morrisville, NC*

Thomas Heck

SVP
BioBridges

We have meaningful clients working on key life science projects that can be lifesaving needing grant funds to advance cures.



BioSensys, Inc., *Raleigh, NC*

Lindsay La Fleur, Ph.D.

BioSensys, Inc.

We are a start-up that is trying to develop a wearable real-time biosensor to prevent hospital deaths from sepsis. This technology was developed at NC State University. At the least, **not having SBIR/STTR funding will result in valuable time and effort to find and apply for additional funding.** At the most, it prevents us from getting funding at all. Please reauthorize the SBIR/STTR programs. Innovators like us around the country are counting on you. By not fighting for the reauthorization of these programs, you are preventing life-saving technologies from being developed. Thank you for your consideration.




BioTechnology Transfer, *Raleigh, NC*

Cynthia Pritchard, Ph.D.

CEO

BioTechnology Transfer



This has strongly affected our company, both financially and operationally as we have lost clients due to the loss of funding and operationally, as we have had to cut staff.

National Science Foundation and Department of War SBIR/STTR portfolio company.

Cerulean Scientific Inc, *Durham, NC*

Tess Cunningham

CAO

Cerulean Scientific Inc



SBIR/STTR funding has been critical to our development of medical devices that will change the standard of care - hydrocephalus shunts, hemodialysis catheters, vascular grafts, etc. Obstruction is a major failure that has not been addressed for many, many years. **Without this funding, we would not be able to develop these devices to commercialization.**


National Institutes of Health SBIR/STTR portfolio company.

Chipmunk Enterprises, *Efland, NC*

Ingrid Harm-Ernandes PT, WCS

Physical Therapist, Author, International Speaker

Chipmunk Enterprises



I grew up in a family-owned small business. The struggle to survive and hopefully thrive is real. Small businesses are what drive US success and are the largest employers in the country. Funding small businesses ensures that our country can be a leader in all fields of innovation, research, healthcare, and development.

Collaborations Pharmaceuticals, Inc., Raleigh, NC

Sean Ekins, Ph.D., DSc

CEO

Collaborations Pharmaceuticals, Inc.



As a small company that works on rare and neglected diseases, the SBIR/STTR program has been critical for our development. **Over the past year, we paused our growth and did not even have any paid interns** as we were solely focused on developing other revenue streams. This grant program has been central to funding our work on diseases that other companies or organizations will not support.

National Institutes of Health SBIR/STTR portfolio company.

CytxOrtho, Durham, NC

Bradley Estes, Ph.D.

President, CEO

CytxOrtho



Our company lost access to a \$2M SBIR award at a pivotal moment in our development, significantly disrupting our R&D plans. We are advancing a life-altering medical implant designed to restore function and delay or prevent major surgery, but delayed SBIR reviews have forced us to slow key research and defer hiring. We currently have three SBIR applications under review representing millions in potential funding. Because SBIR cycles are already long, missing even one cycle can delay progress by years. **In an economy where risk capital is scarce, SBIR funding is critical to delivering transformative treatments to patients.**

Christine Estes

Director of Business and Finance

CytxOrtho



The evaluation and potential award of two important projects that may provide critical healing technologies to patients with chronic rotator cuff disease and patients with knee cartilage degeneration is in jeopardy! CytxOrtho has award-winning regenerative technology solutions that need government grant support for development and proof of concept to attract and retain investors. **The**

lapse of the SBIR program may prevent this technology from ever being developed, as investors in our field are too risk-adverse to fund new regenerative technologies.

Deep Creek Pharma, Winston-Salem, NC

William Gmeiner, Ph.D., MBA

President
Deep Creek Pharma



Deep Creek Pharma has leveraged Phase 1 and Phase 2 STTR grants from NCI to advance CF10, a promising new therapeutic for metastatic colorectal cancer. The lapse in program funding is making a challenging situation even more difficult as we seek to identify funds to complete IND-enabling studies with the FDA and to initiate clinical trials. **The lapse in SBIR/STTR program support is delaying both company progress and the entry of a viable new therapeutic option for cancer patients from initiating clinical development.**

National Institutes of Health SBIR/STTR portfolio company.

Delgen Biosciences, Chapel Hill, NC

Yanchun Song

President, Co-Founder
Delgen Biosciences



Delgen Biosciences is a faculty-founded biotech startup company based in Chapel Hill, NC. Using an intellectual property (IP) licensed from the University of North Carolina (UNC), the company has been developing a novel drug delivery platform that will eventually turn into a long-acting biologic drug to better treat macular degeneration. In addition to ophthalmic drugs, our technology can have broader applications for precision medicine to treat other types of diseases, such as cancer.

In 2023, the company received a Phase I SBIR grant from the National Institutes of Health (NIH), which has funded researcher hiring, lab rental, and the validation of the technology. As a result, the company received another two grants from North Carolina and UNC to allow further development of this technology. In 2025, we submitted a Phase II SBIR proposal to NIH, which will be used to fund preclinical development of the macular degeneration drug using our platform technology. **Disruption of the SBIR**

funding is going to cast great doubt to the survival of the company, force it to lay off employees, and render UNC's IP worthless.

National Institutes of Health SBIR/STTR portfolio company.

Dignify Therapeutics, Durham, NC

Karl B. Thor, Ph.D.

Chief Scientific Officer

Dignify Therapeutics



Dignify was preparing for clinical studies to help people with spinal injuries, multiple sclerosis, spina bifida, Parkinson's disease, diabetes, and the elderly be able to control their bladder and bowel. These drugs are projected to produce \$3 B peak annual sales if approved, which would provide US Taxpayers with a terrific ROI. **The lapse in SBIR funding delays the start of our clinical trials**, which decreases the value of our product due to patent expiration while we wait for funding and pray for venture capital investments. Please renew this wonderful program that has consistently shown a positive ROI for the government!

National Institutes of Health SBIR/STTR portfolio company.

DNALI Data Technologies, Inc, Cary, NC

Kyle Tomek, Ph.D.

CEO

DNALI Data Technologies, Inc



While DNALI is currently supported by an active NIH STTR award and has operated efficiently on a lean budget, the ongoing lapse in the SBIR/STTR program is creating meaningful risk for the company. **Delays in funding decisions and uncertainty around application timelines are pushing back critical technical and commercialization milestones.** This uncertainty directly affects our ability to plan hiring, manage runway, and sequence follow-on research and development activities. **For an early-stage deep-tech company like DNALI, SBIR/STTR continuity is essential to sustaining momentum, bridging non-dilutive funding gaps, and avoiding premature dilution or project delays that could jeopardize long-term viability.**

National Institutes of Health SBIR/STTR portfolio company.

East America Science, Inc., Durham, NC

Joshua McMenemy

CTO

East America Science, Inc



Our Project Pitch submitted in October 2025 was accepted by the NSF. Our project pitch incorporated advanced manufacturing to build bioelectrical measurement tools to accelerate research progress in tissue engineering, regenerative biology, and treatment of age-related functional decline. Because of the lapse in SBIR funding, we have not gotten the chance to submit a full project proposal, which would provide valuable feedback and a chance to receive company-changing funding.

Epicypher, Durham, NC

Jim Bone

President

Epicypher



The SBIR and STTR programs, known as America's Seed Fund, deliver immense value to the US economy by providing non-dilutive funding (~\$4 billion annually) to small businesses for high-risk R&D, driving technological innovation, commercialization, and federal mission needs. Key impacts include: Supporting ~4,000 companies yearly across all states. Generating significant economic returns, such as an average of 65,578 jobs per year (from DoW programs alone, 1995–2017). Producing billions in value-added output, patents, sales, and private investment (e.g., Navy/Air Force studies show tens of billions in economic activity and high job creation per dollar invested).

These programs fuel startups, create high-quality jobs, enhance national competitiveness in critical fields like defense, health, and energy, and bridge the gap between research and market-ready technologies. Immediate reauthorization is essential because the programs' statutory authority expired on September 30, 2025, halting new awards and solicitations across agencies (e.g., NIH, DoW, NSF). **This lapse creates uncertainty, delays innovation, threatens jobs, and weakens US technological leadership at a time of global competition.** Congress must act swiftly—potentially via early 2026 appropriations or NDAA—to restore funding continuity and avoid irreparable harm to the innovation ecosystem.

National Institutes of Health SBIR/STTR portfolio company.

ForagR Medicines, Durham, NC

Jordan Koehn, Ph.D.

Head of Platform & Chemical Genomics
ForagR Medicines



We are a small biotech startup whose progress has been directly impacted by the lapse in SBIR/STTR reauthorization. **We submitted an NIH SBIR application in April 2025 that remains under consideration but cannot be awarded until the program is reauthorized, delaying critical research and hiring plans.** We also intended to submit a new SBIR application in January, but no solicitations are currently available. SBIR funding, including a prior NSF SBIR award, is our primary lifeline, as private investment is currently extremely challenging. **This lapse creates significant financial uncertainty and slows innovation at a pivotal stage for our company.**

National Science Foundation SBIR/STTR portfolio company.

H3Pelvic Therapy Systems, Lewisville, NC

Zack Lyon

CEO/Founder

H3Pelvic Therapy Systems



We are in the funding "Valley of Death". **For medtech, no investor will take their solutions seriously until derisked. This is the necessity and forte of the SBIR/STTR program.** Without it, NO Private Investor, PE, VC, or Family Office will take them seriously, and the taxpayer suffers. Of all of the stupid programs that are taken advantage of, the SBIR program is NOT ONE OF THEM! Please turn it back on for AMERICAN TAXPAYERS.

National Institutes of Health SBIR/STTR portfolio company.

Hutchison PLLC, *Raleigh, NC*

Fred Hutchison

Retired Founder
Hutchison PLLC

I am a venture lawyer who works with early-stage life science companies that spin out of universities. To succeed, these companies need to receive SBIR/STTR funding. Without that funding, these companies cannot conduct research and undertake clinical trials to progress and eventually raise venture capital funds. These federal grants are a vital part of the ecosystem needed for these companies to succeed. **We have seen many companies unable to progress due to a lapse in funding.**




Impulse Wellness, *Raleigh, NC*

Jasper Mark

CEO
Impulse Wellness

We received an intent to fund for our NSF SBIR, with an anticipated start date of June 2025. In preparation, we hired three additional team members and scaled operations to meet project milestones and deliverables. However, due to the SBIR/STTR lapse, our award has been stuck at Treasury and no funds have been disbursed. **This has created an immediate cash-flow crisis:** we took out a small business loan to cover payroll and essential operating costs through the end of 2025. Despite this, **the continued delay forced us to terminate the three employees because we could no longer afford to retain them.**



Administration for Community Living SBIR/STTR portfolio company.

INHEALTH USA, Inc., *Elizabeth City, NC*

Laverne Morrow Carter, Ph.D., MPH

President

INHEALTH USA, Inc.

I have used SBIR/STTR seed funding to build and commercialize digital health products for more than 10 years. **Our work has been halted, and our company has been adversely impacted by the loss of dedicated personnel and market momentum.**



Innovation Therapies PLLC, *Fayetteville, NC*

Denise Dawson, Ph.D.

President/Owner

Innovation Therapies PLLC

I'm unable to generate R&D income at all. **As a small company this means I cannot grow and expand products and services, and my income is significantly restricted.**



Innovative Viral Solutions, Inc., *Leland, NC*

James Mark Hammer, DVM

President and Founder

Innovative Viral Solutions, Inc

Innovative Viral Solutions, Inc.

Innovative Viral Solutions is a startup focusing on proof-of-concept animal vaccines developed in university settings. Without access to non-dilutive grant money, the viability of my business is in jeopardy. Providing non-dilutive funding is an integral part of technology startup businesses such as mine. No grant funding will **decrease innovation and hurt small businesses**. Please authorize funding through Small Business Innovative Research and Small Business Technology Transfer programs, as well as other grants to university discovery research.

US Department of Agriculture SBIR/STTR portfolio company.

Intelli-Products Inc., Asheville, NC

Rick Clemenzi, PE

Innovation Engineer, Co-Founder
Intelli-Products Inc.



It appeared we were selected for two SBIRs in June to start in July, but that round is just now canceled, meaning the loss of \$413K in federal and \$100K+ in state funds for important commercial innovations we're bringing to market. **This effectively destroyed our small business as we had to cancel other work for the SBIR. The innovations may now be lost from our country, as we don't have the funds to prosecute the patents.** Our strength as a country depends on innovation, and the loss of the SBIR program means far less innovation is occurring in the US.

Department of Energy SBIR/STTR portfolio company.

iOrganBio, Chapel Hill, NC

Eric Bankaitis, Ph.D.

Principal Scientist and Funding Lead
iOrganBio



Our small business is revolutionizing manufacturing in North Carolina and we need the support of the SBIR/STTR program.

Jason Doherty, Durham, NC

Jason Doherty

Senior Director, Investments; Emerging Company Development
North Carolina Biotechnology Center



We support a portfolio of startup companies, a large number of which have had SBIR funding pulled (totaling tens of millions of dollars) in the past year. **For small businesses, this is an existential threat. Several have already shut down; many more are expected this year. Additional technologies are now shelved, potentially permanently, due to lack of SBIR/STTR funds to advance them.**

MEMWKS, Raleigh, NC

Joseph Lavoie, Ph.D.

Founder
MEMWKS



We incorporated our start-up biotech company in 2025, and due to the lapse in SBIR/STTR authorization, **we have faced significant headwinds as we try to launch our business.** The SBIR program could have provided a key bridge between inception and commercialization of our technology. Please stand behind American innovation and reauthorize the program without further delay.

Mireya McKee, Ph.D., Raleigh, NC

Mireya McKee, Ph.D.

Director, New Ventures and Partnerships
UNC Chapel Hill



We work with a portfolio of startups from UNC Chapel Hill based on university research. Several of them have shut down or are at risk of closing for lack of funding. **This will result in a loss of many collective years of research and investment from the government in key areas, most likely abandoning key intellectual property and resulting in missed therapies, innovations and products for society.**

mithrilAI Corp, *Raleigh, NC*

Aydin Aysu, Ph.D.

President
mithrilAI Corp



The SBIR lapse has halted our transition to a Phase II, creating a 'valley of death' that our adversaries are actively exploiting. While our US funding is frozen, our engineers—world-class experts in hardware security—are being aggressively targeted by China-linked entities offering unrestricted capital. We aren't just losing a project; we are witnessing a state-sponsored brain drain of American semiconductor IP. If Congress doesn't act, we are effectively subsidizing China's hardware supremacy by training elite talent in US universities only to force them into foreign hands due to domestic bureaucratic paralysis."

National Science Foundation SBIR/STTR portfolio company.

MSI Software Solutions and iMass Innovations, *Raleigh, NC*

David Muddiman, Ph.D.

CTO and CSO
MSI Software Solutions and iMass Innovations




We have two NC State start-ups - one for software with AI/ML and one for innovative hardware for imaging - novel technology. **Without the SBIR/STTR programs, we can not bring these to the level to commercialize a competitive project.** Without support from these programs we will have to shut both companies down. With funding, we could have major job creation and a huge impact on human health and disease.

Mucommune, LLC, Durham, NC

Sam Lai, Ph.D.

Founder and CEO
Mucommune, LLC



We are advancing multiple products in women's reproductive health, and are about a year away from initiating a clinical trial. **The current impasse over the SBIR/STTR reauthorization, which not only blocks new applications but also funding of subsequent years of already issued awards, would directly lead to the bankruptcy and closing down of operations by mid-2026.**

National Institutes of Health SBIR/STTR portfolio company.

MyoMech, Inc., Raleigh, NC

Nitin Sharma, Ph.D.

President
MyoMech, Inc.



We are an early-stage startup focused on commercializing a medical technology with the potential to significantly improve quality of life for individuals with mobility impairments. A lapse in SBIR/STTR funding has **slowed translation of our laboratory-validated technology to clinical settings**, as this non-dilutive support is critical for de-risking development and attracting private investment. Without continued SBIR/STTR support, advancing toward clinical deployment and securing follow-on investment has become substantially more challenging.

NabGen, Inc., Durham, NC

Charles Askew, Ph.D.

President
NabGen, Inc.



My small biotech business, NabGen Inc., is just getting off the ground with a treatment that could save the lives of thousands of children who are born with rare genetic diseases each year. The SBIR/STTR program is the single most important factor that has determined whether we will be able to get this drug out of the lab and into patients. We received the 1st year of what is supposed to be a 3-year Phase II award. **Without continued funding, our company will not be able to complete the Investigational New Drug (IND) animal studies necessary for translating this life-saving drug candidate into people. Furthermore, the existence of our company at this fragile early stage is at risk without government funding, and we may have to dissolve the company without SBIR/STTR re-authorization.** I urge you, please fully fund the SBIR/STTR program and make it permanent for the future of these patients and all the small businesses like ours who are the real innovators bringing about new medicines in the USA!

National Institutes of Health SBIR/STTR portfolio company.

NC SBTDC, Raleigh, NC

Ramya Vijapurapu, MMB

Technology Commercialization Counselor
NC SBTDC



My clients cannot apply for the SBIR/STTR program due to this lapse. I really want to help them get the funding they need to move forward with R&D and commercialization of innovations in life science, agriculture, artificial intelligence, etc.

NOBiotics, Raleigh, NC

Jiten Pant, Ph.D.

CEO

NOBiotics



We have received a score of 30 from NIGMS from April 30th cycle and have made several resubmissions to NIH and NSF. The lapse is causing a delay in critical research we aim to do in the area of trauma burn wounds and antibiotic resistance. **We are running out of resources but more importantly out of motivation to continue going. These topics are of national importance and require urgent attention.**

Olfax Medical, Asheville, NC

Jonathan Beckwith

CEO

Olfax Medical



Olfax Medical has been previously awarded a Phase I SBIR through the NIH HEAL initiative to develop a non-addictive therapeutic for rapid pain management. Our program, which has surpassed expectations to date, directly relates to the national opioid crisis. Our Phase II SBIR application, which is critical to bringing this product to market, has now been delayed for a year due to the government's review of NIH, the 2025 federal shutdown, and the SBIR program lapse. This comes at a critical time for the company, where all systems are in place, and additional VC funding is pending upon the SBIR award. **Without the immediate renewal of the SBIR program, our company - and the life-changing products in development - may cease to exist.**

National Institutes of Health SBIR/STTR portfolio company.

OpenAgBio LLC, Cary, NC

Kasi Azhakanandam, Ph.D.

CEO

OpenAgBio LLC

I am a new entrepreneur and just established my startup, OpenAgBio last year. I was hopeful to get some funding from SBIR/STTR this year. But I was disappointed to hear about cutting funding, which will severely affect people like me. I would request Congress to continue to support SBIR/STTR.



PATH2Caregiving, Chapel Hill, NC

Barbara Lutz, Ph.D., RN, CRRN, PHNA-BC

Founder

PATH2Caregiving



Our company, PATH2Caregiving, LLC, received a Phase I SBIR grant in 2023 to develop an mHealth app to assess and provide support for family caregivers. We have a minimally viable product (MVP) but **cannot move to commercialization without Phase II SBIR funding**. We are in the process of revising our Phase II proposal but are in limbo because the SBIR program funding has not been reauthorized. Please consider reauthorizing the program for its full time period (not just one year) so that small businesses like ours can compete for startup funds to move our highly valuable product to market.

National Institutes of Health SBIR/STTR portfolio company.

Perfusio Corp., Greenville, NC

Elizabeth Clarke

Product Development Engineer

Perfusio Corp.



Small businesses are the heart of innovation, and the removal of research funding halts innovation, puts jobs at risk, and wastes the knowledge and expertise of hardworking Americans trying to make a difference. From my personal experience, SBIR/STTR funding allowed a local medtech business to hire me as a young engineer.

This has allowed my passion for helping people through technology to flourish instead of being potentially crushed by a large corporation focused only on its bottom line. We are currently working on a product that we believe will have a large positive impact on burn wound health, and we have been able to use SBIR funds to prove that to the medical community. These ideas are not just for the benefit of us but for all American citizens and our military personnel who suffer the most from burn and blast injuries.

National Institutes of Health SBIR/STTR portfolio company.

Piximune, Inc., Durham, NC

Michael Hannan

CEO

Piximune, Inc.



We are developing therapies to treat retinitis pigmentosa, a rare disease that causes blindness, and geographic atrophy, a sight-threatening disease affecting millions of patients over 65. **Not having SBIR funding by April will delay our work, and frankly, with the lack of available private money at our early stage, may threaten our program permanently.**

No SBIR means hundreds of new therapies never get developed to the point where private investment can take over, which threatens lives and quality of life for millions of Americans.

PolyPV LLC, Cary, NC

Harald Ade, Ph.D.

CEO

PolyPV LLC



PolyPV, cofounded by NCSU faculty Ade and O'Connor, is a very small company with three employees but great potential. The STTR is currently the only source of funds we have to survive. Even a short break in support might bankrupt it, **wasting three years of work at the company and even more years at NCSU before. This would likely also make me retreat from research prematurely out of frustration.** As a highly decorated researcher with international standing, it would be a significant loss to NCSU.

National Science Foundation and Department of War SBIR/STTR portfolio company.

Practical Scientific Solutions, Inc., *Fuquay Varina, NC*

Brandon Conover, Ph.D.

CEO

Practical Scientific Solutions, Inc.



We assist many small businesses every year in executing all phases of STTR contracts. In 2025, it was 15 businesses with dozens more pending when SBIR authorization ceased. We are currently awaiting decisions on over 50 Air Force STTR proposals. This will represent millions of dollars in revenue directly benefiting emerging US technologies. **Without reauthorization, this will cease and these companies will seek funding elsewhere, to include investment from other countries.**

PRSONAS Software, Inc., *Raleigh, NC*

Charles Rinker

President, CEO

PRSONAS Software, Inc.



Advance AI to remain competitive.

Qi LLC, Raleigh, NC

Raymond Lewis III, CPA

CFO

Qi LLC

My organization's SBIR was fully funded and ended this year. But I have seen firsthand how the disruption in funding affected an organization's ability to develop technology that is ultimately for the benefit of our country.



I don't want our **country to fall behind in technology and scientific discoveries**. I am for the economic renaissance that appears to be unfolding over the past year. But **defunding the SBIR programs is counterintuitive**. I personally have met many brilliant scientific minds from around the world through SBIR, and this collaboration needs to take place for the benefit of America, and indirectly, the benefit of all.

Department of War SBIR/STTR portfolio company.

Quanticision Diagnostics Inc., Chapel Hill, NC

Jianbo Zhang

CEO

Quanticision Diagnostics Inc.

We are to apply for a Direct to Phase II SBIR grant if not for the lapse. With the funding, we will be able to commercialize quicker.



Ramona Optics, Durham, NC

Roarke Horstmeyer, Ph.D.

Scientific Director
Ramona Optics



SBIRs are a vital source of support for the latest advanced technology coming out of the research triangle area here in North Carolina. **Recent graduates and new entrepreneurs that I mentor are now choosing other paths without this important support, which is leaving game-changing technology on the table.**

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

RFPi, Inc., Raleigh, NC

Thomas Bruce Ferguson, Jr., MD

CEO
RFPi, Inc



RFPi, Inc. received \$4M in SBIR/STTR funding as a medical imaging startup. Developments and science would not have happened otherwise. **For 30+ years, these programs have made possible the link between basic science and entrepreneurial development by the private sector - can't survive without it.**

National Institutes of Health SBIR/STTR portfolio company.

Scyntek, Inc., Morrisville, NC

Karthik Ramakrishnan, B.S.

Co-Founder and CTO

Scyntek, Inc.



As a pre-revenue medical device company looking to solve the problem of undetected Deep Vein Thrombosis at home, we applied to the NIH SBIR Phase I program back in September 2025 as we seek to move our company forward with several key milestones including trials. However, the **continued uncertainty regarding funding leaves us stuck and not being able to plan out things like study design and study partners. While this happens, thousands of people die every day due to a Deep Vein Thrombosis that could have been prevented with our device.**

Silent Crown, Wendell, NC

Ted Slusher

CEO

Silent Crown



We submitted under the USAF open topic in August and were eligible for award in November 2025. We have letters of support from two operational Squadron Commanders at Fort Bragg requesting we begin work with them as the end users. We currently have a CRADA with SOCOM to work with them but **we are unable to hire 3 new positions for this SBIR because we are a Service Disabled Veteran Small Business startup non-traditional contractor and needed this SBIR to fund those positions.** Our end users need this technology by October 2026, meaning this delay has set us back 20% of our available time to execute the requirements. We have now maxed out our internal IRAD dollars continuing to press forward during the delay. **Any additional delay will affect National Mission Force training objectives.**

SimplusDx, Durham, NC

Jacob Heggestad, Ph.D.

CEO

SimplusDx



We had plans to submit a follow-on Phase II proposal, which is currently on hold until the program is reauthorized.

Spinhance, LLC, Chapel Hill, NC

Shara Nejad, LEED AP, PEM

Director of Operations

Spinhance, LLC



Spinhance is an early-stage medical device company that received its first Phase I SBIR award in 2025. That funding enabled the company to secure dedicated R&D space and bring on its first employee, allowing meaningful technical progress to begin. With that momentum, the team was preparing to submit a Phase II SBIR application in January 2026. The recent uncertainty surrounding the SBIR program, however, now threatens the company's ability to sustain operations and maintain or grow its workforce. Without continued support, further development of our pulmonary imaging platform may stall at the feasibility stage, putting the future of this promising and innovative technology in jeopardy.

Stephen Kadlecik, Ph.D.

Research Director

Spinhance, LLC

Spinhance is a relatively new company making medical products with a significant regulatory burden. **We got our first SBIR in 2025 and, based on that funding, have rented a space and hired our first manufacturing staff. A second grant was scored very well in late 2025, which, if funded, will allow us to address our regulatory needs to begin marketing, hopefully becoming self-sustaining in late 2026 or early 2027.** Reauthorization of the SBIR/STTR program will honestly make the difference between our nursing existing funding along until mid-year and shutting down, and (optimistically, of course) being in a position to manufacture, sell and hire within a year. We have no intention of being permanently dependent on the program, but especially given the additional regulatory burdens of the medical device business, it is urgently needed to allow us to be successful.

National Institutes of Health SBIR/STTR portfolio company.

Teen Health Research, *Raleigh, NC*

Laura Widman, Ph.D.

CEO and Founder

Teen Health Research

We are waiting on funding decisions from two STTR proposals that have been scored but are not yet funded. **This funding is vital to our company. We have less than 6 months of funding runway remaining. We have slowed down our progress to make our funding stretch as long as possible, but without the STTR funding, we will be forced to close the business.**



National Institutes of Health SBIR/STTR portfolio company.

Timothy N. Martin, *Raleigh, NC*

Timothy N. Martin

Interim Assistant Vice Chancellor of New Ventures and

Investments

NC State University

SBIR is the single most **impactful program** the federal government has to support innovation and commercialization.




Trig, LLC, Chapel Hill, NC

Ty Hagler, MBA

Principal

Trig, LLC



The SBIR/STTR program has been essential to bridging the Valley of Death for many promising early technologies that need further support to become commercially viable. This is an incredible economic engine that will have long-term consequences in our leadership across many sectors of defense, transportation, and medical technologies if it isn't renewed. Renew now and work out the bugs over time!

National Institute of Health SBIR/STTR portfolio co-partnering company.

Verenovo Energy, North Wilkesboro, NC

Brewer Logan, M.S.

CEO

Verenovo Energy



We submitted a LOI for a funding proposal in August 2024 with expectations to hear back by October. We were not notified about anything until Jan 2026. We have important work to complete for our new patented technology, and this **funding is crucial as traditional banks do not lend for innovation.**

ViaVerus LLC, Mebane, NC

Chris Morrison

Owner
ViaVerus LLC

My clients have been impacted across the board. I work with Medtech, life science, and healthcare startups launching disruptive technologies for improving human health. This is the **lifeblood of improving human health and a large part of our entrepreneurial engine in the US that makes us the #1 innovator in healthcare worldwide. Every single one of my customers has been negatively impacted by the current state of the STTR/SBIR program.**



Vindhya Data Science Inc., Morrisville, NC

Anupama Reddy, Ph.D.

COO
Vindhya Data Science Inc.

We are developing an innovative platform to accelerate precision medicine and biomarkers for patients. Our **platform development has been halted because we cannot submit for Phase II funding. We have also had to lay off employees because of this lapse.**



National Institutes of Health SBIR/STTR portfolio company.

Vitality Robotics, Inc., Cary, NC

Joe Webb, Ph.D.

CEO
Vitality Robotics, Inc.

I lost over \$2.5M in federal funding, causing my company to lay off 10 AI engineers building the future of life science diagnostics and automated surgical robotics.



XSONX, LLC, *Charlotte, NC*

Wade Farrow, MD, CWSP

CEO

XSONX, LLC

We are filing for a \$2 million NIH grant for our innovative technology to scrub and deride wounds (XSONX). We need funding to develop this important technology, as **there is no funding otherwise**. It was developed by me, as a wound care physician.



Department of War SBIR/STTR portfolio company.

North Dakota

Economic Impact of Program:

SBIR/STTR Funds Received: **\$35,356,104.00**

Small Business SBIR/STTR Awards: **156**

Letter to Congress Co-signers

Alex Benson	COO	Microbeam Technologies, Inc.
-------------	-----	------------------------------

Selected Case Studies from Impacted Companies:

Microbeam Technologies Inc., *Grand Forks, ND*

Alex Benson

Chief Operating Officer

Microbeam Technologies Inc.



We are developing technologies that are in direct alignment with the current administration's objectives of developing a domestic supply chain for critical minerals. This supply chain is needed as soon as possible and the current lapse in funding is only further delaying our ability to commercialize this technology.

Department of Energy, National Institutes of Health, and National Science Foundation SBIR/STTR portfolio company.

Ohio

Economic Impact of Program:

SBIR/STTR Funds Received: **\$2,934,099,635.31**

Small Business SBIR/STTR Awards: **8,253**

Letter to Congress Co-signers

Patrick N. Longo	President and CEO	Alloy Development Co., Inc. and Alloy Growth Lab
Kelly McCall, Ph.D.	CEO	AOHBIO Corporation
Aaron Crookes	CEO	Apricity Robotics
Daniel S. Savage, MSME, PE	CTO	ArthroNovus, Inc.
Ronald Triolo	Professor and Senior Research Career Scientist	Case Western Reserve University
Raghvendra Srivastava, Ph.D.	Assistant Professor	Cleveland Clinic
Anthony Berdis, Ph.D.	Professor	Cleveland State University
Subba Shankar, Ph.D.	CTO	CollaMedix, Inc.
William Chambers	Analyst	CSCC
Ronald Thompson, MD	Managing Partner	CT Development One, LLC
Samuel Lee, MD, MBA	President	Eikonoklastes Therapeutics
Nick Edwards	Managing Partner	Funding Ninja
Dr. Peng Zhang	CSO	H2 Sensors, LLC
Ujjal Didar Singh Sekhon, Ph.D.	Principal Scientist	Haima Therapeutics
Zhiqing Cheng	CEO	Innovision
Silvia Duarte Sanmiguel	Research and Development Director	Neucore Bio
Yingjie Shen, Ph.D.	CSO	PEARL Neuroscience
Robert Arnoff	President	Quality of Life to The Nth Degree
Missy Lavender, MBA	CEO	Renalis Health
Xiaoting Zhang, Ph.D.	President and Founder	RNA Nanotherapeutics
Brian Lawrence, Ph.D.	CEO	Silk Technologies, Ltd.

Sukesh Roy Sivaram P. Gogineni, Ph.D.	CEO President	Spectral Energies, LLC
Dr. Corinn Taylor	CEO	The Empowerment Foundation
Zhiwei Hu, MD, Ph.D.	Co-Director, Center for Antibody Therapeutics at PIIO	The Ohio State University Comprehensive Cancer Center
Adam Perzynski, Ph.D.	Chief Science and Strategy Officer	TritonX

Selected Case Studies from Impacted Companies:

ArthroNovus, Inc., *Cleveland, OH*

Daniel S. Savage, MSME, PE
CTO
ArthroNovus, Inc.



ArthroNovus, Inc. is a startup organization pursuing technologies that will help unburden the US Healthcare system of costs associated with osteoarthritis, leading to total joint replacement. Currently we spend >\$150k for each patient from diagnosis to final treatment. With the help of STTR support, ArthroNovus aims to deploy earlier solutions that greatly reduce this burden.

AOHBIO Corporation, *Dayton, OH*

Kelly McCall, Ph.D.
CEO
AOHBIO Co.

Without this funding, we will likely have to close our doors.

National Institutes of Health SBIR/STTR portfolio company.



CollaMedix Inc., *Cleveland, OH*

Christian T. Denny, Ph.D.

Research Scientist
CollaMedix Inc.



I have an NIH Phase II SBIR grant that is building upon studies to develop a biologic for healing anterior cruciate ligament primary repair, which **was delayed in review. This slows down development of the medical device and leaves uncertainty in future development plans.**

National Institutes of Health SBIR/STTR portfolio company.

Innovision, *Dayton, OH*

Zhiqing Chen

CEO
Innovision



Due to the lapse of SBIR/STTR funding, we are unable to plan our technology development, transition, and commercialization. **We are struggling to retain key employees.**

Department of War and National Science Foundation SBIR/STTR portfolio company.

Renalis Health, *Cleveland, OH*

Missy Lavender, MBA

CEO
Renalis Health



We have a successful Phase 1 which we completed at the end of Sept 2025, and are waiting to submit a Phase 2 application. We WERE going submit for January 5th but are now on hold. This has put us under **severe financial constraints** as a company such that we have **laid off all employees and contractors.**


National Institutes of Health SBIR/STTR portfolio company.

Silk Technologies, Ltd., Lewis Center, OH

Brian Lawrence, Ph.D.

CEO

Silk Tech



We apply for SBIR/STTR funding continually and without this program our company will shudder **despite the lifesaving medicines we produce for the world.**

Department of War and National Science Foundation SBIR/STTR portfolio company.

Spectral Energies, LLC, Dayton, OH

Sivaram P. Gogineni, Ph.D.

President

Spectral Energies



The lapse in SBIR/STTR reauthorization certainly affected our company in terms of personnel, financial, and future strategic goals. **Our company has contributed to SBIR/STTR over the past 30 years, developed state-of-the-art technologies and commercialized products worth more than \$100M.** We sincerely urge congress to reauthorize so that we can continue to make notable contributions to Department of War and other government agencies.

Department of War SBIR/STTR portfolio company.

Sukesh Roy, Ph.D.

CEO

Spectral Energies



If we don't start writing proposals or receive the already selected contracts, we might have to start laying off our engineers.

TritonX, *Cleveland, OH*

Adam Perzynski, Ph.D.

CSO

TritonX



Our business has been able to build and commercialize a wearable hydration monitor, **saving lives** and **health care dollars** with SBIR/STTR funding.

National Institutes of Health SBIR/STTR portfolio company.

Oklahoma

Economic Impact of Program:

SBIR/STTR Funds Received: **\$249,429,711.18**

Small Business SBIR/STTR Awards: **772**

Letter to Congress Co-signers:

Hector Medina, MBA	CEO	Monte Caldera Technologies, Inc.
Anne Kasus-Jacobi, Ph.D.	Associate Professor	University of Oklahoma
Mark Hamrick	President	Velogenix, Inc.

Selected Case Studies from Impacted Companies:

Monte Caldera Technologies, Inc., *Tulsa, OK*

Hector Medina, MBA
CEO
Monte Caldera Tech

Due to the delays in funding, I had to let go of 4 highly technical (Ph.D. level) employees, and I won't be able to hire this year. I am at risk of shutting down.



Velogenix, Inc., *Tulsa, OK*

Mark Hamrick, Ph.D.
Co-Founder and President
Velogenix

We currently have a Phase 1 SBIR in review at NIH. This project seeks to develop novel therapies to prevent muscle loss, falls and fractures with aging. Please support small business innovation in America!



Oregon

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,068,052,080.69**
Small Business SBIR/STTR Awards: **2,824**

Letter to Congress Co-signers:

Devin Wiley, MD, Ph.D.	Co-Founder	Circumvent Pharmaceuticals
Jeanne Hahne, RN, MSN	CEO	FaceView Mask
Patti White	CEO	Hemex Health
David McFeeters-Krone	President	Intellectual Assets, Inc.
Kathryn McCormick, Ph.D.	CEO	InVivo Biosystems
Dr. Catherine Robinson	CEO and President	KeyBiome, Inc.
Jennifer Wells	CEO	LATERAL.systems
Daniel R. Kimbell, JD	Partner	Loza and Loza
Holly Rockweiler, MS	CEO	Madora
Mridul Mittal	Co-Founder	Mittal Consulting
Jiri Sklenar	CEO	narnar, LLC
Klaus Frueh, Ph.D.	CSO	Saravir
Jeff Gaus	Founder and CEO	The Provenance Chain Network

Selected Case Studies from Impacted Companies:

FaceView Mask, LLC, *Medford, OR*

Jeanne Hahne, RN, MSN
CEO
FaceView Mask

My grant started my business and is helping change many lives!



National Institutes of Health SBIR/STTR portfolio company.

Intellectual Assets, Inc., *Portland, OR*

David McFeeters-Krone, MBA

President

Intellectual Assets, Inc.



I am a commercialization consultant and have had to defer 6 companies in exportable and critical industries from applying to SBIRs. These are companies that have impact on critical mineral discovery, energy generation, agriculture, drone production, and material research. While we dither the rest of the world is winning the day AND these companies are relocating abroad.

InVivo Biosystems, Inc., *Eugene, OR*

Kathryn McCormick, Ph.D.

CEO

InVivo Biosystems



We've been waiting since November for dispersal of funds for a grant to develop a gene therapy for retinal disorders. The grant scored well and we would normally expect an award and be working on it already. We've **also lost new opportunities** to apply at the typical Jan 5th deadline. Please help!

National Institutes of Health SBIR/STTR portfolio company.

KeyBiome, Inc., Eugene, OR

Catherine Robinson

President and CEO

KeyBiome, Inc.



Our small business has been severely impacted by the lapse in SBIR/STTR funding. We are a nascent university spin-out company whose primary program is solely supported through STTR funding. After successful achievement of our Phase I milestones, we received laudatory reviews and a favorable score for the Phase 2 application which may now not have the opportunity for funding. Consequently, **our progress on the development of this promising new drug is at a complete standstill.**

National Institutes of Health SBIR/STTR portfolio company.

LATERAL.Systems, Lake Oswego, OR

Jennifer Wells, ED.D.

CEO

LATERAL.systems



There is a well-known critical gap between early invention and commercialization; the SBIR program helps companies like us to bridge this gap to ensure that communities actually benefit from technical innovations. Most private investors are not interested in investing in pre-revenue companies, which means that most innovations never leave the labs, even great inventions that contribute powerful solutions to clear, demonstrated needs. Less than 3% of private investment goes to women led companies in the U.S., SBIR helps bridge this gap ensuring that gender is not the deciding factor as to whether or not powerful inventions/companies make it to market. Even if companies are lucky enough to get private investment early on, premature equity dilution often leaves an insufficient amount of equity to offer investors to support successful product launch and scale up. The SBIR program helps companies like ours to bridge that so-called "valley of death" gap to ensure technology makes it to market to do the good work it's meant to do. This form of community investment is essential, **delaying funding the SBIR program slows and, in many cases, will halt, American innovations** that represent breakthrough solutions in the service of humanity.

Department of Agriculture and National Science Foundation SBIR/STTR portfolio company.

Loza & Loza, LLP, Beaverton, OR

Daniel R. Kimbell, JD

Partner

Loza & Loza, LLP



I am a US patent attorney who specializes in representing medical device companies, biotech companies, and other startup tech companies. In the past, my clients have been able to get started on the path to commercialization with the help of SBIR/STTR grants. With these programs being shut down, **many companies are having difficulties in surviving and progressing**, which will **starve** the country of the important technology, products, and **high payment jobs** they provide. Most important technology is launched by small startups. This will very much hurt US competitiveness now and in the future. Let's not shoot ourselves in the foot and please reauthorize the SBIR/STTR programs post haste.

Madorra, Portland, OR

Holly Rockweiler, MS

CEO

Madorra



We are an SBIR recipient, and the SBIR program saved our company. We were days away from shutting down when our grant came in and completely revived the company. We would like to apply for follow on funding and supplements to continue to support our growth, but we have been unable to because of the delayed reauthorization. **Please reauthorize this program now. It is the lifeblood of medtech innovation in our country.**

National Science Foundation and National Institutes of Health SBIR/STTR portfolio company.

Narnar, LLC, Lake Oswego, OR

Daniel R. Kimbell, J.D.

Co-Founder

Narnar, LLC



Without SBIR funding we would have zero chance of developing innovative image analysis software for contrast echocardiography **that saves lives**. Our product is now FDA cleared and ready to launch in the U.S.

National Institutes of Health SBIR/STTR portfolio company.

Saravir Biopharma, Portland, OR

Klaus Frueh, Ph.D.

Chief Scientific Officer

Saravir Biopharma



A Phase II SBIR is ready to go for the pre-clinical study of a treatment for measles. If successful, our product will protect vulnerable individuals who cannot get vaccinated.

Pennsylvania

Economic Impact of Program:

SBIR/STTR Funds Received: **\$3,026,210,998.57**

Small Business SBIR/STTR Awards: **7,832**

Letter to Congress Co-signers

Orna Azulay MA, CCC-SLP	CEO	Abington Speech Pathology Services
Jay Reddy, Ph.D.	CEO	Advanced Optronics, Inc.
Pemra Doruker, Ph.D.	CEO and Co- Founder	Allotar Therapeutics
Andrew Tsourkas, Ph.D.	Founder	AlphaThera, Inc.
Charles D Sith, Ph.D.	President and CEO	Apogee Biotechnology Corporation
John P. Hamill	Sr. Vice President and CFO	Aprea Therapeutics, Inc.
Joe Erckert, MA	Chief Development Officer	Baruch S. Blumberg Institute
Ellie Gordon	Founder and CEO	Behaivior
Scott Nissenbaum	CEO	Ben Franklin Technology Partners
Catherine V. Mott	Managing Partner	BlueTree VC
Nishita Shastri, Ph.D.	CEO	BreakSight, Inc.
Hongzhang He Brandon Park	CEO Research Scientist	Captis Diagnostics
Tulin Morcol, Ph.D.	President and CSO	CaPtivate Pharmaceuticals, LLC
Ashley Magnavita, MPH	Director, Clinical Research Project Management	Carelon Research
Gavin Schmidt	Research Associate	Carnegie Mellon University
Pulkit Grover, Ph.D.	Professor	Carnegie Mellon University
Melanie Simko	Senior Program Manager	Carnegie Mellon University
Patrick J. Cahill, MD	Endowed Chair	Children's Hospital of Philadelphia

Larry Zana	President and CEO	Consegna Pharma, Inc.
Dr Rebecca Grant	Senior Director	Dept of Commerce
Eamon Gallagher	Director, Center for Law and Transformational Technology	Drexel University
Richard A. Longo	Director	Duquesne University Small Business Development Center
Zak Koyn	CEO	Energy Driven Technologies, LLC
Thomas Kim	CEO	Epivario
Caitlin DeAngelo, Ph.D.	Project Manager	Evrys Bio
Eric Rugart	CEO	FetaMed, Inc.
Kate Hermans	CEO	Glya Health
John Nosek, Ph.D.	President	Guiding Technologies Corp.
Greg Basarab, Ph.D.	Independent Consulting in Medicinal Chemistry	
Jane Joseph	Director of Communications	Innovation Works
Costa Nikou, MS Robert B. Slaymaker Isaac Swink	CTO Principal Engineer System Research Engineer	iotaMotion, Inc.
Jonathan Maderic	Owner and Engineer	JMad Creations, LLC
Jesse Butch, BS	Senior Engineer	Johnson & Johnson
Mark Rentschler	Financing and Technology Specialist	Kutztown University Small Business Development Center
Jordyn Ting, Ph.D.	CEO	Lexi Medical, Inc.
Michele Washko, MA, MBA	President and CEO	Life Sciences Greenhouse Investments
Jonathan Kaufman	CEO	Lipella Pharmaceuticals, Inc.
Helen Behn	Chief of Staff	Magee-Womens Research Institute
Paul KT Liu	President	Media and Process Technology, Inc.
Randall N. Hyer, MD, Ph.D., MPH	CEO	Merlin Biotech, Inc.
Alex De Marco, MASc	CEO	MoneyStack, Inc.
Donald Samulack, Ph.D.	President	Myeutics, LLC

Steve Davis	CEO	Mynari Biomedical, LLC
F. Gregory Grillo, MD	Owner	Nanolytics
Melissa Becker, CPP	Government Contracting Specialist	Northwest Commission APEX Accelerator
John Welsh, Ph.D.	CEO	OsciFlex, LLC
Lou Kassa	CEO	Pennsylvania Biotechnology Center
Kelly S. Wylam	Executive Director	Pennsylvania's Innovation Partnership (IPart)
Nicholas Ritchie	Technical Advisor	PennTAP
Adrianne Blocklin	Innovation Program Manager	Plasma Futures
Lixia Yao, Ph.D.	CEO and Founder	Polygon Health Analytics, LLC
Michel Nederlof	CEO	Quantitative Imaging Systems
Michelle J. Johnson, Ph.D.	CSO	Recupero Robotics, LLC
Alexander Gutsol, Ph.D.	Chief Scientist	RedShift Energy, Inc.
Yuriy Mirochnik	Lead Engineer	
Nance K. Dicciani, Ph.D.	CEO	
Denise L. Devine, CPA, MBA, MST	Co-Founder and CRO	RTM Vital Signs, LLC
Thomas Runyon	Founder	Runyon Solutions, LLC
Kumaril Bhargava, Ph.D., MBA	CEO	Serentrix
Jeremy Elser, Ph.D.	CEO	Ship of Theseus
Kiarash Emami, Ph.D.	Director of Business Development	Spinrance, LLC
Wayne Zachary, Ph.D.	Managing Partner	Starship Health Technologies
Karin Eisinger	CEO	SyzOnc
Lynn Brusco	President	The Caileigh Lynn McDowell Foundation
Tanna Pugh	Director	The Pennsylvania State University
Erika Swift, MBA, MHA	Executive Director, Center for Medical Innovation	The Pennsylvania State University, College of Medicine
Jean Cho	CEO	Trevarx Biomedical, Inc.
Sam Choe	CEO	UCleaner
Heather McMonnies	CMO	Universal Schedule and Booking

Bhavana Mohanraj, Ph.D.	Interim Executive Director, PCI Ventures	University of Pennsylvania
Devraj Basu, MD, Ph.D.	Associate Professor	University of Pennsylvania
Ahmad Amirshaghaghi	Senior Research Investigator	University of Pennsylvania
John O'Donnell, Ph.D.	Assistant Professor of Neurosurgery	University of Pennsylvania
Robert Ricciardi, Ph.D.	Professor	University of Pennsylvania, Department of Basic and Translational Sciences
Tracy Cui	Professor	University of Pittsburgh
Francisco Schopfer, Ph.D., MBA	Professor and Vice Chair of Biotechnology	University of Pittsburgh
Carola Neumann, MD	Associate Professor	University of Pittsburgh
Nicole Oshurak	Director, Inventor Engagement	University of Pittsburgh
Takashi Koxai	Professor	University of Pittsburgh
Paul J Petrovich, CPA	Director, New Ventures	University of Pittsburgh - Innovation Institute
Bruce Freeman, Ph.D.	Distinguished Professor and Chair, Pharmacology and Chemical Biology	University of Pittsburgh School of Medicine
Jocelyn Fitzgerald, MD	Assistant Professor, Urogynecology and Reconstructive Pelvic Surgery	UPMC
Jonathan Revere	CEO	Valisci, Inc.
Christine Rohan, MBA	CEO	Vasowatch, Inc.
Stefanie Modri, MSN, RNC-OB, C-MNN	Co-Founder	Vasowatch, Inc. and University of Pennsylvania School of Nursing
Kirthika Parmeswaran	CEO	Vital Start Health
Matthew R. Maltese, Ph.D.	Chief Engineer and Co-Founder	X-Biomedical, Inc.

Selected Case Studies from Impacted Companies:

Behaivior LLC, *Pittsburgh, PA*

Ellie Gordon

Founder and CEO
Behaivior LLC



Due to the lapse in SBIR funding we have been unable to receive funding through our valid administrative supplement application. Our NIH/VA study supporting veterans with opioid use disorder transitions to a no-cost extension period January 31, after which we will no longer be eligible to receive the supplement.

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Ben Franklin Technology Partners, *Philadelphia, PA*

Scott Nissenbaum

President and CEO
Ben Franklin Technology Partners




SBIRs drive innovation. Innovation drives America. This is critical funding to drive our economy.

Bruce Freeman, Ph.D., *Pittsburgh, PA*

Bruce Freeman, Ph.D.

Distinguished Professor and Chair
Pharmacology and Chemical Biology
University of Pittsburgh School of Medicine



My Pharmacology and Chemical Biology department is one of the top 5 in the USA, with 35 tenure stream faculty, 75 MS and Ph.D. students and 30 research staff. Our Federal research and training support is down by 25% this past year, which has led to job terminations, career goal changes by trainees and loss of

innovation and new discoveries. Personally, my own research and clinical development of an anti-cancer drug, rated outstanding by a recent NIH/NCI grant review panel, has been stalled by delays in congressional approval of NIH STTR/SBIR programs. **This is a lifesaving drug for untreatable breast, prostate, ovarian and pancreatic cancers designed to bring new drug treatments to the population.**

National Institutes of Health SBIR/STTR portfolio company.

Captis Diagnostics, Pittsburgh, PA

Brandon Park, Ph.D.
Research Scientist
Captis Diagnostics

I was recently employed at this small start-up, looking to apply for my first grant.

National Institutes of Health SBIR/STTR portfolio company.



Carola Neumann, MD, Pittsburgh, PA

Carola Neumann, MD
Associate Professor
University of Pittsburgh



With the help of a Phase I STTR, we have developed an anti-cancer drug that kills breast and ovarian cancer, both deadly diseases. We are very close to applying to the FDA for approval to test the drug in humans. In order to move the drug further along, we applied for Phase II STTR funding that will fund the necessary experiments to generate this FDA approval. **We received an outstanding score at the review by the NCI. The only thing holding us back now is the approval by congress for re-authorization of STTR/SBIR funding. PLEASE fund this program that has resulted in essential innovation that benefits humankind.**

National Institutes of Health SBIR/STTR portfolio company.

Eamon Gallagher, Havertown, PA

Eamon Gallagher, J.D.

Director, Center for Law & Transformational Technology
Drexel University



I run an Entrepreneurial Law Clinic out of Drexel/Kline Law School that works with technology and technology-enabled startups in the greater Philadelphia Region -- many of these clients apply to or plan to apply to SBIR/STTR funding to develop and commercialize their businesses.

Having worked with hundreds of startups that have raised tens of millions in SBIR/STTR funding over the last decade, I can attest that these funds are critical to continue to drive innovation in both University settings and the community more broadly.

Energy Driven Technologies, LLC, Stage College, PA

Zac Koyn, MS

CEO and CTO
Energy Driven Technologies, LLC



We are a small start-up working to commercialize new manufacturing processes for next-generation nuclear energy. Despite being chosen for an award last year, due to program delays, the shutdown, and now the lapse in reauthorization, we have not been able to start on our next phase of development. **We are now facing the harsh reality that our company may not survive if the reauthorization is not addressed soon.**

Department of Energy SBIR/STTR portfolio company.

Epivario, Inc., Philadelphia, PA

Thomas Kim, M.S., J.D.

President and CEO

Epivario



Our company would've closed without the support of NIDA through STTR and SBIR grants, and research collaborations. We would be one of countless numbers of biotech companies that would never get a chance to mature without this critical program.

National Institutes of Health SBIR/STTR portfolio company.

Feta Med, Inc., Philadelphia, PA

Eric Rugart

CEO

Feta Med



As both an entrepreneur and angel investor, I say unhesitatingly the SBIR program, and its expert review process, has been essential for engendering private investment in the high risk/high return projects that aim to translate science to business. Without the NIH's imprimatur, I suspect very few seed stage companies would ever emerge from the lab.

Gavin Schmidt, MBA, Pittsburgh, PA

Gavin Schmidt, MBA

Research Associate

Medical Devices

Carnegie Mellon



Many researchers at my University are unable to progress their intellectual property towards becoming actual products in the market as a result of not being able to obtain SBIR and STTR funding.

Glya Health, *Malvern, PA*

Kate Hermans

CEO

Glya Health



Small businesses are the lifeblood of the town of Malvern and the surrounding area. The biotech industry in the greater Philadelphia area and the growth of women's health as a sector in our area is dependent on the funding and support provided by programs like the SBIR / STTR grants. The innovation that stems from the biotech community in the greater Philadelphia region in turns stimulates the U.S. economy by **providing economic development, job growth, and leadership in healthcare**. Please reauthorize these programs so that we can continue to be a world leader in research, development, and commercialization of life saving medicines and technologies.

Guilding Technologies Corp., *Philadelphia, PA*

John Nosek, Ph.D.

President, Founder, and CEO

Guilding Technologies



SBIR is the best way to leverage basic research to generate jobs in technologies of the future. SBIR tackles those high-payoff, high-risk projects that are too risky for commercial companies. SBIR leverages the talent of entrepreneurs who are willing to take little salary to achieve future success. We are working on tackling the difficult job of helping the millions of individuals with autism and related disorders by leveraging advanced AI to help them to become more independent. This will help achieve a higher quality of life for them and their families, while reducing the financial burdens on government. In addition, the advances in applied AI which we are pursuing to help those with autism could be broadly used to serve many others beyond autism and in many fields including defense. The lapse in SBIR funding has dramatically impacted our ability **to pursue these advanced AI technologies and threatens the existence of our small business**.

iotaMotion, Pittsburgh, PA

Robert B Slaymaker

Principal Engineer
iotaMotion



We are doing important research to help patients retain better hearing with cochlear implants and the lapse in funding is preventing us from helping patients.

Isaac Swink, M.S.

Systems Research Engineer
iotaMotion

Our company exists partially because of this program, and its continued existence is a big part of our ability to continue to grow and advance the market.



National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Johnson & Johnson, Prospect Park, PA

Jesse Butch, BS

Senior Engineer
Johnson & Johnson



I began my career employed by a company that, at the time, was freshly awarded a Ph1 SBIR grant through the NSF (and later was awarded a Ph2 grant after successful Ph1). The SBIR/STTR program played a major role in jump-starting my career in product innovation and providing a network of entrepreneurial scientists and engineers working on advanced product innovations for the health and economic welfare of our nation. The companies relying on the funding from these programs are the engines that drive innovation at a time when our large corporations are sclerosed by regulatory and compliance inefficiencies, thwarting internal innovation and delaying commercial availability of transformative technologies. **Our nation depends on the scientific and engineering breakthroughs generated through the funding provided by SBIR/STTR.** Now we depend on you and your fellow members of Congress to reauthorize funding for SBIR/STTR.

National Science of Foundation SBIR/STTR portfolio researcher.

Media and Process Technology, Inc., Pittsburgh, PA

Paul K.T. Liu, Ph.D.

President

Media and Process Technology



We have planned based upon the phase I selected for award and phase ii to be submitted. Now we have to lay off the personnel involved intense work.

National Science Foundation, Department of Energy, and Department of War SBIR/STTR portfolio company.

Melanie Simko, M.S., Pittsburgh, PA

Melanie Simko, M.S.

Senior Program Manager

Swartz Center for Entrepreneurship

Carnegie Mellon University



The uncertainty and delay in SBIR/STTR funding have had a major impact on university startups. For many, this funding is a critical step in de-risking deep technology commercialization efforts. Without this support, **many high potential innovations will not be able to be deployed for the benefit of society.**

Merlin Biotech, Inc., Doylestown, PA

Randall N. Hyer, MD, Ph.D., M.P.H.

CEO

Merlin Biotech



SBIR funding helps Merlin develop life-saving pediatric cancer drugs. We must stay ahead of our competitors like China, who are rapidly moving into biotechnology dominance. The SBIR program is **one of our most effective programs towards innovation, job creation, and life extension.**

National Institutes of Health SBIR/STTR portfolio company.

Mynari Biomedical, LLC, Horsham, PA

Steve Davis

CEO

Mynari Biomedical



The lapse in SBIR/STTR funding has directly disrupted our operations. We have been forced to delay planned R&D activities, suspend hiring of technical staff, and postpone contracts with U.S.-based clinical and manufacturing partners. **These delays increase development costs, extend time to market, and weaken the ability of small businesses to translate federally funded innovation into real-world medical solutions.** Although SBIR/STTR does not add to the federal budget, the interruption creates immediate and measurable harm to startups advancing critical technologies and supporting high-quality domestic jobs.

OsciFlex LLC, Philadelphia, PA

John Welsh, Ph.D.

CEO

OsciFlex LLC



We have a project that we hope to support with SBIR funding that aims to provide effective and low-cost treatments to pediatric heart patients. **This device has strong evidence of potential clinical efficacy but it's a rare pediatric disease indication so private investment is not forthcoming for this project.** SBIR funding would support continued development of this technology.


National Science Foundation and National Institutes of Health SBIR/STTR portfolio company.

Patrick J. Cahill, Merion Station, PA

Patrick J. Cahill, MD

Endowed Chair

Children's Hospital of Philadelphia



The final step for scientific innovation is taking ideas from the lab and using them to cure diseases and help people. **This is crucially supported by SBIR/STTR mechanisms.** Please support scientific innovation and entrepreneurship.

Paul Petrovich, *Pittsburgh, PA*

Paul J. Petrovich, CPA

Director, New Ventures

University of Pittsburgh - Innovation Institute



The SBIR/STTR funding lapse is significantly impacting University of Pittsburgh faculty by halting critical commercialization pathways for federally-funded research. Faculty who've invested years developing discoveries now face stalled startup formation and technology licensing, as SBIR/STTR grants typically bridge the gap between academic research and market-ready products. **This disruption prevents university-licensed startups from advancing innovations in healthcare, biotechnology, and other fields where Pitt excels.** Without these commercialization vehicles, taxpayer-funded research discoveries risk remaining in laboratories rather than reaching patients and markets, undermining both the university's innovation ecosystem and the broader return on federal research investments.

Pennsylvania Biotechnology Center, *Doylesstown, PA*

Lou Kassa

CEO

Pennsylvania Biotechnology Center




SBIR/STTR funding is critical for early stage startups to advance their science.

Pennsylvania's Innovation Partnership (IPart), *Harrisburg, PA*

Kelly Wylam, M.A.

Executive Director

IPart



We assist Pennsylvania-based SBIR/STTR applicants with preparing & submitting their proposals. At the current time, we have a cache of 30+ clients who are unable to move forward with their submissions and countless others who are awaiting proposal reviews. **ALL of our clients are entrepreneurial or early-stage start-ups with little to no capital to move their vital projects forward.**

Philadelphia Department of Commerce, *Philadelphia, PA*

Rebecca Grant, DVM

Senior Director

Philadelphia Department of Commerce



Cuts to SBIR/STTR funding create major uncertainty for Philadelphia life science startups, putting the USA at risk for slower innovation, increased competition for fewer grants, delayed market entry (Valley of Death), and investor caution.

Startups face stalled new opportunities, longer runways needed to de-risk R&D, and potential job impacts, with some founders considering moving to less uncertain countries despite local ecosystem strengths.

Polygon Health Analytics LLC, *Philadelphia, PA*

Lixia Yao, Ph.D.

Founder, President, and CEO

Polygon Health Analytics



Polygon Health Analytics, a three-year-old small business specializing in healthcare data analytics and AI solutions, has been directly harmed by the lapse in SBIR/STTR reauthorization. We previously secured two Phase I awards, but our planned Phase II renewal was abruptly interrupted. As a result, travel was booked but never reimbursed, newly recruited talent could not be paid, and a major collaboration with a large institution to recruit patients was halted mid-planning. **The disruption has stalled critical research progress and created significant operational uncertainty.** Without resumption of funding, we face a real risk of running out of cash in 2026.

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Pulkit Grover, Ph.D., *Pittsburgh, PA*

Pulkit Grover, Ph.D.

Associate Professor

Electrical and Computer Engineering, Biomedical
Engineering
Carnegie Mellon Neuroscience Institute

Our work on a new treatment for major depressive disorder
is stuck because of lack of STTR/SBIR funds.




Quantitative Imaging Systems (Qi), *Pittsburgh, PA*

Michael Nederlof, Ph.D.

CEO

Qi



Our company, like many others, has paused SBIR applications due to uncertainty surrounding the program and substantial reductions in NIH funding. Over the past 35 years, I have founded and led ten cancer-focused startups that received multiple SBIR awards, enabling advances such as **digital pathology, drug-safety technologies, and clinical systems that improve cancer outcomes**. SBIR funding has a proven return: when funding is reduced or delayed, innovation slows; when innovation slows, patient impact is delayed; and delays translate directly into lives lost. Restoring predictable SBIR support is essential to sustaining U.S. biomedical leadership and patient care.

National Institutes of Health SBIR/STTR portfolio company.

Recupero Robotics LLC, *Philadelphia, PA*

Michelle J Johnson, Ph.D.

Co-Founder & CSO

Recupero Robotics LLC



My company is an early start-up that is in the rehabilitation healthcare technology development sector. We rely on the STTR/SBIR process. It is an excellent process for developing ideas from the lab to the real-world. **We were fortunate to receive fast-track funds and had made**

great progress. We have submitted Phase 2B grants, but the shutdown and now this lack of authorization is jeopardizing our survival! HELP

National Institutes of Health SBIR/STTR portfolio company.

RedShift Energy, Inc., Warminster, PA

Yuriy Mirochnik, M.S.

Lead Engineer
RedShift Energy

REDSHIFT
energy



Our very important proposals were rejected because of lack of funding and delays.

National Science Foundation and Department of Energy SBIR/STTR portfolio company.

Robert Ricciardi, Ph.D., Philadelphia, PA

Robert Ricciardi, Ph.D.

Professor
Department of Basic and Translational Sciences
U Penn Dental Medicine



Our research is on drug development. We have one drug moving forward to cure the greatest cause of infectious blindness in the USA and the world. NIH has made it possible to reach the stage which is looking very hopeful as a cure. We also have another drug made a reality by STTR/SBIR funding as the first cure for skin disease in children; it is about to enter into human testing. We are devastated by the disruption in STTR/SBIR funding which is halting our work. By loss of funding, our research on other drugs will stagnate, business opportunities that enhance the US economy will halt, and **the USA will become second** rate to other countries in medical research. Please get USA science back on track by reaffirming STTR/SBIR funding.

National Institutes of Health SBIR/STTR portfolio company.

RTM Vital Signs, LLC, *Philadelphia, PA*

Nance Diccianni, Ph.D.

Founder and CEO
RTM Vital Signs



RTM Vital Signs, LLC, currently has a Fast Track to Phase II SBIR grant from the National Institutes of Health. This award includes a large 120-patient clinical trial to prove the capability of our proprietary respiratory function monitor to detect respiratory decompensation in post-surgical patients on the general floor of hospitals receiving opioids for pain management – a significant patient safety concern. All of the preparatory work for the trial has been completed, institutional review board (IRB) approval and required insurance are in place, and additional staff have been hired and trained.

The funding has been halted since December 1, 2025, due to the government shutdown, and we cannot proceed with the trial until the funds are released. If the funding is not released soon, we will have to decrease staff and stop ancillary lab and bench tests, which will impact both RTM and hospital staff. **In short – the funding issue has halted our product development, impacted hiring, and put a cash flow strain on the company.**

RTM received its first FDA clearance last June and the clinical trial data are required to bring the monitor to commercialization. **It should be noted that other countries have not stopped funding their product development progress.**

National Institutes of Health SBIR/STTR portfolio company.

Denise Devine, C.P.A., MBA, M.S.T.

Co-Founder and CFO
RTM Vital Signs




RTM Vital Signs is in the middle of an NIH Fast Track grant - conducting a clinical trial at Thomas Jefferson University with its small, wearable FDA approved device that detects changes in respiratory status prior to exhibiting symptoms; allowing prevention of costly respiratory deterioration, better patient outcomes, improving nurse workload and facilitating early hospital discharges as patients can be easily monitored at home or in nursing homes. The very cost-effective platform technology also has industrial safety, opioid rehab and military battlefield triaging applications.

Ship of Theseus, LLC, *Eagleville, PA*

Jeremy Elser, Ph.D.

CEO, Founder

Ship of Theseus, LLC



Ship of Theseus has been and continues to be a grateful beneficiary of the SBIR/STTR program. Our awarded National Heart, Lung, and Blood Institute (NHLBI) Phase II will ensure that our lead candidate will be tested in humans. At our stage and given the unfavorable biotech macroeconomic environment, **bridging the final preclinical gap would have been impossible without our SBIR award**. We look forward to competing for future awards, particularly as our data and progress have attracted academic collaborators who bring expanded applications for our core technology, which we will pursue as soon as the program is reinstated. **However, we will be unable to initiate these programs without SBIR/STTR support.**

National Institutes of Health SBIR/STTR portfolio company.

Serentrix, *Exton, PA*

Kumaril Bhargava, Ph.D., MBA

CEO

Serentrix



We are developing a non-opioid pain medication, we received a Phase 1 grant, to move forward with the project we need Phase 2 SBIR funding.

National Institutes of Health SBIR/STTR portfolio company.

Spinhance, LLC, *Philadelphia, PA*

Kiarash Emami, Ph.D.

Director of Business Development

Spinhance, LLC



As a young startup company in the medical device space, Spinhance was awarded its very first Phase I SBIR grant in 2025. Subsequently the company proceeded with leasing an

R&D facility and hiring its first employee. The company has made significant progress on this project and was planning to apply for a Phase II grant in Jan 2026. **The current circumstances around SBIR program have created significant uncertainty in the viability of Spinrance and its ability to retain/add employees this year.** Furthermore, the inability to develop our pulmonary imaging platform beyond this feasibility stage, puts the faith of this novel technology at risk.

National Institutes of Health SBIR/STTR portfolio company.

Starship Health Technologies, *Fort Washington, PA*

Wayne Zachary, Ph.D.
Managing Partner
Starship Health Tech



Starship Health Technologies has been developing an NIH STTR application with a university consortium to develop a product to help people experiencing chronic pain learn how to navigate the fragmented care system facing pain sufferers. The lapse and uncertain STTR future have the consortium on the edge of breaking up, with university partners concerned that the program may not be re-authorized. This, in turn, is harming our small business' ability to survive, given all the time and resources we have already placed in this important problem.

Takashi Koxai, *Pittsburgh, PA*

Takashi Koxai, Ph.D.
Professor
University of Pittsburgh working with Actuated Medical

Operational instability delays in helping patients, reduced economic spending (supplies).



Trevarx Biomedical, Inc., *Philadelphia, PA*

Jean Cho, MBA

CEO

Trevarx Biomedical



The SBIR/STTR program has been a critical supporter of our radiopharmaceutical alpha therapeutic and molecular imaging product, **which has the potential to cure recalcitrant tumors such as ovarian, breast and prostate cancer**. This program is a critical step towards building a company that can attract venture capital and pharma partners.

National Institutes of Health SBIR/STTR portfolio company.

Valisci Inc., *Coatsville, PA*

Jonathan Revere

CEO

Valisci

Valisci is a disabled veteran-owned company, innovating data analytics for the pharmaceutical industry. The lapse in SBIR funding means I will personally risk retirement savings and home equity to continue funding research and development. An NSF SBIR grant would significantly derisk the development of Valisci's critical technology innovations **that aim to improve access, safety, and affordability of medications**.

Vasowatch Inc., *Philadelphia, PA*

Christine Rohan, MBA

CEO

Vasowatch



Vasowatch is working to make childbirth safer to all women by predicting 4 out of 5 incidents of postpartum hemorrhage missed by the current standard of care. We have applied for SBIR Phase II funding to fund a 300-patient clinical pilot that will demonstrate that **we can reduce hemorrhage rates by up to 60%, saving lives, reducing maternal complications and cutting obstetrics costs**. The lack of SBIR funding is delaying the commercialization of our innovation.

Stefanie Modri, MSN, RNC-OB, C-MNN
Co-Founder
Vasowatch, Inc.



We are awaiting a notice of funding after receiving a score of 22. We wish to start our pilot to test our software we developed to predict a postpartum hemorrhage in laboring mothers. This lapse in funding has led to a delay in testing and ultimately time to market, thus immediately impacting mothers and the team that cares for them.

National Institutes of Health SBIR/STTR portfolio company.

X-Biomedical Inc., Clifton Heights, PA

Matthew R. Maltese, Ph.D.
Co-Founder and CEO
X-Biomedical



Our small business is developing revolutionary medical device equipment in the surgical visualization space. Medical devices is one of the few industries that can retain manufacturing jobs in the United States. The SBIR program is essential to the development of innovative products that **keep America at the front of the pack economically and technologically.**

Department of War and Department of Transportation SBIR/STTR portfolio company.

Puerto Rico

Economic Impact of Program:

SBIR/STTR Funds Received: **\$16,516,546**

Small Business SBIR/STTR Awards: **58**

Letter to Congress Co-signers

Michelle Martinez, Ph.D.	CEO and Co-Founder	Dynamiko Pharmaceutics
Lorna Baez Amely	Director	Healthcare Innovation Center by CIRACET
Marcos Lopez, Ph.D.	Assistant Professor	University of Puerto Rico

Selected Case Studies from Impacted Companies:

Marcos Lopez, Ph.D., Humacao, PR

Marcos Lopez, Ph.D.

Assistant Professor
University of Puerto Rico



The lapse in SBIR/STTR reauthorization has had a direct and disruptive impact on Puerto Rico's innovation and research ecosystem. Multiple NIH and NSF SBIR/STTR NOFOs were canceled or paused, abruptly halting planned submissions and stalling early-stage company formation. For our organization, this has meant delayed partnerships, postponed hiring, and uncertainty for investigators and entrepreneurs who were preparing to transition federally funded research into commercial solutions. **SBIR/STTR is a cornerstone of regional R&D capacity building.** Its absence undermines innovation momentum, workforce development, and the ability of underserved regions like Puerto Rico to compete and contribute to the national innovation economy.

Rhode Island

Economic Impact of Program:

SBIR/STTR Funds Received: **\$304,516,682**

Small Business SBIR/STTR Awards: **846**

Letter to Congress Co-signers

Lisa Marceau	CEO and Founder	Alpha Millennial Health
Karen R Drexler	Investor	Astia
Arijit Bose	Co-Founder and Chief Scientific Advisor	Audiance
Melissa Bowley	CEO and Founder	Flourish Care
Yow-Pin Lim, MD, Ph.D.	CEO	ProThera Biologics, Inc.
Michelle Wu, MSCEP	Medical Device Executive	Wu Consulting, LLC
Nicholas Napp	CEO	Xmark Labs, LLC

Selected Case Studies from Impacted Companies:

Xmark Labs, LLC, Barrington, RI

Nicholas Napp

Co-Founder and CEO
Xmark Labs

We are developing products that tackle real-world problems, but they are too high risk for Angel and Venture investors. Federal support via SBIR is vital for both its financial support and the credibility it confers.



Department of Commerce SBIR/STTR portfolio company.

South Carolina

Economic Impact of Program:

SBIR/STTR Funds Received: **\$353,651,749.06**

Small Business SBIR/STTR Awards: **858**

Letter to Congress Co-signers

Paul C. Browne, MD	President	EMF Disturbance Monitors, Inc.
Stanley Hoffman	President and CEO	FibroTherapeutics, Inc.
Nathan Dolloff, Ph.D.	Founder and CSO	Leukogene Therapeutics, Inc.
Dieter Haemmerich	CEO	OncoBLAZE
Jeffrey J. Borckardt, Ph.D.	Founder and President	Palmetto Innovative Education, LLC
Joseph Carson	Co-Founder and CTO	Pensievision
Amanda Clark, RRT	CEO	PulManage, Inc.
Steven A. Rosenzweig, Ph.D.	Founder and CEO	Somatoceutics, LLC
Allen Conger, MBA	CEO	Vessel Wave Technologies, Inc.
Scott Pancoast, MBA	CEO and Founder	Zylo Therapeutics

Selected Case Studies from Impacted Companies:

EMF Disturbance Monitors, Inc., *Fripp Island, SC*

Paul C. Browne, MD
President and Founder
EMF Disturbance Monitors



Our company is an American medical device start-up founded in 2013. We recently completed our FDA Phase 1 clinical trial which was successful. Our company applied for an SBIR grant which was scheduled to be reviewed in November 2025. Our review has been postponed until 1/22/26. **SBIR funding is critical to our company to complete our FDA Stage II trial and move for FDA approval.** Our clinical trial is already planned with a Southeastern University Medical

School but cannot move forward without additional funding. Please restore funding to the SBIR program so that our company can begin manufacturing in the USA.

FibroTherapeutics, Inc., *Charleston, SC*

Stanley Hoffman, Ph.D.

President and CEO
FibroTherapeutics



Our company has been developed with STTR funding. We now have a pending outstanding score for Phase II funding which will put us in position to receive private investment and FDA approval for clinical trials. We need the reauthorization to bridge to private investment!!

National Institutes of Health SBIR/STTR portfolio company.

Leukogene Therapeutics, Inc., *Charleston, SC*

Nathan Dolloff, Ph.D.

Founder and CSO
Leukogene Therapeutics



Our company is close to a **breakthrough in immunotherapy treatment for acute myeloid leukemia and pancreatic cancer, which are two of the deadliest cancer types.** SBIR/STTR funding has catalyzed our program, and it is now approaching the stage where investors are taking interest. We would not have made it this far without NCI SBIR/STTR support.

National Institutes of Health SBIR/STTR portfolio company.

Palmetto Innovative Education LLC, Mount Pleasant, SC

Jeffrey J. Borckardt, Ph.D.

Founder and President
Palmetto Innovative Education




My company completed a successful controlled trial under a funded NIH STTR R41 grant and was poised to move our product to Phase-II for expansion and commercialization. The lapse has completely halted our progress as well as the further development of our **training technology that is designed to help health professional students safely manage opioids in high-risk patients in the US.**

National Institutes of Health SBIR/STTR portfolio company.

Somatoceutics LLC, Mount Pleasant, SC

Steven A. Rosenzweig, Ph.D.

Founder and CEO
Somatoceutics



I had plans to submit a Phase II application as our Phase I work is starting to take off. I have real concerns that blocking funding of SBIRs and STTRs being enforced will result in Somatoceutics ending its chance to develop and apply its novel drug delivering nanotubes.

National Institutes of Health SBIR/STTR portfolio company.

Zylo Therapeutics, Greenville, SC

Scott Pancoast, MBA

Founder and CEO
Zylo Therapeutics

We have already laid off two employees due to this disruption; others may be next. We have several compelling drug-development programs in areas of high unmet need that will continue to be delayed due to lack of grant funding.



National Institutes of Health SBIR/STTR portfolio company.

South Dakota

Economic Impact of Program:

SBIR/STTR Funds Received: **\$73,699,114.60**

Small Business SBIR/STTR Awards: **256**

Letter to Congress Co-signers

Jeremy Javers, Ph.D.	VP of Technology	Houdek
----------------------	------------------	--------

Selected Case Studies from Impacted Companies:

Houdek, *Brookings, SD*

Jeremy Javers, Ph.D.

Vice President of Technology

Houdek

Our company was based on a SBIR grant. It has generated hundreds of jobs, led to investment of 10s of millions of dollars in rural community investment in advanced fermentation assets, added significant value to soybean value added agriculture, and created significant export markets for US Soy.



Department of Agriculture and National Science Foundation SBIR/STTR portfolio company.

Tennessee

Economic Impact of Program:

SBIR/STTR Funds Received: **\$634,794,964.26**

Small Business SBIR/STTR Awards: **1,891**

Letter to Congress Co-signers

Daniel Clark	CEO	3DSolar
Scott Webster, Ph.D.	COO	EndoTheia, Inc.
Burt Sharp	Professor	EnvisBio
Brittany Barreto, Ph.D.	CEO	FemHealth Insights
Matthew Yandell, Ph.D.	Chief Innovation Officer	HeroWear, LLC
Dr. John Simmons		InnoVision
Evan Stacy, Ph.D., Innovation Crossroads Fellow	Founder and CEO	Lumios Materials
Michael McCaman, Ph.D.	VP and Chief Strategy Officer	Orion Therapeutics, Inc.
Zhijia Du	Director of Battery Development	Safire
Ashleigh Brown	Managing Partner	Snatch Health
Audrey Bowden, Ph.D., MBA	Professor	Vanderbilt University
Tracy Skinner	Therapist and Innovator	Verora Solutions
Mark Moore	CEO	Whisper Aero

Selected Case Studies from Impacted Companies:

EnvisBio, Memphis, TN

Burt Sharp

Professor

EnvisBio



We are a start-up recently funded by the NIAAA SBIR program and focused on a novel brain target to dramatically improve the outcome of alcohol-dependent individuals who seek to eliminate their dependency. Developing our laboratory program to identify unique drugs that modify the function of this molecule that regulates the brain reward center requires the critical start-up capital available through the SBIR program. We are in the process of writing another SBIR proposal to expand our reach to the treatment of smoked tobacco. However, **the lack of SBIR program reauthorization has delayed our efforts and introduced a strong element of confusion and uncertainty into the situation. This is especially threatening to a very young start-up, where bringing together all the elements required for the successful execution of a drug discovery program is very challenging without the uncertain status of the SBIR program.**

National Institutes of Health SBIR/STTR portfolio company.

HeroWear, LLC, Nashville, TN

Matthew Yandell, Ph.D.

Chief Innovation Officer

HeroWear, LLC



The lapse in funding is jeopardizing HeroWear's ability to continue developing multiple DoD wearable devices intended to reduce injuries and increase warfighter readiness through the SBIR program. Without program authorization we will be forced to cancel the program or find private sources of funding to continue these DoD projects.

Department of Defense, Centers for Disease Control and Prevention, and National Science Foundation SBIR/STTR portfolio company.

Orion Therapeutics, Inc., *Knoxville, TN*

Michael McCaman, Ph.D,
VP and Chief Strategy Officer
Orion Therapeutics, Inc.



Our small startup received a modest SBIR grant from NSF, and it was critical to our ongoing success to develop new modes of delivering RNA cargos for gene editing applications. Please don't pull this resource out from under other small startup efforts!

National Science Foundation SBIR/STTR portfolio company.

Safire, *Knoxville, TN*

Zhijia Du
Director of Battery Development
Safire



SBIR/STTR has helped Safire move from an innovative concept into an impactful product for our Defense industry.

Department of War SBIR/STTR portfolio company.

Verora Solutions, *Kingsport, TN*

Tracy Skinner
Therapist/Innovator
Verora Solutions

I have created a new therapy device for stroke rehabilitation that has already gone through a pilot study and was hoping to seek out non-diluted funding to help bring this innovation to more patients. I'm discouraged as a new business owner.

Whisper Aero, Crossville, TN

Mark Moore

CEO

Whisper Aero



The SBIR program has been critical for Whisper Aero to incubate new technologies. As a start-up advancing critical electric propulsion technologies for DoW applications, the SBIR program is critical for our success. Also, as a startup located in rural TN, it is essential to ramp up employment to help with disadvantaged communities. **The delay in SBIR reauthorization has already cost Whisper from delaying hiring 5 engineers that would otherwise have received offers to accelerate our technological efforts.**

Department of War and National Aeronautics and Space Administration SBIR/STTR portfolio company.

Texas

Economic Impact of Program:

SBIR/STTR Funds Received: **\$3,286,442,320.33**

Small Business SBIR/STTR Awards: **9,436**

Letter to Congress Co-signers

Joe Price, JD, MBA	President and Chairman	4E Therapeutics, Inc.
Upendra Marathi	CEO	7 Hills Pharma
Jane Lea Hicks, Ph.D.	Member Manager and CEO	Affirmed Pharma
Usha Andley	Head, Preclinical Research	
Vijay Devarakonda, Ph.D.	President	Analytical Scientific Products, LLC
Trang Vu, Ph.D.	Co-Founder	Astraea Bio
John Miller, Ph.D.	Head of Antibody Development	Asylia Therapeutics
Dennis I. Robbins, Ph.D.	Chairman, Board of Directors	Avsana Labs, Inc.
George W. Jackson, Ph.D.	Founder and CEO	Base Pair Biotechnologies, Inc.
Francisco A. Fierro	Owner	Big Lake Midstream Industries, LLC
Gregg Siegel, MS	President	Biomedical Development Corporation
Susan Marriott	Professor and Founder	BioScience Writers, LLC
Ashok Gowda, Ph.D.	Executive Director	Biotex, Inc.
David Howell, Ph.D.	CEO	Bondwell Technologies
Darrell Carney, Ph.D., CEP	CEO	Chrysalis BioTherapeutics, Inc.
Christina Cheng, CFA	Principal	Concordance Tech
Emmanuelle Schuler, Ph.D., MBA	President	Corallis Consulting
Kelechi Iroegbu, MPH	Community Program Manager	CUBiO Innovation Hub
Rohit Khanna	President	Durahip, LLC
Mark Niederauer, Ph.D.	President and CTO	Electrochemical Oxygen Concepts, Inc.
Ron Presswood	CTO	Elemental Advanced Material

Dave Gallup	CEO	EMPIRI, Inc.
Dr. Nathalie Ionesco	Co-Founder and CTO	EWES
Constance Woodman, Ph.D.	Managing Partner	Field Data Services
Lara August Gabriele Niederauer, Ph.D., FAIMBE	Board Member CEO and Co-Founder	Freyya, Inc.
Patricia Geppert, Ph.D.	Principal	Gap Analytics, LLC
John Kincke	CFO	Greenfire Bio
Oussama Hassan	Co-Founder and CMO	Health Discovery Labs, LLC
Nico Carlson	Senior Venture Associate	Houston Angel Network
Niti Vanee, Ph.D.	CEO	iGenomeDx
Brandi Timmons, MEd, BCBA, LBA	Education Director	Incuentro, LLC
Tatiana Fofanova, Ph.D.	Co-Founder and CEO	Koda Health
Jospeh H. Koo, Sc.D.	VP and CTO	Koo and Associates International, Inc.
Kunal Rai, Ph.D.	Professor and Founder	Koshika Therapeutics
Alex Ignatiev	CTO	Lunar Resources, Inc.
Lauren Cornell, Ph.D., ME	CEO	NovoThelium
Uffaf Khan, Ph.D., MS	Business Development	Pleozyme
Mark Feng, Ph.D.	CEO	Polykala Technologies, LLC
Narendra Kumar	Tenured Associate Professor and Co-Founder	ProJ-diapeutics, Inc.
Jonathan Butts, Ph.D.	Co-Founder	QED Secure Solutions
Brenna Nava	Deputy General Counsel	Rackspace Technology
Samantha Snabes	CEO	re:3D, Inc.
Hector Alila, Ph.D.	Co-Founder and CEO	Remunity Therapeutics, Inc.
Justin Mares	CEO	Resonant Health
Stan Watowich, Ph.D.	CEO and Founder	Ridgeline Therapeutics
Harshini Neelakantan, Ph.D.	Executive Director, R&D	

Rashim Singh	President and CEO	Sanarentero, LLC
James W Hugg, Ph.D., MBA	CEO and President	SmartBreast Corp.
Bradley Sallee	VP Systems Development	SPEC
Shoba Sharma	Co-Founder	SygnaMap
Aureliano Perez, MS	President	Texas High Energy Materials, LLC
Laura Hayes	CEO	The Learning Bridge
Daniel McMorris	Co-Founder and Chief Strategy Officer	The Provenance Chain Network
Seth J. Schwartz, Ph.D.	Professor	University of Texas at Austin
Dr. German Rosas-Acosta	Associate Professor	University of Texas at El Paso
Carson Rast	CEO	Versa Materials Technology

Selected Case Studies from Impacted Companies:

7 Hills Pharma, Houston, TX

Upendra Marathi, Ph.D., MBA
CEO
7 Hills Pharma



7 Hills has received about \$14 million in SBIR funds to conceive a new drug and start treating cancer patients with life threatening disease. **Without SBIR funding, we would not have been able to raise complementary funding of about \$28 million.** This therapy has the potential to save 85,000 lives in the US, and already supported/created numerous jobs.

National Institutes of Health SBIR/STTR portfolio company.

Affirmed Pharma, LLC, Conroe, TX

Jane Lea Hicks, Ph.D.

Member Manager and CEO
Affirmed Pharma, LLC



Most new drug interventions are developed by dedicated teams at small businesses like Affirmed Pharma. As an early-stage biopharmaceutical company, we rely on the Small Business SBIR/STTR grant programs to validate our pharmaceuticals and our company. Venture capitalists and big pharma companies are acutely aware of the cost and high risk of moving a new drug to the clinic. They will not invest until the drug has moved along its development pathway and been validated through research funded by the SBIR/STTR mechanisms. With an annual budget of only \$4 billion (1% of the total budget for NIH), this program has a substantial ROI when just one drug successfully launched can generate revenues in the Billions of dollars. **We operate on a shoestring and with personal investments. There is no financial safety net for our small drug development companies**, so please do whatever you need to do to get this program back up and running. Thank you, Jane Lea Hicks

Usha Andley

Head, Preclinical Research
Affirmed Pharma, LLC



Our important preclinical research will be jeopardized by a cut in STTR funding. Our research directly impacts patient health and wellbeing. Please reauthorize STTR and SBIR.

National Institutes of Health SBIR/STTR portfolio company.

Analytical Scientific Products LLC, *Dallas, TX*

Vijay Devarakonda, Ph.D.

President

Analytical Scientific Products LLC



Analytical Scientific Products is currently developing technologies to improve the fire safety of lithium-ion batteries, harvesting energy from the environment, and improving the safety of spacecraft radiators for future manned missions to the moon and beyond. **The lapse in funding affected our R&D efforts and added uncertainty to our planning for future technological development.**

Department of War and National Aeronautics and Space Administration SBIR/STTR portfolio company.

Asylia Therapeutics, *Houston, TX*

John Miller, Ph.D.

Head of Antibody Development
Asylia Therapeutics



Our company is likely to dissolve due to a lack of funding.

The current landscape has made federal support even more critical. Having been awarded, and successfully completed, a Phase I SBIR award, we applied for a Phase II, building on this same work. Despite scoring well and advancing to the collection of JIT, we were ultimately denied due to an erroneous determination of "foreign risk". This was likely the final straw, and **will likely result in the company's closure.**

National Institutes of Health SBIR/STTR portfolio company.

Base Pair Biotechnologies, Pearland, TX

George W. Jackson, Ph.D.

Founder and CEO

Base Pair Technologies, Inc.



My company was founded 14 years ago in 2012 based on technology that I had the fortune to develop under NIH SBIR funding. Since then, my company has employed over 100 different scientists and other professionals, and we have maintained a *non-grant* revenue of roughly \$1M per year.

Nevertheless, we still utilize the SBIR Program from time to time to help us fund cutting edge research that may or may not yet be commercially viable. The lack of a Reauthorized SBIR Program has left us in a limbo of uncertainty. We have a Phase I grant with an excellent score. The grant is entitled, "Platform approach for aptamer-based guidance of payloads across the blood-brain barrier (BBB)". **With no functioning SBIR Program, we cannot make hiring decisions or do any of the important work on this exciting project that has the potential to enable a host of novel therapies for neurological disorders, including Alzheimer's, Parkinsons, addiction, and PTSD.**

In short, the stagnation of the SBIR Program has had unintended similar consequences for what must be 100s or 1000s of companies developing some of the most cutting edge technologies under development in the United States. Congress needs to act!

Alex Chiu, Ph.D.

Director of Laboratory Operations

Base Pair Biotechnologies, Inc.



We have suffered delays in payroll and acquiring resources for projects due to funding delays.

National Institutes of Health SBIR/STTR portfolio company.

Big Lake Midstream Industries LLC, Big Lake, TX

Francisco A. Fierro

Owner

Big Lake Midstream Industries LLC

Financially need it to build Equipment to eliminate emissions from fossil fuel engines.

Chrysalis BioTherapeutics, Inc., Galveston, TX

Darrell Carney, Ph.D., CEP

CEO

Chrysalis BioTherapeutics, Inc.



Our Chrysalis lead drug product has an approved IND for acute respiratory distress syndrome, which kills ~450,000 people each year and contributes to chronic lung disease. Yet there is no FDA-approved solution to this problem. A single injection of our drug reduces lung inflammation and restores lung function to save lives and prevent chronic conditions. **Our SBIR clinical trial grant application was reviewed and received a high priority for funding in 2025. Without the SBIR funding, this project is on hold and may not move forward to save lives.**

National Institutes of Health SBIR/STTR portfolio company.

Corallis Consulting, Houston, TX

Emmanuelle Schuler, Ph.D., MBA

President

Corallis Consulting



When SBIR/STTR funding lapses, life science innovation stalls at its most fragile stage. Small biotech companies are forced to delay experiments, pause clinical-enabling work, and lay off highly skilled scientists. Promising therapies for cancer, rare diseases, and national health priorities remain stuck in laboratories instead of reaching patients. Universities and startups lose momentum, private investors retreat due to increased risk, and U.S. leadership in biomedical innovation erodes as other countries move faster. **Delayed reauthorization doesn't save money—it increases long-term healthcare costs, wastes prior federal investments, and slows the translation of publicly funded research into lifesaving treatments.**

Elemental Advanced Materials Inc., Houston, TX

Ron Presswood, M.E.C.E

CTO

Elemental Advanced Materials



We are working on a SBIR DOW grant funding to improve battery cases, increasing their puncture resistance and decrease their flammability. We have been waiting since October of 2025 to file the application and start the work. Please work to pass this funding.

EMPIRI, Inc., Houston, TX

Dave Gallup

Co-Founder and CEO
EMPIRI



SBIR funding is crucial to our efforts to improve cancer care - both with drug development and in finding the right treatment for each patient on an individual basis. **All of these funds go to helping cancer care and create high paying jobs and allow the US to lead the world.** Without it, scientists and researchers will leave and go to other countries. I spoke firsthand with a company that changed their plans and are in Australia now because of uncertainty around SBIR funding. We will lose our leadership in technology without this funding.

Field Data Services, Austin, TX

Constance Woodman, Ph.D.

Managing Partner
Field Data Services



We completed our first SBIR II, and a number of other academic spin-outs contacted us and asked how to use the SBIR II program to create US businesses from laboratory innovations... and now... that option isn't there. All these groups spent five years on research, six months on an I-Corps program, a year and half on NSF AIR-TT and similar technology transfer work, all with the goal of building US businesses dead. Seven years of preparation, for whole groups of specialists has been wasted. These groups need trickles of small funding, which SBIR I offers. And without that trickle to build the innovation, the group splits up

and people move on from innovation to status quo jobs and we lose the amazing potential of what might have been.

Innovation dies in a file folder without SBIR. To gain a Ph.D., our engineers, chemists, and biomedical scientists spend 11 years after graduating high school increasing knowledge. Without a pathway from I-Corp to SBIR, over a decade of human effort to specialize and create new knowledge dead-ends. The innovations are too new to be immediately used, they need to be built upon and commercialized. **We are burying thousands of years of American man hours, in 11 year chunks, by stopping SBIR.**

United States Department of Agriculture and Department of Commerce SBIR/STTR portfolio company.

Freyya, Inc., San Antonio, TX

Gabriele Niederauer, Ph.D., FAIMBE

CEO & Co-Founder

Freyya, Inc



Freyya is a women's health company developing a wearable medical device to help 40 million US women with pelvic floor disorders. We received a Phase 1 SBIR grant to support development of our device and have applied for a Phase 2 SBIR grant in July; however, review is on hold at this time.

We urge your support for the timely reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs so we can continue to commercialize this innovative product.

National Science Foundation SBIR/STTR portfolio company.

Gap Analytics LLC, San Antonio, TX

Patricia Geppert, Ph.D.

Principal

Gap Analytics LLC



SBIR/STTR funding is a critical funding source to de-risking cutting-edge technology. Commercializing innovative technology depends on leveraging SBIR-funded development to get additional funding.

Greenfire Bio, *Round Rock, TX*

John Kincke

Chief Financial Officer
Greenfire Bio

The stalemate has virtually stopped all new bio med research and related devices development.



Houston Angel Network, *Houston, TX*

Nico Carlson

Senior Venture Associate
Houston Angel Network



For founders building life-saving medical innovations, SBIR/STTR funding is more than capital, it is a critical validation signal for private investors. **The current lapse has paralyzed fundraising efforts; venture partners are increasingly unwilling to bridge the 'Valley of Death' when the non-dilutive federal match is frozen in legislative limbo.** By stalling clinical milestones and chilling private investment, this lapse is **effectively halting the development of next-generation therapies.** We need a predictable funding environment to ensure these life-saving breakthroughs aren't abandoned before they can ever reach a patient.

Incuentro LLC, Houston, TX

Brandi Timmons, M.Ed., BCBA, LBA

Education Director
Incuentro LLC



Incuentro is a very small (5 -10 employees) startup company that depends on funding from our STTR grant to keep operations going during this crucial period in our company's history. We are an educational technology company focused on providing transition to employment training and assessments for teens and young adults who historically have difficulty finding employment (autistic individuals and youth involved in the criminal justice system). We are completing our prototype and are depending on a Phase 2 grant to further the translation of our research and development to commercialization.

National Science Foundation SBIR/STTR portfolio company.

Koda Health, Houston, TX

Tatiana Fofanova, Ph.D.

Co-founder and CEO
Koda Health



SBIR/STTR funding is **critical to early stage American innovation**. We benefited significantly from these funds when starting Koda Health - now a venture backed, revenue generating company. Without that early support for research and validation, we would not have grown to serve over a million Medicare patients Nationwide. Our work, like many other SBIR funded companies, **serves the American populace and has a massive ROI to the US budget on overall healthcare spend**. Although we are not currently directly impacted, I worry that future innovations that depend on this funding will sputter out before they have the chance to benefit our country. SBIR/STTR is a smart investment.

National Science Foundation SBIR/STTR portfolio company.

Koo & Associates International, Inc., Austin, TX

Jospeh H. Koo, Sc.D.

VP and CTO

KAI, LLC



Our company depends 90% on federal funding, especially on SBIR/STTR programs.

Department of War, National Aeronautics and Space Administration, Department of Energy, Department of Transportation, and National Science Foundation SBIR/STTR portfolio company.

Lucidify, Frisco, TX

Richard Kulavik

CTO

Lucidify



Our company submitted an SBIR application in the September cycle that has not yet been reviewed due to the government shutdown. **We had planned a January 2026 submission, with SBIR funds critical to support a pilot study, early clinical trial, U.S.-based hardware manufacturing, and U.S. payroll. All of this work is now on hold.** Hiring a university-based research assistant is also stalled due to hiring freezes tied to funding uncertainty. **Without SBIR support, we cannot de-risk our core technology, slowing or preventing private investment and threatening company survival—undermining the very purpose of the SBIR program.**

I cannot emphasize enough - the SBIR mechanism was developed explicitly to help de-risk science and technology to make it attractive for development with later-stage private investment. The lapse in funding hurts American excellence in science and technology and small businesses in equal measure.

NovoThelium, LLC, San Antonio, TX

Lauren Cornell, Ph.D., M.S.
Co-Founder and CEO
NovoThelium




SBIR funding has been what has kept our doors open and our innovation moving towards the point of investment. **It is critical to the economy and pushing forward innovation.**

National Science Foundation SBIR/STTR portfolio company.

Polykala Technologies LLC, San Antonio, TX

Mark Feng, Ph.D.
CEO
Polykala Technologies

The SBIR program is so critical and will enable my company to further commercialize our rare earth metals recycling technology, which will strengthen the independence of the supply chain of critical minerals, especially rare earth metals.



Department of Energy and Environmental Protection Agency SBIR/STTR portfolio company.

The Provenance Chain Network, Dallas, TX

Daniel McMorris
Co-founder, Chief Strategy Officer
The Provenance Chain Network



Our organization is developing technology necessary for the USG, DoW, and DoC. Specifically protecting and licensing IP for semiconductors. **This lapse has held up funding for contracts to continue this work and threatens the company's survival.**

Department of War and Department of Commerce SBIR/STTR portfolio company.

Remunity Therapeutics, Inc., Houston, TX

Hector Alila, Ph.D.

Co-founder and CEO
Remunity Therapeutics, Inc.



Our company is developing next-generation targeted cancer therapeutics that will transform and improve the lives of people with cancer. **As a start-up, we rely on SBIR/STTR financial support to advance our products.** We cannot rely on VCs because we are too early for them. Companies like ours also create jobs.

Ridgeline Therapeutics, Houston, TX

Stan Watowich, Ph.D.

Founder and CEO
Ridgeline Therapeutics



We are rapidly advancing a transformative oral pill designed to reverse muscle weakness in aging adults.

The initial patient population are the >20M elderly Americans with sarcopenia, frailty, and mobility impairment. The current hold on SBIR funding is preventing the final manufacture of our drug, thus delaying our planned clinical trials and preventing our drug from improving the health, well-being, and independence of millions of older Americans.

Harshini Neelakantan, Ph.D.

Executive Director, Research and Development
Ridgeline Therapeutics



Ridgeline is developing life-saving drugs to address chronic diseases of aging. Our company's technology has been fully supported through federal-funded (SBIR/STTR and DOD) grants, which has been instrumental to complete pivotal therapeutic development research. The lapse in this program has stalled our research efforts, and caused havoc to key employees' jobs in our company. The existence of our company and further development of our oral drug technology are at stake without reauthorization of this program. We request immediate action to reauthorize SBIR/STTR federal fundings programs.

National Institutes of Health and Department of War SBIR/STTR portfolio company.

Sanarentero LLC, Pearland, TX

Rashim Singh, Ph.D.

President and CEO
Sanarentero




The R&D and business operations have come to a halt with rent and other expenses still ongoing. We have worked hard for 5 years to build our start-up and continuation of STTR/SBIR support is critical for moving us closer to derisking our technologies for commercialization. We have already missed one grant cycle and further delay in reauthorization threaten the loss of valuable R&D.

National Institutes of Health SBIR/STTR portfolio company.

Seth J. Schwartz, Ph.D., Austin, TX

Seth J. Schwartz, Ph.D.

Professor
University of Texas at Austin



We are developing an app to help Hispanic youth succeed in school. **The lapse in funding has stopped us from having Phase II funded. Kids are suffering because of that.**

National Institutes of Health SBIR/STTR portfolio investigator.

SmartBreast Corporation, Tyler, TX

James W Hugg, Ph.D., MBA

President and CEO
SmartBreast Co



SmartBreast is developing medical imaging technology to detect breast cancer earlier in women with dense breasts (40-50% of women), for whom screening mammography fails 70% of the time. Our progress has been stymied by the lapse in SBIR funding.

SyngaMap, San Antonio, TX

Shoba Sharma

Co-founder
SyngaMap



As a small startup located in Texas, **we are seriously impacted by not having SBIR funding to hire more employees and create innovation in biotech.** Please reauthorize SBIR/STTR so that we can continue to positively impact life sciences in the US.

Department of Commerce, National Institutes of Health, and National Science Foundation SBIR/STTR portfolio company.

Texas High Energy Materials LLC, Austin, TX

Aureliano Perez, MS.

President
Texas High Energy Materials LLC



The lapse in the US Department of War (DoW) SBIR program has caused hardship to our research and development company. **As President of the company, I had to recently lay off one BS level scientist and two technicians. It is likely that I will have to lay off my two remaining scientists in April of 2026 as a result of the SBIR program lapse.**

I myself have been working without pay since October of 2025 due to the government shutdown and SBIR lapse. Our small team just completed the successful development of a new fuel bladder for all DoW combat aircraft to improve aircraft and crew survivability. Those efforts are in jeopardy of never being fielded by the DoW due to the program lapse. I remain cautiously optimistic.

Department of War SBIR/STTR portfolio company.

Utah

Economic Impact of Program:

SBIR/STTR Funds Received: **\$853,609,089.35**

Small Business SBIR/STTR Awards: **2,268**

Letter to Congress Co-signers

Wendy Huang	COO	Biologic Input Output Systems (BIOS)
Ishan Capila	Co-Founder and CEO	Bioparin
Kelvyn Cullimore	President and CEO	BioUtah
Kimberly White	Director of Administration	Coreform, Inc.
Charles Testa, Ph.D.	CEO	Curza, Inc
Brian Bentley	CEO	Diagnostic Ventures
Julie Z. Miller, Ph.D.	Founder	EarthSAR, LLC
Mark Lehmkuhle, Ph.D.	CTO	Epitel
Chadwick Davis	Founder and Principal	Evident Therapeutics
Zia L'Ecuyer	CEO	Eyescreen
Stefan Niederauer, Ph.D.	Co-Founder and VP Engineering	Freyya, Inc.
Chris Hopkins, Ph.D., MBA	CEO	Glafabra Therapeutics
Daniel McDonnell, Ph.D.	Research Scientist	Hideo Scientific
G. Michael Alder, Director BYU TTO (Ret.)	Resident Mentor	iHub Utah
Shoehleh Assemi, Ph.D.	Founder and CEO	Imessa Research, Inc.
Kristin Brogaard, Ph.D.	Co-Founder and CSO	Inherent Biosciences
Anthony Sutera Rhett Spencer	CEO CSO	nCAP Medical, Inc.
Andrew Gotshalk	CEO	Neurologic Solutions, Inc.
Lorry Schneider	COO	Path Fertility
Joshua Schiffman, MD	CEO	Peel Therapeutics

Rudy Wilcox	CEO	RefloDx, Inc.
Sheryl Hohle, MS MS-MOT, CLP	Sr. Sponsored Project Strategist	Seek Labs, Inc.
Ryan M. Bock, Ph.D.	CTO	SINTX Technologies
Feng Zhao	CEO	Storagenergy Technologies, Inc.
Anna Gooch, Ph.D. Christof Westenfelder, MD, FACP	CSO CEO	SymbioCellTech
Kapil Sharma	Founder and CEO	Vira Regen, Inc.
Margo Adams Larsen, Ph.D.	Director of Research	VirtuallyBetter Health, LLC

Selected Case Studies from Impacted Companies:

Coreform Inc., Orem, UT

Kimberly White

Director of Administration
Coreform Inc.




Because of delays and cancellations for SBIR funding, we had to let go of half our personnel.

Department of Energy and Department of War SBIR/STTR portfolio company.

Diagnostic Ventures, Saratoga Springs, UT

Brian Bentley

CEO
Diagnostic Ventures



We are working to find a rapid solution to detect Sepsis causing pathogens from whole blood in 20 minutes. We need help getting funding to develop this technology and government funding is critical.

Epitel, Salt Lake City, UT

Mark Lehmkuhle, Ph.D.

CTO

Epitel



As the founder of Epitel, a Medtech startup, the SBIR/STTR program has been critical to enabling us to go from idea to prototype to demonstrating clinical utility of our wireless wearable EEG solution. With the support of the SBIR program we were able to de-risk our technology enough to attract venture capital and would not have been able to raise such private funding otherwise. **The Small Business Innovation Research Program is truly "America's Seed Fund".**

National Institutes of Health SBIR/STTR portfolio company.

Eyescreen, Salt Lake City, UT

Zia L'Ecuyer

CEO

Eyescreen



We were unable to apply for a Phase II application after successfully completing Phase 1 milestones, which means **our company has run out of funding**. We are trying to find alternatives which put all of our operational efforts rather than developing our company.

National Institutes of Health SBIR/STTR portfolio company.

Freyya Inc, Salt Lake City, UT

Stefan Niederauer, Ph.D.

Co-founder & VP Engineering

Freyya Inc



Our company was only able to be formed and conduct early technology risk mitigation through SBIR funds. Without these funds, we would never have been able to raise private capital and our technology would never have been commercialized. **The recent lapse of funding has severely slowed our translational progress, as we had submitted a**

phase 2 application in July 2025 that is on hold pending reauthorization of the SBIR program.

National Science Foundation SBIR/STTR portfolio company.

Glafabra Therapeutics, Park City, UT

Chris Hopkins, Ph.D., MBA
CEO
Glafabra Therapeutics

I have in the past been recipient of SBIRs. They are essential engines for Biotech. SBIR unlock investment money. Without them, we are stuck going nowhere. Please bring them back asap. **They are lifeblood of our international competitiveness.**



iHub Utah, Provo, UT

G. Michael Alder
Resident Mentor
iHub Utah



Government should help with projects that have some risk. The private sector will not take risk. I have been involved in 30 startups that have gotten off the ground thanks to an SBIR or STTR grants in the past. **These grant programs made it possible to get new ideas partially funded to get proof of concept when investors would simply wait rather than fund something so risky.**

Imessa Research Inc., Salt Lake City, UT

Shoehah Assemi Ph.D.
Founder and CEO
Imessa Research Inc.



We are a startup company making instruments that can go to the market in a couple of years and accelerate the production of modern vaccines and drugs. **The non-dilutive funding from NIH is essential for us at this stage. This shutdown is depriving of the chance to get our product to the finishing stage or at least have the feedback**

of the experts about it. Please re-instate SBIR and let the science thrive again. Thank you.

Inherent Biosciences, Salt Lake City, UT

Kristin Brogaard, Ph.D.

Co-Founder and Chief Scientific Officer
Inherent Biosciences



Our NIH SBIR Phase IIB project addressing the most severe form of male infertility received a score of 20 and completed all Just In Time requirements, with funding expected to begin in December 2025. The project aims to improve diagnostic and treatment decision making for an underserved patient population with limited clinical options. Despite being recommended for funding, the award has not yet been released. **Continued delays jeopardize completion of this federally vetted research and threaten salary support for the research scientist assigned to the project. Timely funding is critical to sustain scientific progress, retain skilled biomedical workers, and advance patient care.**

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

nCAP Medical Inc, Heber City, UT

Rhett Spencer

Chief Science Officer
nCAP Medical Inc



Reactivating SBIR funding will allow us to immediately resume three already approved clinical studies evaluating the NeuroCuple® device. These studies are designed to further validate a noninvasive, drug-free pain-management technology that has already demonstrated promising clinical and real-world outcomes. SBIR support is critical to completing patient enrollment, data collection, and statistical analysis without delay. **Turning the funding back on preserves research continuity, protects prior federal investment, and accelerates evidence generation needed for broader clinical adoption.** Timely SBIR reauthorization ensures that clinically meaningful, cost-reducing pain solutions reach patients while reducing reliance on pharmaceuticals and invasive interventions.

National Institutes of Health SBIR/STTR portfolio company.

Path Fertility, Salt Lake City, UT

Lorry Schneider
COO
Path Fertility



As a small business doing innovative research focused on supporting men in their reproductive health journey, **we are deeply impacted by the lapse in SBIR funding that we rely on to keep our business running. We are dedicated to our mission of raising the standard of care in reproductive health, starting with male infertility but without the support of the SBIR funding, we will be unable to keep our team paid and our research moving forward.** We believe that the reauthorization of this program is critical to our company and many others that are building products to help improve the lives of the American people.

Peel Therapeutics, Salt Lake City, UT

Joshua Schiffman, MD
CEO
Peel Therapeutics



This will devastate our research program.

National Institutes of Health SBIR/STTR portfolio company.

SINTX Technologies, Salt Lake City, UT

Ryan M. Bock, Ph.D.
CTO
SINTX Technologies



My organization has recently **won four NIH SBIR awards to commercialize anti-infective implant technologies suitable for manufacturing at the point of care. We also have active applications pending with NIH to help commercialize related technologies for other indications where they are sorely needed - high-risk patient populations and revision surgeries for active infection.** These funds have been vital to help us accelerate the process of translating these technologies from a successful proof of concept at the bench to a fully commercialized technology accessible to providers and their patients. The award has also partially

supported salaries for talented science and engineering professionals at our organization in the UT-2 district and our collaborator labs in the Philadelphia area. Continuing this program is absolutely vital for small businesses in all technology sectors.

National Institutes of Health and Department of War SBIR/STTR portfolio company.

Storagenergy Technologies, Inc., Salt Lake City, UT

Feng Zhao, Ph.D.

CEO

Storagenergy Technologies, Inc.



As a small U.S. energy-technology company, Storagenergy relies on SBIR/STTR funding to bridge early-stage R&D into scalable manufacturing. **The lapse in reauthorization has delayed contract starts, disrupted hiring plans, and forced us to slow critical battery and power-generation development programs already vetted by federal agencies. These interruptions increase cost, extend timelines, and risk losing highly trained technical staff to overseas competitors.** For companies like ours, predictable SBIR/STTR funding is not discretionary, it is essential infrastructure for maintaining U.S. innovation, domestic manufacturing capability, and national energy security.

National Institutes of Health, Department of War, and National Aeronautics and Space Administration SBIR/STTR portfolio company.

SymbioCellTech, Salt Lake City, UT

Christof Westenfelder, MD, FACP

Founder and CEO

SymbioCellTech



The lapse in SBIR/STTR funding has greatly harmed, delayed the clinical testing, and introduction of our fundamentally new therapy for Type 1 Diabetes. It is urgent that this funding is reestablished ASAP.

Vira Regen Inc., Salt Lake City, UT

Kapil Sharma

Founder and CEO
Vira Regen Inc.



We are a biotech startup funded by the US Department of War - we are developing a technology that uses electric stimulation to regenerate tissue and accelerate bone fracture healing/wound healing for the US warfighter and for civilian use. We have made significant progress with our currently military funding (achieved 50% faster fracture healing to potentially reduce recovery time). We are at the tail end of our military funding and were seriously considering applying to SBIR/STTR vehicles to fast track our novel technology to the clinical stage so we can maintain an innovative lead against close competitors in China for example. **With these programs now stalled, we are at risk of delaying our development into clinical trials and on limited options federally, to further develop/enhance this technology.**

Vermont

Economic Impact of Program:

SBIR/STTR Funds Received: **\$215,395,291.42**

Small Business SBIR/STTR Awards: **571**

Selected Case Studies from Impacted Companies:

Ethan LaRochelle, Ph.D.	CEO and Co-Founder	QUEL Imaging
Mose Cassaro	Founder and Director	RDF Ventures
Eric Gallo	Lead	SpikeSense
Nick Grimley, MBA	Deputy Commissioner, Vermont Department of Economic Development	State of Vermont
Jesse Stein	Licensing Officer	University of Vermont
Tina Thornton, Ph.D.	Faculty Entrepreneurship Lead	University of Vermont
Daniel J. Weiss, MD, Ph.D.	Professor of Medicine	University of Vermont
David Bradbury	President and Fund Manager	Vermont Center for Emerging Technologies, Inc.
Patrick J. Clemins, Ph.D.	Director, Research Computing and Data, Large Research Initiatives	Vermont EPSCoR, University of Vermont

QUEL Imaging, *White River Junction, VT*

Ethan LaRochelle, Ph.D.

CEO and Co-Founder

QUEL Imaging



NIH SBIR funding has been **critical to our growth**. In five years, we have **expanded our staff and exported U.S.-manufactured products to more than 20 countries by responsibly using SBIR support** to develop new tools for the emerging field of fluorescence-guided surgery. This market is science-driven and still evolving, and early federal support enabled product development that would not have been viable under a profit-first model. Recent funding uncertainty has made planning difficult. **Without a stable SBIR program, companies like ours may be forced toward merger or acquisition, often by international firms, undermining U.S. jobs and American scientific leadership.**

National Institutes of Health SBIR/STTR portfolio company.

SpikeSense LLC, *South Duxbury, VT*

Eric Gallo

Director

SpikeSense, LLC



SpikeSense LLC submitted an SBIR Proposal to the NSF on new technology that can be used to significantly enhance small and medium scale farms, food safety and environmental monitoring/mapping. **Technology targets inexpensive technologies to enable precision agriculture for family farms and small-scale food producers.** The lapse in the SBIR program **jeopardizes the development of this technology and delays the development of accessible technology for small farmers in Vermont and around the country.** The SBIR funds are vital for SpikeSense to produce technology that is affordable and accessible to small scale business and farmers while establishing itself as a small, sustainable business.

Tina Thornton, Ph.D., *Burlington, VT*

Tina Thornton, Ph.D.

Faculty Entrepreneurship Lead
University of Vermont



As the leader of an NIH-funded national biomedical entrepreneurship education program focused on IDeA states, I work with academic teams and small businesses that rely on SBIR/STTR as the critical bridge from taxpayer-funded research to private investment. Since the lapse, **teams have postponed company formation, delayed investor outreach, and deferred spending** on regulatory, prototyping, and validation milestones because they cannot plan around uncertain award timing. **This uncertainty increases costs, extends time-to-market, and weakens regional innovation ecosystems.** Stable, timely SBIR/STTR reauthorization is essential to keep high-potential biomedical innovations moving toward patient impact.

Virginia

Economic Impact of Program:

SBIR/STTR Funds Received: **\$4,613,162,153.85**

Small Business SBIR/STTR Awards: **12,690**

Letter to Congress Co-signers

Rachelle Turiello, Ph.D.	CEO and Co-Founder	Avant Genomics
Brian Clark Eileen Krepkovich	Technical Director Senior Research Scientist	Barron Associates
Josep Bassaganya-Riera	CEO	BIOTHERAPEUTICS, Inc.
Frankie Leigh Shelton, MHA, MSc	Clinical Research	Cardiovascular Medicine Division, UVA
Nikhil Shenoy	CEO	Colvin Run Networks, Inc.
Anusha Iyer	CEO	Corsha
Ryan O'Quinn, Ph.D.	Partner, Biotechnology and Pharmaceutical Group Leader	Finnegan, LLP
Johanna Craig, Ph.D.	CEO	GATACA, LLC
Shashank Kaul	CEO	JivaJet, Inc.
R Dale DeJarnette, MBA	CEO	Lighthouse XR, LLC
John Schindler	CEO	Liquet Medical, Inc.
Yang Xu	Research Fellow	Luna Labs USA
Susan Chapman	COO	Mayfair Group, LLC dba esumry
William King	CEO	Medical Predictive Science Corporation
Kimberly Chapman	Vice President	Morphix Technologies, Inc.
Jennifer Lalli, Ph.D. Melissa Campbell Ben Woods	CEO and FSO CFO Production Supervisor	NanoSonic, Inc.
Tracy Steffek, MPA	Founder and Principal	Remedy & Root, LLC
Webster Santos	Head of Medicinal Chemistry	S1P Therapeutics, Inc.

Patrick O'Connor, MBA	Principal Consultant	Stokes MedTech Solutions, LLC
Glenn Block	President and CEO	Synap Biotech, Inc.
Spencer Marsh, Ph.D.	CSO	The Tiny Cargo Company
Tiffany Kuo	Owner	Tkuo Consulting
Jay Atkinson	CEO	Tralyte Health, Inc.
James J. Daniero, MD, MS	CMO	University of Virginia
Adam Barnes	Senior Instructor	University of Virginia
Alisa Leavesley, Ph.D.	Research Scientist	Virginia Diodes, Inc.
Megan Sanctuary, MS, Ph.D.	Senior Research Associate	Virginia Tech
Kenneth J. Wynne, Ph.D.	President	WynnVision, LLC


Selected Case Studies from Impacted Companies:

Avant Genomics, Charlottesville, VA

Rachelle Turiello, Ph.D.

CEO and Co-Founder
Avant Genomics

The uncertainty has caused us to increase the size of our seed fundraising round to hit all milestones, unfortunately at the same valuation. We've also had to suspend bringing on another technician we planned to hire.



National Science Foundation SBIR/STTR portfolio company.

Barron Associates, Charlottesville, VA

Brian Clark

Technical Director
Barron Associates



This company of 20+ employees will not last if the lapse in SBIR/STTR program authorization continues.

Eileen Krepkovich

Senior Research Scientist
Barron Associates



Currently facing delays in clinical trial recruitment because of the lapse / concerns about getting the pre-approved extension to go through.

Department of Commerce, Department of Defense, Department of Education, Department of Energy, National Institutes of Health, and National Aeronautics and Space Administration SBIR/STTR portfolio company.

Colvin Run Networks, Inc., Tysons, VA

Nikhil Shenoy

CEO
Colvin Run Networks, Inc.



We have over \$5M in Phase II awards held up, and **had to cut 10% Reduction in Force this month.**

Department of Defense SBIR/STTR portfolio company.

Finnegan LLP, Reston, VA

Ryan O'Quinn, Ph.D.

Partner; Biotechnology and Pharmaceutical Group
Finnegan LLP



As a patent attorney who works frequently with startups, these companies are driving significant innovation in our country. Failing to fund these companies is a tactical mistake with enormous strategic consequences. We cede our technological leadership without renewing these funds.

GATACA, LLC, Newport, VA

Dr. Johanna Craig, Ph.D.

CEO
GATACA, LLC



GATACA, LLC is a small biomedical software company developing advanced analytics to improve viral drug-resistance detection and public-health preparedness. **The lapse in SBIR/STTR reauthorization has directly affected our operations by delaying planned hires, pausing development milestones, and forcing us to defer validation work tied to NIH-reviewed projects already under consideration. Without predictable SBIR funding, small companies like ours must either halt progress or assume unsustainable financial risk. These delays slow innovation, increase downstream costs, and threaten the continuity of highly specialized scientific teams.**

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

JivaJet Inc, *McLean, VA*

Shashank Kaul

CEO

JivaJet Inc



JivaJet's work addresses critical U.S. capability gaps at the intersection of space access, national security, and advanced plasma science. Our SBIR-supported programs enable technologies such as air-breathing plasma propulsion for very-low-Earth orbit hypersonics, and cold plasma systems for oncology and wound healing with defense and biomedical relevance. **The current SBIR/STTR funding lapse places these efforts at risk precisely when the U.S. must accelerate not pause development of sovereign, dual-use technologies.** Interruptions force small teams to slow testing, defer flight-relevant validation, and risk losing highly specialized talent that cannot be easily replaced. **SBIR/STTR continuity is essential to protecting time-critical innovation, maintaining domestic control of sensitive technologies, and ensuring U.S. leadership in next-generation space and plasma systems.**

Liquet Medical Inc, *Glen Allen, VA*

John Schindler

CEO

Liquet Medical Inc



Liquet Medical is a small medical device company developing catheter-based technology for life-threatening blood clots. **The lapse in SBIR/STTR funding has created material uncertainty in our clinical and operational planning.** SBIR funding was intended to support early clinical work and key technical milestones that are difficult to finance through private capital alone at this stage. **Delays force us to slow hiring, defer validation activities, and reallocate limited private funds away from innovation toward basic continuity.** For early-stage medtech companies like ours, predictable SBIR/STTR funding is **critical to de-risk technologies and bring lifesaving innovations to patients efficiently.**

Mayfair Group LLC d/b/a esumry, Norfolk, VA

Susan Chapman

Founder and Chief Operating Officer
Mayfair Group LLC



We received our first SBIR two years ago and it helped us to make great progress with our legal software product, esumry. We have filed for an SBIR II and believe it will greatly impact our ability to take esumry through the growth stage and commercialize the software to help litigators prepare for trial more efficiently, saving time and money. **Freezing the SBIR and STTR grants stops research and can derail prosperous companies from growth.** The AI race is fierce and when a government stops the research grants, **it slows the economic development and allows other countries to surpass us in the technology race.**

National Science Foundation SBIR/STTR portfolio company.

Medical Predictive Science Corporation, Charlottesville, VA

William King

CEO
Medical Predictive Science Corporation



We are a small business that has leveraged NIH funding to develop a product that has saved the lives of 1000's of premature infants in neonatal ICUs throughout the US and world, **creating good jobs here in Virginia.** Continuing the NIH SBIR/STTR program will help us, and countless others, **spawn the next generation of innovations that will deliver better lives for patients, create jobs, and maintain our position as the worldwide leader in medical devices.**

National Institutes of Health SBIR/STTR portfolio company.

Morphix Technologies, Inc, Virginia Beach, VA

Kimberly Chapman

Vice President

Morphix Technologies, Inc



Morphix is an SBIR success story with the commercialization of two products developed under SBIR. We are strong proponents of this program and the funding of this program is imperative to drive innovation by small businesses.

Department of Agriculture, Department of Defense, Department of Homeland Security, National Institutes of Health, and National Science Foundation SBIR/STTR portfolio company.

NanoSonic Inc, Pembroke, VA

Melissa Campbell

Chief Financial Officer

NanoSonic Inc



My small business has **reduced our labor force by 50% (20 employees laid off)** due to the lapse in funding. If reauthorization is delayed, we have a 95% chance of closing. We are a major employer in our rural area and closing would decimate the families in the area.

Ben Woods

Production Supervisor

NanoSonic Inc



The lapse in SBIR/STTR funding has prevented us from getting real world solutions to major problems into the Warfighter's hand. **Our research helps keep the American soldier and the American public safe.** Without this competitive research funding, **innovative solutions for the issues facing our military will not be resolved and our military will fall behind our adversaries in technology.**

Department of Agriculture, Department of Commerce, Department of War, Department of Education, Department of Energy, Department of Transportation, Environmental Protection Agency, National Aeronautics and Space Administration, National Institutes of Health, and National Science Foundation SBIR/STTR portfolio company.

SonoFx, Charlottesville, VA

James J. Daniero, MD, MS

Chief Medical Officer

SonoFx



I am in the beginning stages of launching a Biotech company. We have several projects that are critical to generating intellectual property for commercialization of our base technology. We were ready to submit our project for an accepted NSF pitch proposal when we were notified of the SBIR/STTR deauthorization. If not reauthorized we, and many other early-stage tech companies, **will be forced to abandon our innovative work** and go back into patient care and academia limiting medical innovation in this country.

Synap Biotech Inc., Norfolk, VA

Glenn Block

President

Synap Biotech Inc.



Synap Biotech, Inc. is a small U.S. biotechnology company developing a first-in-class intranasal nanobody therapy to restore neurological function after stroke and traumatic brain injury. **The lapse in SBIR/STTR reauthorization has had immediate and material consequences for our company—delaying critical preclinical research, forcing us to slow hiring plans, and increasing reliance on scarce private capital to sustain federally aligned innovation. SBIR/STTR funding is essential to bridge early-stage scientific risk and translate breakthrough research into patient-ready therapies. Continued delays directly threaten timelines, competitiveness, and America's leadership in neurotherapeutics.**

The Tiny Cargo Company, Roanoke, VA

Spencer Marsh, Ph.D.

Chief Scientific Officer

The Tiny Cargo Company

This isn't about individual organizations being impacted; losing startups is difficult and painful, but **this is about the impact on the US economy and our technological superiority over the world. Cutting SBIR/STTR funding is the quickest path to ceding our technological superiority over our competitors.** Fund technology research, beat our adversaries. **Cut this funding, and within a few short years you'll be the administration responsible for the evaporation of our technological superiority and the deterioration of our nation's position in the world.**



National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Tralyte Health, Inc., Richmond, VA

Jay Atkinson

CEO

Tralyte Health, Inc.

We are a startup commercializing life sciences technology out of VCU and the lapse in SBIR funding has negatively impacted our ability to bring our product to market and make a positive change in the lives of countless Americans.



WynnVision LLC, *Richmond, VA*

Kenneth J. Wynne, Ph.D.

President

WynnVision LLC



Prevented the 5 January submission of an NIH SBIR proposal aimed at Reducing Urinary Tract Infections after Cancer-Driven Radical Cystectomy (Bladder Removal) and Intracorporeal Urinary Diversion with an Ileal Neobladder. Places in jeopardy Phase II funding for an NIH SBIR project aimed at lifesaving technology for hydrocephalus patients: "Reducing infections and blockage associated with long-term implantation of ventriculoperitoneal and related shunts.

National Institutes of Health SBIR/STTR portfolio company.

Washington

Economic Impact of Program:

SBIR/STTR Funds Received: **\$1,672,479,812.55**

Small Business SBIR/STTR Awards: **4,718**

Letter to Congress Co-signers

Elizabeth Ruzzo, Ph.D.	Founder and CEO	Adyn
Leah Klein	Founder	Anavatos Bio, Inc.
Stephen J. Bone	CEO	Crimson Medical Solutions
Bharath Modayur, Ph.D.	Founder	EARLY MARKERS (Bsolutions, Inc.)
Mike Perry	CEO	Forest Concepts, LLC
Seema L. Clifasefi, MSW, Ph.D.	CEO	HaRT3S
Alyssa Hatsukami, MSW	Director of Operations	
Mark P. Jensen, Ph.D.	Professor	HypnoScientific
Gabriele Varani	Professor of Chemistry	Ithax Pharmaceuticals
John (Jake) C. Kraft, II, Ph.D.	CEO	Lila Biologics, Inc.
Oliver Nakano-Baker, Ph.D.	Founder and CEO	Odo Labs
Marc Mayberg, MD	CEO and Professor	Patchclamp Medtech, Inc.
Bob McPherson	COO	
Mary Fenske	CEO	Posture Wings
Chandima Bandaranayaka	CEO	Precision Quantomics
Stacy Anderson, Ph.D.	CEO	Primary Bioscience
Max ISmailov	CEO	Rocket Propulsion Systems, LLC
Sarah Koehler	Supervisor	School District
Amanda DePalma, MBA	SVP, Global Marketing Ultrasound	Siemens Healthineers
Timothy Hodge	CEO	Strata Sustainability
Ken Fujise, MD	Professor	University of Washington

Neil Fanger, Ph.D.	President and CEO	Virtici, LLC
Michelle Kriner, Ph.D.	Head of Program Development	Wayfinder Biosciences

Selected Case Studies from Impacted Companies:

Anavatos Bio, Inc., Seattle, WA

Leah Klein

Founder

Anavatos Bio, Inc.



Because of the lapse and delays in federal funding, our founding team has had to work on minimum wage salaries to keep our company going. These are deep industry experts trying to bring critical new infrastructure to biologics manufacturing.

EARLY MARKERS (Bsolutions, Inc.), Seattle, WA

Bharath Modayur, Ph.D.

Founder

Bsolutions, Inc.



We create mobile technology for infants to be screened for developmental risks from home videos. In the US, 5-10% of children have a developmental disability, but fewer than a third of them are diagnosed before school entry, preventing opportunities for early intervention. In the US, there are almost 1 million children living in areas with no local child physician. An additional 15 million children live in areas with an average of 22 pediatricians per 100,000 children. Lack of access to qualified professionals hinders the ability to screen all children at the appropriate age.

Our solution, Cribsy, has the potential to **redefine the landscape of developmental screening and early intervention** – transforming developmental care into an accessible, proactive, data-driven model that could improve outcomes for at-risk infants and reduce the long-term societal and economic burden of delayed diagnoses.

We have successfully completed Phase 1 of this project. NIH was initiating the process for funding our Phase 2, which will focus on clinical validation of Cribsy to make it

available for the public. **Currently, we are unable to sustain our payroll and have only the founders continuing to develop the tool and technology for no compensation.** Phase 2 funding will allow us to commercialize this tool. By bridging the gap between clinical need and resource availability, Cribsy can ensure that no child, regardless of location or circumstance, is denied the opportunity for early risk screenings.

Please help re-authorize the SBIR program.

National Institutes of Health SBIR/STTR portfolio company.

HaRT3S, Spokane, WA

Seema L. Clifasefi, MSW, Ph.D.
CEO
HaRT3S



The current pause in the SBIR/STTR program has **created a critical bottleneck for small, innovation-driven digital health companies** like ours. We received and successfully completed a Phase I STTR to develop a digital health product that will help millions of people struggling with substance use who are traditionally left out of care. Despite a strong, fundable Phase II STTR score to move this idea forward into the next round of scientific testing, our award remains stalled, forcing us to pause development. **The consequences are real: we are losing exceptional staff, halting momentum, and delaying access to science backed tools that could save lives now.** These delays undermine prior federal investments and slow the translation of publicly funded science—at a time when millions urgently need care.

Alyssa Hatsukami, MSW
Director of Operations
HaRT3S



HaRT3S was founded by scientists who have spent 20+ years developing and testing substance use interventions to make evidence-based tools more accessible to people who use drugs and their providers. We relied on SBIR/STTR to bridge the gap between research and implementation.

Without SBIR/STTR, we cut staff hours and halted development while we pivot to other funding sources. Frankly, our business cannot operate to the standard and capacity it does without SBIR/STTR. As scientists, building an evidence base is a great achievement, but we strive to make a direct impact by making these tools

available to those who need them.

National Institutes of Health SBIR/STTR portfolio company.

HypnoScientific, Kirkland, WA

Mark P. Jensen, Ph.D.

Professor

HypnoScientific



Prevents our healthcare app from full development and testing. Designed to address caregiver's physical and mental well-being when caring a discharged patient. Unique app that would assist, support & provide material to caregiver about themselves and for the patient. Greatly shortens response time, thereby anticipating fewer readmissions and recognized need for support of caregivers. This money will allow us to move forward with insurance and IT maintenance fees.


National Institutes of Health SBIR/STTR portfolio company.

Lila Biologics, Inc., Seattle, WA

John (Jake) C. Kraft, II, Ph.D.

CEO

Lila Biologics, Inc.



Lila is an early-stage startup that spun out of David Baker lab (2024 Nobel laureate in chemistry). We recently received a highly competitive score for our first ever Fast-Track SBIR application submitted in April 2025. This SBIR award would make a meaningful impact in our business and it is currently in limbo and preventing the advancement of a very important therapeutic for patients.

Patchclamp Medtech, Inc., Seattle, WA

Marc Mayberg, MD
CEO
Patchclamp Medtech, Inc.



I am the CEO of an early stage Seattle startup building a device for the repair of leaks in the dura (covering of the brain) through minimally invasive surgery. Successful repair of leaks can save lives and save over \$3 million in healthcare costs annually. Our company has made substantial progress with a SBIR Phase I grant, and are awaiting a Phase II grant for refinement and commercialization of the device. The lapse in SBIR funding has left us without funding in a critical phase of development, which may lead to delay or cancellation of further progress with the device.

Bob McPherson
COO
Patchclamp Medtech, Inc.



Our company, PatchClamp Medtech Inc., is delayed by at least 6 months and \$US 3M by the recent lapse of government programs, as we are introducing a valuable improvement to spinal and cranial surgical procedures - improving a \$2B market. Our device needs FDA approval which was to be enabled significantly by an SBIR/STTR grant. We are being thereby forced to go to private equity channels, and may lose market opportunity in our recovery period.

We need the SBIR grant support regardless - **Please help us help this critical US industry.**

National Institutes of Health SBIR/STTR portfolio company.

Posture Wings, Everett, WA

Mary Fenske

CEO

Posture Wings

Please keep this program.



West Virginia

Economic Impact of Program:

SBIR/STTR Funds Received: **\$123,514,149.27**

Small Business SBIR/STTR Awards: **330**

Letter to Congress Co-signers

Tapan K. Khan	Founder and CEO	BiolImaginix
John B. Barnett, Ph.D. Dr. Allie Karshenas	President and CSO Professor Emeritus and AVP of Clinical Research Operations	ExesaLibero Pharma, Inc.
Auggie Chico, MBA	CEO	Parthian Battery Solutions
Shawn R. Hutchinson, MS, MS, MDiv	CTO and Founder	Universal Schedule and Booking

Selected Case Studies from Impacted Companies:

ExesaLibero, Morgantown, WV

John B. Barnett, Ph.D.

President and Chief Scientific Officer
ExesaLibero



We are advancing a first-in-class therapeutic to prevent and treat bone destruction caused by arthritis, cancer, and prolonged exposure to microgravity. Despite its transformative potential, early-stage drug development of this kind falls outside the risk tolerance of most venture capital investors due to long timelines and substantial upfront costs. SBIR support is therefore essential to sustain this work at a critical inflection point. With continued funding, this program has the potential to dramatically improve quality of life for tens of millions of patients affected by degenerative bone disease, while also delivering a uniquely suited countermeasure for astronauts and future space travelers.

Dr. Allie Karshenas

Chair of the Board of Directors
ExesaLibero



I currently serve as Chair of the Board of Directors for ExesaLibero, a small start-up biopharmaceutical company focused on developing a novel therapeutic for Rheumatoid Arthritis. The company is at a pivotal inflection point, positioned to overcome long-standing limitations in RA treatment through an innovative scientific strategy. Advancing our program from preclinical research into the clinical phase is essential to realizing its full therapeutic potential. Progress at this stage is highly dependent on securing federal funding, which is critical to supporting translational research, meeting regulatory requirements, accelerating clinical readiness, and ultimately delivering meaningful benefits to patients living with Rheumatoid Arthritis.

National Institutes of Health SBIR/STTR portfolio company.

Parthian Battery Solutions, Morgantown, WV

Auggie Chico, MBA
CEO
Parthian Battery Solutions



Parthian stands at the forefront of America's quest to reassert domestic control over critical rare-earth supply chains, which stands as an issue with deep economic and national security implications. Our work is enabled by revolutionary technology that had been developed through NSF STTR funding. However, despite the successful completion of our Phase I project, there is no clarity on when, or even if, our Phase II award will be funded.

While our team remains fully committed to Parthian's mission, the reality of this ongoing uncertainty surrounding the SBIR/STTR program's authorization has forced us to temporarily look beyond the company to sustain ourselves. **This indefinite lapse in authorization has materially stalled Parthian's progress. Prolonged disruption at this stage not only threatens Parthian's operations, it compromises the resiliency of America's economic interests and national security.**

National Science Foundation SBIR/STTR portfolio company.

Universal Schedule and Booking (USB), *Harpers Ferry, WV*

Shawn R. Hutchinson, MS MS MDiv

CTO, Founder

Universal Schedule and Booking (USB)



USB pioneered market-driven tech-enabled solutions, with SBIR & STTR funds, to top challenges facing Americans: food costs, housing costs, farm profitability, rural prosperity, and reducing healthcare costs—at scale! Our pending proposals and follow-on market-driven solutions are in limbo until the program is Reauthorized. Please reauthorize the SBIR program ASAP!

United States Department of Agriculture, Department of Commerce, and Department of Energy SBIR/STTR portfolio company.

Wisconsin

Economic Impact of Program:

SBIR/STTR Funds Received: **\$752,490,637.08**

Small Business SBIR/STTR Awards: **2,038**

Letter to Congress Co-signers

Su-Chun Zhang, MD, Ph.D.	Founder and Chairman of Board of Directors	BrainXell, Inc.
Jean Brittain, Ph.D.	CEO	Calimetricx
Chris Dockendorff, Ph.D.	CEO and CSO	Function Therapeutics
Christof Koch	President	Intrinsic Powers, Inc.
Zeinab Barati, Ph.D., MBA	CEO	Intrinsic Powers, Inc.
Karen Orr	CEO	KODA Ideaworks, Inc.
Mirhamed Mirmozafari, Ph.D.	Founder and CEO	Maxwave, LLC
Mary Ozers, Ph.D.	Owner and CSO	Proteovista, LLC
Bill Murphy	CSO	Stem Pharm
Taufeeque Ali	CEO	SynXT Therapeutics, Inc.
Lesley Lizalek, Ph.D.	Director of Surgical Technologies	TenseNSE, LLC
David Mead, Ph.D.	CEO	Terra Bioforge
Debiprasad Panda	President and CTO	Universal Real Time Power Conversion, LLC
Scott Reeder, MD, Ph.D.	Professor and Chair	University of Wisconsin
Richard A Rovin, MD	CEO	UP Oncolytics, Inc.
Margaret Ramey Robert Baranowski	Director Technical Consultant	Wisconsin Center for Technology Commercialization

Selected Case Studies from Impacted Companies:

Function Therapeutics, Milwaukee, WI

Chris Dockendorff, Ph.D.

CEO and CSO

Function Therapeutics



The SBIR program has provided almost all of the initial support to help us develop new treatments for kidney disease, pain, and other inflammatory diseases. Most investors are too risk-averse to fund such discovery stage projects. Despite having new inventions in hand and extremely promising results, our growth is stalled by the lapse in the SBIR program. **One of America's greatest competitive advantages over EVERY other nation is at risk by these Congressional delays.**

National Institutes of Health and National Science Foundation SBIR/STTR portfolio company.

Intrinsic Powers Inc., Madison, WI

Christof Koch

President

Intrinsic Powers Inc.



Intrinsic Powers

This helps the entire ecosystem of small American start-ups to survive these tough times.

National Institutes of Health SBIR/STTR portfolio company.

KODA Ideaworks, Inc, Waunakee, WI

Karen Orr

CEO

KODA Ideaworks, Inc



We are a medical device startup and government grants/funds are a significant portion of our non-dilutional funding. This delay severely impacts our go-to-market strategy.

Maxwave, LLC, *Madison, WI*

Mirhamed Mirmozafari, Ph.D.

Founder and CEO
Maxwell, LLC



Maxwave has submitted one AFWERX proposal and is currently preparing another in response to an Army solicitation. The first proposal has remained unanswered, and the submission deadline for the second has been repeatedly postponed. The lapse in SBIR reauthorization will negatively impact our engagement with stakeholders and hinder our commercialization efforts.

National Science Foundation SBIR/STTR portfolio company.

Proteovista, LLC, *Madison, WI*

Mary Ozers, Ph.D.

Owner and CSO
Proteovista, LLC



Proteovista LLC has a recently well-scored SBIR Phase I grant which is within the payline but in limbo because of the lapse in SBIR funding. This has **prevented us from hiring scientists** and conducting this innovative genomic research on **developing methods to address antibiotic resistance**, severely affecting our research programs and delaying innovation for all. This delay, coupled with the recent Section 174 R&D taxes of 2021-2025, has **significantly hurt the financial stability of the company** and targeted small biotechnology companies.

National Institutes of Health SBIR/STTR portfolio company.

Scott Reeder, MD, Ph.D., *Madison, WI*

Scott Reeder, MD, Ph.D.

Professor and Chair
University of Wisconsin



The impact of SBIR/STTR on the local med tech and biotech industry on the local economy cannot be understated. Such funding plays a critical role in retiring early technical and commercial risk necessary for new advanced technology-based companies that **create high-paying jobs based in Wisconsin.**

Such funding has played a fundamental role in supporting the thriving **medical imaging industry for which Wisconsin is known.** Discontinuation of such funding will have a **detrimental impact on maintaining and expanding the leadership position the United States has in this field.**

Stem Pharm, *Fitchburg, WI*

Bill Murphy

CSO
Stem Pharm



Our start-up company is dependent on federal funding to continue to build a revolutionary technology, which we are building in order to discover **groundbreaking treatments for neurodegenerative diseases such as Alzheimer's Disease and Epilepsy.** We **will not survive in this investment environment** without support from the SBIR/STTR programs.

National Institutes of Health SBIR/STTR portfolio company.

SynXT Therapeutics Inc, *Milwaukee, WI*

Taufeeque Ali

CEO
SynXT Therapeutics Inc



The SBIR/STTR lapse has frozen our critical work in cancer therapeutics. This funding was our sole means to advance high-risk, high-reward triple negative breast cancer research that large companies and traditional grants won't support. Operationally, we've halted key experiments and may lose

specialized staff. Financially, our runway has collapsed. Without it, breakthrough discoveries for hard-to-treat diseases will remain shelved in labs instead of reaching patients. **This delay isn't just bureaucratic—it directly translates to lost time, lost innovation, and ultimately, lost lives we could have saved.**

Terra Bioforge, Madison, WI

David Mead, Ph.D.

CEO

Terra Bioforge



IT WILL PUT US OUT OF BUSINESS.

National Institutes of Health SBIR/STTR portfolio company.

Wisconsin Center for Technology Commercialization (CTC), Madison, WI

Robert Baranowski

Technical Consultant

Wisconsin CTC



We help small businesses access the funding from this program, and our clients are in limbo right now, with great breakthroughs in technology ready to go, but no funding available.

Wyoming

Economic Impact of Program:

SBIR/STTR Funds Received: **\$113,230,889.80**

Small Business SBIR/STTR Awards: **364**

Letter to Congress Co-signers

Austen Williamson	CEO	Final Frontiers Aerospace, LLC
Rama Nair	CEO	Nutriwyo, LLC
Sreejayan Nair	Co-Founder	Nutriwyo, LLC

Selected Case Studies from Impacted Companies:

Nutriwyo, LLC, Laramie, WY

Sreejayan Nair

Co-Founder

Nutriwyo LLC



Using a previous NIH Phase I award, which helped build a University startup small business (Nutriwyo LLC) we have been able to identify a novel treatment target for diabetic wound healing, based on which are currently in the process of developing a molecule treating diabetic wounds. We have since submitted a Phase 2 proposal aimed at performing preclinical efficacy and toxicity studies which would support IND application to the FDA.

National Institutes of Health SBIR/STTR portfolio company.